WO2003045912A1 - Inhibitors of factor xa and other serine proteases involved in the coagulation cascade - Google Patents

Inhibitors of factor xa and other serine proteases involved in the coagulation cascade Download PDF

Info

Publication number
WO2003045912A1
WO2003045912A1 PCT/IB2002/004757 IB0204757W WO03045912A1 WO 2003045912 A1 WO2003045912 A1 WO 2003045912A1 IB 0204757 W IB0204757 W IB 0204757W WO 03045912 A1 WO03045912 A1 WO 03045912A1
Authority
WO
WIPO (PCT)
Prior art keywords
amide
phenyl
chloro
pyrrolidine
dicarboxylic acid
Prior art date
Application number
PCT/IB2002/004757
Other languages
French (fr)
Other versions
WO2003045912A8 (en
Inventor
Christopher Franklin Bigge
Danette Andrea Dudley
Jeremy John Edmunds
Chad Alan Van Huis
Agustin Casimiro-Garcia
Kevin James Filipski
Jeffrey Thomas Kohrt
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP02803885A priority Critical patent/EP1465864B1/en
Priority to MXPA04003606A priority patent/MXPA04003606A/en
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Priority to DK06110738T priority patent/DK1671949T3/en
Priority to NZ532384A priority patent/NZ532384A/en
Priority to JP2003547364A priority patent/JP4238135B2/en
Priority to SI200230316T priority patent/SI1465864T1/en
Priority to BR0214519-7A priority patent/BR0214519A/en
Priority to EA200400606A priority patent/EA007579B1/en
Priority to CN028238370A priority patent/CN1582274B/en
Priority to KR1020047008251A priority patent/KR100688814B1/en
Priority to UA20040504094A priority patent/UA77456C2/en
Priority to HU0402529A priority patent/HUP0402529A3/en
Priority to IL16182602A priority patent/IL161826A0/en
Priority to YUP-436/04A priority patent/RS51087B/en
Priority to DE60209944T priority patent/DE60209944T2/en
Priority to CA2468715A priority patent/CA2468715C/en
Priority to AU2002365313A priority patent/AU2002365313B2/en
Priority to APAP/P/2004/003035A priority patent/AP1744A/en
Publication of WO2003045912A1 publication Critical patent/WO2003045912A1/en
Publication of WO2003045912A8 publication Critical patent/WO2003045912A8/en
Priority to IS7220A priority patent/IS2552B/en
Priority to HR20040470A priority patent/HRP20040470A2/en
Priority to TNP2004000098A priority patent/TNSN04098A1/en
Priority to CY20061100448T priority patent/CY1105374T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to cyclic amino acid and proline derivatives which display inhibitory effects of the serine protease factor Xa.
  • the invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.
  • cardiovascular disease represents a major cause of mortality.
  • abnormal coagulation and inappropriate thrombus formation within blood vessels precipitates many acute cardiovascular disease states.
  • plasma proteins such as fibrinogen, serine proteases, and cellular receptors are involved in hemostasis, it is abnormal regulation that has emerged as impoTtant contributing factors to cardiovascular disease.
  • Thrombin can be considered the key or principal regulatory enzyme in the coagulation cascade; it serves a pluralistic role as both a positive and negative feedback regulator in normal hemostasis.
  • the positive feedback regulation is amplified through catalytic activation of cofactors required for thrombin generation.
  • cofactors include factor Xa, a serine protease which occupies a pivotal position in the coagulation cascade.
  • Factor X is the zymogen of factor Xa.
  • Factor X can be activated by either the intrinsic or extrinsic pathways of the coagulation system. Initiation of coagulation by either pathway in response to vascular injury activates factor X to factor Xa.
  • Factor Xa and its cofactor, factor Va combine on a phospholipid membrane to form the "prothombinase" complex, which activates prothrombin to thrombin.
  • Thrombin cleaves fibrinogen to fibrin, activates platelets, and converts factor Xi ⁇ to Xllla which is the principal enzyme involved in thrombus generation, growth, and stabilization. Accordingly, the location of the prothrombinase complex at the convergence of both the intrinsic and extrinsic coagulation pathways suggests that inhibition of factor Xa, and hence thrombin generation, may be a viable approach to limiting the procoagulant activity of thrombin.
  • Antistasin a potent inhibitor of blood coagulation factor Xa from the Mexican leech, Haementeria qfficinalis, displays antithrombotic activity in various models of arterial and venous thrombosis (Lapatto et al., Embo. J, 1997:5151-5161).
  • protein or polypeptide factor Xa inhibitors include recombinant tick anticoagulant peptide (rTAP), which is known to accelerate the recombinant tissue plasminogen activator mediated clot lysis and prevent acute reocclusion in the dog, hence indicating factor Xa inhibitors may be useful as an adjunct to thrombolytic therapy (Mellott et al., Fibrinolysis, 1993: 195-202).
  • rTAP tick anticoagulant peptide
  • rTAP was demonstrated to reduce thrombus mass and time to occlusion in the absence of dramatic hemodynamic or hemostatic changes indicating the primary role for factor Xa in the process of arterial thrombosis (Lynch et al., Thromb. Haemostasis, 1995:640-645; Schaffer et al., Circulation, 1991 : 1741- 1748).
  • rTAP was also demonstrated to reduce fibrin deposition in a rabbit model of venous thrombosis while having little affect on systemic hemostatic parameters (Fioravanti et al., Thromb. Res., 1993: 317-324).
  • factor Xa inhibition potentially provides a large therapeutical window between antithrombotic efficacy and bleeding tendency. Consequently, there may exist a range in which factor Xa inhibition is achieved without an concurrent increase in a patients susceptibility to bleeding.
  • B is -NH -C— (C ⁇ -C 6 )alkyl, -NH — C— (C 3 -C 7 )cycloalkyl, - NH , (C 3 -C 7 )cycloalkyl, (C 3 -C 7 )heterocyclo, (C 4 -
  • C is phenyl or heteroaryl, wherein phenyl or heteroaryl is optionally substituted with one or more substituents selected from aryl, heteroaryl, halogen, hydroxy, -CO2R 2 , -COR 2 , -CONR 2 R 2 ', alkoxy, alkyl, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido;
  • G is H, halo, (C r C 6 )alkyl, halo(d-C 6 )alkyl, hydroxy(C,-C 6 )alkyl, -CH 2 O-(C,-C 6 )alkyl, -CH 2 -CO 2 (C,-C 6 )alkyl, -CH 2 -NR2R2', or -CH 2 -CONH(C r C 6 )alkyl;
  • R 1 is (C C 6 )alkoxy, (C 3 -C )cycloalkyl, (C 3 -C 7 )heterocycloalkyl, (C 4 - C 7 )cycloalkenyl, (C -C )heterocycloalkenyl, aryl, monocyclic heteroaryl, or-
  • R 2 and R 2 ' are each independently H or (CpC 6 )alkyl; and R 3 and R 4 are each independently H, (CrC 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring.
  • the invention is also directed to a compound of formula II: ⁇
  • R and R are each independently H, -OH, halo, alkyl, haloalkyl, -
  • A is aryl and substituted aryl or monocyclic heteroaryl or substituted monocyclic heteroaryl;
  • B is -NH— C— (C r C 6 )alkyl, -NH — C— (C 3 -C 7 )cycloalkyl, -
  • C is phenyl or heteroaryl, wherein phenyl or heteroaryl is optionally substituted with one or more substituents selected from halogen, hydroxy, - CO 2 R 2 , -COR 2 , -CONR 2 R 2 ', alkoxy, alkyl, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido;
  • G is H, halo, (C C 6 )alkyl, halo(C,-C 6 )alkyl, hydroxy(C,-C 6 )alkyl,
  • R 1 is (C C 6 )alkoxy, (C 3 -C 7 )cycIoalkyl, (C 3 -C 7 )heterocycloalkyl, (C 4 - C 7 )cycloalkenyl, (C -C )heterocycloalkenyl, aryl, monocyclic heteroaryl, or -
  • R 2 and R 2 ' are each independently H or (C]-C 6 )alkyl
  • R 3 and R 4 are independently H, (C]-C 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO 2 alkyl, or joined together to form a saturated or unsaturated 5 to 7 membered ring.
  • the invention is also directed to a compound of Formula III
  • Z is C-H, C-halo, C-(CrC 6 )alkyl, C-halo(C C 6 )alkyl, C-(C r C 6 )alkoxy, or
  • A is aryl and substituted aryl or monocyclic heteroaryl or substituted monocyclic heteroaryl;
  • O O B is -NH — C- (C,-C 6 )alkyl, -NH — C— (C 3 -C 7 )cycloalkyl, -
  • C 7 cycloalkenyl, unsaturated (C 4 -C 7 )heterocyclo, aryl, or heteroaryl, any of which may be optionally substituted by halo, (C ⁇ -C 6 )alkyl, or halo(C ⁇ -C 6 )alkyl, O-(C ⁇ -C ⁇ ), -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido; G is H, halo, (C r C 6 )alkyl, halo(C r C 6 )alkyl, hydroxy(C,-C 6 )alkyl,
  • R 2 and R 2 ' are each independently H or (C ⁇ -C 6 )alkyl
  • R and R are each independently H, halo, (Ci-C ⁇ ); C 6 )alkyl, or (C r C 6 )alkoxy.
  • X ⁇ is CH 2 , CH, O, ⁇ H or ⁇ ;
  • R 3 and R 4 are independently H, (C ⁇ -C 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO 2 alkyl, or joined together to form a saturated or unsaturated 5 to 7 membered ring;
  • R and R .13 are each independently H, halo, (C]-C 6 )alkyl, or halo(Q- C 6 )alkyl, or (C C 6 )alkoxy;
  • R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R 8 and R 9 are as defined for R 3 and R 4 ;
  • X and Y are each C, or one of X and Y is C and the other is N, provided that when one of X or Y is N, R 14 or R 15 is absent at that position.
  • Z is C-H, C-halo, C-(C C 6 )alkyl, C-halo(CrC 6 )alkyl, C-(C r C 6 )alkoxy, or N;
  • G is H, halo, (C r C 6 )alkyl, halo(C C 6 )alkyl, hydroxy(C r C 6 )alkyl, -CH O-(C ⁇ -C 6 )alkyl, -CH2-CO 2 (CrC 6 )alkyl, -CH 2 -CONH 2 , or -CH 2 -CONH(C,- C 6 )alkyl;
  • X n is CH 2 , CH, O, NH or N; io ..
  • R and R are each independently H, -OH, halo, alkyl, haloalkyl, -
  • R and R are each independently H, halo, (C ⁇ -C ⁇ )alkyl, or halo(C ⁇ - C 6 )alkyl, or (C ⁇ -C 6 )alkoxy;
  • R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R 8 and R 9 are as defined for R 3 and R 4 ;
  • X and Y are each independently C or N, provided that when one of X or Y is N, R l4 or R 1 5 is absent at that position.
  • X' and Y' are each independently CH or N;
  • -' is absent or is a fused heterocyclic or fused heteroaryl ring
  • R 16 and R 17 are each independently H, halo, cyano, (C]-C 6 )alkoxy carbonyl, aminomethyl. t-butyl, H 2 NSO 2 — , Me 2 NSO 2 — , (C ⁇ -C 6 )alkoxy, MeSO 2 — , MeSO— , MeS— , NR 8 R 9 , or hydroxy
  • G is H, halo, (C r C 6 )alkyl, halo(C r C 6 )alkyl, hydroxy(C,-C 6 )alkyl, -CH 2 O-(CrC 6 )alkyl, -CH 2 -CO 2 (C,-C 6 )alkyl, -CH 2 -CONH 2 , or -CH 2 -CONH(C,- C 6 )alkyl;
  • Q is NH or is absent;
  • X ⁇ is CH 2 , CH, O, NH or N;
  • R 1 is OH, -O-(C,-C 6 )alkyl, (C 3 -C 7 )cycloalkyl, (C 3 -C 7 )heterocycloalkyl, (C 4 -C 7 )cycloalkenyl, (C 4 -C )heterocycloalkenyl, aryl, monocyclic heteroaryl, or - NR R 4 , wherein R 3 and R 4 are independently H, (C ⁇ -Ce)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO alkyl, or joined together to form a saturated or unsaturated 5 to 7 membered ring;
  • R 2 is H or (C ⁇ -C 6 )alkyl
  • R 3 and R 4 are independently H, (C ⁇ -C 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO 2 alkyl, or joined together to form a 5 to 7 membered ring;
  • R and R are each independently H, halo, (C]-C 6 )alkyl, or halo(C ⁇ - C 6 )alkyl, or (C]-C 6 )alkoxy;
  • R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R 8 and R 9 are as defined for R 3 and R 4 ;
  • Rl5 is absent at that position.
  • G is H, halo, (C C 6 )alkyl, halo(C r C 6 )alkyl, hydroxy(C r C 6 )alkyl,
  • X ⁇ is CH 2 , CH, O, NH or N;
  • R 2 and R 2 ' are each independently H or (d-C6)alkyl; and R 3 and R 4 are each independently H, (CrC 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO 2 alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring;
  • R and R are each independently H, halo, (C ⁇ -C6)alkyl, or halo(Cj-
  • R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R 8 and R 9 are as defined for R 3 and R 4 ;
  • X and Y are each independently C or N, provided that when one of X or Y is N, R 14 or
  • R'5 is absent at that position
  • Z is C-H, C-halo, C-(d-C 6 )alkyl, C-halo(d-C 6 )alkyl, C-(d-C 6 )alkoxy, or ⁇ ;
  • G is H, halo, (d-C 6 )alkyl, halo(d-C 6 )alkyl, hydroxy(C,-C 6 )alkyl, -CH 2 O-(C,-C 6 )aIkyl, -CH 2 -CO 2 (C r C 6 )alkyl, -CH 2 -CONH 2 , or -CH 2 -CONH(C,- C 6 )alkyl;
  • R and R are each independently H, -OH, halo, alkyl, haloalkyl, -
  • R 2 and R 2 ' are each independently H or (d-C6)alkyl
  • R 3 and R 4 are each independently H, (C 1 -C 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO 2 alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring;
  • R and R are each independently H, halo, (C ⁇ -C 6 )alkyl, or halo(C C 6 )alkyl, or (C r C 6 )alkoxy;
  • Y ⁇ is CH 2 , CH(d-C 6 alkyl), NH, or N(C r C 6 alkyl);
  • R 18 is H, (d-Q alkyl, hydroxymethyl, CH 2 O-(CrC 6 )alkyl, or NR 3 R 4 .
  • Z is C-H, C-halo, C-(C ⁇ -C 6 )alkyl, C-halo(C,-C 6 )alkyl, C-(C C 6 )alkoxy, or N;
  • G is H, halo, (C 1 -C 6 )alkyl, halo(d-C 6 )alkyl, hydroxy(C r C 6 )alkyl, -CH 2 O-(C C 6 )alkyl, -CH 2 -CO 2 (C,-C 6 )alkyl, -CH 2 -CONH 2 , or -CH 2 -CONH(C ⁇ - C 6 )alkyl;
  • X" is CH 2 , CH, NH or N;
  • R 2 and R 2 ' are each independently H or (C C6)alkyl; and R 3 and R 4 are each independently H, (d-C 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO 2 alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring; R are each independently H, halo, (C ⁇ -C 6 )alkyl, or halo(d- C 6 )alkyl, or (d-C 6 )alkoxy;
  • R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R 8 and R 9 are as defined for R 3 and R 4 ;
  • X and Y are each independently C or N, provided that when one of X or Y is N, R* or R J 5 is absent at that position;
  • R 18 is H, (C C 6 )alkyl, hydroxymethyl, CH 2 O-(C,-C 6 )alkyl, CH 2 NR 2 , or
  • the invention also provides a compound of Formula X
  • Z is C-H, C-halo, C-(d-C 6 )alkyl, C-halo(d-C 6 )alkyl, C-(C C 6 )alkoxy, or N;
  • G is H, halo, (d-C 6 )alkyl, halo(d-C 6 )alkyl, hydroxy(d-C 6 )alkyl, -CH 2 O-(C r C 6 )alkyl, -CH 2 -CO 2 (C ⁇ -C 6 )alkyl, -CH 2 -CONH 2 , or -CH 2 -CONH(C,- C 6 )alkyl;
  • R 2 and R 2 ' are each independently H or (d-C ⁇ )alkyl
  • R 3 and R 4 are each independently H, (d-C 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring;
  • R and R are each independently H, halo, (d-C 6 )alkyl, or halo(d- C 6 )alkyl, or (d-C 6 )alkoxy;
  • R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R 8 and R 9 are as defined for R 3 and R 4 ;
  • X and Y are each independently C or N, provided that when one of X or Y is N, R j 4 or R!5 is absent at that position;
  • Ji, J 2 , J 3 , and J 4 are C or one of Jj, J 2 , J 3 , and J 4 is N;
  • R 19 , R 20 , R 21 , and R 22 are each independently H, halo, hydroxy, NH 2 , NR 23 R 24 , NO 2 , SH, (C,-C 6 )alkyl, halo(C r C 6 )alkyl, (C C 6 )alkanoyl, (C Co)alkoxycarbonyl, or (C]-C 6 )alkoxy, wherein R 23 and R 24 are each independently H, (d-C 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring, or R 19 and R 20 , R 20 and R 21 , or R 21 and R 22 , together with the carbons to which they are attached, form a 5, 6, or 7 membered saturated or unsaturated cycloalkyl or heterocycloalkyl
  • Piperidine-1 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3-fluoro- 2'-methanesulfonyl-biphenyl-4-yl)-amide];
  • the invention is also directed to a compound which is: (2R,4R)-4-Methoxy-pyrrolidi ⁇ e-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- ⁇ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide);
  • the invention is also directed to a compound which is:
  • (2R,4R)-4-Ethoxy-pyrrolidine-l 2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2- ⁇ [2-fluoro-4-(pyrrolidine-l-carbonyl)-phenyl]-amide ⁇ ; (2R,4R)-4-Ethoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(4-dimethylcarbamoyl-2-fluoro-phenyl)-amide];
  • Pyrrolidine-1 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3,5- difluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; Pyrrolidine- 1 ,2 -dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-2-methyl-biphenyl-4-yl)-amide];
  • (2R,4R)-4-Methoxy-pyrrolidine-l 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2- ⁇ [4-(3,5-dimethoxy-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]- amide ⁇ ;
  • (2R,4R)-4-Methoxy-pyrrolidine-l 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- ⁇ [2-fluoro-4-(5-methoxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide ⁇ ;
  • the invention is also directed to a compound which is: (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- ⁇ [2-fluoro-4-(2-oxo-2H-quinolin-l-yl)-phenyl]-amide ⁇ ; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- ⁇ [2-fluoro-4-(3-oxo-3H-isoquinolin-2-yl)-phenyl]-amide ⁇ ;
  • (2R,4R)-4-Methoxy-pyrrolidine-l 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- ⁇ [4-(2,5-dihydro-pyrrole-l -carbonyl)-phenyl]-amide ⁇ ;
  • (2R,4R)-4-Methoxy-pyrrolidine-l 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- ⁇ [4-(2,5-dihydro-pyrrole-l-carbonyl)-2-fluoro-phenyl]-amide ⁇ ;
  • (2R,4R)-4-Methoxy-pyrrolidine-l 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- ⁇ [2-fluoro-4-(2-oxo-l-aza-spiro[4.5]dec-l-yl)-phenyl]-amide ⁇ ;
  • (2R,4R)-4-Methoxy-pyrrolidine-l 2-dicarboxylic acid 2- ⁇ [4-(3-benzoyl-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide ⁇ l-[(4-chloro-phenyl)-amide];
  • the invention is also directed to a compound which is: (2R,4R) 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2- ⁇ [2-fluoro-4-(2-oxo-piperidin-l -yl)-phenyl]-amide ⁇ ;
  • 5-Methyl-4,5-dihydro-pyrazole-l 5-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2- ⁇ [2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide ⁇ ;
  • (2R,4R)-4-Methoxy-pyrrolidine-l 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2- ⁇ [2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide ⁇ ;
  • (2R,4R)-4-Methoxy-pyrrolidine-l 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- ⁇ [4-(2,5-dihydro-pyrrole-l-carbonyl)-2-fluoro-phenyl]-amide ⁇ ;
  • the invention is also directed to a method for preventing or treating acute, subacute, and chronic thrombotic disorder in a mammal is comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of any of formulas I-X.
  • the invention is also directed to a process for preparing a compound of Formula I comprising:
  • alkyl refers to a straight or branched hydrocarbon of from 1 to 11 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like.
  • (d-Q alkyl) refers to a subset of alkyl which means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like.
  • C -Cgalkyl Sometimes herein lower alkyl is referred to as "C -Cgalkyl.”
  • (C ⁇ -C 6 )hydroxyalkyl or "hydroxy(C C 6 )alkyl” as used herein means a straight or branched alcohol having from 1 to 6 carbon atoms and includes, for example, hydroxymethyl, hydroxyethyl, hydroxy-propyl and the like.
  • (C 2 -C 6 )alkenyl means a straight or branched unsaturated hydrocarbon radical having from 2 to 6 carbon atoms and includes, for example, ethenyl, 2-propenyl, 1 -butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-methyl-3- butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 3-heptenyl, 1-octenyl, 1-nonenyl, 1- decenyl, 1 -undecenyl, 1-dodecenyl, and the like.
  • alkylene refers to a divalent group derived from a straight or branched chain saturated hydrocarbon having from 1 to 10 carbon atoms by the removal of two hydrogen atoms, for example methylene, 1,2- ethylene, 1 ,1 -ethylene, 1 ,3-propylene, 2,2- dimethylpropylene, and the like.
  • the alkylene groups of this invention can be optionally substituted.
  • the alkylene group can also be substituted with one or more of the substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, halogen, nitro, cyano, oxo, thio,
  • C6alkyl 0 , -CONR 8 R9, or -N(C]-C6alkyl) 2 .
  • Preferred alkylene groups have from 1 to 6 carbon atoms (C- -C alkyl).
  • heteroatom represents oxygen, nitrogen, or sulfur (O, N, or S) as well as sulfoxyl or sulfonyl (SO or SO ), unless otherwise indicated.
  • alkyl chains interrupted by one or more heteroatoms means that a carbon atom of the chain is replaced with a heteroatom having the appropriate valency.
  • an alkyl chain is interrupted by 1 to 4 heteroatoms and that two adjacent carbon atoms are not both replaced. Examples of such groups include methoxymethyl, 3-thiomethylpropyl, and 2- thiomethoxyethoxymethyl.
  • hetero(CrC 6 )alkyl refers to an alkyl group that includes one or more heteroatoms such as oxygen, sulfur, or nitrogen (with valence completed by hydrogen or oxygen) in the carbon chain or terminating the carbon chain.
  • hydrocarbon chain refers to a straight hydrocarbon of from 2 to 6 carbon atoms.
  • the hydrocarbon chain is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, halogen, nitro, cyano, oxo, thio, -OH, -SH, -F, -CF3, -OCF3,
  • hydrocarbon-heteroatom chain refers to a hydrocarbon chain wherein one or more carbon atoms are replaced with a heteroatom.
  • the hydrocarbon-heteroatom chain is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy,
  • heteroalkylene refers to an alkylene radical as defined above that includes one or more heteroatoms such as oxygen, sulfur, or nitrogen (with valence completed by hydrogen or oxygen) in the carbon chain or terminating the carbon chain.
  • (C 3 -C 7 )cycloalkyl means a cyclopropyl, cyclobutyl, cylopentyl, cyclohexyl, or cycloheptyl ring, respectively.
  • the (C 3 -C 7 )cycloalkyl ring may be optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, halogen, nitro, cyano, oxo, thio,
  • Monocyclic heterocyclic rings contain from about 3 to 12 ring atoms, with from 1 to 5 heteroatoms selected from N, O, and S, and preferably from 3 to 7 member atoms, in the ring.
  • Bicyclic heterocyclics contain from 7 to 17 member atoms, preferably 7 to 12 member atoms, in the ring.
  • Bicyclic heterocyclics contain from about 7 to about 17 ring atoms, preferably from 7 to 12 ring atoms.
  • Bicyclic heterocyclics rings may be fused, spiro, or bridged ring systems. Any of the heterocycles may be substituted with up to three groups as selected from the substitutions provided for alkyl.
  • Heterocyclo groups containing nitrogen are groups such as pyrrolidine, piperidine, pyridin-2-one, piperazine, tetrahydrotriazine, tetrahydropyrazole, and substituted groups such as 3-aminopyrrolidine, 4- methylpiperazin-1-yl, and the like.
  • Typical sulfur containing heterocycles include tetrahydrothiophene, dihydro-l,3-dithiol-2-yl, and hexahydrothiepin-4-yl.
  • heterocycles include dihydro-oxathiol-4-yl, tetrahydro- oxazolyl, tetrahydro-oxadiazolyl, tetrahydro-dioxazolyl, tetrahydro-oxathiazolyl, hexahydrotriazinyl, tetrahydro-oxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl.
  • heterocycles containing sulfur the oxidized sulfur heterocycles containing SO or SO 2 groups are also included.
  • examples include the sulfoxide and sulfone forms of tetrahydrothiophene.
  • unsaturated heterocyclic groups include pyridones (1-H pyridin-2-ones), pyrimidones (IH pyrimidin-2-one, IH pyrimidin- 4-one), pyrazones (IH pyrazin-2-ones), pyridazones (IH pyridazin-3-one), dihydropyrroles, dihydro- and tetrahydro pyridines and the like, as well as any unsaturated heterocyclic groups specifically disclosed herein.
  • Examples include, but are not limited to phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2- methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methoxyphenyl, 3- methoxyphenyl, 4-methoxyphenyl, 2-chloro-3-methylphenyl, 2-chloro-4- methylphenyl, 2-chloro-5-methylphenyl, 3-chloro-2-methylphenyl, 3-chloro-4- methylphenyl, 4-chloro-2-methylphenyl, 4-chloro-3-methylphenyl, 5-chloro-2- methylphenyl, 2,3-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2,3- dimethylphenyl, 3,4-dimethylphenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imi
  • (C 4 -C )heterocycloalkenyl refers to a subset of unsaturated heterocyclo, examples of which are provided above.
  • aralkyl refers to an alkyl radical to which is appended an aryl group.
  • Representative arylalkyl groups include benzyl, phenylethyl, hydroxybenzyl, fluorobenzyl, fluorophenylethyl, and the like.
  • the arylalkyl groups of this invention can be optionally substituted.
  • arylene refers to a divalent group derived from an aromatic ring.
  • the arylene group can also be substituted with one or more of the substituents listed above for aryl.
  • heteroaryl means an aromatic cyclic or fused polycyclic ring system having from 1 to 8 heteroatoms selected from N, O, and S.
  • the heteroaryl groups or fused heteroaryl groups may be unsubstituted or substituted by 1 to 3 substituents selected from those described above for alkyl, alkenyl, and alkynyl, for example, cyanothienyl and formylpyrrolyl.
  • Typical heteroaryl groups include 2- or 3-thienyl, 2- or 3-furyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-1 ,2,4-triazolyl, 4- or 5-1 ,2,3-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridyl, 3- or 4- pyridazinyl, 3-, 4-, or 5-pyrazinyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl.
  • Aromatic fused heteroaryl groups of from 8 to 20 atoms include but are not limited to 1-, 2-, 3-, 5-, 6-, 7-, or 8-indolizinyl, 1-, 3-, 4-, 5-, 6-, or 7- isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-indazolyl, 2-, 4-, 5-, 6-, 7-, or 8-purinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-quinolizinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinoliyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinoliyl, 1-, 4-, 5-, 6-, 7-, or 8- phthalazinyl, 2-, 3-, 4-, 5-, or 6-naphthyridinyl, 2-, 3-, 5-, 6-, 7-, or 8-quinazol
  • Typical fused heteroaryl groups include, but are not limited to 2 — , 3 — , — , 5 — , 6 — , 7 — , or 8-quinolinyl, 1 — , 3 — , 4 — , 5 — , 6 — , 7 — , or 8-isoquinolinyl, 2 — , 3 — , 4 — , 5 — , 6 — , or 7-indolyl, 2 — , 3 — , 4 — , 5 — , 6 — , or 7-benzo[b]thienyl, 2 — , — , 5 — , 6 — , or 7-benzoxazolyl, 2 — , — , 5 — , 6 — , or 7-benzimidazolyl, 2 — , 4 — , 5 — , 6 — , or 7-benzothiazolyl.
  • heteroaryl groups include the following groups wherein '"w ⁇ " indicates the point of attachment, and any of which may be substituted as provided
  • monocyclic heteroarylene refers to a divalent group derived from a monocyclic heteroaryl.
  • the arylene group can also be substituted with one or more of the substituents listed above for aryl.
  • (C 4 -C 7 )cycloalkenyl means a cycloalkyl group having one or more carbon-carbon double or triple bond.
  • Example includes cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclobutadiene, cyclopentadiene, and the like.
  • the symbol “ " means a bond. If an asymetric carbon is created by such a bond, a particular stereochemistry is not to be implied.
  • HPLC High Pressure Liquid Chromatography
  • a “therapeutically effective amount” is an amount of a compound of the present invention that when administered to a patient ameliorates a symptom of thrombotic disorders, venous thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, cerebral infarction, restenosis, cancer, angina, diabetes, atrial fibrillation, or heart failure.
  • a therapeutically effective amount of a compound of the present invention can be easily determined by one skilled in the art by administering a quantity of a compound to a patient and observing the result.
  • thrombotic disorders venous thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, cerebral infarction, restenosis, cancer, angina, diabetes, atrial fibrillation, or heart failure.
  • salts refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
  • salts refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention.
  • the present invention encompasses any racemic, optically- active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine activity or cytotoxicity using the standard tests described herein, or using other similar tests which are well known in the art.
  • Certain compounds of the present invention can exist in unsolvated form as well as solvated form including hydrated form.
  • the solvated form including hydrated form is equivalent to unsolvated form and is intended to be encompassed within the scope of the present invention.
  • R 6 is H, alkyl, aralkyl, aryl, or monocyclic heteroaryl
  • R 7 and R 8 are each independently H, halo, OH, or (d-C ⁇ alkyl)-O
  • Another specific value for B is pyridyl or pyridyl substituted as provided in the previous postion.
  • Another specific value for B is , wherein " - indicates the point of attachment.
  • B is Another specific value for B is , wherein " — " indicates the point of attachment and which is an optionally substituted 4, 5, 6 or 7- membered ring.
  • R and R y can be H, halo, (Cj-
  • Y ⁇ can be CH 2 , CH(C C 6 )alkyl, C-CH 2 OH, C-CH 2 O-(d-C 6 )alkyl, NH, or N(C
  • R 18 is H, (C r C 6 )alkyl, hydroxymethyl, CH 2 O-(CrC 6 )alkyl, or NR 3 R 4 .
  • B is a 5-membered heteroaryl ring which contains at least one nitrogen atom such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, any of which may be optionally substituted with halo, (C ⁇ -C 6 )alkyl, hydroxy(d-C 6 )alkyl, CH 2 O-(d-C 6 )alkyl, or halo(C r C 6 )alkyl.
  • B can also be
  • R 19 and R 20 , R 20 and R 21 , or R 21 and R 22 can be together with the carbons to which they are attached to form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring.
  • Ji, J2, J3, or J is N
  • R 19 , R 20 , R 21 or R 22 is absent at that
  • R 20 , and R 21 , R 22 are each independently H, halo, hydroxy, NH 2 , NR 23 R 24 , NO 2 , SH, (C C 6 )alkyl, (d-C 6 )alkoxy, halo(d-C 6 )alkyl, (C r C 6 )alkanoyl, (C r
  • X" is CH 2 .
  • Other specific values for X 11 include CH, O, NH and N.
  • Specific values for R'° and R 11 include H, hydroxy, methoxy, ethoxy, cyano,
  • a specific value for G is H, F, or methyl.
  • a specific value for C is phenyl.
  • Another specific value for C is pyridyl.
  • Other specific values for C include ortho- and p— halo phenyl, ortho, p— dihalophenyl, ortho, meta-dihalophenyl, p-(Ci-C 6 )alkoxyphenyl, p-(d- C 6 )alkylphenyl, and meta-halo, p ⁇ (d-C 6 )alkylphenyl.
  • a specific value for A is phenyl. Another specific value for A is pyridyl.
  • B is , wherein " « ⁇ " indicates the point of attachment; Q is NH or is absent; and wherein R 1 is OH, — O-(d-
  • B is phenyl or phenyl which is substituted at an ortho position with formyl, H 2 NSO 2 , MeSO 2 , MeSO, MeS, (d- 6 )alkoxycarbonyl, cyano, H N-CH 2 — , HN-(C ⁇ -C 6 )alkyl-CH2— , (d-C 6 )alkyl 2 N-CH2
  • Another specific value for B is pyridyl or pyridyl substituted as provided in the previous postion.
  • R x and R y can be H, halo, (Cj-
  • Another specific value for B is R1 or a tautomer thereof such
  • Y ⁇ can be CH 2 , CH(C,-C 6 )alkyl, C-CH 2 OH, C-CH 2 O-(C ⁇ -C 6 )alkyl, NH, or N(C,-
  • R 18 is H, (C C 6 )alkyl, hydroxymethyl, CH 2 O-(CrC 6 )alkyl, or NR 3 R 4 .
  • B is a 5-membered heteroaryl ring which contains at least one nitrogen atom such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, any of which may be optionally substituted with halo, (C ⁇ -C 6 )alkyl, hydroxy(d-C 6 )alkyl, CH 2 O-(C ⁇ -C 6 )alkyl, or halo(C r C 6 )alkyl.
  • B can also be
  • X a , Y a , and Z a are each independently CR C or N, wherein R c is H or (d-C 6 )alkyl;
  • R 18 is H, (CrQ alkyl, hydroxymethyl, CH 2 O-(d-C 6 )alkyl, CH 2 NR R 4 or NR R 4 , wherein R 3 and R 4 are as defined herein.
  • J 4 can each be C, or one or more of Jj, J 2 , J 3 , or J 4 can be N.
  • R 19 , R 20 , R 21 , and R 22 are each independently H, halo, hydroxy, NH 2 , NR 23 R 24 , NO 2 , SH, (C ⁇ C 6 )alkyl, (C ⁇ -C 6 )alkoxy, halo(C r C 6 )alkyl, (d-C 6 )alkanoyl, (C r C 6 )alkoxycarbonyl, or (Ci-
  • R 23 and R 24 are each independently H, (Cj-C 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO 2 alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring.
  • R 19 and R 20 , R 20 and R 21 , or R 21 and R 22 can be together with the carbons to which they are attached to form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring.
  • R 20 , and R 21 , R 22 are each independently H, halo, hydroxy, NH 2 , NR 23 R 24 , NO 2 , SH, (C,-C 6 )alkyl, (C C 6 )alkoxy, halo(C C 6 )alkyl, (C,-C 6 )alkanoyl, (C r
  • R 23 and R 24 are each independently H, (C ⁇ -C 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring, or R 19 and R 20 , R 20 and R 21 , or R 21 and R 22 , together with the carbons to which they are attached, form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring.
  • X" is CH .
  • Other specific values for X" include CH, O, NH and N.
  • Specific values for R 10 and R n include H, hydroxy, methoxy, ethoxy, cyano,
  • Z is N, CH, C(C,-C 6 )alkyl, C(d-C 6 )alkoxy, or C- halo.
  • R12 and R13 are each independently H, halo, (C ⁇ -C ⁇ )alkyl, or (Ci-
  • C 6 C 6 )alkoxy.
  • Specific values for therefore include phenyl, pyridyl, p-chlorophenyl, p-fluorophenyl, p-bromophenyl, p-methoxyphenyl, p- toluyl, p-chloropyridyl, ortho, p-difluorophenyl, meta, p-difluorophenyl, and meta fluoro, paratoluyl.
  • a specific value for G is H, F, or methyl.
  • a specific value for A is phenyl. Another specific value for A is pyridyl. Other specific values for A include the following, wherein " ⁇ vw " indicates the points attachment to either B or NH and halo, (C C6)alkyl, and halo(C C 6 )alkyl are as defined earlier in the definitions section:
  • B is wherein " " indicates the point of attachment; Q is NH or is absent; and wherein R 1 is OH, — O-(d- C 6 )alkyl, or NR 'R 4 ', wherein R 3 ' and R 4 ' are independently H, (C]-C- 6 )alkyl, or are joined together to form a optionally substituted saturated or unsaturated 5 to 7 membered ring.
  • B is phenyl or phenyl which is substituted at an ortho position with formyl, H 2 NSO 2 , MeSO 2 , MeSO, MeS, (Cj-6)alkoxycarbonyl, cyano, H2N-CH2— , HN-(C 1 -C 6 )alkyl-CH 2 — , (C r C 6 )alkyl 2 N-CH2— .
  • Another specific value for B is pyridyl or pyridyl substituted as provided in the previous postion.
  • Another specific value for B is or a tautomer thereof such as
  • Y u can be CH 2 , CH(C,-C 6 )alkyl, C-CH 2 OH, C-CH 2 O-(d-C 6 )alkyl, NH, or N(C r C 6 )alkyl.
  • R 18 is H, (C C 6 )alkyl, hydroxymethyl, CH 2 O-(C C 6 )alkyl, or NR 3 R 4 .
  • B is a 5-membered heteroaryl ring which contains at least one nitrogen atom such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, any of which may be optionally substituted with halo, (d-C6)alkyl, hydroxy(C C 6 )alkyl, CH 2 ⁇ -(C C 6 )alkyl, or halo(C r C 6 )alkyl.
  • B can also be
  • X a , Y a , and Z a are each independently CR C or N, wherein R c is H or (C,-C 6 )alkyl; and R 18 is H, (C r C 6 )alkyl, hydroxymethyl, CH 2 O-(C r C 6 )alkyl, CH 2 NR 3 R 4 , or
  • J 4 can each be C, or one or more of J], J 2 , J 3 , or J can be N.
  • R 19 , R 20 , R 21 , and R 22 are each independently H, halo, hydroxy, NH 2 , NR 23 R 24 , NO 2 , SH, (C,-C 6 )alkyl, (C ⁇ -C 6 )alkoxy, halo(C ⁇ -C 6 )alkyl, (d-C 6 )alkanoyl, (C ⁇ -C 6 )alkoxycarbonyl, or (Q-
  • R 23 and R 24 are each independently H, (Cj-C 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO 2 alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring.
  • R 19 and R 20 , R 20 and R 21 , or R 21 and R 22 can be together with the carbons to which they are attached to form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring.
  • R 19 , R 20 , and R 21 , R 22 are each independently H, halo, hydroxy, NH 2 , NR 23 R 24 , NO 2 , SH, (C,-C 6 )alkyl, (C,-C 6 )alkoxy, halo(d-C 6 )alkyl, (d-C 6 )alkanoyl, (C C 6 )alkoxycarbonyl, or (d-C ⁇ )alkoxy, wherein R 23 and R 24 are each independently H, (C ⁇ -C 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO 2 alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring, or R 19 and R 20 , R 20 and R 21 , or R 21 and R 22 , together with the carbons to which they
  • X" is CH 2 .
  • Other specific values for X" include CH, O, NH and N.
  • Specific values for R 10 and R 11 include H, hydroxy, methoxy, ethoxy, cyano,
  • Z is N, CH, C(C r C 6 )alkyl, C-(C 1 -C 6 )alkoxy, or C- halo.
  • R 12 and R 13 are each independently H, halo, (d-C 6 )alkyl, (C C6)alkoxy.
  • R 14 and R 15 are each independently H, halo, (Cj-C 6 )alkyl, halo(C]-C 6 )alkyl, or heterocyclo.
  • a specific value for G is H, F, or methyl.
  • B is > wherein " ⁇ TM " indicates the point of attachment; Q is NH or is absent; and wherein R 1 is OH, — O-(C ⁇ -
  • C 6 )alkyl or NR 3 'R 4 ', wherein R 3 ' and R 4 ' are independently H, (Cj-C- 6 )alkyl, or are joined together to form a optionally substituted saturated olr unsaturated 5 to 7 membered ring.
  • B is phenyl or phenyl which is substituted at an ortho position with formyl, H 2 NSO 2 , MeSO 2 , MeSO, MeS, (Cro)alkoxycarbonyl, cyano, H 2 N-CH 2 — , HN-(C 1 -C 6 )alkyl-CH 2 — , (C ] -C 6 )a ⁇ ky ) 2 ⁇ -CE 2 —-
  • Another specific value for B is pyridyl or pyridyl substituted as provided in the previous postion.
  • Another specific value for B is , wherein " - indicates the point of attachment.
  • TM indicates the point of attachment and which is an optionally substituted 4, 5, 6 or 7-
  • R x and R y can be H, halo, (C r )
  • Another specific value for B is or a tautomer thereof such as
  • Y H can be CH 2 , CH(C,-C 6 )alkyl, C-CH 2 OH, C-CH2 ⁇ -(C,-C 6 )alkyl, NH, or N(C,-
  • R 18 is H, (C r C 6 )alkyl, hydroxymethyl, CH2 ⁇ -(C r C 6 )alkyl, or NR 3 R 4 .
  • B is a 5-membered heteroaryl ting which contains at least one nitrogen atom such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, any of which may be optionally substituted with halo, (C ⁇ -C 6 )alkyl, hydroxy(C,-C 6 )alkyl, CH 2 ⁇ -(C]-C 6 )alkyl, or halo(d-C 6 )alkyl.
  • B can also be
  • X a , Y a , and Z a are each independently CR C or N, wherein R c is H or (C C 6 )alkyl;
  • R' 8 is H, (C,-C 6 )alkyl, hydroxymethyl, CH 2 O-(CrC 6 )alkyl, or NR 3 R 4 .
  • R 19 , R 20 , R 21 , and R 22 are each independently H, halo, hydroxy, NH 2 , NR 2 R 24 , NO 2 , SH, (C,-C 6 )alkyl, (C C 6 )alkoxy, halo(C r C 6 )alkyl, (d-C 6 )alkanoyl, (C C 6 )alkoxycarbonyl, or (Ci-
  • R 23 and R 24 are each independently H, (d-Q)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO 2 aIkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring.
  • R 19 and R 20 , R 20 and R 21 , or R 21 and R 22 can be together with the carbons to which they are attached to form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring.
  • R 19 , R °, and R , R are each independently H, halo, hydroxy, NH 2 , NR 23 R 24 , NO 2 , SH, (d-C 6 )alkyl, (C C 6 )alkoxy, halo(C C 6 )alkyl, (C ⁇ -C 6 )alkanoyl, (C r C 6 )alkoxycarbonyl, or (Ci-
  • X ⁇ is CH 2 .
  • Other specific values for X 11 include CH, ⁇ H and ⁇ .
  • Specific values for R 10 and R 1 ' include H, hydroxy, methoxy, ethoxy, cyano, trifluoromethyl,
  • X and Y are each independently N, CH, C-halo, C(C,-C 6 )alkyl, C-halo(C r C 6 )alkyl, or C-heterocyclo.
  • R 14 and R 15 are each independently H, halo, (d-C 6 )alkyl, halo(d-C 6 )alkyl, or heterocyclo.
  • a specific value for G is H, F, or methyl.
  • X' and Y' are eaqch independently N, CH, C-halo, C-halo, C-(C ⁇ -C 6 )alkyl, C-halo(d- C 6 )alkyl, C-(d-C 6 )alkoxy, C-OH, C-SO 2 Me, C-SO 2 NH 2 , C-SOMe, C-SMe, C- CO 2 (C ⁇ -C 6 )alkyl, C-CN, or C-CH 2 NH 2 .
  • X ⁇ is CH 2 .
  • Other specific values for X ⁇ include CH, ⁇ H and ⁇ .
  • Specific values for R 10 and R include H, hydroxy, methoxy, ethoxy, cyano, trifluoromethyl,
  • Z is N, CH, C(C,-C 6 )alkyl, C-(C C 6 )alkoxy ,or C- halo.
  • R 12 and R 13 are each independently H, halo, (d-C6)alkyl, (d-C 6 )alkoxy.
  • a specific value for G is H, F, or methyl.
  • Q is NH or is absent.
  • R 1 is OH, -O-(C r C- 6 )alkyl, (C 3 -C- 7 )cycloalkyl, (C 3 -C- 7 )heterocyclo, (C 4 -C- 7 )cycloalkenyl, (C 4 -C-
  • R 4 are independently H, (C]-C- 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO 2 alkyl, or joined together to form a saturated or unsaturated 5 to 7 membered ring.
  • Z is N, CH, C(C,-C 6 )alkyl, C(C r C 6 )alkoxy, or C- halo.
  • R n and R 13 are each independently H, halo, (d-C 6 )alkyl, (C ⁇ -C 6 )alkoxy.
  • Specific values for 13 therefore include phenyl, pyridyl, p- chlorophenyl, p-fluorophenyl, p-bromophenyl, p-methoxyphenyl, p-toluyl, p- chloropyridyl, ortho, p-difluorophenyl, meta, p-difluorophenyl, and meta fluoro, p-methyl phenyl.
  • X and Y are each independently N, CH, C-halo,
  • a specific value for G is H, F, or methyl.
  • halo (C]-C 6 )alkyl, halo(C ⁇ -C 6 )alkyl, or hydroxymethyl.
  • X" is CH .
  • Other specific values for X 11 include CH, O, NH and N.
  • Specific values for R , 1 1 0 U and R" include H, hydroxy, methoxy, ethoxy, cyano,
  • Z is N, CH, C(C,-C 6 )aIkyl, C(C,-C 6 )alkoxy, or C- halo.
  • R 12 and R 13 are each independently H, halo, (d-C 6 )alkyl, (C C 6 )alkoxy.
  • Specific values for 13 therefore include phenyl, pyridyl, p- chlorophenyl, p-fluorophenyl, p-bromophenyl, p-methoxyphenyl, p-toluyl, p- chloropyridyl, ortho, p-difluorophenyl, meta, p-difluorophenyl, and meta fluoro, p-methyl phenyl.
  • X and Y are each independently N, CH, C- halo, C(C ⁇ -C 6 )alkyl, C-halo(C r C 6 )alkyl, or C-heterocyclo.
  • R 14 and R 15 are each independently H, halo, (d-C 6 )alkyl, halo(C C 6 )alkyl, or heterocyclo. Specific values for
  • Y ⁇ is CH, CR 18 , or ⁇ .
  • R 18 is H, (C C 6 )alkyl, hydroxymethyl,
  • R 3 and R 4 are each independently H, (Cj-C 6 )alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO 2 alkyl, or joined together to form a saturated or unsaturated
  • X and Y are each independently N, CH, C-halo,

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention provides compounds of Formula (I), wherein A, B, C, G, and W1 have any of the values defined in the specification, and pharmaceutically acceptable salt thereof, that are useful to treat thrombotic disorders. Also disclosed are pharmaceutical compositions comprising one or more compounds of Formula (I), processes for preparing compounds of Formula (I), and intermediates useful for preparing compounds of Formula (I).

Description

INHffilTORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE
FIELD OF THE INVENTION The present invention relates to cyclic amino acid and proline derivatives which display inhibitory effects of the serine protease factor Xa. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disease states in mammals characterized by abnormal thrombosis.
BACKGROUND OF THE INVENTION In economically developed countries, cardiovascular disease represents a major cause of mortality. In particular, abnormal coagulation and inappropriate thrombus formation within blood vessels precipitates many acute cardiovascular disease states. While it has long been recognized that a variety of plasma proteins such as fibrinogen, serine proteases, and cellular receptors are involved in hemostasis, it is abnormal regulation that has emerged as impoTtant contributing factors to cardiovascular disease.
Thrombin can be considered the key or principal regulatory enzyme in the coagulation cascade; it serves a pluralistic role as both a positive and negative feedback regulator in normal hemostasis. However, in some pathologic conditions, the positive feedback regulation is amplified through catalytic activation of cofactors required for thrombin generation. Such cofactors include factor Xa, a serine protease which occupies a pivotal position in the coagulation cascade. Factor X is the zymogen of factor Xa. Factor X can be activated by either the intrinsic or extrinsic pathways of the coagulation system. Initiation of coagulation by either pathway in response to vascular injury activates factor X to factor Xa. Factor Xa and its cofactor, factor Va, combine on a phospholipid membrane to form the "prothombinase" complex, which activates prothrombin to thrombin. Thrombin cleaves fibrinogen to fibrin, activates platelets, and converts factor Xiπ to Xllla which is the principal enzyme involved in thrombus generation, growth, and stabilization. Accordingly, the location of the prothrombinase complex at the convergence of both the intrinsic and extrinsic coagulation pathways suggests that inhibition of factor Xa, and hence thrombin generation, may be a viable approach to limiting the procoagulant activity of thrombin.
Evidence exists for the role of factor Xa inhibitors as anticoagulants. Antistasin, a potent inhibitor of blood coagulation factor Xa from the Mexican leech, Haementeria qfficinalis, displays antithrombotic activity in various models of arterial and venous thrombosis (Lapatto et al., Embo. J, 1997:5151-5161). Other protein or polypeptide factor Xa inhibitors include recombinant tick anticoagulant peptide (rTAP), which is known to accelerate the recombinant tissue plasminogen activator mediated clot lysis and prevent acute reocclusion in the dog, hence indicating factor Xa inhibitors may be useful as an adjunct to thrombolytic therapy (Mellott et al., Fibrinolysis, 1993: 195-202). Furthermore, in a canine coronary artery electrolytic lesion model, rTAP was demonstrated to reduce thrombus mass and time to occlusion in the absence of dramatic hemodynamic or hemostatic changes indicating the primary role for factor Xa in the process of arterial thrombosis (Lynch et al., Thromb. Haemostasis, 1995:640-645; Schaffer et al., Circulation, 1991 : 1741- 1748). On the venous side, rTAP was also demonstrated to reduce fibrin deposition in a rabbit model of venous thrombosis while having little affect on systemic hemostatic parameters (Fioravanti et al., Thromb. Res., 1993: 317-324). In addition to these relatively high molecular weight proteins that are not suitable as oral antithrombotic agents, there also exist examples of low molecular weight factor Xa inhibitors. In particular DX9065a, a low molecular weight synthetic factor Xa inhibitor, has also shown antithrombotic potential in various experimental thrombosis rat models. In both arteriovenous shunt and venous stasis models, inhibition of thrombus formation was achieved at doses that had little effect on APTT, indicating that DX9065a is effective in preventing thrombosis and hence has therapeutic antithrombotic potential (Wong et al., Thromb. Res., 1996: 117-126). Recently, it has been appreciated that factor Xa inhibition may provide sustained antithrombotic protection. Specifically, several animal studies show that inhibition of short term exposure to factor Xa produces a sustained antithrombotic. (Leadley, Curr. Top. Med. Chem., 2001 : v. 1, 151-159.) Finally, the article by Leadley observes that factor Xa inhibition potentially provides a large therapeutical window between antithrombotic efficacy and bleeding tendency. Consequently, there may exist a range in which factor Xa inhibition is achieved without an concurrent increase in a patients susceptibility to bleeding.
The majority of factor Xa inhibitors known to date have been summarized in two reviews (Edmunds et al., Annual Reports in Medicinal Chemistry, 1996:51 and Kunitada and Nagahara, Curr. Pharm. Des., 1996:531-542). However, it is readily apparent that there still exists a need for more effective agents that regulate factor Xa proteolytic activity.
SUMMARY OF THE INVENTION These and other needs are met by the present invention which is directed to a compound of Formula I
Figure imgf000004_0001
or a pharmaceutically acceptable salt thereof wherein: A is aryl or substituted aryl or monocyclic heteroaryl or substituted monocyclic heteroaryl;
O O
B is -NH -C— (Cι-C6)alkyl, -NH — C— (C3-C7)cycloalkyl, - NH
Figure imgf000005_0001
, (C3-C7)cycloalkyl, (C3-C7)heterocyclo, (C4-
C )cycloalkenyl, unsaturated (C -C7)heterocyclo, aryl, or heteroaryl, any of which may be optionally substituted by halo, (C C6)alkyl, or halo(Cι-C6)alkyl,
O-(C]-C6), -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido; C is phenyl or heteroaryl, wherein phenyl or heteroaryl is optionally substituted with one or more substituents selected from aryl, heteroaryl, halogen, hydroxy, -CO2R2, -COR2, -CONR2R2', alkoxy, alkyl, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido;
G is H, halo, (CrC6)alkyl, halo(d-C6)alkyl, hydroxy(C,-C6)alkyl, -CH2O-(C,-C6)alkyl, -CH2-CO2(C,-C6)alkyl, -CH2-NR2R2', or -CH2-CONH(Cr C6)alkyl;
Wl is a saturated or unsaturated, substituted or unsubstituted hydrocarbon chain or hydrocarbon-heteroatom chain having from 2 to 6 atoms, wherein W^ connects the nitrogen atom at position 1 to the carbon atom at position 2 to form a four to eight membered ring;
R1 is (C C6)alkoxy, (C3-C )cycloalkyl, (C3-C7)heterocycloalkyl, (C4- C7)cycloalkenyl, (C -C )heterocycloalkenyl, aryl, monocyclic heteroaryl, or-
NR3R4;
R2 and R2' are each independently H or (CpC6)alkyl; and R3 and R4 are each independently H, (CrC6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring.
The invention is also directed to a compound of formula II:
Figure imgf000006_0001
π
or a pharmaceutically acceptable salt thereof wherein " - - - " is a bond or is absent;
Xπ is CH2, CH, O, NH or N; io u
R and R are each independently H, -OH, halo, alkyl, haloalkyl, -
NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4 or are taken together to form =O, =NOR2, =C(Cι-C6alkyl)2, or =CR2H, with the proviso that when " - - - " is a bond, R11 is absent, and X11 is CH or N, and R10 is H, -OH, halo, alkyl, haloalkyl, -NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4;
A is aryl and substituted aryl or monocyclic heteroaryl or substituted monocyclic heteroaryl;
O O
B is -NH— C— (CrC6)alkyl, -NH — C— (C3-C7)cycloalkyl, -
NH
Figure imgf000006_0002
, (C3-C7)cycloalkyl, (C3-C7)heterocyclo, (C4- C7)cycloalkenyl, unsaturated (C4-C7)heterocyclo, aryl, or heteroaryl, any of which may be optionally substituted by halo, (CrC6)alkyl, or halo(C C6)alkyl, O-(Cι-Cβ). -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido;
C is phenyl or heteroaryl, wherein phenyl or heteroaryl is optionally substituted with one or more substituents selected from halogen, hydroxy, - CO2R2, -COR2, -CONR2R2', alkoxy, alkyl, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido;
G is H, halo, (C C6)alkyl, halo(C,-C6)alkyl, hydroxy(C,-C6)alkyl,
-CH2O-(C,-C6)alkyl, -CH2-CO2(C C6)alkyl, -CH2-NR R2', or -CH2-CONH(C,- C6)alkyl;or -CH2-CONH(C C6)alkyl;
R1 is (C C6)alkoxy, (C3-C7)cycIoalkyl, (C3-C7)heterocycloalkyl, (C4- C7)cycloalkenyl, (C -C )heterocycloalkenyl, aryl, monocyclic heteroaryl, or -
NR3R4;
R2 and R2' are each independently H or (C]-C6)alkyl; and
R3 and R4 are independently H, (C]-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 5 to 7 membered ring.
The invention is also directed to a compound of Formula III
Figure imgf000007_0001
III
or a pharmaceutically acceptable salt thereof wherein
" - - - " is a bond or is absent;
Z is C-H, C-halo, C-(CrC6)alkyl, C-halo(C C6)alkyl, C-(CrC6)alkoxy, or
N;
Xπis CH2, CH, O, NH or N; 10 n
R and R are each independently H, -OH, halo, alkyl, haloalkyl, - NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or-CONR3R4 or are taken together to form =O, =NOR2, =C(C]-C6alkyl) , or =CR2H, with the proviso that when " - - - " is a bond, Rn is absent, and X11 is CH or N, and R10 is H, -OH, halo, alkyl, haloalkyl, -NR8R9, -OR2, -CN, -CH2OH, -CH2-NR R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4;
A is aryl and substituted aryl or monocyclic heteroaryl or substituted monocyclic heteroaryl;
O O B is -NH — C- (C,-C6)alkyl, -NH — C— (C3-C7)cycloalkyl, -
NH —
Figure imgf000008_0001
, (C3-C7)cycloalkyl, (C3-C7)heterocyclo, (C4-
C7)cycloalkenyl, unsaturated (C4-C7)heterocyclo, aryl, or heteroaryl, any of which may be optionally substituted by halo, (Cι-C6)alkyl, or halo(Cι-C6)alkyl, O-(Cι-Cό), -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido; G is H, halo, (CrC6)alkyl, halo(CrC6)alkyl, hydroxy(C,-C6)alkyl,
-CH2O-(C,-C6)alkyl, -CH2-CO2(C,-C6)alkyl, -CH2-CONH2, or -CH2-CONH(C C6)alkyl;
R2 and R2' are each independently H or (Cι-C6)alkyl; and
R3 and R4 are independently H, (C]-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 5 to 7 membered ring; and
12 ,,
R and R are each independently H, halo, (Ci-Cό); C6)alkyl, or (CrC6)alkoxy.
What is also provided is a compound of Formula IV
Figure imgf000009_0001
IN
or a pharmaceutically acceptable salt thereof wherein
" - - - " is a bond or is absent;
Z is C-H, C-halo, C-(C C6)alkyl, C-halo(d-C6)alkyl, C-(CrC6)alkoxy, or
Ν;
Xπis CH2, CH, O, ΝH or Ν;
10 11
R and R are each independently H, -OH, halo, alkyl, haloalkyl, - NR8R9, -OR2, -CN, -CH2OH, -CH -NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH OR2, -COR2, -CO2R2, or -CONR3R4 or are taken together to form =O, =NOR2, =C(Cj-C6alkyl)2, or =CR2H, with the proviso that when " - - - " is a bond, Rn is absent, and X11 is CH or N, and R10 is H, -OH, halo, alkyl, haloalkyl, -NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4;
O O
B is -NH — C— (CrC6)alkyl, -NH — C— (C3-C7)cycloalkyl, -
NH —
Figure imgf000009_0002
, (C3-C7)cycloalkyl, (C3-C7)heterocyclo, (C4- C7)cycloalkenyl, unsaturated (C4-C )heterocyclo, aryl, or heteroaryl, any of which may be optionally substituted by halo, (C]-C6)alkyl, or halo(C C6)alkyl, O-(C|-C6), -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido;
G is H, halo, (CrC6)alkyl, ha]o(C C6)alkyl, hydroxy(C C6)alkyl, -CH2O-(C,-C6)alkyl, -CH2-CO2(C,-C6)alkyl, -CH2-CONH2, or -CH2-CONH(C C6)alkyl;
R2 and R2' are each independently H or (CpC6)alkyl; and
R3 and R4 are independently H, (Cι-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 5 to 7 membered ring;
12
R and R .13 are each independently H, halo, (C]-C6)alkyl, or halo(Q- C6)alkyl, or (C C6)alkoxy;
14 ] S 8 9
R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R8 and R9 are as defined for R3 and R4;
X and Y are each C, or one of X and Y is C and the other is N, provided that when one of X or Y is N, R14 or R15 is absent at that position.
What is also provided is a compound of Formula V
Figure imgf000010_0001
V
or a pharmaceutically acceptable salt thereof wherein
" — " is a bond or is absent;
Z is C-H, C-halo, C-(C C6)alkyl, C-halo(CrC6)alkyl, C-(CrC6)alkoxy, or N;
G is H, halo, (CrC6)alkyl, halo(C C6)alkyl, hydroxy(CrC6)alkyl, -CH O-(Cι-C6)alkyl, -CH2-CO2(CrC6)alkyl, -CH2-CONH2, or -CH2-CONH(C,- C6)alkyl; Xnis CH2, CH, O, NH or N; io ..
R and R are each independently H, -OH, halo, alkyl, haloalkyl, -
NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH OR2, -COR2, -CO2R2, or -CONR R4 or are taken together to form =O, =NOR2, =C(C]-C6alkyl) , or =CR2H, with the proviso that when " - - - " is a bond, R1 ' is absent, and Xπ is CH or N, and R10 is H, -OH, halo, alkyl, haloalkyl, -NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4;
R2 is H or (C C6)alkyl; and
R3 and R4 are independently H, (C]-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 5 to 7 membered ring;
12 13
R and R are each independently H, halo, (Cι-Cό)alkyl, or halo(Cι- C6)alkyl, or (Cι-C6)alkoxy;
14 1 S 8 9
R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R8 and R9 are as defined for R3 and R4;
X and Y are each independently C or N, provided that when one of X or Y is N, Rl4 or R15 is absent at that position.
X' and Y' are each independently CH or N;
( )
-' is absent or is a fused heterocyclic or fused heteroaryl ring,
! provided that when '' is present, Y' is C; and
R16 and R17 are each independently H, halo, cyano, (C]-C6)alkoxy carbonyl, aminomethyl. t-butyl, H2NSO2 — , Me2NSO2 — , (Cι-C6)alkoxy, MeSO2— , MeSO— , MeS— , NR8R9, or hydroxy
What is also provided is a compound of Formula VI
Figure imgf000012_0001
VI
or a pharmaceutically acceptable salt thereof wherein " — " is a bond or is absent; Z is C-H, C-halo, C-(C,-C6)alkyl, C-halo(C C6)alkyl, C-(C,-C6)alkoxy, or
N;
G is H, halo, (CrC6)alkyl, halo(CrC6)alkyl, hydroxy(C,-C6)alkyl, -CH2O-(CrC6)alkyl, -CH2-CO2(C,-C6)alkyl, -CH2-CONH2, or -CH2-CONH(C,- C6)alkyl; Q is NH or is absent;
Xπ is CH2, CH, O, NH or N;
R and Rn are each independently H, -OH, halo, alkyl, haloalkyl, - NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4 or are taken together to form =O, =NOR2, =C(Cι-C6alkyl)2, or =CR2H, with the proviso that when " - - - " is a bond, Rπ is absent, and Xπ is CH or N, and R10 is H, -OH, halo, alkyl, haloalkyl, -NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4;
R1 is OH, -O-(C,-C6)alkyl, (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, (C4-C7)cycloalkenyl, (C4-C )heterocycloalkenyl, aryl, monocyclic heteroaryl, or - NR R4, wherein R3 and R4 are independently H, (Cι-Ce)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO alkyl, or joined together to form a saturated or unsaturated 5 to 7 membered ring;
R2 is H or (Cι-C6)alkyl; and
R3 and R4 are independently H, (Cι-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a 5 to 7 membered ring;
12 13
R and R are each independently H, halo, (C]-C6)alkyl, or halo(Cι- C6)alkyl, or (C]-C6)alkoxy;
14 ic 8 9
R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R8 and R9 are as defined for R3 and R4;
X and Y are each independently C or N, provided that when one of X or Y is N, R14 or
Rl5 is absent at that position.
What is also provided is a compound of Formula VII
Figure imgf000014_0001
Nπ
or a pharmaceutically acceptable salt thereof wherein G is H, halo, (C C6)alkyl, halo(CrC6)alkyl, hydroxy(CrC6)alkyl,
-CH2O-(C1-C6)alkyl, -CH2-CO2(C1-C6)alkyl, -CH2-COΝH2, or -CH2-CONH(Cj- C6)alkyl;
Xπ is CH2, CH, O, NH or N;
10 11
R and R are each independently H, -OH, halo, alkyl, haloalkyl, - NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4 aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4 or are taken together to form =O, =NOR2, =C(Cι-C6alkyl)2, or =CR2H, with the proviso that when "--- " is a bond, Rn is absent, and Xπis CH or N, and R10 is H, -OH, halo, alkyl, haloalkyl, -NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4;
R2 and R2' are each independently H or (d-C6)alkyl; and R3 and R4 are each independently H, (CrC6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring;
12 R and R are each independently H, halo, (Cι-C6)alkyl, or halo(Cj-
C6)alkyl, or (d-C6)alkoxy; 14 ,<; 8 9
R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R8 and R9 are as defined for R3 and R4;
X and Y are each independently C or N, provided that when one of X or Y is N, R14 or
R'5 is absent at that position; and
Figure imgf000015_0001
is an optionally substituted 4, 5, 6 or 7-membered πng; wherein Rx and Ry are H, halo, hydroxymethyl, (d-C6)alkyl, (Ci- C6)alkoxy, or taken together are O=; X1" is CH2, O, S, NH, or N(C C6)alkyl, provided that when R* and Ry taken together are O=, X H"I1 ; is CH2.
What is also provided is a compound of Formula NHJ
Figure imgf000015_0002
NTH
or a pharmaceutically acceptable salt or tautomer thereof wherein " - - - " is a bond or is absent;
Z is C-H, C-halo, C-(d-C6)alkyl, C-halo(d-C6)alkyl, C-(d-C6)alkoxy, or Ν; G is H, halo, (d-C6)alkyl, halo(d-C6)alkyl, hydroxy(C,-C6)alkyl, -CH2O-(C,-C6)aIkyl, -CH2-CO2(CrC6)alkyl, -CH2-CONH2, or -CH2-CONH(C,- C6)alkyl;
X" is CH2, CH, O, NH or N;
10 n R and R are each independently H, -OH, halo, alkyl, haloalkyl, -
NR8R9, -OR2, -CN, -CH2OH, -CH -NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or-CONR R4 or are taken together to form =O, =NOR2, =C(C]-C6alkyl)2, or =CR2H, with the proviso that when " - - - " is a bond, Rn is absent, and X11 is CH or N, and R10 is H, -OH, halo, alkyl, haloalkyl, -NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR R4;
R2 and R2' are each independently H or (d-C6)alkyl; and
R3 and R4 are each independently H, (C1-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring;
12 1-3
R and R are each independently H, halo, (Cι-C6)alkyl, or halo(C C6)alkyl, or (CrC6)alkoxy;
14 ,c 8 9
R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R8 and R9 are as defined for R3 and R4; X and Y are each independently C or N, provided that when one of X or Y is N, R14 or
Rχ5 is absent at that position; and
Yπ is CH2, CH(d-C6alkyl), NH, or N(CrC6 alkyl); and
R18 is H, (d-Q alkyl, hydroxymethyl, CH2O-(CrC6)alkyl, or NR3R4.
What is also provided is a compound of Formula DC
Figure imgf000017_0001
IX
or a pharmaceutically acceptable salt thereof wherein " - - - " is a bond or is absent;
Z is C-H, C-halo, C-(Cι-C6)alkyl, C-halo(C,-C6)alkyl, C-(C C6)alkoxy, or N;
G is H, halo, (C1-C6)alkyl, halo(d-C6)alkyl, hydroxy(CrC6)alkyl, -CH2O-(C C6)alkyl, -CH2-CO2(C,-C6)alkyl, -CH2-CONH2, or -CH2-CONH(Cι- C6)alkyl; X"is CH2, CH, NH or N;
R and R11 are each independently H, -OH, halo, alkyl, haloalkyl, - NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4 aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH OR2, -COR2, -CO2R2, or -CONR3R4 or are taken together to form =O, =NOR2, =C(C]-C6alkyl) , or =CR2H, with the proviso that when " - - - " is a bond, R1 ' is absent, and Xπ is CH or N, and R10 is H, -OH, halo, alkyl, haloalkyl, -NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4;
R2 and R2' are each independently H or (C C6)alkyl; and R3 and R4 are each independently H, (d-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring; R
Figure imgf000018_0001
are each independently H, halo, (Cι-C6)alkyl, or halo(d- C6)alkyl, or (d-C6)alkoxy;
14 .15 8_ 9
R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R8 and R9 are as defined for R3 and R4;
X and Y are each independently C or N, provided that when one of X or Y is N, R* or RJ5 is absent at that position;
Xa, Ya, and Za are each independently CH, CR18 or N; and
R18 is H, (C C6)alkyl, hydroxymethyl, CH2O-(C,-C6)alkyl, CH2NR2, or
NR3R4.
The invention also provides a compound of Formula X
Figure imgf000018_0002
X
or a pharmaceutically acceptable salt thereof wherein
" - - - " is a bond or is absent;
Z is C-H, C-halo, C-(d-C6)alkyl, C-halo(d-C6)alkyl, C-(C C6)alkoxy, or N;
G is H, halo, (d-C6)alkyl, halo(d-C6)alkyl, hydroxy(d-C6)alkyl, -CH2O-(CrC6)alkyl, -CH2-CO2(Cι-C6)alkyl, -CH2-CONH2, or -CH2-CONH(C,- C6)alkyl;
X"is CH2, CH, O, NH or N; 10
R and R , H are each independently H, -OH, halo, alkyl, haloalkyl, - NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4 or are taken together to form =O, =NOR2, =C(C]-C6alkyl)2, or =CR2H, with the proviso that when " - - - " is a bond, Rn is absent, and X11 is CH or N, and R10 is H, -OH, halo, alkyl, haloalkyl, -NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4;
R2 and R2' are each independently H or (d-Cό)alkyl; and
R3 and R4 are each independently H, (d-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring;
12 13
R and R are each independently H, halo, (d-C6)alkyl, or halo(d- C6)alkyl, or (d-C6)alkoxy;
14 1 S 8 9
R and R are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R8 and R9 are as defined for R3 and R4;
X and Y are each independently C or N, provided that when one of X or Y is N, Rj 4 or R!5 is absent at that position;
Ji, J2, J3, and J4 are C or one of Jj, J2, J3, and J4 is N;
R19, R20, R21, and R22 are each independently H, halo, hydroxy, NH2, NR23R24, NO2, SH, (C,-C6)alkyl, halo(CrC6)alkyl, (C C6)alkanoyl, (C Co)alkoxycarbonyl, or (C]-C6)alkoxy, wherein R23 and R24 are each independently H, (d-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring, or R19 and R20, R20 and R21, or R21 and R22, together with the carbons to which they are attached, form a 5, 6, or 7 membered saturated or unsaturated cycloalkyl or heterocycloalkyl ring, or an aryl or heteroaryl ring; provided that when any of Ji , J2, J3, or J4 is N, R , R , R , or R is absent at that position. The invention is also directed to a compound which is:
Pyrrolidine-l,2-dicarboxylic acid ]-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; Pyrrolidine- 1, 2 -dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yI)-amide];
Pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1, 2 -dicarboxylic acid l-[(2,4-difluoro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-bipheny]-4-y])-amide];
Pyrrolidine-1 ,2 -dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] 1-p-tolylamide;
Pyrrolidine-1 ,2-dicarboxyIic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] 1 -[(4-methoxy-phenyl)-amide]; Pyrrolidine-1 , 2 -dicarboxylic acid l-[(4-bromo-phenyl)-amide] 2-1(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 ,2 -dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] l-[(4-isopropyl-phenyl)-amide];
Pyrrolidine-1 ,2 -dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] 1-phenylamide;
Pyrrolidine- ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] l-[(4-trifluoromethyl-phenyl)-amide];
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyI-biphenyl-4- yl)-amide] 1 -[(3-methoxy-phenyl)-amide]; Pyrrolidine- 1 ,2-dicarboxylic acid l -[(5-chloro-pyridin-2-yl)-amide] 2-[(3- fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 , 2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 , 2-dicarboxylic acid 1 -[(4-ethyl-phenyl)-amide] 2-[(3-fluoro- 2'-sulfamoyI-biphenyl-4-yl)-amide];
Pyrrolidine-1, 2-dicarboxylic acid l-[(3,4-difluoro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; Pyrrolidine-1, 2-dicarboxylic acid l-[(3-fluoro-4-methyl-phenyl)-arnide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [5-(2- sulfamoyl-phenyl)-pyridin-2-yl]-amide}; Pyrrolidine-1, 2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl- biphenyl-4-yl)-amide] l-[(5-chloro-pyridin-2-yl)-amide];
Pyrrolidine-1 , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl- biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide];
Pyrrolidine-1, 2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)-amide] 2-{[5- (2-sulfamoyl-phenyl)-pyridin-2-yl]-amide};
Pyrrolidine-1 , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[4-(lH- tetrazol-5-yl)-phenyl]-amide} ; 4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Oxo-pyrrolidine-l, 2 -dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Methylene-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; 4-Methyl-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-
[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4,4-Difluoro-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Amino-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxymethyl-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; l-(4-Chloro-phenylcarbamoyl)-5-(3-fluoro-2'-methanesulfonyl-biphenyl- 4-ylcarbamoyl)-pyrrolidine-3-carboxylic acid; l-(4-Chloro-phenylcarbamoyl)-5-(3-fluoro-2'-methanesulfonyl-biphenyl- 4-ylcarbamoyl)-pyrrolidine-3-carboxylic acid methyl ester; Pyrrolidine-1 ,2,4-tricarboxylic acid 4-amide 1 -[(4-chloro-phenyl)-amide]
2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Aminomethyl-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Methoxymethyl-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Ethoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2- [(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Methylamino-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- a ide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; 4-Acetylamino-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Methanesulfonylamino-pyrrolidine-l ,2-dicarboxylic acid -[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
5-Oxo-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(3-fluoro-2 '-methanesulf ony 1-biphen yl -4-yl )-ami de] ;
Piperidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3-fluoro- 2'-methanesulfonyl-biphenyl-4-yl)-amide];
Morpholine-3,4-dicarboxylic acid 4-[(4-chloro-phenyl)-amide] 3-[(3- fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; Piperazine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3-fluoro-
2'-methanesulfonyl-biphenyl-4-yl)-amide];
2,5-Dihydro-pyrrole-l, 2-dicarboxylic acid l-[(4-ch!oro-phenyl)-amide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-3-methyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(2'-methanesulfonyl-3-methyl-biphenyl-4-yl)-amide]; Pyrrolidine-1 , 2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'-methanesulfonyl-biphenyl-4-yl)-amide]; Pyrrolidine-1 , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[5-(2- methanesulfonyl-phenyl)-pyrimidin-2-yl]-amide};
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [5-(2-methanesulfonyl-phenyl)-pyrimidin-2-yl]-amide};
Pyrrolidine- 1 ,2-dicarboxylic acid I-[(4-chloro-phenyI)-amide] 2-{[5-(2- methanesulfonyl-phenyl)-3-methyl-pyridin-2-yl]-amide} ;
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{[5-(2-methanesulfonyl-phenyl)-3-methyl-pyridin-2-yl]-amide};
Pyrrolidine-1 , 2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-3-trifluoromethyl-biphenyl-4-yl)-amide]; 4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-[(2'-methanesulfonyl-3-trifluoromethyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 , 2 -dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[5-(2- methanesulfonyl-phenyl)-6-methyl-pyridin-2-yl]-amide};
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [5-(2-methanesulfonyl-phenyl)-6-methyl-pyridin-2-yl]-amide};
Pyrrolidine-1 , 2-dicarboxylic acid l -[(4-chloro-phenyl)-amide] 2-[(3-ethyl- 2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3-ethyl-2'-methanesulfonyl-biphenyl-4-yl)-amide]; 4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-[(3,5-difluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3,5- dichloro-2'-methanesulfonyl-biphenyl-4-yI)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3,5-dichloro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
Pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-3,5-dimethyl-biphenyl-4-yl)-amide]; 4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(2'-methanesulfonyl-3,5-dimethyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl-5- methyl-biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide]; 4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(3-chloro-2'- methanesulfonyl-5-methyl-biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide];
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(2-chloro-2'-methanesulfonyl- biphenyl-4-yl)-amide] 1 -[(4-chloro-phenyl)-amide];
4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid 2-[(2-chloro-2'- methanesulfonyl-biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide];
Pyrrolidine-1 , 2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-2-methyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'-methanesulfonyl-2-methyl-biphenyl-4-yl)-amide]; Pyrrolidine- 1,2 -dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2- fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-{ [l-(4-Chloro-phenylcarbamoyl)-pyrrolidine-2-carbonyl]-amino}-2'- methanesulfonyl-biphenyl-3-carboxylic acid methyl ester;
4-{ [l-(4-Chloro-phenylcarbamoyl)-4-hydroxy-pyrrolidine-2-carbonyl]- amino}-2'-methanesulfonyl-biphenyl-3-carboxylic acid methyl ester;
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] 1 -[(4-trifluoromethyl-phenyl)-amide]; Pyrrolidine-1, 2-dicarboxylic acid 2-[(3-fiuoro-2'-sulfamoyl-biphenyl-4- yl)-amide] 1-m-tolylamide;
Pyrrolidine-1, 2-dicarboxylic acid 1 -[(3-acetyl-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1, 2-dicarboxylic acid l-[(5-chloro-2-methyl-phenyl)-amide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 , 2-dicarboxylic acid l-[(2-fluoro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; Pyrrolidine-1 , 2-dicarboxylic acid l-[(3-chloro-4-fluoro-phenyl)-amide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1, 2-dicarboxylic acid l-[(3-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; Pyrrolidine-1, 2-dicarboxylic acid l-[(4-cyano-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 , 2-dicarboxylic acid l-[(4-chloro-2-methyl-phenyl)-amide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 , 2 -dicarboxylic acid l-[(3,4-dichloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] 1 -[(3-trifluoromethyl-phenyl)-amide];
Pyrrolidine-1 , 2-dicarboxylic acid l-[(4-dimethylamino-phenyl)-amide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; (2S)-Pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 , 2 -dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(4- cyano-phenyl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide] l-[(4-fluoro-phenyl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro-pyridin-2-yl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; 4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide] 1 -p-tolylamide;
4-Oxo-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; and
4-Fluoro-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; or a pharmaceutically acceptable salt thereof. A compound which is:
(R)-Pyrrolidine-l ,2-dicarboxyIic acid l-[(4-chloro-phenyI)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
(S)-Pyrrolidine- 1,2 -dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4S)-4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yI)-amide] l-[(4-fluoro-phenyl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide] 1 -p-tolylamide;
(2R)-4-Oxo-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; and (2R,4S)-4-Fluoro-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];or a pharmaceutically acceptable salt thereof.
The invention is also directed to a compound which is: (2R,4R)-4-Methoxy-pyrrolidiπe-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide);
(2R,4R)-4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Hydroxy-pyrroIidine-l, 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l -yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Ethoxy-pyrrolidine- 3 ,2-dicarboxylic acid l-[(5-chloro-pyridin- 2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}; (2R,4R)-4-Ethoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Propoxy-pyrroIidine-l ,2-dicarboxylic acid I-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Propoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin- 2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Fluoro-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-azetidin-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(2-oxo-azetidin-l-yI)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-pyrrolidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fiuoro-4-(2-oxo-pyrrolidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-p'yrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-azepan-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-azepan-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin- 2-yl)-amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-hydroxymethyl-5-oxo-pyrrolidin-l-yl)-phenyl]- amide};
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(2,3-dimethyl-5-oxo-2,5-dihydro-pyrazol-l-yl)-phenyl]- amide};
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- { [4-(2-hydroxymethy]-pyrrolidin- 1 -yl)-phenyl]-amide } ;
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(4-pyrrolidin-l-yl-phenyl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(4-pyrazol-l-yl-phenyl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2-fluoro-4-pyrazol-l -yl-phenyl)-amide]; (2R,4R)-4-Hydroxy-pyrrolidine- 1,2 -dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-[l ,2,4]triazol-l-yl-phenyl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-[l ,2,3]triazol-2-yl-phenyl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-[l,2,3]triazol-l-yl-phenyl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(4-acetylamino- phenyl)-amide] 1 -[(4-chloro-phenyl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(cyclopentanecarbonyl-amino)-phenyl]-amide} ; and 4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-[(4-pyrimidin-5-yl-phenyl)-amide]; or a pharmaceutically acceptable salt thereof.
A compound which is: 1 -(4-Chloro-phenylcarbamoyl)-5-[2-fluoro-4-(2-oxo-piperidin-l -yl)- phenylcarbamoyl]-pyrrolidine-3-carboxylic acid; l-(4-Chloro-phenylcarbamoyl)-5-[2-fluoro-4-(2-oxo-piperidin-l-yl)- phenylcarbamoyl]-pyπolidine-3-carboxylic acid methyl ester; l-(4-Chloro-phenylcarbamoyl)-5-[2-fluoro-4-(2-oxo-piperidin-l -yl)- phenylcarbamoyl]-pyrrolidine-3-carboxylic acid ethyl ester; Pyrrolidine-1, 2,4-tricarboxylic acid 4-amide l-[(4-chloro-phenyl)-amide]
2-{ [2-fluoro-4-(2-oxo-piperidin-l -yl)-phenyl]-amide} ;
4-Cyano-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- {[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
4-(lH-Tetrazol-5-yl)-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
4-Aminomethyl-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2- { [2-fluoro-4-(2-oxo-piperidin- 1 -yl)-phenyl]-amide } ;
4-Methylaminomethyl-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}; 4-Dimethylaminomethyl-pyrrolidine- 1,2 -dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
4-Acetyl-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-piperidin-l -yl)-phenyl]-amide} ;
Pyrrolidine-1, 2,4-tricarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{[2- fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} 4-methylamide;
Pyrrolidine-1, 2,4-tricarboxylic acid l-[(4-chloro-phenyl)-amide] 4- dimethylamide 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
4-Trifluoromethyl-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}; 4-Methyl-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-
{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
4-Isopropoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
4-Fluoro-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-piperidin- 1 -yl)-phenyl]-amide } ;
4,4-Difluoro-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l -yl)-phenyl]-amide} ; 1 -(4-{ [1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino) -phenyl)-pyrrolidine-2 -carboxylic acid;
1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-hydroxy-pyrrolidine-2-carbonyl]- amino}-phenyl)-pyrrolidine-2 -carboxylic acid; 4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l ,3']bipyridinyl-6'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l ,2']bipyridinyl-5'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-ch!oro-pyridin-2-yl)- amide] 2-{ [5-(2-oxo-piperidin-l -yl)-pyrimidin-2-yl]-amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- a ide] 2-{ [2-(2-oxo-piperidin-l -yl)-pyrimidin-5-yl]-amide} ;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [5-(2-oxo-piperidin-l-yl)-pyrimidin-2-yl]-amide}; 4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{ [2-(2-oxo-piperidin-l-yl)-pyrimidin-5-yl]-amide};
4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 2-{[2-fluoro-4-(2-oxo- piperidin-l-yl)-phenyl]-amide) l-[(5-fluoro-pyridin-2-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-fluoro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l ,3']bipyridinyl-6'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-fluoro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,2']bipyridiπy]-5'-yl)-amide];
4-FIuoro-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2- [(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide]; 4-Fluoro-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide];
4-Fluoro-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-fluoro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide];
4-Fluoro-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(2-oxo-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-5'-yl)-amide];
4-Fluoro-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-5'-yl)-amide]; 4-Fluoro-pyrrolidine-l , 2-dicarboxylic acid l-[(5-fluoro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l ,2,]bipyridinyl-5'-yl)-amide];
4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyI)-amide] 2-{ [2-fluoro-4-(2-hydroxymethyl-5-oxo-pyrrolidin-l-yl)-phenyl]-amide}; 1 -(4-{ [1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyI]- amino}-3-fluoro-phenyl)-5-oxo-pyrrolidine-2-carboxylic acid;
1 -(4-{ [1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrroIidine-2-carbonyl]- amino}-3-fluoro-phenyl)-5-oxo-pyrrolidine-2-carboxylic acid;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [4-(4,4-dimethyl-2,5-dioxo-imidazolidin-l-yl)-2-fluoro-phenyl]-amide};
[ 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-2,5-dioxo-imidazolidin-4-yl]-acetic acid;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{[4-(5,5-dimethyl-2,4-dioxo-oxazolidin-3-yl)-2-fluoro-phenyl]-amide}; 4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{ [4-(2,5-dioxo-pyrrolidin-l -yl)-2-fluoro-phenyl]-amide) ;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-oxazolidin-3-yl)-phenyI]-amide} ;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{[4-(2,5-dioxo-oxazolidin-3-yl)-2-fluoro-phenyl]-amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-imidazolidin-l-yl)-phenyl]-amide};
4-Methoxy-pyrrolidine-l,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [4-(2,5-dioxo-imidazolidin-l -yl)-2-fluoro-phenyl]-amide} ; 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{ [2-fluoro-4-(3-methyl-2,5-dioxo-imidazolidin-l-yl)-phenyl]-amide};
3-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino}-3-fluoro-phenyl)-2-oxo-imidazolidine-4-carboxylic acid;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2,4,5-trioxo-imidazolidin-l-yl)-phenyl]-amide} ;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[4-(2,5-dioxo-2,5-dihydro-pyrrol-l-yl)-2-fluoro-phenyl]-amide}; 4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(2-aminomethyl-5- oxo-pyrrolidin-l-yl)-2-fluoro-phenyl]-amide) l-[(4-chloro-phenyl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(2-aminomethyl-5- oxo-pyrrolidin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide]; 4-Methoxy-pyrrolidine-l,2-dicarboxylic acid 2-{ [4-(2-carbamoyl-5-oxo- pyrrolidin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid ' 2-{ [4-(2-carbamoyl-5-oxo- pyrrolidin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 2-{[4-(2,2-bis- hydroxymethyl-5-oxo-pyrrolidin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro- phenyl)-amide];
3-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino}-3-fluoro-phenyl)-2-oxo-imidazolidine-4-carboxylic acid;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [4-(3,3-dimethyl-2,5-dioxo-pyrrolidin-l-yl)-2-fluoro-phenyl]-amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(3,3,4-trimethyl-2,5-dioxo-pyrrolidin-l-yl)-phenyl]-amide};
]-(4-{ [l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino}-3-fluoro-phenyl)-5-oxo-pyrrolidine-2,2-dicarboxylic acid; 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2- { [2-fluoro-4-(2-methyl-5-oxo-pyrrolidin- 1 -yl)-phenyl]-amide } ;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-methyl-6-oxo-piperidin-l-yl)-phenyl]-amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(3-hydroxy-2-oxo-piperidin-l-yl)-phenyl]-amide} ;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- { [2-fluoro-4-(5-methyl-2,6-dioxo-tetrahydro-pyrimidin-l -yl)-phenyl]-amide} ;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-tetrahydro-pyrimidin-l-yl)-phenyl]-amide} ; 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{[2-fluoro-4-(3-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}; 4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [4-(2,5-dioxo-piperazin-l -yl)-2-fluoro-phenyl]-amide} ;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(3-hydroxy-2-oxo-2H-pyridin-l -yl)-phenyl]-amide} ; 4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide]
2-{[2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(6-methyl-2-oxo-4-trifluoromethyl-2H-pyridin-l-yl)-phenyl]- a ide}; 4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide]
2-{ [4-(2,6-dioxo-piperidin-l-yl)-2-fluoro-phenyl]-amide};
1 -(4-{ [1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino } -3-fluoro-phenyl)-2-oxo-piperidine-3-carboxylic acid;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [4-(5,5-dihydroxy-2,4,6-trioxo-tetrahydro-pyrimidin-l -yl)-2-fluoro-phenyl]- amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{[2-fluoro-4-(2,4,6-trioxo-tetrahydro-pyrimidin-l-yl)-phenyl]-amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [4-(4,4-dimethyl-2,6-dioxo-piperidin-l-yl)-2-fluoro-phenyl]-amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-hydroxy-4-oxo-azetidin-l-yl)-phenyl]-amide} ;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2- { [4-(acetyl-methyl-amino)- 2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide]; 4-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino}-3-fluoro-phenyl)-lH-pyrrole-3-carboxylic acid;
2-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino}-3-fluoro-phenyl)-2H-pyrazole-3-carboxylic acid;
1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino }-3-fluoro-phenyl)-lH-imidazole-2-carboxylic acid; l-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino}-3-fluoro-phenyl)-]H-pyrrole-2-carboxylic acid; 3-(4-{ [l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino } -3-fluoro-phenyl)- 1 H-pyrrole-2-carboxylic acid;
3-(4-{ []-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino}-3-fluoro-phenyl)-furan-2 -carboxylic acid; 3-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino}-3-fluoro-phenyl)-thiophene-2-carboxylic acid;
4-(4-{ [l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrroIidine-2-carbonyl]- amino}-3-fluoro-phenyl)-furan-3-carboxylic acid;
4-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino }-3-fluoro-phenyl)-thiophene-3-carboxylic acid;
4,5-Dihydro-pyrazole-l j5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
3-Oxo-pyrazolidine-l ,5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; 3-Oxo-pyrazolidine-l ,5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5-
{ [2-fluoro-4-(2-oxo-piperidin-l -yl)-phenyl]-amide} ;
4,5-Dihydro-pyrazole-l ,5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5-{ [4-(2-oxo-piperidin-l-yl)-phenyl]-arhide};
4,5-Dihydro-pyrazole-l ,5-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 5-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
4,5-Dihydro-pyrazole-l ,5-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 5-{ [4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
4,5-Dihydro-pyrazole-l ,5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide]; 4,5-Dihydro-pyrazole-l , 5-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 5-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro-pyridin-2-yl)- amide] 2-[(3,5'-difluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(5'-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 2-[(3,5'-difluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; 4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(3,5'-difluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(5'-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; 4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-[(3,5'-difluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1
Figure imgf000035_0001
amide] 2-[(3,5'-difluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(3,5'-difluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(3,5'-difluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide], or a pharmaceutically acceptable salt thereof.
The invention is also directed to a compound which is:
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-pyrazol-l-yl-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2-fluoro-4-pyrazol-l-yl-phenyl)-amide]; (2R,4R)-4-Ethoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(2-fluoro-4-pyrazol-l-yl-phenyl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(4-pyrazol-l-yl-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methyl-pyrazol-l-yl)-phenyl]-amide};
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-methyl-pyrazol-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(5-methyl-pyrazol-l-yl)-phenyl]-amide} ; (2R,4R)-4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(3,5-dimethyl-pyrazol-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3,5-dimethyl-pyrazol-l -yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3,5-dimethyl-pyrazol-l -yl)-2-fluoro-phenyl]-amide}; (2R,4S)-4-Amino-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Amino-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2 -dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
(2R)-4-Hydroxyimino-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- pheny -amide] 2-[(3-fluoro-2'-methylsulfamoyl-biphenyl-4-yl)-amide]; (2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(2'-dimethylsulfamoyl-3-fluoro-biphenyl-4-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro-pyridin- 2-yl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; (2R,4R)-4-Ethoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-sulfamoyl-bipheny]-4-yl)-amide];
(2R,4S)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yI)-amide];
(2R,4R)-4-Fluoro-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R)-4,4-Difluoro-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide] l-[(4-fluoro-phenyl)-amide];
(2R,4R)-4-Acetylamino-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; (2R,4R)-4-Methanesulfonylamino-pyrrolidine- 1 ,2 -dicarboxylic acid l-[(4- chloro-phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4S)-4-(lH-Tetrazol-5-yl)-pyrrolidine-l , 2-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4S)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Cyano-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-(lH-Tetrazol-5-yl)-pyrrolidine-l,2-dicarboxylic acid 1 -[(4- chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l -yl)-phenyl]-amide} ; (2R,4R)-4-Trifluoromethyl-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(2'-cyano-3-fluoro-biphenyl-4-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2-[(2'-aminomethyl- 3-fluoro-biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide];
(2R,4R)-4'-{ [l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3'-fluoro-biphenyl-2-carboxylic acid methyl ester;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(2,5-dihydro-pyrrole-l -carbonyl)-phenyl]-amide} ; (2R,4R)-4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-dimethylcarbamoyl-2-fluoro-phenyl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(pyrrolidine-l-carbonyl)-phenyl]-amide};
Pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [4- (pyrrolidine- 1 -carbonyl)-phenyl]-amide } ;
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2-methyl-pyrrolidine-l-carbonyl)-phenyl]-amide} ; (2R,4R)-4-Hydroxy-pyrrolidine-l , 2 -dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(ethyl-methyl-carbamoyl)-phenyl]-amide} ;
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(4-dimethylcarbamoyl-phenyl)-amide]; (2R,4R)-4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(2R-methyl-pyrrolidine-l-carbonyl)-phenyl]-amide};
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(2S-methyl-pyrrolidine-l-carbonyl)-phenyl]-amide};
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- ρhenyl)-amide] 2-{[2-fluoro-4-(pyrrolidine-l-carbonyl)-phenyl]-amide};
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[4-(pyrrolidine-l-carbonyl)-2-pyrrolidin-l-yl-phenyl]-amide};
(2R,4R)-4-{ [l-(4-Chloro-phenylcarbamoyl)-4-hydroxy-pyrrolidine-2- carbonyl]-amino}-3-pyrrolidin-l-yl-benzoic acid methyl ester; (2R,4R)-4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid 2-{[4-(azetidine-l- carbonyl)-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(pyrrolidine-l -carbonyl)-phenyl]-amide};
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(pyrrolidine-l -carbonyl)-phenyl]-amide};
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-[(4-dimethylcarbamoyl-phenyl)-amide];
(2R,4R)-4-{ [l-(4-Chloro-phenylcarbamoyl)-4-hydroxy-pyrrolidine-2- carbonyl]-amino}-3-dimethylamino-benzoic acid methyl ester; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(pyrrolidine-l-carbonyl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(4-dimethylcarbamoyl-phenyl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-{[4-(pyrrolidine-l-carbonyl)-phenyl]-amide};
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(4-dimethylcarbamoyl-phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(pyrrolidine-l -carbonyl)-phenyl]-amide};
(2R,4R)-4-Ethoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-{ [2-fluoro-4-(pyrrolidine-l-carbonyl)-phenyl]-amide}; (2R,4R)-4-Ethoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(4-dimethylcarbamoyl-2-fluoro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-methyl-4-(2-oxo-piperidin-l-yl)-phenylJ-amide};
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-{ [2-methyl-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
Pyrrolidine-1 , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2- fluoro-4-quinolin-8-yl-phenyl)-amide];
Pyrrolidine-1 , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3,5- difluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; Pyrrolidine- 1 ,2 -dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-2-methyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(2'-methanesulfinyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-methyl-2'-methylsulfanyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(2-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; (2R,4R)-4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2'-methanesulfonyl-3-methyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(2'-methanesulfonyl-3-trifluoromethyl-biphenyl-4-yl)-amide];
5-Methyl-4,5-dihydro-pyrazole-l ,5-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
3-Hydroxymethyl-4,5-dihydro-pyrazole-l ,5-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 5-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; 4,5-Dihydro-pyrazole-l ,5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
(R) 4,5-Dihydro-pyrazole-l , 5-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; 4,5-Dihydro-pyrazole-l , 5-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
5-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
4,5-Dihydro-pyrazole-l ,5-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 5-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; l-(4-Chloro-phenylcarbamoyl)-5-(3-fluoro-2'-methanesulfonyl-biphenyl- 4-ylcarbamoy])-4,5-dihydro-lH-pyrazole-3-carboxylic acid ethyl ester;
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(2'-methoxy-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chlorophenyl )-amide] 2-[(2'-hydroxy-biphenyl-4-yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2-fluoro-4-iodo-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-hydroxy-2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-tetrahydro-pyrimidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-imidazolidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-oxazolidin-3-yl)-phenyl]-amide} ; (2R,4R)-1 -(4-{ [1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-piperidine-3-carboxylic acid ethyl ester;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(3-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(4-mo holin-4-y]-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(2-methyl-5-oxo-pyrrolidin-l-yl)-phenyI]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(2-methyl-5-oxo-pyrrolidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-methoxy-2-oxo-2H-pyridin-l -yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(4-methoxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide);
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-chloro-2- oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide]; 4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid 2-[(4-tert-butyl-phenyl)- amide] 1 -[(4-chloro-phenyl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2[(3,5'difluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l ,2']bipyridinyl-5'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l ,3']bipyridinyl-6'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- a ide] 2-{ [4-(2,3-dimethyl-5-oxo-2,5-dihydro-pyrazol-l-yl)-phenyl]-amide}; 4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{ [4-(2,3-dimethyl-5-oxo-2,5-dihydro-pyrazol-l-yl)-phenyl]-amide}; -4].
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2-oxo-2H-[l,3']bipyridinyl-6'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- a ide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l ,3']bipyridinyl-6'-yl)-amide]-TFA Salt; 4-Ethoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-
[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide];
4-Ethoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(2-oxo-2H-[l ,3']bipyridinyl-6'-yl)-amide]; or
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(6-oxo-6H-pyridazin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(6-methyl-5-oxo-5H-[l,2,4]triazin-4-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-chloro-5- methyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} 1 -[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(3-methyl-5-oxo-4,5-dihydro-pyrazol-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-chloro-3- methyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide) l-[(4-chloro-phenyl)- a ide];
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[4-(3,5-dimethoxy-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-methoxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-3-pyrrol-l -yl-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-3-phenyl-2H-pyridin-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methyl-2-oxo-pyrrolidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methyl-2-oxo-imidazolidin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3,5-dimethyl-2-oxo-imidazolidin-l -yl)-2-fluoro-phenyl]- a ide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3,5,5-trimethyl-2-oxo-imidazolidin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(3-isopropyl-5,5-dimethyl-2-oxo-imidazolidin-l- yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-methyl-2-oxo-imidazolidin-l -yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(5,5-dimethyl-2-oxo-imidazolidin-l-yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(3,4-dimethyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{[4-(4-chloro-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-methyl-2-oxo-pyrrolidin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-methyl-2-oxo-imidazolidin-l-yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(3,5-dimethyl-2-oxo-imidazolidin-l-yl)-2-fluoro- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yI)-amide] 2-{[2-fluoro-4-(3,5,5-trimethyl-2-oxo-imidazolidin-l-yI)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(3-isopropyl-5,5-dimethyl-2-oxo- imidazolidin-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(5-methyl-2-oxo-imidazolidin-l -yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(5,5-dimethyl-2-oxo-imidazolidin-l-yl)-2-fluoro- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(3,4-dimethyl-2-oxo-2H-pyridin-l -yl)-2-fluoro- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(4-chloro-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2-yl)-amide]; or a pharmaceutically acceptable salt thereof.
The invention is also directed to a compound which is: (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-2H-quinolin-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-oxo-3H-isoquinolin-2-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(l-oxo-lH-isoquinolin-2-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-oxo-5H-[l,2,4]triazin-4-yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(6-oxo-6H-pyrimidin-l-yl)-phenyl]-amide};
2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyrazin-l-yl)-phenyl]-amide}; (2R,4R)- 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyrimidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-2H-[l ,3,5]triazin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(6-methyl-2-oxo-2H-[l ,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(l -methyl- lH-imidazol-2-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(l-methyl-lH-pyrrol-2-yl)-phenyl]-amide}; (2R,4R)-5-Aza-spiro[2.4]heptane-5,6-dicarboxylic acid 5-[(4-chloro- phenyl)-amide] 6-{ [2-fluoro-4-(2-oxo-2H-pyridin-l -yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridine-l -carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methyl-3H-imidazol-4-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-methyl-2H-pyrazol-3-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [5-(2,5-dihydro-pyrrole-l -carbonyl)-pyridin-2-yl]-amide} ; (2R,4R)- 4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(3-methyl-5-oxo-2,5-dihydro-pyrazol-l-yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(5-methoxymethyl-3-methyl-pyrazol-l-yl)- phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- pheny!)-amide] 2-{[2-fluoro-4-(3-methoxymethyl-5-methyl-pyrazol-l-yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(5-ethyl-3-methyl-pyrazol-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-isobutyl-3-methyl-pyrazol-l -yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(5-isopropyl-pyrazol-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-ethyl-pyrazol-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chlorophenyl )-amide] 2-{[2-fluoro-4-(5-isobutyl-pyrazol-l-yl)-phenyl]-amide}; (2R,4R)-2-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolodine-2- carbonyl]-amino}-3-fluoro-phenyl)-2H-pyrazole-3-carboxylic acid methyl ester;
(2R,4R)-2-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolodine-2- carbonyl]-amino}-3-fluoro-phenyl)-2H-pyrazole-3-carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-methoxymethyl-pyrazol-l -yl)-phenyl]-amide} ;
(2R,4R)-5-(4-{ [l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-oxazole-4-carboxylic acid ethyl ester;
(2R,4R)-5-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-hydroxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-oxazole-4-carboxylic acid ethyl ester; (2R,4R)-5-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-oxazole-4-carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-methoxymethyl-oxazol-5-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(4-ethyl-oxazol-5-yl)-2-fluoro-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(4-isopropyl-oxazol-5-yl)-phenyl]-amide}; (2R,4R)-5-(6-{ [l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-pyridin-3-yl)-oxazole-4-carboxylic acid ethyl ester;
(2R,4R)-5-(6- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-pyridin-3-yl)-oxazole-4-carboxylic acid; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [5-(4-methoxymethyl-oxazol-5-yl)-pyridin-2-yl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[5-(4-ethyl-oxazol-5-yl)-pyridin-2-yl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [5-(4-vinyl-oxazol-5-yl)-pyridin-2-yl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [5-(4-isobutyl-oxazol-5-yl)-pyridin-2-yl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-methyl-isoxazol-3-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(4-methyl-isoxazol-3-yl)-phenyl]-amide} ;
(2R,4R)-3-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-isoxazole-4-carboxylic acid methyl ester;
(2R,4R)-3-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-isoxazole-4-carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(4-methoxymethyl-isoxazol-3-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-isopropyl-isoxazol-3-yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(4-cyclopropyl-isoxazol-3-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(4-cyclopropyl-isoxazol-3-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-methyl-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{ [2-methyl-4-(2-oxo-2H-pyridin-l -yl)-phenyl]-amide} ; (2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro-pyridin- 2-yl)-amide] 2-{ [2-methyl-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(4-chloro- pheπyl)-amide] 1 -{ [2,6-difluoro-4-(2-oxo-2H-pyridin-l -yl)-phenyl]-amide } ; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 2-[(5-chloro- pyridin-2-yl)-amide] l-{[2,6-difluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(4-chloro-phenyl)- a ide] l-{[2,6-difluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(5-chloro-pyridin- 2-yl)-amide] 1 -{ [2,6-difluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(5'-methyl-2-oxo-2H-[l,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-[(5'-methyl-2-oxo-2H-[l,3']bipyridinyl-6'-yl)-amide]; (2R,4R)-4-Ethoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(5'-methyl-2-oxo-2H-[l ,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin- 2-yl)-amide] 2-[(5*-methyl-2-oxo-2H-[l ,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(2'-methyl-2-oxo-2H-[l ,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-[(2'-methyl-2-oxo-2H-[l,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2'-methyl-2-oxo-2H-[l ,3']bipyridinyl-6'-yl)-amide]; (2R,4R)-4-Ethoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(5-chloro-pyridin-
2-yl)-amide] 2-[(2'-methyl-2-oxo-2H-[l,3']biρyridinyl-6'-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(ethyl-isopropyl-carbamoyl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(ethyl-isopropyl-carbamoyl)-2-fluoro-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(3-ethyl-pyrrolidine-l -carbonyl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3-ethyl-pyrrolidine-l-carbonyl)-2-fluoro-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3R-amino- pyrrolidine-l -carbonyl)-phenyl]-amide} l-[(4-chloro-phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3R-amino- pyrrolidine-l-carbonyl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3S-aminθ pyrrolidine-1 -carbon yl)-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3S-amino- pyrrolidine-1 -carbony])-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(3R-methylamino-pyrrolidine-l -carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(3R-methylamino-pyrrolidine-l-carbonyl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(3S-methylamino-pyrrolidine-l-carbonyI)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3S-methylamino-pyrrolidine-l-carbonyl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[4-(3R-ethylamino-pyrrolidine-l-carbonyl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(3R-ethylamino-pyrrolidine-l-carbonyl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3S-ethylamino-pyrrolidine-l -carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3S-ethylamino-pyrrolidine-l-carbonyl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(2,5-dihydro-pyrrole-l -carbonyl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2,5-dihydro-pyrrole-l-carbonyl)-2-fluoro-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(2,5-dihydro-pyrrole-l -carbonyl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(pyrrole-l -carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(pyrrole-l-carbonyl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [4-(pyrrole-l -carbon yl)-phen yl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(pyrrole-l-carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-fluoro-2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-l-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l,6-dihydro-pyridine-3-carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(6-hydroxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)- 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3-carbόxylic acid;
(2R,4R)- 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l,6-dihydro-pyridine-2-carboxylic acid methyl ester;
(2R,4R)-[1 -(4-{ [1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-phenyl)-2,5-dioxo-imidazolidin-4-yl]-acetic acid;
(2R,4R)-1 -(4-{ [1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3-carboxylic acid methyl ester; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-3-trifluoromethyl-2H-pyridin-l-yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fiuoro-4-(4-hydroxy-2-oxo-2H-pyridin-l -yl)-phenyl]- amide};
(2R,4R)- 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l ,6-dihydro-pyridine-2-carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-5-trifluoromethy]-2H-pyridin-l -yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(6-cyclopropyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]- a ide}; (2R,4R)- 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l,6-dihydro-pyridine-3-carboxylic acid ethyl ester;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3,3-dimethyl-2-oxo-azetidin-l -yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l , 2 -dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(7-oxo-7H-thieno[2,3-c]pyridin-6-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-l-aza-spiro[4.5]dec-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-benzoyl-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 2-{[4-(3- acetylsulfamoyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro- phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-thiazolidin-3-yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methyl-2-oxo-piperidin-l -yl)-phenyl] -a ide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-3-sulfamoyl-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(2,5-dioxo-2,5-dihydro-pyrrol-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 2-{ [4-(3-amino-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1,2 -dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-3-phenoxy-2H-pyridin-l -yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2,2-dimethyl-5-oxo-pyrrolidin-l -yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-nitro-2-oxo-2H-pyridin-l -yl)-phenyl]-amide} ;
(2R,4R)-l-(4-{ [l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l ,2-dihydro-pyridine-3-carboxylic acid tert-butyl ester;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2,5-dioxo-pyrrolidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 2-{ [4-(3- benzothiazol-2-yl-2-oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]-amide} 1 -[(4-chloro- phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-amino-4,6- dimethyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3-diethylaminomethyl-2-oxo-2H-pyridin-l-yl)-2-fluoro- phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 2-{ [4-(3- aminomethyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} 1 -[(4-chloro- phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methyl-5-nitro-2-oxo-2H-pyridin-l -yl)-phenyl]- a ide};
(2R,4R)-Acetic acid l-(4-{ [l-(4-chloro-phenylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridin-3-yl ester; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-({4-[3-(cyclopentanecarbonyl-amino)-2-oxo-2H-pyridin-l-yl]- 2-fluoro-phenyl } -amide);
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-amino-3- methyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-({2-fluoro-4-[2-oxo-3-(pyridin-4-ylcarbamoyl)-2H-pyridin-l- yl]-phenyl }-amide);
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3,5-dichloro-2-oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-amino-5- bromo-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)- amide]; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3-cyano-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3-cyano-2-oxo-5-phenyl-2H-pyridin-l-yl)-2-fluoro- phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3-ethyl-6-methyl-2-oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(3-cyano-4-dimethylamino-2-oxo-2H-pyridin-l -yl)-2- fluoro-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl )-amide] 2-{ [2-fluoro-4-(4-methyl-3-nitro-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-nitro-2-oxo-3-trifluoromethyl-2H-pyridin-l-yl)- phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 2-{[4-(5-amino-6- oxo-6H-[3,4']bipyridinyl-l-yl)-2-fluoro-phenyl]-amide) l-[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-chloro-3- nitro-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-carbamoyl- 2-oxo-5-trifluoromethy]-2H-pyridin-l-yl)-2-fluoro-pheny]]-amide} l-[(4-chloro- phenyl)-amide];
(2R,4R)-5-Bromo-l -(4-{ [1 -(4-chloro-phenylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3- carboxylic acid isobutyl ester;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-chloro-2- oxo-5-trifluoromethyl-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro- phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-bromo-5- chloro-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} 1 -[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{[4-(5-bromo-3- nitro-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)- amide]; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-nitro-2-oxo-5-trifluoromethyl-2H-pyridin-l-yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-methyl-3-nitro-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-5-Chloro-l-(4-{ [3-(4-chloro-phenylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l ,2-dihydro-pyridine-3- carboxylic acid methyl ester; (2R,4R)-5-Chloro- 1 -(4- { [ 1 -(4-chloro-phenylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyi)-2-oxo-l ,2-dihydro-pyridine-3- carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(4-benzyloxy- 2-oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]-amide} 1 -[(4-chloro-phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 2-{[4-(4-amino-5- fluoro-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(6-methyl-3-oxo-3H-isoquinolin-2-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- , phenyl)-amide] 2-{ [2-fluoro-4-(4-methyl-5-nitro-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 2-{ [4-(5- acetylamino-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro- phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(4-amino-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(6-oxo-6H-[3,4']bipyridinyl-l -yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(4-bromo-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-oxo-4H-furo[3,2-c]pyridin-5-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(l -oxo-lH-[2,6]naphthyridin-2-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-bromo-2- oxo-2H-pyridin-l-yl)-2-fIuoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-oxo-4H-thieno[3,2-c]pyridin-5-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-oxo-l ,4-dihydro-imidazo[4,5-c]pyridin-5-yl)- phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid 2-{[4-(5-chloro-2- oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]-amide} 1 -[(5-chloro-pyridin-2-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(5-fluoro-2-oxo-2H-pyridin-l-yl)-phenyl]- amide}; (2R,4R)-l-(4-{ [l-(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l ,6-dihydro-pyridine-3- carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(6-hydroxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-1 -(4-{ [1 -(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3- carboxylic acid;
(2R,4R)- 1 -(4- { [ 1 -(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l,6-dihydro-pyridine-2- carboxylic acid methyl ester; (2R,4R)-[l-(4-{[l-(5-Chloro-pyridin-2-yIcarbamoyI)-4-rnethoxy- pyrrolidine-2-carbonyl]-amino}-phenyl)-2,5-dioxo-imidazolidin-4-yl]-acetic acid;
(2R,4R)- 1 -(4- { [ 1 -(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l ,2-dihydro-pyridine-3- carboxylic acid methyl ester;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-3-trifluoromethyl-2H-pyridin-l-yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(4-hydroxy-2-oxo-2H-pyridin-l-yJ)-phenyI]- amide};
(2R,4R)- 1 -(4- { [ 1 -(5-Chl oro-pyri din-2-ylcarbamoyl )-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l,6-dihydro-pyridine-2- carboxylic acid; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-5-trifluoromethyl-2H-pyridin-l -yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(6-cyclopropyl-2-oxo-2H-pyridin-l-yl)-2-fluoro- phenyl]-amide};
(2R,4R)-l-(4-{ [l-(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l,6-dihydro-pyridine-3- carboxylic acid ethyl ester;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-hydroxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(3,3-dimethyl-2-oxo-azetidin-l -yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2 -dicarboxylic acid -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(7-oxo-7H-thieno[2,3-c]pyridin-6-yl)- phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-l -aza-spiro[4.5]dec-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrroiidine-l , 2-dicarboxylic acid 2-{[4-(3-benzoyl-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(2-methyl-5-oxo-pyrrolidin- 1 -yl)-phenyl]- a ide};
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-methyl-6-oxo-piperidin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 2-{[4-(3- acetylsulfamoyl-2-oxo-2H-pyridin-] -yl)-2-fluoro-phenyl]-amide} 1 -[(5-chloro- pyridin-2-yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-thiazolidin-3-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yI)-amide] 2-{ [2-fluoro-4-(3-methyI-2-oxo-piperidin-l-yl)-phenyI]- a ide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-3-sulfamoyl-2H-pyridin-l-yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(2,5-dioxo-2,5-dihydro-pyrrol-l -yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-amino-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-3-phenoxy-2H-pyridin-l-yl)-phenyl]- a ide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(2,2-dimethyl-5-oxo-pyrrolidin-l-yl)-2-fluoro-pheπyl]- amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-nitro-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-l-(4-{[]-(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3- carboxylic acid tert-butyl ester;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(2,5-dioxo-pyrrolidin-]-yl)-phenyI]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 2-{ [4-(3- benzothiazol-2-yl-2-oxo-2H-pyridin-l -yl)-2-fluoro-pheny]]-amide} 1 -[(5-chloro- pyridin-2-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-amino-4,6- dimethyl-2-oxo-2H-pyridin-]-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2- yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2 -dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(3-diethylaminomethyl-2-oxo-2H-pyridin-l-yl)-2- fluoro-phenyI]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 2-{ [4-(3- aminomethyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} 1 -[(5-chloro- pyridin-2-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-methyl-5-nitro-2-oxo-2H-pyridin-l-yl)- phenyl]-amide};
(2R,4R)-Acetic acid l-(4-{[l-(5-chloro-pyridin-2-ylcarbamoyl)-4- ■ methoxy-pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro- pyridin-3-yl ester;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-({4-[3-(cyclopentanecarbonyl-amino)-2-oxo-2H-pyridin-l- yl]-2-fluoro-phenyl } -amide); (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-amino-3- methyl-2-oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]-amide} 1 -[(5-chloro-pyridin-2- yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro- pyridin-2-y])-amide] 2-({2-fluoro-4-[2-oxo-3-(pyridin-4-ylcarbamoyl)-2H- pyridin- 1 -yl]-phenyl } -amide);
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(3,5-dichloro-2-oxo-2H-pyridin-l -yl)-2-fluoro- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-amino-5- bromo-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} 1 -[(5-chloro-pyridin-2- y])-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(3-cyano-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(3-cyano-2-oxo-5-phenyl-2H-pyridin-l-yl)-2-fluoro- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(3-ethyl-6-methyl-2-oxo-2H-pyridin-l-yl)-2-fluoro- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(3-cyano-4-dimethylamino-2-oxo-2H-pyridin-l-yl)-2- fluoro-phenyl]-amide } ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(4-methyl-3-nitro-2-oxo-2H-pyridin-l-yl)- phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(5-nitro-2-oxo-3-trifluoromethyl-2H-pyridin- l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-amino-6- oxo-6H-[3,4']bipyridinyl-l-yl)-2-fluoro-pheny]]-amide} l-[(5-chloro-pyridin-2- yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-chloro-3- nitro-2-oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]-amide} 1 -[(5-chloro-pyridin-2-yl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-carbamoyl- 2-oxo-5-trifluoromethyl-2H-pyridin-l -y])-2-fluoro-phenyl]-amide} l-[(5-chloro- pyridin-2-yl)-amide];
(2R,4R)-5-Bromo-l-(4-{ [l-(5-chIoro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l ,2-dihydro-pyridine-3- carboxylic acid isobutyl ester; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-chloro-2- oxo-5-trifluoromethyl-2H-pyridin-l-yl)-2-fluoro-pheny]]-amide} l-[(5-chloro- pyridin-2-yI)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-bromo-5- chloro-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2- yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-bromo-3- nitro-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl]-amide } 1 -[(5-chloro-pyridin-2-yl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-nitro-2-oxo-5-trifluoromethyl-2H-pyridin- l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(5-methyl-3-nitro-2-oxo:2H-pyridin- 1 -yl)- phenyl]-amide}; (2R,4R)-5-Chloro-l-(4-{ [l-(5-chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3- carboxylic acid methyl ester;
(2R,4R)-5-Chloro-l-(4-{ [l-(5-chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3- carboxylic acid; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 2-{[4-(4-benzyloxy- 2-oxo-2H-pyridin- 1 -y])-2-fluoro-phenyl]-amide } 1 -[(5-chloro-pyridin-2-yl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(4-amino-5- fluoro-2-oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2- yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(5-nitro-2-oxo-2H-pyridin-l -yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(6-methyl-3-oxo-3H-isoquinolin-2-yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(4-methyl-5-nitro-2-oxo-2H-pyridin-l -yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 2-{[4-(5- acetylamino-2-oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]-amide} 1 -[(5-chloro- pyridin-2-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(l-oxo-lH-isoquinolin-2-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(4-amino-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(6-oxo-6H-[3,4']bipyridinyl-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-oxo-3H-isoquinolin-2-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(4-bromo-2- oxo-2H-pyridin-l-yl)-2-fluoro-pheny]]-amide} l-[(5-chloro-pyridin-2-yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(4-oxo-4H-furo[3,2-c]pyridin-5-yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(l-oxo-lH-[2,6]naphthyridin-2-yl)-phenyl]- amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-bromo-2- oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(4-oxo-4H-thieno[3,2-c]pyridin-5-yl)- phenyl] -amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(4-oxo-l ,4-dihydro-imidazo[4,5-c]pyridin-5- yl)-phenyl]-amide};
4,5-Dihydro-pyrazole-l ,5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
3-Hydroxymethyl-4,5-dihydro-pyrazole-l ,5-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 5-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
5-Methyl-4,5-dihydro-pyrazole-l ,5-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 5-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
3-Methoxymethyl-4,5-dihydro-pyrazole-l ,5-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 5-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide}; 4,5-Dihydro-pyrazole-l , 5-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- a ide] 5-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
3-Hydroxymethyl-4,5-dihydro-pyrazole-l ,5-dicarboxylic acid l-[(5- chloro-pyridin-2-yl)-amide] 5-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyI]- amide}; 5-Methyl-4,5-dihydro-pyrazole-l, 5-dicarboxylic acid l-[(5-chloro-pyridin-
2-yl)-amide] 5- { [2-fIuoro-4-(2-oxo-2H-pyridin- 1 -yl)-phenyl]-amide } ;
3-Methoxymethyl-4,5-dihydro-pyrazole-l ,5-dicarboxylic acid l-[(5- chloro-pyridin-2-yl)-amide] 5-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]- a ide}; 4,5-Dihydro-pyrazole- 1 ,5-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide]
5-{ [4-(2-methyl-thiazol-4-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-2-methyl-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4- chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide) ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(3,4,5,6-tetrahydro-2H-[l ,4']bipyridinyl-4-ylmethyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2-dimethylaminomethyl-imidazol-l -yl)-2-fluoro-phenyI]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [2-chloro-4-(2- oxo-2H-pyridin-l-yI)-phenyl]-amide} l-[(4-chloro-phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [2-chloro-4-(2- oxo-2H-pyridin-l-yl)-phenyI]-amide} l-[(5-chloro-pyridin-2-yl)-amide];
(2R,4R)-4-Methyl-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-methylamino-imidazol-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-isopropyl-imidazol-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(2-ethyl-imidazol-l-yl)-2-fluoro-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(2-ethyl-imidazol-l-yl)-2-fluoro-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-isopropyl-imidazol-l-yl)-phenyl]-amide} ;
(2R,4R)-2-Ethyl-4-methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
4-Methoxy-2-methoxymethyl-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4- chloro-phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
2-Hydroxymethyl-4-methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}; { l-(4-Chloro-phenylcarbamoyl)-2-[2-f]uoro-4-(2-oxo-piperidin-l-yl)- phenylcarbamoyl]-4-methoxy-pyrrolidin-2-yl } -acetic acid methyl ester; { 1 -(4-Chloro-phenylcarbamoyl)-2-[2-fluoro-4-(2-oxo-piperidin-l -yl)- phenylcarbamoyI]-4-methoxy-pyrrolidin-2-yl }-acetic acid;
4-Hydroxymethyl-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2- { [2-fluoro-4-(2-oxo-piperidin- 1 -yl)-phenyl]-amide } ; { 1 -(4-Chloro-phenylcarbamoyl)-5-[2-fluoro-4-(2-oxo-piperidin-l -yl)- phenylcarbamoyl]-pyrrolidin-3-yl }-acetic acid;
{ 1 -(4-Chloro-phenylcarbamoyl)-5-[2-fluoro-4-(2-oxo-piperidin-l-yl)- phenylcarbamoyl]-pyrrolidin-3-yl}-acetic acid methyl ester;
(2R,4R)-4-Ethyl-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-l -yl)-phenyl]-amide} ;
(2R,4R)-4-Isopropyl-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-fluoro-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2 -dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(3-fluoro-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-chloro-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2-yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-chloro-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-bromo-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyI]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-bromo-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-iodo-2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(3-iodo-2-oxo-2H-pyridin-l-yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(3-ethyl-2-oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]- amide}; and
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[4-(3-ethyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide; a pharmaceutically acceptable salt thereof.
The invention is also directed to a compound which is: (2R,4R) 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l -yl)-phenyl]-amide} ;
(2R,4R) 4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R.4R) 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide}; (2R,4R) 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridin-l -yl)-phenyl]-amide} ;
(2R,4R) 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2-oxo-2H-[l ,3']bipyridinyl-6'-yl)-amide];
(2R,4R) 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin-l -yl)-phenyl]- amide};
(2R,4R) 4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3-methyl-2-oxo-2H-pyridin-l -yl)-phenyl]-amide} ; (2R,4R) 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-methyl-imidazol-l-yl)-phenyl]-amide}; (2R,4R) 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(4-dimethylcarbamoyl-2-fluoro-phenyl)-amide];
(2R,4R) 4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-methyl-pyrazol-l -yl)-phenyl]-amide} ; (2R,4R) 4,5-Dihydro-pyrazole-l,5-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; (2R,4R) 4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2-fluoro-4-pyrazol-l-yl-phenyl)-amide];
(2R,4R) 4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(pyrrolidine-l-carbonyl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(3-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chlorophenyl )-amide] 2-{ [2-fluoro-4-(2-methyl-imidazol-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2-oxo-2H-[l ,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- a ide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-dimethylcarbamoyl-2-fluoro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-methyl-pyrazol-l-yl)-phenyl]-amide};
5-Methyl-4,5-dihydro-pyrazole-l , 5-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methyl-2-oxo-2H-pyridin-l-y])-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 2-{ [2-chloro-4-(2- oxo-2H-pyridin-l-yl)-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-methyl-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(6-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(3-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(5-methyl-2-oxo-2H-pyridin-l -yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-methyl-2-oxo-2H-pyridin-l -yI)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]- amide;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2,5-dihydrom-pyyrole-l -carbonyl)-2-fluoro-phenyl- a ide};
(2R,4R)-4-Methoxy-ρyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chlorophenyl )-amide] '2-{ [4-(2,5-dihydrom-pyyrole-l -carbonyl)-phenyl-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(2-methyl-5-oxo-pyrrolidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(2,5-dihydro-pyrrole-l-carbonyl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2,5-dihydro-pyrrole-l-carbonyl)-2-fluoro-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2-methyl-5-oxo-pyrrolidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2,5-dihydro-pyrrole-l -carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-ρyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-l -yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(2,5-dihydro-pyrrole-l-carbonyl)-2-fluoro-phenyl]-amide} or a pharmaceutically acceptable salt thereof.
The invention is also directed to a pharmaceutical composition comprising a compound of formula I admixed with a carrier, diluent, or excipient.
The invention is also directed to a method for preventing or treating acute, subacute, and chronic thrombotic disorder in a mammal is comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of any of formulas I-X.
The invention is also directed to a method of inhibiting Factor Xa in a mammal, comprising administering to a mammal in need of Factor Xa inhibition a Factor Xa inhibition amount of a compound of any of formulas I-X.
The invention is also directed to a process for preparing a compound of Formula I comprising:
(a) reacting an amino acid of formula IA
Figure imgf000069_0001
with a reagent capable of placing a protecting group P1 on the amino group of an amino acid to form a protected amino acid given by formula IB:
Figure imgf000069_0002
wherein P' is a protecting group and W^ is the same as defined above;
(b) converting the acid moiety in the compound of formula IB to a acid halide;
(c) reacting the acid halide with a haloaniline or a haloamino- heterocycle to form a compound having formula IC:
Figure imgf000070_0001
IC
wherein l is a halogen and A is as defined above;
(d) coupling the compound of formula IC with a compound H-B to give a compound having formula ID:
Figure imgf000070_0002
ID
(e) removing the protecting group from Compound ID and reacting the resulting acid moiety with a C-isocyanate to form a compound of the invention. DETAILED DESCRIPTION OF THE INVENTION The following definitions are used, unless otherwise described: halo is fluoro, chloro, bro o, or iodo. Alkyl, alkoxy, alkenyl, alkynyl, etc. denote both straight and branched groups; but reference to an individual radical such as "propyl" embraces only the straight chain radical, a branched chain isomer such as "isopropyl" being specifically referred to.
The term "alkyl" as used herein refers to a straight or branched hydrocarbon of from 1 to 11 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like. The alkyl group can also be substituted with one or more of the substituents selected from lower alkoxy, lower thioalkoxy, halogen, nitro, cyano, oxo, thio, -OH, -SH, -F, -CF3, -OCF3, -NO2, -CO2H, -CO2(C -C6)alkyl,
-NH2, -NH(C]-C6)alkyl, ~ —° 0> , -CONR8R9, or -N(Cι-C6alkyl)2. Preferred alkyl groups have from 1 to 6 carbon atoms (Cj-Cg alkyl).
The term "(d-Q alkyl" as used herein refers to a subset of alkyl which means a straight or branched hydrocarbon radical having from 1 to 6 carbon atoms and includes, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, n-hexyl, and the like. Sometimes herein lower alkyl is referred to as "C -Cgalkyl."
The term "(Cι-C6)hydroxyalkyl" or "hydroxy(C C6)alkyl" as used herein means a straight or branched alcohol having from 1 to 6 carbon atoms and includes, for example, hydroxymethyl, hydroxyethyl, hydroxy-propyl and the like.
The term "(C2-C6)alkenyl" means a straight or branched unsaturated hydrocarbon radical having from 2 to 6 carbon atoms and includes, for example, ethenyl, 2-propenyl, 1 -butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 3-methyl-3- butenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 3-heptenyl, 1-octenyl, 1-nonenyl, 1- decenyl, 1 -undecenyl, 1-dodecenyl, and the like.
The term "alkylene" as used herein refers to a divalent group derived from a straight or branched chain saturated hydrocarbon having from 1 to 10 carbon atoms by the removal of two hydrogen atoms, for example methylene, 1,2- ethylene, 1 ,1 -ethylene, 1 ,3-propylene, 2,2- dimethylpropylene, and the like. The alkylene groups of this invention can be optionally substituted. The alkylene group can also be substituted with one or more of the substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, halogen, nitro, cyano, oxo, thio,
-OH, -SH, -F, -CF3, -OCF3, -NO2, -CO2H, -CO2C!-C6 alkyl, -NH2, -NH)C]-
C6)alkyl, 0 , -CONR8R9, or -N(C]-C6alkyl)2. Preferred alkylene groups have from 1 to 6 carbon atoms (C- -C alkyl).
The term "heteroatom" as used herein represents oxygen, nitrogen, or sulfur (O, N, or S) as well as sulfoxyl or sulfonyl (SO or SO ), unless otherwise indicated. It is to be understood that alkyl chains interrupted by one or more heteroatoms means that a carbon atom of the chain is replaced with a heteroatom having the appropriate valency. Preferably, an alkyl chain is interrupted by 1 to 4 heteroatoms and that two adjacent carbon atoms are not both replaced. Examples of such groups include methoxymethyl, 3-thiomethylpropyl, and 2- thiomethoxyethoxymethyl.
The term "hetero(CrC6)alkyl" as used herein, refers to an alkyl group that includes one or more heteroatoms such as oxygen, sulfur, or nitrogen (with valence completed by hydrogen or oxygen) in the carbon chain or terminating the carbon chain.
The term "hydrocarbon chain" as used herein refers to a straight hydrocarbon of from 2 to 6 carbon atoms. The hydrocarbon chain is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, halogen, nitro, cyano, oxo, thio, -OH, -SH, -F, -CF3, -OCF3,
-NO2, -CO2H, -CO2(Cι-C6)alkyl, -NH2, -NH(Cι-C6)alkyl, — O , -CONR8R9, or -N(Ci-C6alkyl)2.
The term "hydrocarbon-heteroatom chain" as used herein refers to a hydrocarbon chain wherein one or more carbon atoms are replaced with a heteroatom. The hydrocarbon-heteroatom chain is optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy,
halogen, ήitro, cyano, oxo, thio,
Figure imgf000073_0001
-OH, -SH, -F, -CF3, -OCF3, -NO2, -CO2H, -CO2(C1-C6)alkyl, -NH2, -NH(C!-C6)alkyl, -CONR8R9, or -N(Ci- C6alkyl)2.
The term "heteroalkylene" as used herein, refers to an alkylene radical as defined above that includes one or more heteroatoms such as oxygen, sulfur, or nitrogen (with valence completed by hydrogen or oxygen) in the carbon chain or terminating the carbon chain.
The term "(C3-C7)cycloalkyl" means a cyclopropyl, cyclobutyl, cylopentyl, cyclohexyl, or cycloheptyl ring, respectively. The (C3-C7)cycloalkyl ring may be optionally substituted with one or more substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, halogen, nitro, cyano, oxo, thio,
Figure imgf000073_0002
, -OH, -SH, -F, -CF3, -OCF3, -NO2, -CO2H, -CO2(Cι-CD)alkyl, -NH2,
-NH(C!-C6)alkyl, -CONR8R9, 0r -N(C]-C6alkyl)2.
The term "halo(C1-C6)alkyl" as used herein means a lower alkyl radical, as defined above, bearing at least one halogen substituent, for example, chloromethyl, fluoroethyl, or trifluoromethyl, and the like. Haloalkyl can also include perfluoroalkyl wherein all hydrogens of a loweralkyl group are replaced with fluorides.
The term "heterocycle" or "heterocyclo" means a saturated or unsaturated mono- or polycyclic (i.e. bicyclic) fused, bridged, or spiro bicyclic heterocyclic ring system ring incorporating one or more (i.e. 1-4) heteroatoms selected from N, O, and S. It is to be understood that a heterocycle is optionally substituted with -OH, -O(alkyl), SH, S(alkyl), amine, halogen, acid, ester, amide, amidine, alkyl ketone, aldehyde, nitrile, fluoroalkyl, nitro, sulphone, sulfoxide or Cl-6 alkyl.
Monocyclic heterocyclic rings contain from about 3 to 12 ring atoms, with from 1 to 5 heteroatoms selected from N, O, and S, and preferably from 3 to 7 member atoms, in the ring. Bicyclic heterocyclics contain from 7 to 17 member atoms, preferably 7 to 12 member atoms, in the ring. Bicyclic heterocyclics contain from about 7 to about 17 ring atoms, preferably from 7 to 12 ring atoms. Bicyclic heterocyclics rings may be fused, spiro, or bridged ring systems. Any of the heterocycles may be substituted with up to three groups as selected from the substitutions provided for alkyl.
Examples of heterocyclic groups include cyclic ethers (oxiranes) such as ethyleneoxide, tetrahydrofuran, dioxane, and substituted cyclic ethers, wherein the substituents are those described above for the alkyl and cycloalkyl groups. Typical substituted cyclic ethers include propyleneoxide, phenyloxirane (styrene oxide), cis-2-butene-oxide (2,3-dimethyloxirane), 3-chlorotetrahydrofuran, 2,6-dimethyl- 1 ,4-dioxane, and the like. Heterocyclo groups containing nitrogen are groups such as pyrrolidine, piperidine, pyridin-2-one, piperazine, tetrahydrotriazine, tetrahydropyrazole, and substituted groups such as 3-aminopyrrolidine, 4- methylpiperazin-1-yl, and the like. Typical sulfur containing heterocycles include tetrahydrothiophene, dihydro-l,3-dithiol-2-yl, and hexahydrothiepin-4-yl. Other commonly employed heterocycles include dihydro-oxathiol-4-yl, tetrahydro- oxazolyl, tetrahydro-oxadiazolyl, tetrahydro-dioxazolyl, tetrahydro-oxathiazolyl, hexahydrotriazinyl, tetrahydro-oxazinyl, morpholinyl, thiomorpholinyl, tetrahydropyrimidinyl, dioxolinyl, octahydrobenzofuranyl, octahydrobenzimidazolyl, and octahydrobenzothiazolyl. For heterocycles containing sulfur, the oxidized sulfur heterocycles containing SO or SO2 groups are also included. Examples include the sulfoxide and sulfone forms of tetrahydrothiophene. Examples of unsaturated heterocyclic groups include pyridones (1-H pyridin-2-ones), pyrimidones (IH pyrimidin-2-one, IH pyrimidin- 4-one), pyrazones (IH pyrazin-2-ones), pyridazones (IH pyridazin-3-one), dihydropyrroles, dihydro- and tetrahydro pyridines and the like, as well as any unsaturated heterocyclic groups specifically disclosed herein.
The term "aryl" as used herein refers to an aromatic ring which is unsubstituted or optionally substituted by 1 to 4 substituents selected from lower alkyl, lower alkoxy, lower thioalkoxy, halogen, nitro, cyano -OH, -SH, -F, -CF3,
-OCF3, -NO2, — 0 -CO2H, -CO2(C!-C6)alkyl, -NH2, -NH(C!-C6)alkyl, -CONR8R9, -, SO2alkyl, -SO2NH2, or -N(C]-C6alkyl)2. Examples include, but are not limited to phenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2- methylphenyl, 3-methylphenyl, 4-methylphenyl, 2-methoxyphenyl, 3- methoxyphenyl, 4-methoxyphenyl, 2-chloro-3-methylphenyl, 2-chloro-4- methylphenyl, 2-chloro-5-methylphenyl, 3-chloro-2-methylphenyl, 3-chloro-4- methylphenyl, 4-chloro-2-methylphenyl, 4-chloro-3-methylphenyl, 5-chloro-2- methylphenyl, 2,3-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2,3- dimethylphenyl, 3,4-dimethylphenyl, thienyl, furanyl, pyrrolyl, pyridyl, pyrimidyl, imidazoyl, pyrazinyl, oxazolyl, thiazolyl, naphthyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, isoquinolinyl, and quinazolinyl, and the like.
The term "(C4-C )heterocycloalkenyl" refers to a subset of unsaturated heterocyclo, examples of which are provided above.
The term "aralkyl" as used herein refers to an alkyl radical to which is appended an aryl group. Representative arylalkyl groups include benzyl, phenylethyl, hydroxybenzyl, fluorobenzyl, fluorophenylethyl, and the like. The arylalkyl groups of this invention can be optionally substituted.
The term "arylene" as used herein refers to a divalent group derived from an aromatic ring. The arylene group can also be substituted with one or more of the substituents listed above for aryl.
The term "heteroaryl" means an aromatic cyclic or fused polycyclic ring system having from 1 to 8 heteroatoms selected from N, O, and S. The heteroaryl groups or fused heteroaryl groups may be unsubstituted or substituted by 1 to 3 substituents selected from those described above for alkyl, alkenyl, and alkynyl, for example, cyanothienyl and formylpyrrolyl.
Typical heteroaryl groups include 2- or 3-thienyl, 2- or 3-furyl, 2- or 3-pyrrolyl, 2-, 4-, or 5-imidazolyl, 3-, 4-, or 5-pyrazolyl, 2-, 4-, or 5-thiazolyl, 3-, 4-, or 5-isothiazolyl, 2-, 4-, or 5-oxazolyl, 3-, 4-, or 5-isoxazolyl, 3- or 5-1 ,2,4-triazolyl, 4- or 5-1 ,2,3-triazolyl, tetrazolyl, 2-, 3-, or 4-pyridyl, 3- or 4- pyridazinyl, 3-, 4-, or 5-pyrazinyl, 2-pyrazinyl, 2-, 4-, or 5-pyrimidinyl.
Aromatic fused heteroaryl groups of from 8 to 20 atoms include but are not limited to 1-, 2-, 3-, 5-, 6-, 7-, or 8-indolizinyl, 1-, 3-, 4-, 5-, 6-, or 7- isoindolyl, 2-, 3-, 4-, 5-, 6-, or 7-indolyl, 2-, 3-, 4-, 5-, 6-, or 7-indazolyl, 2-, 4-, 5-, 6-, 7-, or 8-purinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-quinolizinyl, 2-, 3-, 4-, 5-, 6-, 7-, or 8-quinoliyl, 1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinoliyl, 1-, 4-, 5-, 6-, 7-, or 8- phthalazinyl, 2-, 3-, 4-, 5-, or 6-naphthyridinyl, 2-, 3-, 5-, 6-, 7-, or 8-quinazolinyl, 3_, 4-, 5-, 6-, 7-, or 8-cinnolinyl, 2-, 4-, 6-, or 7-pteridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-4aH carbazolyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, or 8-carbzaolyl, 1-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-carbolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenanthridinyl, 1-, 2-, 3-, 4-, 5-, 6-, 7-, 8-, or 9-acridinyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-perimidinyl, 2-, 3-, 4-, 5-, 6-, 8-, 9-, or 10-phenathrolinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, or 9-phenazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10-phenothiazinyl, 1-, 2-, 3-, 4-, 6-, 7-, 8-, 9-, or 10- phenoxazinyl, 2—, 3—, 4-, 5—, 6—, or 1-, 3-, 4-, 5-, 6-, 7-, 8-, 9-, or 10- benzisoqinolinyl, 2-, 3-, 4-, or thieno[2,3-b]furanyl, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-, or 1 l-7H-ρyrazino[2,3-c]carbazolyl,2-, 3-, 5-, 6-, or 7-2H-furo[3,2-b]-pyranyl, 2-, 3-, 4-, 5-, 7-, or 8-5Η-pyrido[2,3-£T|-ooxazinyl, 1-, 3-, or 5-lH-pyrazolo[4,3-./]- oxazolyl, 2-, 4-, or 5-4H-imidazo[4,5-<J|thiazolyl, 3-, 5-, or 8-pyrazino[2,3- ]pyridazinyl, 2-, 3-, 5-, or 6-imidazo[2,l-b]thiazolyl, 1-, 3-, 6-, 7-, 8-, or 9- furo[3,4-c]cinnolinyl, 1-, 2-, 3-, 4-, 5-, 6-, 8-, 9-, 10, or 11 -4H-pyrido[2,3- c]carbazolyl, 2-, 3-, 6-, or 7-imidazo[l,2-b][l,2,4]triazinyl, 7-benzo[b]thienyl, 2 — , 4 — , 5 — , 6 — , or 7-benzoxazolyl, 2 — , — , 5 — , 6 — , or 7-benzimidazolyl, 2 — , 4 — , 5 — , 6 — , or 7-benzothiazolyl, 1-, 2-, 4-, 5-, 6-, 7-, 8-, or 9-benzoxapinyl, 2-, 4-, 5-, 6-, 7-, or 8-benzoxazinyl, 1-, 2-, 3-, 5-, 6-, 7-, 8-, 9-, 10-, or 11-1H- pyrrolo[l,2-b][2]benzazapinyl. Typical fused heteroaryl groups include, but are not limited to 2 — , 3 — , — , 5 — , 6 — , 7 — , or 8-quinolinyl, 1 — , 3 — , 4 — , 5 — , 6 — , 7 — , or 8-isoquinolinyl, 2 — , 3 — , 4 — , 5 — , 6 — , or 7-indolyl, 2 — , 3 — , 4 — , 5 — , 6 — , or 7-benzo[b]thienyl, 2 — , — , 5 — , 6 — , or 7-benzoxazolyl, 2 — , — , 5 — , 6 — , or 7-benzimidazolyl, 2 — , 4 — , 5 — , 6 — , or 7-benzothiazolyl.
Other heteroaryl groups include the following groups wherein '"w^" indicates the point of attachment, and any of which may be substituted as provided
N above.
Figure imgf000077_0001
The term "monocyclic heteroarylene" as used herein refers to a divalent group derived from a monocyclic heteroaryl. The arylene group can also be substituted with one or more of the substituents listed above for aryl.
The term "(C4-C7)cycloalkenyl" means a cycloalkyl group having one or more carbon-carbon double or triple bond. Example includes cyclobutene, cyclopentene, cyclohexene, cycloheptene, cyclobutadiene, cyclopentadiene, and the like. The symbol " " means a bond. If an asymetric carbon is created by such a bond, a particular stereochemistry is not to be implied.
The symbol " ==== " means a double bond.
The symbol " r nn^' " indicates covalent points of attachment.
The following abbreviations are used herein:
HOAc = Acetic acid DCM = Dichlomethane
TFA = Trifluoroacetic acid
THF = tetrahydrofuran
Me = Methyl
APCI = Atmospheric pressure chemical ionization Et = Ethyl
EtOAc = Ethyl acetate
MeOH = Methanol
HPLC = High Pressure Liquid Chromatography
MPLC = Medium Pressure Liquid Chromatography EEDQ = N-Ethoxycarbonyl-2-ethoxy-l ,2-dihydroquinoline
PyBOP = Benzotriazol-1-yloxytripyrolidinophosphonium hex afl uorophosphate
When a bond to a substituent is shown to cross the bond connecting 2 atoms in a ring, then such substituent may be bonded to any atom in the ring, provided the atom will accept the substituent without violating its valency. When there appears to be several atoms of the substituent that may bond to the ring atom, then it is the first atom of the listed substituent that is attached to the ring.
When a bond from a substituent is shown to cross the bond connecting 2 atoms in a ring of the substituent, then such substituent may be bonded from any atom in the ring that is available. When a bond is represented by a line such as " " this is meant to represent that the bond may be absent or present, provided that the resultant compound is stable and of satisfactory valency.
The term "patient" means all mammals including humans. Examples of patients include humans, cows, dogs, cats, goats, sheep, pigs, and rabbits.
A "therapeutically effective amount" is an amount of a compound of the present invention that when administered to a patient ameliorates a symptom of thrombotic disorders, venous thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, cerebral infarction, restenosis, cancer, angina, diabetes, atrial fibrillation, or heart failure. A therapeutically effective amount of a compound of the present invention can be easily determined by one skilled in the art by administering a quantity of a compound to a patient and observing the result. In addition, those skilled in the art are familiar with identifying patients having thrombotic disorders, venous thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, cerebral infarction, restenosis, cancer, angina, diabetes, atrial fibrillation, or heart failure.
The term "pharmaceutically acceptable salts, esters, amides, and prodrugs" as used herein refers to those carboxylate salts, amino acid addition salts, esters, amides, and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "salts" refers to the relatively non-toxic, inorganic and organic acid addition salts of compounds of the present invention. These salts can be prepared in situ during the final isolation and purification of the compounds or by separately reacting the purified compound in its free base form with a suitable organic or inorganic acid and isolating the salt thus formed. In some situations, compounds of the invention may exist in isomeric form; for example, as tautomers, enantiomers, or diasteromers. Some compounds may exhibit polymorphism. All tautomers, enantiomers, and diasteromers are inorporated within the definition of the compounds of the invention. It is further to be understood that the present invention encompasses any racemic, optically- active, polymorphic, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine activity or cytotoxicity using the standard tests described herein, or using other similar tests which are well known in the art.
Certain compounds of the present invention can exist in unsolvated form as well as solvated form including hydrated form. In general, the solvated form including hydrated form is equivalent to unsolvated form and is intended to be encompassed within the scope of the present invention.
Referring now to a compound of Formula I,
Figure imgf000080_0001
A specific value for G is H, F, or methyl.
O A specific value for W^ is CH2CH2- other specific values for W* are — CH2-CH2-CH2— , — CH2-CH2-O-CH2— , — CH2-HC=CH-CH2— , — CH2-CH2CR5R6— , — CH2CR5R°CH — ,
— CH2-CH CR7R8— — CH2CR7R8CH2— , — CH2-C=R9CH2— ,
— CH2-CH2C=R9— , _CH2CH2CH2CH2— , — CH2-HC=CH— ,
— CH2CH2NR5_, _CH2NR5CH2— , — CH2CH2-NH-CH2— ,
— CO-CHR5-CH2— , — CO-CH2-CHR5— , — N=CR5-CH=, — N=CR5-CH2— ,
— N=CH-CR5=, — O-CHR5-CH=, — O-CHR^-CHs— , and — 0-CH -CR5=, ' wherein R5 is -OH, alkyl, halo(C,-C6)alkyl, -NR3R4, -OR2, halo, -CN, - CH2OR2 -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CONR3R4, -
COR2, halo(C]-C6)alkyl, or -CO2R2; R6 is H, alkyl, aralkyl, aryl, or monocyclic heteroaryl; R7 and R8 are each independently H, halo, OH, or (d-Cό alkyl)-O; and R9 is =O or =NOR2;
A specific value for A is phenyl. Another specific value for A is pyridyl. Other specific values for A include the following, wherein " ,V\ΛΛ» » indicates the points attachment to either B or NH and halo, (C]-C6)alkyl, and halo(Cι-C6)alkyl are as defined earlier in the definitions section:
Figure imgf000081_0001
halo(CrC6)a
Figure imgf000081_0002
Figure imgf000081_0003
A specific value for C is phenyl. Another specific value for C is pyridyl and para-halo pyridyl. Other specific values for C include ortho- and para-halo phenyl, ortho-, para-dihalophenyl, ortho, meta-dihalophenyl, para-(d- C6)alkoxyphenyl, para-(d-C6)alkylphenyl, and meta-halo, para-(C C6)alkylphenyl.
One specific value for B is
Figure imgf000082_0001
wherein " ~ " indicates the point of attachment; Q is NH or is absent; and wherein Rr is OH, — O-(d-
C6)alkyl, or NR3'R4', wherein R3' and R4' are independently H, (Cι-C-6)aIkyl, or are joined together to form a optionally substituted saturated or unsaturated 5 to 7 membered ring.
Another specific value for B is phenyl or phenyl which is substituted at an ortho position with formyl, H2NSO2, MeSO2, MeSO, MeS, (Cι- )alkoxy carbonyl, OH, Ome, cyano, H2N-CH2— , HN-(C,-C6)alkyl-CH2— , (d- C6)alky]2N-CH2— .
Another specific value for B is pyridyl or pyridyl substituted as provided in the previous postion.
Another specific value for B is
Figure imgf000082_0002
, wherein " - indicates the point of attachment.
Another specific value for B is
Figure imgf000082_0003
, wherein " — " indicates the point of attachment and which is an optionally substituted 4, 5, 6 or 7- membered ring. When B is
Figure imgf000083_0001
R and Ry can be H, halo, (Cj-
C6)alkyl, (C]-C6)alkoxy, (Ci-C6)carboxyalkyl, or taken together can be O=. XUI can be CH2, CH-OH, CH-CO2(Ci-C6)alkyl, O, S, NH, or N(CrC6)alkyl, provided that when R" and Ry taken together are O=, X1" is CH2.
Another specific value for B is
Figure imgf000083_0002
or a tautomer thereof such as
Figure imgf000083_0003
or . When B is or a tautomer thereof, Yπ can be CH2, CH(C C6)alkyl, C-CH2OH, C-CH2O-(d-C6)alkyl, NH, or N(C
C6)alkyl. R18 is H, (CrC6)alkyl, hydroxymethyl, CH2O-(CrC6)alkyl, or NR3R4.
Another specific value for B is a 5-membered heteroaryl ring which contains at least one nitrogen atom such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, any of which may be optionally substituted with halo, (Cι-C6)alkyl, hydroxy(d-C6)alkyl, CH2O-(d-C6)alkyl, or halo(CrC6)alkyl. B can also be
Figure imgf000083_0004
" indicates the point of attachment;
Xa, Ya, and Za are each independently CRC or N, wherein Rc is H or (CrC6)alkyl; and R18 is H, (C C6)alkyl, hydroxymethyl, CH2O-(C C6)alkyl, CH2NR3R ,or, NR R4, wherein R3 and R4 are as defined herein.
Another specific value for B is
Figure imgf000084_0001
, wherein "-
indicates the point of attachment. When B is
Figure imgf000084_0002
, Jι, J2, J3, and J can each be C, or one or more of J\ , J2, J3, or J can be N. R19, R20, R21, and R22 are each independently H, halo, hydroxy, NH2, NR23R24, NO2, SH, (Cι-C6)alkyl, (C C6)alkoxy, halo(CrC6)alkyl, (C C6)alkanoyl, (C C6)alkoxycarbonyl, or (C
C6)alkoxy, wherein R23 and R24 are each independently H, (C]-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring.
Alternatively, R19 and R20, R20 and R21, or R21 and R22, can be together with the carbons to which they are attached to form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring. When any of Ji, J2, J3, or J is N, R19, R20, R21 or R22, respectively, is absent at that
position. Thus, specific values for B include
Figure imgf000084_0003
Figure imgf000085_0001
R20, and R21, R22 are each independently H, halo, hydroxy, NH2, NR23R24, NO2, SH, (C C6)alkyl, (d-C6)alkoxy, halo(d-C6)alkyl, (CrC6)alkanoyl, (Cr
C6)alkoxycarbonyl, or (Cι-C6)alkoxy, wherein R23 and R24 are each independently H, (C]-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring, or R19 and R20, R20 and R21, or R21 and R22, together with the carbons to which they are attached, form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring.
Reference will now be made to a compound of Formula II.
Figure imgf000085_0002
In
Figure imgf000086_0001
, " - - - " is a bond or is absent. A specific value for
X" is CH2. Other specific values for X11 include CH, O, NH and N. Specific values for R'° and R11 include H, hydroxy, methoxy, ethoxy, cyano,
N N
I trifluoromethyl, fluoro, NH2, carboethoxy, Me-"— NH- 1 MeSO2N— , H wherein "™" " indicates the point of attachment. Also, R10 and Rn can be taken
together to form =O or =NOH. Thus, specific values for
Figure imgf000086_0002
Figure imgf000086_0003
Figure imgf000087_0001
A specific value for G is H, F, or methyl.
A specific value for C is phenyl. Another specific value for C is pyridyl. Other specific values for C include ortho- and p— halo phenyl, ortho, p— dihalophenyl, ortho, meta-dihalophenyl, p-(Ci-C6)alkoxyphenyl, p-(d- C6)alkylphenyl, and meta-halo, p~(d-C6)alkylphenyl.
A specific value for A is phenyl. Another specific value for A is pyridyl.
Other specific values for A include the following, wherein " t~^- » indicates the points attachment to either B or NH and halo, (d-C6)alkyl, and halo(C1-C6)alkyl are as defined earlier in the definitions section:
Figure imgf000087_0002
Figure imgf000087_0003
Figure imgf000088_0001
Figure imgf000088_0002
, or halofC CgJalky
One specific value for B is
Figure imgf000088_0003
, wherein " «~~ " indicates the point of attachment; Q is NH or is absent; and wherein R1 is OH, — O-(d-
C6)alkyl, or NR3'R4', wherein R3' and R4' are independently H, (d-C-6)alkyl, or are joined together to form a optionally substituted saturated or unsaturated 5 to 7 membered ring.
Another specific value for B is phenyl or phenyl which is substituted at an ortho position with formyl, H2NSO2, MeSO2, MeSO, MeS, (d-6)alkoxycarbonyl, cyano, H N-CH2— , HN-(Cι-C6)alkyl-CH2— , (d-C6)alkyl2N-CH2
Another specific value for B is pyridyl or pyridyl substituted as provided in the previous postion.
Another specific value for B is
Figure imgf000088_0004
, wherein " • indicates the point of attachment.
Another specific value for B is
Figure imgf000088_0005
, wherein " *~ " indicates the point of attachment and which is an optionally substituted 4, 5, 6 or 7- membered ring. When B is
Figure imgf000089_0001
, Rx and Ry can be H, halo, (Cj-
C6)alkyl, (d-C6)alkoxy, (Cι-C6)carboxyalkyl, or taken together can be O=. Xιπ can be CH2, CH-OH, CH-CO2(Cι-C6)alkyl, O, S, NH, or N(CrC6)alkyl, provided that when Rx and Ry taken together are O=, Xπι is CH2.
Figure imgf000089_0002
Another specific value for B is R1 or a tautomer thereof such
Figure imgf000089_0004
. When B is
Figure imgf000089_0003
or a tautomer thereof, Yπ can be CH2, CH(C,-C6)alkyl, C-CH2OH, C-CH2O-(Cι-C6)alkyl, NH, or N(C,-
C6)alkyl. R18 is H, (C C6)alkyl, hydroxymethyl, CH2O-(CrC6)alkyl, or NR3R4.
Another specific value for B is a 5-membered heteroaryl ring which contains at least one nitrogen atom such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, any of which may be optionally substituted with halo, (Cι-C6)alkyl, hydroxy(d-C6)alkyl, CH2O-(Cι-C6)alkyl, or halo(CrC6)alkyl. B can also be
Figure imgf000089_0005
, wherein " ~ " indicates the point of attachment;
Xa, Ya, and Za are each independently CRC or N, wherein Rc is H or (d-C6)alkyl; and
R18 is H, (CrQ alkyl, hydroxymethyl, CH2O-(d-C6)alkyl, CH2NR R4 or NR R4, wherein R3 and R4 are as defined herein.
Another specific value for B is
Figure imgf000090_0001
, wherein "-
indicates the point of attachment. When B is
Figure imgf000090_0002
, , , and
J4 can each be C, or one or more of Jj, J2, J3, or J4 can be N. R19, R20, R21, and R22 are each independently H, halo, hydroxy, NH2, NR23R24, NO2, SH, (CπC6)alkyl, (Cι-C6)alkoxy, halo(CrC6)alkyl, (d-C6)alkanoyl, (CrC6)alkoxycarbonyl, or (Ci-
C6)alkoxy, wherein R23 and R24 are each independently H, (Cj-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring. Alternatively, R19 and R20, R20 and R21, or R21 and R22, can be together with the carbons to which they are attached to form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring. When any of J)5 J2, J3, or J is N, R19, R20, R21 or R22, respectively, is absent at that
position. Thus, specific values for B include
Figure imgf000090_0003
Figure imgf000091_0001
R20, and R21, R22 are each independently H, halo, hydroxy, NH2, NR23R24, NO2, SH, (C,-C6)alkyl, (C C6)alkoxy, halo(C C6)alkyl, (C,-C6)alkanoyl, (Cr
C6)alkoxycarbonyl, or (Cj-C6)alkoxy, wherein R23 and R24 are each independently H, (Cι-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring, or R19 and R20, R20 and R21, or R21 and R22, together with the carbons to which they are attached, form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring.
Reference will now be made to a compound of Formula III:
Figure imgf000091_0002
In
Figure imgf000092_0001
, " — " is a bond or is absent. A specific value for
X" is CH . Other specific values for X" include CH, O, NH and N. Specific values for R10 and Rn include H, hydroxy, methoxy, ethoxy, cyano,
trifluoromethyl, fluoro, NH2, carboethoxy,
Figure imgf000092_0002
wherein "-~- " indicates the point of attachment. Also, R10 and R11 taken together
can be =O or =NOH. Thus, specific values for
Figure imgf000092_0003
include
Figure imgf000092_0004
Figure imgf000093_0001
In
Figure imgf000093_0002
, Z is N, CH, C(C,-C6)alkyl, C(d-C6)alkoxy, or C- halo. R12 and R13 are each independently H, halo, (Cι-Cό)alkyl, or (Ci-
C6)alkoxy. Specific values for
Figure imgf000093_0003
therefore include phenyl, pyridyl, p-chlorophenyl, p-fluorophenyl, p-bromophenyl, p-methoxyphenyl, p- toluyl, p-chloropyridyl, ortho, p-difluorophenyl, meta, p-difluorophenyl, and meta fluoro, paratoluyl.
A specific value for G is H, F, or methyl.
A specific value for A is phenyl. Another specific value for A is pyridyl. Other specific values for A include the following, wherein " ~vw " indicates the points attachment to either B or NH and halo, (C C6)alkyl, and halo(C C6)alkyl are as defined earlier in the definitions section:
Figure imgf000094_0001
halotC CeJalkyl/
Figure imgf000094_0003
(C1-C6)alkyl
Figure imgf000094_0004
One specific value for B is
Figure imgf000094_0006
wherein " " indicates the point of attachment; Q is NH or is absent; and wherein R1 is OH, — O-(d- C6)alkyl, or NR 'R4', wherein R3' and R4' are independently H, (C]-C-6)alkyl, or are joined together to form a optionally substituted saturated or unsaturated 5 to 7 membered ring.
Another specific value for B is phenyl or phenyl which is substituted at an ortho position with formyl, H2NSO2, MeSO2, MeSO, MeS, (Cj-6)alkoxycarbonyl, cyano, H2N-CH2— , HN-(C1-C6)alkyl-CH2— , (CrC6)alkyl2N-CH2— .
Another specific value for B is pyridyl or pyridyl substituted as provided in the previous postion.
Another specific value for B is , wherein " ~"Λ " indicates the point of attachment.
Another specific value for B is
Figure imgf000095_0001
, wherein " ~ " indicates the point of attachment and which is an optionally substituted 4, 5, 6 or 7-
membered ring. When B is
Figure imgf000095_0002
C6)alkyl, (Cι-C6)alkoxy, (Cι-C6)carboxyaIkyl, or taken together can be O=. XUI can be CH2, CH-OH, CH-CO (CrC6)alkyl, O, S, NH, or N(C C6)alkyl, provided that when Rx and Ry taken together are O=, X,π is CH2.
Another specific value for B is
Figure imgf000095_0003
or a tautomer thereof such as
Figure imgf000095_0004
When B is
Figure imgf000095_0005
or a tautomer thereof, Yu can be CH2, CH(C,-C6)alkyl, C-CH2OH, C-CH2O-(d-C6)alkyl, NH, or N(Cr C6)alkyl. R18 is H, (C C6)alkyl, hydroxymethyl, CH2O-(C C6)alkyl, or NR3R4.
Another specific value for B is a 5-membered heteroaryl ring which contains at least one nitrogen atom such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, any of which may be optionally substituted with halo, (d-C6)alkyl, hydroxy(C C6)alkyl, CH2θ-(C C6)alkyl, or halo(CrC6)alkyl. B can also be
Figure imgf000096_0001
herein "•— " indicates the point of attachment;
Xa, Ya, and Za are each independently CRC or N, wherein Rc is H or (C,-C6)alkyl; and R18 is H, (CrC6)alkyl, hydroxymethyl, CH2O-(CrC6)alkyl, CH2NR3R4, or
NR R4, wherein R3 and R4 are as defined herein.
Another specific value for B is
Figure imgf000096_0002
wherein
indicates the point of attachment. When B
Figure imgf000096_0003
J4 can each be C, or one or more of J], J2, J3, or J can be N. R19, R20, R21, and R22 are each independently H, halo, hydroxy, NH2, NR23R24, NO2, SH, (C,-C6)alkyl, (Cι-C6)alkoxy, halo(Cι-C6)alkyl, (d-C6)alkanoyl, (Cι-C6)alkoxycarbonyl, or (Q-
C6)alkoxy, wherein R23 and R24 are each independently H, (Cj-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring. Alternatively, R19 and R20, R20 and R21 , or R21 and R22, can be together with the carbons to which they are attached to form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring. When any of Jl s J2, J3, or J4 is N, R19, R20, R21 or R22, respectively, is absent at that
position. Thus, specific values for B include
Figure imgf000097_0001
Figure imgf000097_0002
, wherein "•«« " indicates the point of attachment; and R19, R20, and R21, R22 are each independently H, halo, hydroxy, NH2, NR23R24, NO2, SH, (C,-C6)alkyl, (C,-C6)alkoxy, halo(d-C6)alkyl, (d-C6)alkanoyl, (C C6)alkoxycarbonyl, or (d-Cό)alkoxy, wherein R23 and R24 are each independently H, (Cι-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring, or R19 and R20, R20 and R21, or R21 and R22, together with the carbons to which they are attached, form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring.
Reference will now be made to a compound of Formula IN:
In
Figure imgf000098_0001
, " — " is a bond or is absent. A specific value for
X" is CH2. Other specific values for X" include CH, O, NH and N. Specific values for R10 and R11 include H, hydroxy, methoxy, ethoxy, cyano,
N N
•N
I trifluoromethyl, fluoro, NH2, carboethoxy, Me-0— NH- , MeSO2N— , H wherein " ~ " indicates the point of attachment. Also, R ιo „ a„nd. R ,π , taken together
can be =O or =NOH. Thus, specific values for
Figure imgf000098_0002
include
Figure imgf000098_0003
Figure imgf000099_0001
Figure imgf000099_0002
Z is N, CH, C(CrC6)alkyl, C-(C1-C6)alkoxy, or C- halo. R12 and R13 are each independently H, halo, (d-C6)alkyl, (C C6)alkoxy.
Specific values for
Figure imgf000099_0003
include phenyl, pyridyl, p- chlorophenyl, p-fluorophenyl, p-bromophenyl, p-methoxyphenyl, p-toluyl, p- chloropyridyl, ortho, p-difluorophenyl, meta, para-difluorophenyl, and meta fluoro, p-methyl phenyl.
In
Figure imgf000100_0001
5 x and Y are each independently N, CH, C-halo,
C(C,-C6)alkyl, C-halo(d-C6)alkyl, or C-heterocyclo. R14 and R15 are each independently H, halo, (Cj-C6)alkyl, halo(C]-C6)alkyl, or heterocyclo. Specific
values for
Figure imgf000100_0002
Figure imgf000100_0003
A specific value for G is H, F, or methyl.
One specific value for B is
Figure imgf000100_0004
> wherein "~™ " indicates the point of attachment; Q is NH or is absent; and wherein R1 is OH, — O-(Cι-
C6)alkyl, or NR3'R4', wherein R3' and R4' are independently H, (Cj-C-6)alkyl, or are joined together to form a optionally substituted saturated olr unsaturated 5 to 7 membered ring.
Another specific value for B is phenyl or phenyl which is substituted at an ortho position with formyl, H2NSO2, MeSO2, MeSO, MeS, (Cro)alkoxycarbonyl, cyano, H2N-CH2— , HN-(C1-C6)alkyl-CH2— , (C]-C6)a\ky) 2^-CE2—-
Another specific value for B is pyridyl or pyridyl substituted as provided in the previous postion.
Another specific value for B is
Figure imgf000101_0001
, wherein " - indicates the point of attachment.
Another specific value for B is
Figure imgf000101_0002
wherein " ™" " indicates the point of attachment and which is an optionally substituted 4, 5, 6 or 7-
membered ring. When B is
Figure imgf000101_0003
, Rx and Ry can be H, halo, (Cr
C6)alkyl, (CrC6)alkoxy, (CrC6)carboxyalkyl, or taken together can be O=. Xm can be CH2, CH-OH, CH-CO2(CrC6)alkyl, O, S, NH, or N(C C6)alkyl, provided that when Rx and Ry taken together are O=, X1" is CH2. Another specific value for B is
Figure imgf000102_0001
or a tautomer thereof such as
Figure imgf000102_0003
. When B is
Figure imgf000102_0002
or a tautomer thereof, YH can be CH2, CH(C,-C6)alkyl, C-CH2OH, C-CH2θ-(C,-C6)alkyl, NH, or N(C,-
C6)alkyl. R18 is H, (CrC6)alkyl, hydroxymethyl, CH2θ-(CrC6)alkyl, or NR3R4.
Another specific value for B is a 5-membered heteroaryl ting which contains at least one nitrogen atom such as imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, any of which may be optionally substituted with halo, (Cι-C6)alkyl, hydroxy(C,-C6)alkyl, CH2θ-(C]-C6)alkyl, or halo(d-C6)alkyl. B can also be
Figure imgf000102_0004
, wherein " •— " indicates the point of attachment;
Xa, Ya, and Za are each independently CRC or N, wherein Rc is H or (C C6)alkyl; and
R'8 is H, (C,-C6)alkyl, hydroxymethyl, CH2O-(CrC6)alkyl, or NR3R4.
Another specific value for B is
Figure imgf000102_0005
, wherein " -«~ " indicates the point of attachment. When B is
Figure imgf000103_0001
, Jj, J2, J3, and J can each be
C, or one or more of Jj, J2, J3, or J can be N. R19, R20, R21, and R22 are each independently H, halo, hydroxy, NH2, NR2 R24, NO2, SH, (C,-C6)alkyl, (C C6)alkoxy, halo(CrC6)alkyl, (d-C6)alkanoyl, (C C6)alkoxycarbonyl, or (Ci-
C6)alkoxy, wherein R23 and R24 are each independently H, (d-Q)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2aIkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring. Alternatively, R19 and R20, R20 and R21, or R21 and R22, can be together with the carbons to which they are attached to form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring. When any of J) , J2, J3, or J4 is N, R , R , R or R , respectively, is absent at that position.
Figure imgf000103_0002
".vw. " indicates the point of attachment; and R19, R °, and R , R are each independently H, halo, hydroxy, NH2, NR23R24, NO2, SH, (d-C6)alkyl, (C C6)alkoxy, halo(C C6)alkyl, (Cι-C6)alkanoyl, (CrC6)alkoxycarbonyl, or (Ci-
C6)alkoxy, wherein R23 and R24 are each independently H, (Cι-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring, or R19 and R , R and R" , or R" and R", together with the carbons to which they are attached, form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring.
Reference will now be made to a compound of Formula N:
Figure imgf000104_0001
In , " — " is a bond or is absent. A specific value for
Xπ is CH2. Other specific values for X11 include CH, ΝH and Ν. Specific values for R10 and R1 ' include H, hydroxy, methoxy, ethoxy, cyano, trifluoromethyl,
Ν — Ν
II |[
1 fluoro, ΝH2, carboethoxy, Me— u— H- , MeSO2N— , H , wherein « »» indicates the point of attachment. Also, R10 and R11 taken together can be =O or =NOH. Thus, specific values for
Figure imgf000105_0001
include
Figure imgf000105_0002
or
Figure imgf000105_0003
Z is N, CH, C(CrC6)alkyl, C-(d-C6)alkoxy, or C- halo. R12 and R13 are each independently H, halo, (Cj-C6)alkyl, (C C6)alkoxy. Specific values for
Figure imgf000106_0001
therefore include phenyl, pyridyl, p- chlorophenyl, p-fluorophenyl, p-bromophenyl, p-methoxyphenyl, p-toluyl, p- chloropyridyl, ortho, p-difluorophenyl, meta, p-difluorophenyl, and meta fluoro, p-methyl phenyl.
Figure imgf000106_0002
X and Y are each independently N, CH, C-halo, C(C,-C6)alkyl, C-halo(CrC6)alkyl, or C-heterocyclo. R14 and R15 are each independently H, halo, (d-C6)alkyl, halo(d-C6)alkyl, or heterocyclo. Specific
values for
Figure imgf000106_0003
Figure imgf000106_0004
A specific value for G is H, F, or methyl.
Figure imgf000107_0001
fused heteroaryl ring, provided that when -'' is present, Y' is C. X' and Y' are eaqch independently N, CH, C-halo, C-halo, C-(Cι-C6)alkyl, C-halo(d- C6)alkyl, C-(d-C6)alkoxy, C-OH, C-SO2Me, C-SO2NH2, C-SOMe, C-SMe, C- CO2(Cι-C6)alkyl, C-CN, or C-CH2NH2. Specific values for
Figure imgf000107_0002
thus include 'm >
Figure imgf000107_0003
Figure imgf000108_0001
Reference will now be made to a compound of Formula NI.
In
Figure imgf000108_0002
, " — " is a bond or is absent. A specific value for
Xπ is CH2. Other specific values for Xπ include CH, ΝH and Ν. Specific values for R10 and R include H, hydroxy, methoxy, ethoxy, cyano, trifluoromethyl,
Ν Ν
fluoro, ΝH2, carboethoxy, Me-"— NH- , MeSO2N— , H . wherein " — " indicates the point of attachment. Also, R10 and Rn taken together can be =O or
=NOH. Thus, specific values for
Figure imgf000108_0003
include
Figure imgf000109_0001
MeOaS
Figure imgf000109_0002
or
Figure imgf000109_0003
Figure imgf000109_0004
In 13 , Z is N, CH, C(C,-C6)alkyl, C-(C C6)alkoxy ,or C- halo. R12 and R13 are each independently H, halo, (d-C6)alkyl, (d-C6)alkoxy.
Specific values for
Figure imgf000109_0005
include phenyl, pyridyl, p- chlorophenyl, p-fluorophenyl, p-bromophenyl, p-methoxyphenyl, p-toluyl, p- chloropyridyl, ortho, p-difluorophenyl, meta, p-difluorophenyl, and meta fluoro, p-methyl phenyl.
In
Figure imgf000110_0001
, X and Y are each independently N, CH, C-halo,
C(CrC6)alkyl, C-halo(CrC6)alkyl, or C-heterocyclo. R14 and R15are each independently H, halo, (C]-C6)alkyl, halo(d-C6)alkyl, or heterocyclo. Specific
values for
Figure imgf000110_0002
Figure imgf000110_0003
A specific value for G is H, F, or methyl.
In
Figure imgf000110_0004
, Q is NH or is absent. R1 is OH, -O-(CrC-6)alkyl, (C3-C-7)cycloalkyl, (C3-C-7)heterocyclo, (C4-C-7)cycloalkenyl, (C4-C-
7)heterocycloalkenyl, aryl, monocyclic heteroaryl, or -NR3R4, wherein R3 and
R4 are independently H, (C]-C-6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 5 to 7 membered ring. Thus, specific values for
/UWQ include-NH-COMe,
Figure imgf000111_0001
, CO2Me, CON(Me)2,
CONMeEt,
Figure imgf000111_0002
, and
Figure imgf000111_0003
Reference will now be made to a compound of Formula NH.
Figure imgf000111_0004
In
Figure imgf000112_0001
, " - - - " is a bond or is absent. A specific value for
X" is CH2. Other specific values for Xn include CH, O, NH and N. Specific values for R10 and R11 include H, hydroxy, methoxy, ethoxy, cyano,
N N
«> trifluoromethyl, fluoro, NH2, carboethoxy, Me-11— NH- , MeSO2N— , H wherein " ™» " indicates the point of attachment. Also, R10 and Rn taken together
can be =O or =NOH. Thus, specific values for
Figure imgf000112_0002
include εto.
Figure imgf000112_0003
Figure imgf000112_0004
Figure imgf000112_0005
MeOoS
Figure imgf000113_0001
Figure imgf000113_0002
, Z is N, CH, C(C,-C6)alkyl, C(CrC6)alkoxy, or C- halo. Rn and R13 are each independently H, halo, (d-C6)alkyl, (Cι-C6)alkoxy.
Specific values for
Figure imgf000113_0003
13 therefore include phenyl, pyridyl, p- chlorophenyl, p-fluorophenyl, p-bromophenyl, p-methoxyphenyl, p-toluyl, p- chloropyridyl, ortho, p-difluorophenyl, meta, p-difluorophenyl, and meta fluoro, p-methyl phenyl.
In
Figure imgf000113_0004
, X and Y are each independently N, CH, C-halo,
C(CrC6)alkyl, C-halo(C C6)alkyl, or C-heterocyclo. R14 and R15are each independently H, halo, (C]-C6)alkyl, halo(C C6)alkyl, or heterocyclo. Specific values for
Figure imgf000114_0001
include ~~ —P )r*> ,
Figure imgf000114_0002
A specific value for G is H, F, or methyl.
In compounds of Formula Nil, is an optionally substituted
4, 5, 6 or 7-membered ring, wherein Rx and Ry are H, halo, hydroxymethyl, (d- C6)alkyl, (Cι-C6)alkoxy, or wherein Rx and Ry are H, halo, (Cj-C6)alkyl, (Cr
C6)alkoxy, (C C6)carboxyaIkyl, or taken together are O=. X1" is CH2, CH-OH,
CH-CO2(d-C6)a]kyl, O, S, ΝH, or Ν(CrC6)alkyl, provided that when Rx and Ry taken together are O=, X is CH2. Thus, specific values for
Figure imgf000114_0004
912
-1 14-
Figure imgf000115_0001
alkyl
Figure imgf000115_0002
Figure imgf000115_0003
anH . Any of the specific values for
Figure imgf000115_0004
may be further optionally substituted with one, two or three substitutent groups selected from the group consisting of halo, (C]-C6)alkyl, halo(Cι-C6)alkyl, or hydroxymethyl.
Reference will now be made to a compound of Formula VIII.
Figure imgf000115_0005
In
Figure imgf000116_0001
, " — " is a bond or is absent. A specific value for
X" is CH . Other specific values for X11 include CH, O, NH and N. Specific values for R , 110U and R" include H, hydroxy, methoxy, ethoxy, cyano,
N — N
trifluoromethyl, fluoro, NH2, carboethoxy, Me- -NH- , MeSO2N— , "-A H wherein "— " indicates the point of attachment. Also, R10 and R11 taken together
can be =O or =NOH. Thus, specific values for
Figure imgf000116_0002
include
Figure imgf000116_0003
Figure imgf000117_0001
In 3 , Z is N, CH, C(C,-C6)aIkyl, C(C,-C6)alkoxy, or C- halo. R12 and R13 are each independently H, halo, (d-C6)alkyl, (C C6)alkoxy.
Specific values for
Figure imgf000117_0002
13 therefore include phenyl, pyridyl, p- chlorophenyl, p-fluorophenyl, p-bromophenyl, p-methoxyphenyl, p-toluyl, p- chloropyridyl, ortho, p-difluorophenyl, meta, p-difluorophenyl, and meta fluoro, p-methyl phenyl.
In
Figure imgf000117_0003
, X and Y are each independently N, CH, C- halo, C(Cι-C6)alkyl, C-halo(CrC6)alkyl, or C-heterocyclo. R14 and R15 are each independently H, halo, (d-C6)alkyl, halo(C C6)alkyl, or heterocyclo. Specific values for
Figure imgf000118_0001
Figure imgf000118_0002
In compounds of Formula NITI, exist in tautomeπc
form as
Figure imgf000118_0004
8 , ,
Figure imgf000118_0003
Furthermore, in
Figure imgf000118_0005
, Yπ is CH, CR18, or Ν. R18 is H, (C C6)alkyl, hydroxymethyl,
CH2O-(d-C6)alkyl, or ΝR3R4, wherein R3 and R4 are each independently H, (Cj-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated
3 to 7 membered ring. Thus, specific values for
Figure imgf000119_0001
include
Figure imgf000119_0002
A specific value for G is H, F, or methyl.
Reference will now be made to a compound of Formula IX.
Figure imgf000119_0003
In , " — " is a bond or is absent. A specific value for X11 is CH2. Other specific values for X11 include CH, O, NH and N. Specific values for R10 and Rn include H, hydroxy, methoxy, ethoxy, cyano, N N
I trifluoromethyl, fluoro, NH2, carboethoxy, Me-"— NH- , MeSO2N— , H wherein "~ " indicates the point of attachment. Also, R10 and Rn taken together
can be =O or =NOH. Thus, specific values for
Figure imgf000120_0001
include
Figure imgf000120_0002
In
Figure imgf000121_0001
Z is N, CH, C(C,-C6)alkyl, or C-halo. R12 and R13 are each independently H, halo, (Cι-Cό)alkyl, (C C6)alkoxy. Specific values for
Figure imgf000121_0002
therefore include phenyl, pyridyl, p-chlorophenyl, p- fluorophenyl, p-bromophenyl, p-methoxyphenyl, p-toluyl, p-chloropyridyl, ortho, p-difluorophenyl, meta, p-difluorophenyl, and meta fluoro, p-methyl phenyl.
In
Figure imgf000121_0003
, X and Y are each independently N, CH, C-halo,
C(d-C6)alkyl, C-halo(C C6)alkyl, or C-heterocyclo. R14 and R15 are each independently H, halo, (d-C6)alkyl, halo(C)-C6)alkyl, or heterocyclo. Specific
values for
Figure imgf000121_0004
-0-. -Ch.
Figure imgf000121_0005
Figure imgf000122_0001
Figure imgf000122_0002
and R18 is H, (d-C6)alkyl, hydroxymethyl, CH O-(C C6)alkyl, CH2NR3R4, or
NR R4, wherein R3 and R4 are each independently H, (d-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring. Thus, specific
values for
Figure imgf000122_0003
include imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl, any of which may be optionally substituted with halo, (d-C6)alkyI, hydroxy(Cι-C6)alkyl,
CH2O-(Cι-C6)alkyl, or halo(Cι-C6)alkyl. Other values for
Figure imgf000122_0004
include
Figure imgf000122_0005
Figure imgf000122_0006
A specific value for G is H, F, or methyl.
Reference will now be made to a compound of Formula X.
Figure imgf000123_0001
B X
In
Figure imgf000123_0002
, " - - - " is a bond or is absent. A specific value for
Xπ is CH2. Other specific values for Xπ include CH, O, NH and N. Specific values for R10 and Rn include H, hydroxy, methoxy, ethoxy, cyano,
trifluoromethyl, fluoro, NH2, carboethoxy, Me
Figure imgf000123_0003
wherein "•««« " indicates the point of attachment. Also, R10 and Rn taken together
can be =O or =NOH. Thus, specific values for
Figure imgf000123_0004
include
Figure imgf000124_0001
MeOzS
Figure imgf000124_0002
Figure imgf000124_0003
Figure imgf000124_0004
Figure imgf000124_0005
Z is N, CH, C(CrC6)alkyl, -(C C6)alkoxy, or C- halo. R12 and R13 are each independently H, halo, (d-C6)alkyl, (d-C6)alkoxy. Specific values for
Figure imgf000125_0001
therefore include phenyl, pyridyl, p- chlorophenyl, p-fluorophenyl, p-bromophenyl, p-methoxyphenyl, p-toluyl, p- chloropyridyl, ortho, p-difluorophenyl, meta, p-difluorophenyl, and meta fluoro, p-methyl phenyl.
Figure imgf000125_0002
, X and Y are each independently N, CH, C-halo, C(C C6)alkyl, C-halo(C C6)alkyl, or C-heterocyclo. R14 and R15 are each independently H, halo, (C]-C6)alkyl, halo(C]-C6)alkyl, or heterocyclo. Specific
values for
Figure imgf000125_0003
Figure imgf000125_0004
Figure imgf000126_0001
Ji, J2, J3, and J are each C, or one of Ji, J2, J3, and J4 is N. R19, R20, R21, and R22 are each independently H, halo, hydroxy, NH2, NR23R24, NO2> SH, (d-C6)alkyl, (C,-C6)alkoxy, halo(C,-C6)alkyl, (Cr
C6)alkanoyl, (Cι-C6)alkoxycarbonyl, or (d-Cό)alkoxy, wherein R^3 and R^ are each independently H, (Cι-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring, or R19 and R20, R20 and R21, or R21 and R2", together with the carbons to which they are attached, form a 5, 6, or 7 membered saturated or unsaturated cycloalkyl or heterocyclo ring, or an aryl or heteroaryl ring. Also, when any of J 1, J2, J3, or J is N, R19, R20, R21 or R22, respectively, is absent at that position. Thus, specific values for
Figure imgf000126_0002
Figure imgf000127_0001
A specific value for G is H, F, or methyl.
PREPARATION OF COMPOUNDS OF THE INVENTION Processes and novel intermediates for preparing compounds of formula I are provided as further embodiments of the invention and are illustrated by the following procedures in which the meanings of the generic radicals are as given above unless otherwise qualified. Certain compounds of formula I are useful as intermediates for preparing other compounds of formula I.
It is also noted that compounds of formula I can be prepared using protecting groups. It is to be noted that the appropriate use and choice of protecting groups is well-known by one skilled in the art, and is not limited to the specific examples below. It is also to be understood that such groups not only serve to protect chemically reactive sites, but also to enhance solubility or otherwise change physical properties. A good general reference for protecting group preparation and deprotection is Protecting Groups in Organic Synthesis by T.W. Green and P.G. Wuts. A number of general reactions such as oxidations and reductions etc. are not shown in detail but can be done by methods understood by one skilled in the art. General transformations are well-reviewed in Comprehensive Organic Transformation by Richard Larock, and the series" published by Wiley-Interscience. In general, the starting materials are obtained from commercial sources unless otherwise indicated.
It will be appreciated by those skilled in the art that compounds of the invention having one or more chiral centers may exist in and be isolated in optically active and racemic forms. Some compounds may exhibit polymorphism. It is to be understood that the present invention encompasses any racemic, optically-active, polymorphic, geometric, or stereoisomeric form, or mixtures thereof, of a compound of the invention, which possess the useful properties described herein, it being well known in the art how to prepare optically active forms (for example, by resolution of the racemic form by recrystallization techniques, by synthesis from optically-active starting materials, by chiral synthesis, or by chromatographic separation using a chiral stationary phase) and how to determine activity or cytotoxicity using the standard tests described herein, or using other similar tests which are well known in the art.
It will be further appreciated by the skilled artisan that the following schemes depict the synthesis of some compounds of the invention. It is to be understood, however, that compounds of the invention other than those specifically disclosed can be prepared using the strategies depicted in the schemes.
One method for making compounds of the invention is disclosed in
Scheme 1. The route is useful for a wide variety of starting materials with variable W groups, provided the appropriate protecting group is utilized, if necessary. The scheme is also employed for both racemic mixtures and enantiomerically pure compounds. The method comprises reacting an amino acid having Formula A with a reagent capable of forming a protecting group on the amino group of an amino acid to form compound with Formula A-l. In Scheme
1, pl is a protecting group and W^ is the same as defined above. The compound of Formula A-l is next converted into an acid halide. Alternatively the carboxylic acid may be activated by a number of coupling reagents, but not limited to, such as BOP, PYBOP, HATU, EEDQ, or CDI. The acid halide is then reacted with a haloaniline or a haloaminoheterocycle to form a halide having Formula D, where Y is a halogen and A is as defined above. The compound with Formula D is then subjected to a coupling reaction with a compound having B to give a compound of Formula E. The protecting group is then removed from compound E and the resulting compound reacted with an isocyanate having C to form a compound of Formula I. Finally, as relating to Scheme 1 and subsequent schemes, it is to be noted that compounds of the invention wherein G has any of the provided meanings other than H can be easily prepared by techniques available to the skilled artisan. For example, compounds wherein G is alkyl can be prepared by alkylation of I, or by alkylation of a corresponding ester of A, B D, or E.
Scheme 1
Figure imgf000129_0001
1) Coupling with B
Figure imgf000129_0002
Scheme 2 provides a more detailed approach to the preparation of compounds of the invention. The synthetic route starts by protecting an amino acid A with di-tert-butyl dicarbonate in tetrahydrofuran with 2M NaOH as the base. The resulting BOC-protected amino acid B-l is converted into the acid chloride using oxalyl chloride, with pyridine added to prevent deprotection. The acid chloride or acid is then immediately reacted with a bromoaniline or bromoaminoheterocycle of choice. The resulting bromide is then typically subjected to a Suzuki coupling with a boronic acid, although other coupling conditions may be used to provide D-l . Compound D-l is then deprotected with 33% trifluoroacetic acid in dichloromethane and allowed to react with an isocyanate in the presence of an amine base such as triethylamine in tetrahydrofuran or the like. This route is useful for preparing compounds containing biaryl A-B groups; i.e., where both A and B are aryl. Scheme 2
Figure imgf000130_0001
Another method of making compounds of the invention is depicted in
Scheme 3. The route summarized in Scheme 3 is useful for synthesizing a wide variety of A-B groups. The chemistry is similar to Scheme 1 , but the second step (i.e., the conversion of B to D) introduces different substituted aniline or aminoheterocycle. By selecting an appropriately substituted aniline or aminoheteroaryl group, a wide variety of B groups can be introduced. For example, when Z is a cyano group, the corresponding imidazole and imidazoline compounds can be made using techniques known to the skilled artisan. When Z is a methyl ester or the like, the corresponding amides and ketones can be synthesized via a number of methods available to the skilled artisan. For example, an amide is prepared by hydrolyzing the ester with lithium hydroxide or TMSOK or the like, treating the resulting carboxylic acid with a typical peptide coupling reagent such as HATU or PYBOP followed by introduction of the desired amine. Scheme 3
Figure imgf000131_0001
Various Coupling i_
Protocols and Conditions (See Examples)
Figure imgf000131_0002
Compounds of the invention may also be prepared as provided in Scheme 4. Thus, a mixture of F (where Z is a halide and Y is an amino or nitro group), B (where B is a nitrogen-containing ring, an amine or amide), K3PO4, Cul, and trαns-diaminocyclohexane is heated in dioxane at reflux to obtain compound G. In the case where Y is a nitro group, the moiety is reduced to the amino group with RaNi and EtOH under a hydrogen atmosphere. The appropriate aniline G, EEDQ, triethylamine and carboxylic acid H are heated at reflux in chloroform to produce J. Finally, a solution of compound J, TFA and DCM is stirred at room temperature for 1 h and then concentrated under reduced pressure. The resulting oil is dissolved in THF and cooled to 0 °C followed by the addition of triethylamine and the appropriate isocyanate to produce invention compound K. Scheme 4
Figure imgf000131_0003
Scheme 5 provides an approach to compounds of the invention wherein X11
in
Figure imgf000132_0001
(c.f., Formulas II-X), is N and " — " is a bond. Thus, aniline M is converted to an acrylamide N by the addition of acryoyl chloride and a base, such as saturated sodium bicarbonate, in a solvent such as ethyl acetate at room temperature. Alternatively, the aniline may be converted to N by the addition of an acrylic acid and adding a coupling reagent such as dicyclohexylcarbodi-imide (DCC), O-(7-azabenzotriazol-l -yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (HATU), or EEDQ. To the acrylamide N is then added an excess of trimethylsilyl diazomethane in a solvent such as ethyl acetate or dichloromethane. The resulting dihydropyrazole O may then be treated with an isocyanate, in the presence of base such as pyridine or triethylamine, in a solvent such as dichloromethane, to afford compound P.
Scheme 5.1 formation of conversion to
Figure imgf000132_0002
A= aryl or heteroaryl
reaction with isocyanate
Figure imgf000132_0003
An alternative approach to molecules wherein X in
Figure imgf000133_0001
(c.f., Formulas II-X), is N and " — " is a bond is provided in Scheme 5.2. The chemistry for the preparation of compounds Q-T is similar to that described in Scheme 5.1. Compound T may be converted to an invention compound by a Suzuki coupling with a boronic acid, although other coupling conditions commonly known to the skilled practitioner may also be used. This route is particularly useful for compounds containing a biaryl A-B group. In situations where a tert-butylsulphonamide is present in B, which occurs in some of the particularly preferred compounds, the sulphonamide may be formed by stirring with trifluoroacetic acid for 16 h.
Scheme 5.2 formation of conversion to
h coupling with compound B
Figure imgf000133_0003
Figure imgf000133_0004
Another approach to the preparation of invention compounds wherein X
in
Figure imgf000134_0001
(c.f., Formulas II-X), is N and " — " is a bond is provided in Scheme 5.3. The synthetic routes commences with formation of acrylamide.U as disclosed in Scheme 5.1. A diazoacetate such as ethyl diazoacetate is then mixed with acrylamide U to afford the appropriately substituted dihydropyrazole V. Similar chemistry to that described in Scheme 5.1 allows conversion of V to W. Reduction of the ester moiety in W is then achieved using a reducing agent such as super-hydride to afford the hydroxyl containing invention compound X.
Scheme 5.3 formation of conversion to
H N-
Figure imgf000134_0002
R1 = H or alkyl reaction with isocyanate
Alternatively, inve
Figure imgf000134_0003
ntion compounds wherein X in (c.f., Formulas II-X), is N and " — " is a bond is provided in Scheme 5.4. Here, the acrylic ester Y is reacted with a diazo compound to form the dihydropyrazole Z. Addition of a chloroformate affords compounds of formula AA. Deprotection of the ester is achieved by acid, such as TFA or hydrogen chloride to afford compounds of formula BB. Addition of an aniline with a coupling reagent such as EEDQ and base affords compounds of formula CC. Deprotection of the carbamate with Pd/C and hydrogen affords compounds of formula DD which may then be reacted with isocyanates to afford invention compounds of formula FF.
Scheme 5.4
Protection with chloroformate
R
Figure imgf000135_0002
Figure imgf000135_0001
Selective deprotection of ester
Formation of amide
Figure imgf000135_0003
17
Figure imgf000135_0004
Other methods for making compounds of the invention or variations of the above Schemes are provided in the Examples section. Not all compounds of the invention falling into a given class may be compatible with some of the reaction conditions described. Such restrictions are readily apparent to those skilled in the art of organic synthesis, and alternative methods must then be used.
Some of the compounds of Formula I are capable of further forming pharmaceutically acceptable acid-addition and/or base salts. All of these forms are within the scope of the present invention. Thus, pharmaceutically acceptable acid addition salts of the compounds of Formula I include salts derived from nontoxic inorganic acids such as hydrochloric, nitric, phosphoric, sulfuric, hydrobromic, hydriodic, hydrofluoric, phosphorous, and the like, as well as the salts derived from nontoxic organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Such salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, acetate, trifluoroacetate, propionate, caprylate, isobutyrate, oxalate, malonate, succinates suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, phthalate, benzensoulfonate, toluenesulfonate, phenyl acetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Also contemplated are salts of amino acids such as arginate and the like and gluconate, galacturonate (see, for example, Berge, S.M. et. al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 1977;66:1-19).
The acid addition salt of said basic compounds are prepared by contacting the free base form with a sufficient amount of the desired acid to produce the salt in the conventional manner.
Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines. Examples of metals used as cations are sodium, potassium, magnesium, calcium, and the like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methyl glucamine, and procaine (see, for example, Berge, S.M., supra., 1977).
The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.
Examples of pharmaceutically acceptable, non-toxic esters of the compounds of this invention include Cj-Cg alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C5-C7 cycloalkyl esters as well as arylalkyl esters such as, but not limited to benzyl. C1 -C4 alkyl esters are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.
Examples of pharmaceutically acceptable, non-toxic amides of the compounds of this invention include amides derived from ammonia, primary C\-
Cg alkyl amines and secondary C1-C6 dialkyl amines wherein the alkyl groups are straight or branched chain. In the case of secondary amines, the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C1-C3 alkyl primary amines and C1-C2 dialkyl secondary amines are preferred. Amides of the compounds of the invention may be prepared according to conventional methods.
Certain of the compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms, including hydrated forms, are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention.
Certain of the compounds of the present invention possess one or more chiral centers and each center may exist in the R(D) or S(L) configuration. The present invention includes all enantiomeric and epimeric forms, as well as the appropriate mixtures thereof.
The compounds of Formula I can be formulated as pharmaceutical compositions and administered to a mammalian host, such as a human patient in a variety of forms adapted to the chosen route of administration, i.e., orally or parenterally, by intravenous, intramuscular, topical or subcutaneous routes.
Thus, the present compounds may be systemically administered, e.g., orally, in combination with a pharmaceutically acceptable vehicle such as an inert diluent or an assimilable edible carrier. They may be enclosed in hard or soft shell gelatin capsules, may be compressed into tablets, or may be incoφorated directly with the food of the patient's diet. For oral therapeutic administration, the active compound may be combined with one or more excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like. Such compositions and preparations should contain at least 0.1 % of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 60% of the weight of a given unit dosage form. The amount of active compound in such therapeutically useful compositions is such that an effective dosage level will be obtained.
The tablets, troches, pills, capsules, and the like may also contain the following: binders such as gum tragacanth, acacia, com starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, fructose, lactose or aspartame or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring may be added. When the unit dosage form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier, such as a vegetable oil or a polyethylene glycol. Various other materials may be present as coatings or to otherwise modify the physical form of the solid unit dosage form. For instance, tablets, pills, or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts employed. In addition, the active compound may be incoφorated into sustained-release preparations and devices.
The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Solutions of the active compound or its salts can be prepared in water, optionally mixed with a nontoxic surfactant. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
The pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions or sterile powders comprising the active ingredient which are adapted for the extemporaneous preparation of sterile injectable or infusible solutions or dispersions, optionally encapsulated in liposomes. In all cases, the ultimate dosage form must be sterile, fluid and stable under the conditions of manufacture and storage. The liquid carrier or vehicle can be a solvent or liquid dispersion medium comprising, for example, water, ethanol, a polyol (for example, glycerol, propylene glycol, liquid polyethylene glycols, and the like), vegetable oils, nontoxic glyceryl esters, and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the required particle size in the case of dispersions or by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, buffers or sodium chloride. Prolonged absoφtion of the injectable compositions can be brought about by the use in the compositions of agents delaying absoφtion, for example, aluminum monostearate and gelatin.
Sterile injectable solutions are prepared by incoφorating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filter sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredient present in the previously sterile-filtered solutions.
For topical administration, the present compounds may be applied in pure form, i.e., when they are liquids. However, it will generally be desirable to administer them to the skin as compositions or Formulations, in combination with a dermatologically acceptable carrier, which may be a solid or a liquid.
Useful solid carriers include finely divided solids such as talc, clay, microcrystalline cellulose, silica, alumina and the like. Useful liquid carriers include water, alcohols or glycols or water-alcohol/glycol blends, in which the present compounds can be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants such as fragrances and additional antimicrobial agents can be added to optimize the properties for a given use. The resultant liquid compositions can be applied from absorbent pads, used to impregnate bandages and other dressings, or sprayed onto the affected area using pump-type or aerosol sprayers.
Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified mineral materials can also be employed with liquid carriers to form spreadable pastes, gels, ointments, soaps, and the like, for application directly to the skin of the user. Examples of useful dermatological compositions which can be used to deliver the compounds of Formula I to the skin are known to the art; for example, see Jacquet et al. (U.S. Pat. No. 4,608,392), Geria (U.S. Pat. No. 4,992,478), Smith et al. (U.S. Pat. No. 4,559,157) and Wortzman (U.S. Pat. No. 4,820,508).
Useful dosages of the compounds of Formula I can be determined by comparing their in vitro activity, and in vivo activity in animal models. Methods for the extrapolation of effective dosages in mice, and other animals, to humans are known to the art; for example, see U.S. Pat. No. 4,938,949.
Generally, the concentration of the compound(s) of Formula I in a liquid composition, such as a lotion, will be from about 0.1-25 wt-%, preferably from about 0.5-10 wt-%. The concentration in a semi-solid or solid composition such as a gel or a powder will be about 0.1-5 wt-%, preferably about 0.5-2.5 wt-%.
The amount of the compound, or an active salt or derivative thereof, required for use in treatment will vary not only with the particular salt selected but also with the route of administration, the nature of the condition being treated and the age and condition of the patient and will be ultimately at the discretion of the attendant physician or clinician.
The compounds of the present invention can be administered to a patient at dosage levels in the range of about 0.1 to about 2,000 mg per day. For a normal human adult having a body weight of about 70 kilograms, a dosage in the range of about 0.01 to about 10 mg per kilogram of body weight per day is preferable. However, the specific dosage used can vary. For example, the dosage can depend on a numbers of factors including the requirements of the patient, the severity of the condition being treated, and the pharmacological activity of the compound being used. The determination of optimum dosages for a particular patient is well- known to those skilled in the art. Ideally, the active ingredient should be administered to achieve peak plasma concentrations of the active compound of from about 0.5 nM (nonmolar) to about 75 μM, preferably, about 1 nM to 50 μM, most preferably, about 0.1 to about 5 μM. This may be achieved, for example, by the intravenous injection of a 0.05 to 5% solution of the active ingredient, optionally in saline, or orally administered as a bolus containing about 10-500 mg of the active ingredient. Desirable blood levels may be maintained by multiple oral dosing, or continuous infusion to provide about 0.01-5.0 mg/kg/hr or by intermittent infusions containing about 0.4-15 mg/kg of the active ingredient(s).
The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example, as two, three, four or more sub-doses per day. The sub-dose itself may be further divided, e.g., into a number of discrete loosely spaced administrations; such as multiple inhalations from an insufflator or by application of a plurality of drops into the eye.
The following examples illustrate the various embodiments of the present invention. Those skilled in the art will recognize many variations that are within the spirit of the present invention and scope of the claims.
BIOLOGICAL ASSAYS The invention compounds have demonstrated factor Xa inhibitory activity in the standard assays commonly employed by those skilled in the art.
A. Determination of Factor Xa IC50
The ability of compounds to act as inhibitors of human factor Xa catalytic activity is assessed by determination of that concentration of test substance that inhibits by 50% (IC50) the ability of human factor Xa to cleave the chromogenic substrate S2765 (N-CBz-D-Arg-L-Gly-L-Arg-p-nitroanilide. 2HC1, DiaPharma). The IC50 was determined at 3pM and 30pM concentrations human factor Xa (Enzyme Research Laboratories). These concentrations were achieved by diluting a 21.087 μM stock solution of factor Xa in the appropriate amount of a buffer comprising lpμM HEPES, 150 μM NaCl, 0.1 % BSA, pH 7.4 (HBSA buffer). Accordingly, 5 μL of the compound to be tested in DMSO (2% final) is added to the factor Xa/buffer solution and incubated for 60 minutes at room temperature.
The IC50 is determined by monitoring the increase in absorbance at 390 nm exicitation, 460 nm emission, with a 455 nm cutoff, in a fluorometric plate reader. Results of the IC50 at 3 pM and 30 pM enzyme concentrations are provided in Table 1.
Table 1
Figure imgf000143_0001
Figure imgf000144_0001
Figure imgf000145_0001
Figure imgf000146_0001
Figure imgf000147_0001
Figure imgf000148_0001
Figure imgf000149_0001
Figure imgf000150_0001
Figure imgf000151_0001
Figure imgf000152_0001
Figure imgf000153_0001
Figure imgf000154_0001
Figure imgf000155_0001
Figure imgf000156_0001
Figure imgf000157_0001
Similarly, Table 2 provides the percent inhibition at 3 pM concentration of factor Xa and compound concentrations of 4 μM and 1 μM.
Table 2
Figure imgf000157_0002
Figure imgf000158_0001
The foregoing biological tests establish that the compounds of the present invention are potent inhibitors of the Faxtor Xa. Accordingly, the compounds of the present invention are useful in pharmaceutical formulations for preventing and treating thrombotic disorders. Such disorders include venous thrombosis, deep vein thrombosis, thrombophlebitis, arterialembolism, coronary and cerebral arterial thrombosis, cerebral embolism, kidney embolism, pulmonary embolism, first or recurrent myocardial infarction, unstable angina, cerebral infarction, stroke, and atherosclerosis.
To further assist in understanding the present invention, the following non- limiting examples of such factor Xa inhibitory compounds are provided. The following examples, of course, should not be construed as specifically limiting the present invention, variations presently known or later developed, which would be within the purview of one skilled in the art and considered to fall within the scope of the present invention as described herein. Preferred synthetic routes for intermediates involved in the synthesis as well as the resulting anti-thrombotic compounds of the present invention follow.
Example 1
(R)-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
Figure imgf000159_0001
Step 1: (R)-2-(4-Bromo-2-fluoro-phenylcarbamoyl)-pyrrolidine-l-carboxylic acid 9H-fluoren-9-ylmethyI ester Fmoc-D-Pro (1.2 g, 3.56 mmol) was suspended in 10 mL dry dichloromethane (DCM), cooled in an ice water bath, and then thionyl chloride (0.78 L, 10.7 mmol) was added slowly. After addition was complete, the ice water bath was removed and the reaction was stirred at ambient temperature overnight. The solution was concentrated to dryness. The oil was redissolved in 20 L dry DCM under an Ar atmosphere, and 4-bromo-2-fluoroaniline (0.81 g, 4.3 mmol) was added, followed by dry pyridine (0.87 mL, 10.7 mmol). The mixture was stirred at ambient temperature for 4 hours, then concentrated. The residue was redissolved in 100 mL EtOAc, washed with 1M HCl (3x50 mL), brine (2x50 mL), dried with MgSO filtered and concentrated to yield the title product as a sticky oil. (1.8 g, 99%) APCI (AP+): 509.2, 51 1.2 (M+H)+.
Step 2: (R)-PyrroIidine-2-carboxylic acid (2'-tert-butylsuIfamoyl-3-fluoro- biphenyl-4-yI)-amide (R)-2-(4-Bromo-2-fluoro-phenylcarbamoyl)-pyrrolidine-l-carboxylic acid
9H-fluoren-9-yl ethyl ester (1.78 g, 3.49 mmol), 2-(N-tert- butyl)phenylsulfonamide boronic acid (1.35 g, 5.24 mmol), and tetrabutylammonium bromide (60 mg, 0.17 mmol) were combined in 40 mL toluene. 3.5 mL of an aqueous 2M sodium carbonate solution was then added, followed by tetrakistriphenylphosphine palladium(O) (200 mg, 0.17 mmol). The resulting solution was heated at reflux overnight, and cooled to room temperature, partitioned between EtOAc (250 mL) and water (150 mL). The combined organic layers were washed with water (2x100 mL), brine, dried with MgSO4, filtered and concentrated. Purification by column chromatography on silica gel eluting with 10% EtOAc in hexanes, then EtOAc, and then to MeOH NH4OH/EtOAc (5: 1 :94) provided the title compound as an oil. (1.03 g, 70%) APCI (AP+): 420.3 (M+H)+.
Step 3: (R)-pyrroIidine-l,2-dicarboxylic acid 2-[(2'-tert-butylsulfamoyl-3- fluoro-biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide] (R)-Pyrrolidine-2-carboxylic acid (2'-tert-butylsulfamoyl-3-fluoro- biphenyl-4-yl)-amide (0.25 g, 0.6 mmol) and 4-chlorophenylisocyanate (90 mg, 0.6 mmol) were combined in 10 mL DCM and stirred at ambient temperature for one hour. The solution was concentrated. The residue was purified on a silica gel column eluting with 50% EtOAc in hexanes to provide the title compound as a white foam. (0.225 g, 66%) APCI (AP-): 571.3, 573.3 (M-H)".
Step 4: (R)-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(3-fluoro-2'-sulfamoyl-b-phenyl-4-yl)-amide]
(R)-pyrrolidine-l ,2-dicarboxylic acid 2-[(2'-tert-butylsulfamoyl-3-fluoro- biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide] (0.22 g, 0.38 mmol) was stirred in 20 mL trifluoroacetic acid at ambient temperature overnight. The solution was concentrated, then purified on a silica gel column eluting with 50% EtOAc in hexanes, then 75% EtOAc in hexanes. The pure fractions were combined and concentrated, then redissolved in acetonitrile/water and lyophilized to yield title compound as a white solid. (0.15 g, 76%) APCI (AP-): 515.2, 517.2 (M-H)".
Example 2
Pyrrolidine-1 ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3-fluoro-2'- sulfamoyl-biphenyl-4-yl)-amide]
Figure imgf000161_0001
Step 1: PyrroIidine-l,2-dicarboxylic acid 1-tert -butyl ester
DL-proline (10 g, 86.9 mmol) was dissolved in 120 mL of THF: H2O (2: 1 ), and 87 mL of a 2M NaOH solution was added, followed by B0C2O (24.6 g, 113 mmol). The reaction mixture was stirred at ambient temperature overnight. The THF was removed in vacuo. The remaining aqueous mixture was acidified to pH 3 with aqueous citric acid, extracted twice with EtOAc. The combined organic layers were washed with water, brine, dried with MgSO filtered and concentrated to yield the title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)".
Step 2: 2-(2'-tert-Butylsulfamoyl-3-fluoro-biphenyl-4-ylcarbamoyl)- pyrrolidine-1 -carboxylic acid tert-butyl ester
Pyrrolidine-1 ,2-dicarboxylic acid 1-tert-butyl ester (1.6 g, 7.4 mmol) was dissolved in 40 mL dry diethyl ether under Ar. The solution was cooled in an ice water bath as dry pyridine (3 mL, 37.2 mmol) was added, followed by the dropwise addition of oxalyl chloride (1.6 L, 18.6 mmol). A precipitate formed immediately. The reaction was stirred vigorously at 0°C for one hour, then at ambient temperature for one hour. 50 mL diethyl ether were added, and the mixture was filtered. The filtered off solids were washed with diethyl ether. The filtrates were combined and concentrated to give an off-white oil. The oil was redissolved in 40 mL dry DCM under Ar, cooled to 0°C, and 3 mL of pyridine were added, followed by 4'-amino-3'-fluoro-biphenyl-2-sulfonic acid tert- butylamide (2 g, 6.2 mmol). The reaction was allowed to warm to ambient temperature, stirred for 3 hours then concentrated. The concentrate was redissolved in 250 mL EtOAc, washed with 10% citric acid (2x100 mL), water (3x100 L), brine (100 L), dried with MgSO filtered and concentrated. The concentrate was purified on a silica gel column eluted with 30% moving to 50% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound as a white solid. (1.4 g, 42%) APCI (AP-): 518.2 (M-H)'.
Step 3: Pyrrolidine-2-carboxylic acid (2'-tert-butylsulfamoyl-3-fluoro- biphenyl-4-yl)-amide
2-(2'-tert-Butylsulfamoyl-3-fluoro-biphenyl-4-ylcarbamoyl)-pyrro]idine-l- carboxylic acid tert-butyl ester (1.3 g, 2.5 mmol) was dissolved in 40 mL DCM, cooled in an ice bath, added 10 mL trifluoroacetic acid, stirred at 0°C for 30 minutes then at ambient temperature for one hour. Concentrated solution, redissolved in EtOAc (150 mL), washed with saturated NaHCO3 (2x100 mL), water (100 mL), brine (100 mL), dried with M SO4, filtered and concentrated to yield title compound as a white solid. (1 g, 91 %) APCI (AP-): 418.2 (M-H)".
Step 4: PyrroIidine-l,2-dicarboxylic acid 2-[(2'-tert-butylsulfamoyl-3-fluoro- biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide]
PyrroIidine-2-carboxylic acid (2'-tert-butylsulfamoyl-3-fluoro-biphenyl-4- yl)-amide (0.3 g, 0.72 mmol) was dissolved in 10 mL dry THF under Ar, added 4- chlorophenylisocyanate (0.1 1 g, 0.72 mmol) and stirred at ambient temperature for one hour. Concentrated solution to yield title compound. (0.42 g, quant.) APCI (AP-): 571.2, 573.2 (M-H)".
Step 5: Pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(2'-tert-butylsulfamoyl-3-fluoro- biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide] (0.4 g, 0.7 mmol) was stirred in 10 mL trifluoroacetic acid at ambient temperature overnight, concentrated solution, then purified on a silica gel column eluted with 50% moving to 75% EtOAc in hexanes. Combined and concentrated pure fractions, redissolved in acetonitrile/water and lyophilized to yield title compound as a white fluffy powder. (0.26 g, 72%) APCI (AP-): 515.1, 517.2 (M-H)".
Example 3
Pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
Figure imgf000164_0001
Step 1: Pyrrolidine-1, 2-dicarboxylic acid 1 -tert-butyl ester
DL-proline (10 g, 86.9 mmol) was dissolved in 120 mL of THF: H2O
(2:1), added 87 mL of a 2M NaOH solution followed by B0C2O (24.6 g, 113 mmol). Stirred at ambient temperature overnight. Removed THF in vacuo, acidified water to pH 3 with citric acid, extracted twice with EtOAc, washed organics with water, brine, dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)-.
Step 2: 2-(2'- rt-Butylsulfamoyl-3-fluoro-biphenyl-4-yJcarbamoyl)- pyrrolidine-1-carboxylic acid tert-butyl ester
Pyrrolidine-1 , 2-dicarboxylic acid 1 -tert-butyl ester (1.6 g, 7.4 mmol) was dissolved in 40 mL dry diethyl ether under Ar, cooled in an ice water bath, added dry pyridine (3 mL, 37.2 mmol) followed by the dropwise addition of oxalyl chloride (1.6 mL, 18.6 mmol). A precipitate forms immediately. The reaction was stirred vigorously at 0°C for one hour, then at ambient temperature for one hour. Added 50 L diethyl ether, filtered off solids washing with diethyl ether. Concentrated the filtrates to an off-white oil. Redissolved oil in 40 mL dry DCM under Ar, cooled to 0°C, added 3 L pyridine followed by 4'-amino-3'-fluoro- biphenyl-2-sulfonic acid t -butylamide (2 g, 6.2 mmol). The reaction was allowed to warm to ambient temperature, stirred for 3 hours then concentrated. Redissolved in 250 L EtOAc, washed with 10% citric acid (2x100 mL), water (3x100 mL), brine (100 mL), dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluted with 30% moving to 50% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound as a white solid. (1.4 g, 42%) APCI (AP-): 518.2 (M-H)".
Step 3: Pyrrolidine-2-carboxylic acid (2'-tert-butylsulfamoyl-3-fluoro- biphenyI-4-yl)-amide
2-(2'-tert-Butylsulfamoyl-3-fluoro-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester (1.3 g, 2.5 mmol) was dissolved in 40 mL DCM, cooled in an ice bath, added 10 mL trifluoroacetic acid, stirred at 0°C for 30 minutes then at ambient temperature for one hour. Concentrated solution, redissolved in EtOAc (150 mL), washed with saturated NaHCO3 (2x100 L), water (100 mL), brine (100 mL), dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (1 g, 91%) APCI (AP-): 418.2 (M-H)".
Step 3a: (5-Chloro-pyridin-2-yl)-carbamic acid 4-nitro-phenyl ester 2-Amino-5-chloropyridine (1.05 g, 8.2 mmol) was suspended in 15 mL dry DCM under Ar, added dry pyridine (0.66 mL, 8.2 mmol), cooled to 0°C and added 4-nitrophenol chloroformate. A white precipitate forms rapidly. Stirred at ambient temperature for 1 hour, filtered off solid, washed with water and then DCM. A white solid recovered which is consistent with title compound. (2.1 g, 88%) !H-NMR (D6-DMSO)
Step 4: Pyrrolidine-l,2-dicarboxyIic acid 2-[(2'-tert-butylsulfamoyl-3-fluoro- biphenyl-4-yl)-amide] l-[(5-chloro-pyridin-2-yl)-amide]
Pyrrolidine-2-carboxylic acid (2'-tert-butylsulfamoyl-3-fluoro-biphenyl-4- yl)-amide (245 mg, 0.83 mmol) and (5-Chloro-pyridin-2-yl)-carbamic acid 4- nitro-phenyl ester (0.35 g, 0.83 mmol) were combined in 10 mL dry DMF under Ar, added diisopropylethylamine (0.15 mL, 0.83 mmol) and heated at 80°C for 2 hours. Cooled solution, taken up in EtOAc (200 mL), washed with sat. K2CO3 (3x150 mL), sat. NaHCO3 (3x150 mL), brine, dried with MgSO4, filtered and concentrated to yield title compound as a light pink solid. (0.45 g, 94%) APCI (AP-): 572.3, 574.3 (M-H)".
Step 5: Pyrrolidine-1, 2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)-amide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(2'-tert-butylsulfamoyl-3-fluoro- biphenyl-4-yl)-amide] l-[(5-chloro-pyridin-2-yl)-amide] (0.45 g, 0.78 mmol) was stirred in 10 L trifluoroacetic acid at ambient temperature for 4 hours. Reaction is sluggish. Heated to 80°C for 30 minutes. Cooled solution, concentrated, redissolved in 40 mL toluene and concentrated. Purified on a silica gel column eluted with 75% EtOAc in hexanes. Combined and concentrated pure fractions, redissolved in acetonitrile/water and lyophilized to yield title compound as a white fluffy powder. (0.277 g, 68%) APCI ( AP-): 516.1, 518.1 (M-H)".
Example 4
Pyrrolidine-1, 2-dicarboxylic acid l-[(2,4-difluoro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
Figure imgf000166_0001
Step 1: PyrroIidine-l,2-dicarboxylic acid 1-tert-butyl ester
DL-proline (10 g, 86.9 mmol) was dissolved in 120 mL of THF: H2O (2:1 ), added 87 mL of a 2M NaOH solution followed by B0C2O (24.6 g, 113 mmol). Stirred at ambient temperature overnight. Removed THF in vacuo, acidified water to pH 3 with citric acid, extracted twice with EtOAc, washed organics with water, brine, dried with M SO4, filtered and concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)-.
Step 2: 2-(2'-t^rt-Butylsulfamoyl-3-fluoro-biphenyl-4-ylcarbamoyl)- pyrrolidine-l -carboxylic acid tert-butyl ester
Pyrrolidine- 1 ,2-dicarboxylic acid 1 -tert-butyl ester (1.6 g, 7.4 mmol) was dissolved in 40 mL dry diethyl ether under Ar, cooled in an ice water bath, added dry pyridine (3 mL, 37.2 mmol) followed by the dropwise addition of oxalyl chloride (1.6 L, 18.6 mmol). A precipitate forms immediately. The reaction was stirred vigorously at 0°C for one hour, then at ambient temperature for one hour. Added 50 mL diethyl ether, filtered off solids washing with diethyl ether. Concentrated the filtrates to an off-white oil. Redissolved oil in 40 mL dry DCM under Ar, cooled to 0°C, added 3 L pyridine followed by 4'-amino-3'-fluoro- biphenyl-2-sulfonic acid tert-butylamide (2 g, 6.2 mmol). The reaction was allowed to warm to ambient temperature, stirred for 3 hours then concentrated. Redissolved in 250 mL EtOAc, washed with 10% citric acid (2x100 mL), water (3x100 mL), brine (100 mL), dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluted with 30% moving to 50% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound as a white solid. (1.4 g, 42%) APCI (AP-): 518.2 (M-H)".
Step 3: Pyrrolidine-2-carboxylic acid (2'-tert-butyIsulfamoyl-3-fluoro- biphenyl-4-yl)-amide
2-(2'-tert-Butylsulfamoyl-3-fluoro-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid terf-butyl ester (1.3 g, 2.5 mmol) was dissolved in 40 mL DCM, cooled in an ice bath, added 10 mL trifluoroacetic acid, stirred at 0°C for 30 minutes then at ambient temperature for one hour. Concentrated solution, redissolved in EtOAc (150 L), washed with saturated NaHCO3 (2x100 mL), water (100 mL), brine (100 mL), dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (1 g, 91 %) APCI (AP-): 418.2 (M-H)".
Step 4: Pyrrolidine-1, 2-dicarboxylic acid ]-[(2,4-difluoro-phenyl)-amide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
To a solution of pyrrolidine-2-carboxylic acid (2'-tert-butylsulfamoyl-3- fluoro-biphenyl-4-yl)-amide (0.12 mmol/mL, 0.3 mmol ) in 2.5 mL of THF was added 2,4-difluorophenylisocyanate. The reaction was shaken on an orbital shaker at ambient temperature for 2 hours, then 50 mg of trisamine resin (2.4 mmol/g) was added and shaken for 1 hour. Filtered off resin, washing with THF. The THF was blown down with a stream of nitrogen. Added 2 mL of trifluoroacetic acid and the reaction was shaken at ambient temperature overnight. The trifluoroacetic acid was blown down with a stream of nitrogen. Redissolved in 2 mL EtOAc and loaded onto a silica gel column. Eluted compound with 60% EtOAc in hexanes. Combined and concentrated pure fractions, redissolved in acetonitrile/water and lyophilized to a white fluffy powder. (0.13 g, 84%) APCI
(AP-): 517.2 (M-H)".
Example 5
Pyrrolidine-1,2 -dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)- a ide] 1-p-tolylamide
Figure imgf000168_0001
Step 1: Pyrrolidine-l,2-dicarboxylic acid 1 -tert-butyl ester DL-proline (10 g, 86.9 mmol) was dissolved in 120 mL of THF: H2O
(2:1 ), added 87 mL of a 2M NaOH solution followed by Boc O (24.6 g, 1 13 mmol). Stirred at ambient temperature overnight. Removed THF in vacuo, acidified water to pH 3 with citric acid, extracted twice with EtOAc, washed organics with water, brine, dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)".
Step 2: 2-(2'-tert-Butylsulfamoyl-3-fluoro-biphenyl-4-ylcarbamoyl)- pyrrolidine-1-carboxylic acid tert-butyl ester Pyrrolidine-1 ,2-dicarboxylic acid 1 -lert-butyl ester (1.6 g, 7.4 mmol) was dissolved in 40 mL dry diethyl ether under Ar, cooled in an ice water bath, added dry pyridine (3 mL, 37.2 mmol) followed by the dropwise addition of oxalyl chloride ( .6 mL, 18.6 mmol). A precipitate forms immediately. The reaction was stirred vigorously at 0°C for one hour, then at ambient temperature for one hour. Added 50 mL diethyl ether, filtered off solids washing with diethyl ether. Concentrated the filtrates to an off-white oil. Redissolved oil in 40 mL dry DCM under Ar, cooled to 0°C, added 3 mL pyridine followed by 4'-amino-3'-fluoro- biphenyl-2-sulfonic acid tert-butylamide (2 g, 6.2 mmol). The reaction was allowed to warm to ambient temperature, stirred for 3 hours then concentrated. Redissolved in 250 L EtOAc, washed with 10% citric acid (2x100 mL), water (3x100 mL), brine (100 mL), dried with MgSO4, filtered and concentrated.
Purified on a silica gel column eluted with 30% moving to 50% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound as a white solid. (1.4 g, 42%) APCI (AP-): 518.2 (M-H)-.
Step 3: PyrroIidine-2-carboxylic acid (2'-tert-butylsulfamoyl-3-fluoro- biphenyl -4-yl)-amide
2-(2'-tert-Butylsulfamoyl-3-fluoro-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester (1.3 g, 2.5 mmol) was dissolved in 40 mL DCM, cooled in an ice bath, added 10 mL trifluoroacetic acid, stirred at 0°C for 30 minutes then at ambient temperature for one hour. Concentrated solution, redissolved in EtOAc (150 mL), washed with saturated NaHCO3 (2x100 mL), water (100 mL), brine (100 mL), dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (1 g, 91 %) APCI (AP-): 418.2 (M-H)".
Step 4: Pyrrolidine-l,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl- 4-yl)-amide] 1-p-tolylamide
To a solution of pyrrolidine-2 -carboxylic acid (2'-tert-butylsulfamoyl-3- fluoro-biphenyl-4-yl)-amide (0.12 mmol/mL, 0.24 mmol ) in 2 mL of THF was added p-tolylisocyanate. The reaction was shaken on an orbital shaker at ambient temperature for 2 hours, then 50 mg of trisamine resin (2.4 mmol/g) was added and shaken for 1 hour. Filtered off resin, washing with THF. The THF was blown down with a stream of nitrogen. Added 2 mL of trifluoroacetic acid and the reaction was shaken at ambient temperature overnight. The trifluoroacetic acid was blown down with a stream of nitrogen. Loaded onto a silica gel column and eluted using an automated ISCO system with gradient of 40-100% EtOAc in hexanes over 40 minutes. Combined and concentrated pure fractions, redissolved in acetonitrile/water and lyophilized to a white fluffy powder. (0.084 g, 73%)
APCI (AP-): 495.1 (M-H)".
Example 6
Pyrrolidine-1, 2 -dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)- a ide] 1 -[(4-methoxy-phenyI)-amide]
This compound was prepared using the same procedures as found for Example 5 with p-methoxyphenylisocyanate substituted for p-tolylisocyanate in step 4. (0.089 g, 72%) APCI (AP-): 511.1 (M-H)-.
Example 7 Pyrrolidine-1, 2-dicarboxylic acid l-[(4-bromo-phenyl)-amide] 2-[(3-fluoro-2'- sulfamoyl-biphenyl-4-yl)-amide]
Figure imgf000171_0001
This compound was prepared using the same procedures as found for
Example 5 with 4-bromophenylisocyanate substituted for p-tolylisocyanate in step
4. (0.097 g, 72%) APCI (AP-): 559.0, 561.0 (M-H)".
Example 8
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)- amide] 1-phenylamide
Figure imgf000171_0002
This compound was prepared using the same procedures as found for
Example 5 with phenylisocyanate substituted for p-tolylisocyanate in step 4.
(0.084 g, 73%) APCI (AP-): 481.1 (M-H)". Example 9
Pyrrolidine-1, 2-dicarboxylic acid l-[(3,4-difluoro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyI-biphenyl-4-yl)-amide]
Figure imgf000172_0001
This compound was prepared using the same procedures as found for Example 5 with 3,4-difluorophenylisocyanate substituted for p-tolylisocyanate in step 4. (0.079 g, 63%) APCI (AP-): 517.0 (M-H)'.
Example 10
Pyrrolidine-l,2-dicarboxylic acid l-[(3-fluoro-4-methyl-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
Figure imgf000172_0002
This compound was prepared using the same procedures as found for Example 5 with 3-fluoro-4-methylphenylisocyanate substituted for p- tolylisocyanate in step 4. (0.083 g, 67%) APCI (AP-): 513.0 (M-H)".
Example 11 Pyrrolidine-1, 2-dicarboxylic acid l-[(5-chIoro-pyridin-2-yl)-amide] 2-[(3- fluoro-2'-methanesulfonyl-biphenyl-4-yI)-amide]
Figure imgf000173_0001
Step 1: Pyrrolidine-1 ,2-dicarboxylic acid l-tert-butyl ester
DL-proline (10 g, 86.9 mmol) was dissolved in 120 L of THF: H2O
(2:1), added 87 mL of a 2M NaOH solution followed by B0C2O (24.6 g, 113 mmol). Stirred at ambient temperature overnight. Removed THF in vacuo, acidified water to pH 3 with citric acid, extracted twice with EtOAc, washed organics with water, brine, dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)".
Step 2: 2-(4-Bromo-2-fluoro-phenyIcarbamoyl)-pyrrolidine-l-carboxylic acid tert-butyl ester Pyrrolidine- 1 ,2-dicarboxylic acid l -tert-butyl ester (3.8 g, 18 mmol) was dissolved in 150 mL dry diethyl ether under Ar, cooled in an ice water bath, added dry pyridine (8.6 mL, 106 mmol) followed by the dropwise addition of oxalyl chloride (4.6 mL, 53 mmol). A precipitate formed immediately. The reaction was stirred vigorously at 0°C for one hour, then at ambient temperature for one hour. 100 mL diethyl ether was then added. The solides were filtered off and washed with diethyl ether. The filtrates were concwentrated to an off-white oil. The solid was redissolved oil in 50 mL dry DCM under Ar, cooled to 0°C, and 6 mL pyridine was added, followed by 4-bromo-2-fluoroaniline (3.4 g, 17.7 mmol). The reaction was allowed to warm to ambient temperature, stirred for 3 hours then concentrated. The concentrate was redissolved in 250 mL EtOAc, washed with 10% HCl (3x100 mL), brine (100 mL), dried with MgSO filtered and concentrated. The residue was purified on a silica gel column eluted with 20% moving to 40% EtOAc in hexanes to yield title compound as a white solid. (3.2 g,
47%) APCI (AP-): 385.1 , 387.1 (M-H)".
Step 3: 2-(3-Fluoro-2'-methylsulfanyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester
2-(4-Bromo-2-fluoro-phenylcarbamoyl)-pyrrolidine-l -carboxylic acid tertbutyl ester (2 g, 4.8 mmol), 2-(methylthio)benzene boronic acid (0.98 g, 5.8 mmol), and tetrabutylammonium bromide (78 mg, 0.24 mmol) were combined in 30 mL toluene, added 5 mL of a 2M aqueous Na2CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.28 g, 0.24 mmol). The reaction was heated at reflux for 4 hours, cooled, concentrated, redissolved in EtOAc (250 mL), washed with water (3x200 mL), brine (200 L), dried with MgSO4, filtered, and concentrated in the presence of 4 g coarse silica. The residue was was purified by column chromatography on silica gel eluting with 20% EtOAc in hexanes to yield title compound as a yellow foam. (1.84 g, 88%) APCI (AP-): 429.2 (M-H)".
Step 4: 2-(3-Fluoro-2'-methanesulfonyl-biphenyl-4-yIcarbamoyI)-pyrrolidine- 1 -carboxylic acid tert-butyl ester 2-(3-Fluoro-2'-methylsulfanyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester (0.57 g, 1.32 mmol) was dissolved in 10 mL EtOAc, and m-chloroperoxybenzoic acid (1.5 g, 5.3 mmol) was added in one portion to the resulting mixture. The mixture was stirred at ambient temperature for 3 hours, then diluted with 100 mL EtOAc, washed with sat. N HCO3 (3 100 mL), brine, dried with MgSO4, filtered and concentrated. The residue was purified by column chromatography on silica gel eluting with 33% moving to 50% EtOAc in hexanes to yield title compound as a yellow foam. (0.48 g, 75%) APCI
(AP-): 461.2 (M-H)".
Step 5: PyrroIidine-2-carboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl- 4-yl)-amide 2-(3-Fluoro-2'-methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester (0.45 g, 0.93 mmol) was dissolved in 15 mL DCM and 15 mL trifluoroacetic acid and the resulting mixture was stirred at ambient temperature for 1 hour. The mixture was concentrated, and the residue was redissolved in 100 L EtOAc, washed with sat. NaCl, dried with MgSO4, filtered and concentrated to yield title compound as an oil. (0.27 g, 80%) APCI (AP-):
361.1 (M-H)".
Step 6: Pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)-amide] 2- [(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Pyrrolidine-2-carboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)- a ide (0.27 g, 0.75 mmol) and (5-Chloro-pyridin-2-yl)-carbamic acid 4-nitro- phenyl ester (0.22 g, 0.0.75 mmol; see Example 3, step 3a) were combined in 10 mL DMF and heated at 80°C for 4 hours, then cooled. 200 mL of water were then added and a precipitate formed. The solids were filtered off, washed with water, redissolved in EtOAc, dried with MgSO4, filtered and concentrated. The residue was purified by column chromatography on silica gel eluting with 70% EtOAc in hexanes to yield title compound. (220 mg, 57%) APCI (AP-): 515.1, 517.1 (M-
H)-.
Example 12
Pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000175_0001
Step 1: Pyrrolidine-l,2-dicarboxylic acid l-tert-butyl ester
DL-proline (10 g, 86.9 mmol) was dissolved in 120 mL of THF: H2O
(2: 1 ), and 87 mL of a 2M NaOH solution was added to the resulting mixture, followed by B0C2O (24.6 g, 113 mmol). The mixture was stirred at ambient temperature overnight. THF was removed in vacuo, and the remaining water was acidified to pH 3 with citric acid, then extracted twice with EtOAc. The combined organic layers were washed with water, brine, dried with MgSO4, filtered and • concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-):
214.1 (M-H)".
Step 2: 2-(4-Bromo-2-fluoro-phenylcarbamoyI)-pyrrolidine-l-carboxylic acid tert-butyl ester
Pyrrolidine- 1,2-dicarboxylic acid l-tert-butyl ester (3.8 g, 18 mmol) was dissolved in 150 mL dry diethyl ether under Ar, and the resulting solution was cooled in an ice water bath, while dry pyridine (8.6 mL, 106 mmol) was added, followed by the dropwise addition of oxalyl chloride (4.6 L, 53 mmol). A precipitate formed immediately. The reaction was stirred vigorously at 0°C for one hour, then at ambient temperature for one hour. 100 mL of diethyl ether were then added, and the solids wwere removed by filitration washing with diethyl ether. Concentrated the filtrates to an off-white oil. Redissolved oil in 50 mL dry DCM under Ar, cooled to 0°C, added 6 mL pyridine followed by 4-bromo-2- fluoroaniline (3.4 g, 17.7 mmol). The reaction was allowed to warm to ambient temperature, stirred for 3 hours then concentrated. Redissolved in 250 mL EtOAc, washed with 10% HCl (3x100 mL), brine (100 mL), dried with MgSO filtered and concentrated. Purified on a silica gel column eluted with 20% moving to 40% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound as a white solid. (3.2 g, 47%) APCI (AP-): 385.1, 387.1 (M-H)".
Step 3: 2-(3-Fluoro-2'-methylsulfanyl-biphenyl-4-ylcarbamoyl)-pyrroIidine-l- carboxylic acid tert-butyl ester 2-(4-Bromo-2-fluoro-phenylcarbamoyl)-pyrrolidine- 1 -carboxylic acid tertbutyl ester (2 g, 4.8 mmol), 2-(methylthio)benzene boronic acid (0.98 g, 5.8 mmol), and tetrabutylammonium bromide (78 mg, 0.24 mmol) were combined in 30 mL toluene, added 5 mL of a 2M aqueous Na2CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.28 g, 0.24 mmol). Heated reaction at reflux for 4 hours, cooled, concentrated, redissolved in EtOAc (250 mL), washed with water (3x200 mL), brine (200 mL), dried with MgSO4, filtered, and concentrated in the presence of 4 g coarse silica. Loaded silica onto a silica gel column, eluted with 20% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound as a yellow foam. (1.84 g, 88%) APCI (AP-):
429.2 (M-H)".
Step 4: 2-(3-Fluoro-2'-methanesuIfonyl-biphenyl-4-yJcarbamoyl)-pyrrolidine- l-carboxylic acid tert-butyl ester 2-(3-Fluoro-2'-methylsulfanyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester (1.2 g, 2.8 mmol) was dissolved in 30 L EtOAc, added m-chloroperoxybenzoic acid (3.2 g, 11 mmol) in one portion and stirred at ambient temperature for 3 hours. A 10% aqueous solution (50 mL) of Na2S2θ3 was added to the vigorously stirring reaction in order to quench peroxide. After 30 minutes the solution was diluted with 100 mL EtOAc, separated layers, washed organics with sat. NaHCO3 (3x100 mL), brine, dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluted with 50% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound as a yellow foam. (1.01 g, 78%) APCI (AP-): 461.1 (M-H)".
Step 5: Pyrrolidine-2-carboxylic acid (3-fluoro-2'-methanesuIfonyl-biphenyl- 4-yl)-amide
2-(3-Fluoro-2'-methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester (1 g, 2 mmol) was dissolved in 20 mL DCM and 10 mL trifluoroacetic acid and stirred at ambient temperature for 1 hour. Concentrated solution, redissolved in 100 mL CHCI3, repeated CHCI3 co- concentration 3 times to yield title compound as an oil. (quant, yield) APCI (AP-): 361.1 (M-H)".
Step 6: Pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Pyrrolidine-2-carboxylic acid (3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)- amide (0.23 g, 0.64 mmol) was dissolved in 10 mL THF, added diisopropylethylamine (0.33 mL, 1.9 mmol), followed by 4- chlorophenylisocyanate (97 mg, 0.64 mmol). Stirred reaction at ambient temperature for 1 hour then concentrated. Purified on a silica gel column eluted with 70% EtOAc in hexanes. Pure fractions were combined and concentrated, redissolved in acetonitrile/water and lyophilized to yield title compound as a white powder. (0.23 g, 70%) APCI (AP-): 514.1, 516.1 (M-H)".
Example 13
Pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[5-(2- sulfamoyl-phenyl)-pyridin-2-yl]-amide}
Figure imgf000178_0001
Step 1: Pyrrolidine-l,2-dicarboxyIic acid l-tert-butyl ester
DL-proline (10 g, 86.9 mmol) was dissolved in 120 mL of THF: H2O
(2:1), added 87 mL of a 2M NaOH solution followed by B0C2O (24.6 g, 113 mmol). Stirred at ambient temperature overnight. Removed THF in vacuo, acidified water to pH 3 with citric acid, extracted twice with EtOAc, washed organics with water, brine, dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)".
Step 2: 2-(5-Bromo-pyridin-2-ylcarbamoyl)-pyrrolidine-l-carboxylic acid tert-butyl ester
Pyrrolidine- 1 ,2-dicarboxylic acid 1 -tert-butyl ester (1.97 g, 9.2 mmol) was dissolved in 150 mL dry diethyl ether under Ar, cooled in an ice water bath, added dry pyridine (3.7 mL, 45.8 mmol) followed by the dropwise addition of oxalyl chloride (2 mL, 22.9 mmol). A precipitate forms immediately. The reaction was stirred vigorously at 0°C for 2 hours, then at ambient temperature for one hour. Added 100 mL diethyl ether, filtered off solids washing with diethyl ether. Concentrated the filtrates to an off-white oil. Redissolved oil in 100 mL dry DCM under Ar, cooled to 0°C, added 3 L pyridine followed by 2-amino-5- bromopyridine (1.32 g, 7.6 mmol). The reaction was allowed to warm to ambient temperature, stirred for 3 hours then concentrated. Redissolved in 250 mL
EtOAc, washed with 10% HCl (3x100 mL), brine (100 mL), dried with MgSO4, filtered and concentrated to yield title compound as a yellow sticky solid. (2.74 g,
97%) APCI (AP-): 368.0, 370.0 (M-H)".
Step 3: 2-[5-(2-tert-Butylsulfamoyl-phenyI)-pyridin-2-ylcarbamoyl]- pyrrolidine-l-carboxylic acid tert-butyl ester
2-(5-Bromo-pyridin-2-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tertbutyl ester (0.92 g, 2.48 mmol), 2-(N-tert-butyl)phenylsulfonamide boronic acid (0.64 g, 2.48 mmol), and tetrabutylammonium bromide (40 mg, 0.12 mmol) were combined in 10 mL toluene, added 2 mL of an aqueous 2M sodium carbonate solution followed by the addition of tetrakistriphenylphosphine palladium(O) (144 mg, 0.12 mmol). Refluxed solution for 4 hours, cooled to room temperature, partitioned between EtOAc (150 mL) and water (100 mL), washed organics with . water (3x100 mL), brine, dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluted with 40% moving to 50% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound as a white solid. (0.92 g, 74%) APCI (AP-): 501.1 (M-H)'.
Step 4: Pyrrolidine-2-carboxylic acid [5-(2-tert-butylsulfamoyl-phenyl)- pyridin-2-yI]-amide
2-[5-(2-tert-Butylsulfamoyl-phenyl)-pyridin-2-ylcarbamoyl]-pyrrolidine- 1 -carboxylic acid tert-butyl ester (0.92 g, 1.83 mmol) was dissolved in 30 mL , DCM, added 10 mL trifluoroacetic acid and stirred at ambient temperature for one hour. Concentrated solution, redissolved in CHCI3 and reconcentrated. Repeated co-concentration twice to yield title compound as an oil. (quant, yield) APCI
(AP-): 401.1 (M-H)".
Step 5: Pyrrolidine-1, 2-dicarboxylic acid 2-{[5-(2-tert-butylsulfamoyI- phenyl)-pyridin-2-yI]-amide} l-[(4-chloro-phenyl)-amide] Pyrrolidine-2-carboxylic acid [5-(2-tert-butylsulfamoyl-phenyl)-pyridin-2- yl]-amide (0.44 g, 0.59 mmol) was dissolved in 10 mL THF, added diisopropylethylamine (0.41 mL, 2.4 mmol) followed by 4- chlorophenylisocyanate (91 mg, 0.59 mmol). Stirred at ambient temperature for 2 hours. Diluted reaction with 50 mL EtOAc, washed with 10% citric acid (3x50 mL), water (2x50 mL), brine, dried with MgSO4, filtered and concentrated to yield title compound. (0.28 g, 85%) APCI (AP+): 556.2, 558.2 (M-H)+.
Step 6: Pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[5- (2-sulfamoyl-phenyl)-pyridin-2-yl]-amide} Pyrrolidine-1 ,2-dicarboxylic acid 2-{ [5-(2-tert-butylsulfamoyl-phenyl)- pyridin-2-yl]-amide} 1 -[(4-chloro-phenyl)-amide] (0.28 g, 0.5 mmol) was stirred in 10 L trifluoroacetic acid at ambient temperature for 20 hours. The solution was concentrated and purified on a silica gel column using an automated system with gradient of 40-100% EtOAc in hexanes over 40 minutes. Combined and concentrated pure fractions, redissolved in acetonitrile/water and lyophilized to yield title compound as a light yellow powder. (0.156 g, 62%) APCI (AP+): 500.0, 501.9 (M+H)+.
Example 14
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl-biphenyl- 4-yl)-amide] 1 -[(5-chloro-pyridin-2-yI)-amide]
Figure imgf000181_0001
Step 1: Pyrrolidine-l,2-dicarboxyIic acid l-tert-butyl ester
DL-proline (10 g, 86.9 mmol) was dissolved in 120 mL of THF: H2O
(2:1), added 87 mL of a 2M NaOH solution followed by B0C2O (24.6 g, 113 mmol). Stirred at ambient temperature overnight. Removed THF in vacuo, acidified water to pH 3 with citric acid, extracted twice with EtOAc, washed organics with water, brine, dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)".
Step 2: 2-(4-Bromo-2-chloro-phenylcarbamoyl)-pyrrolidine-l-carboxylic acid tert-butyl ester Pyrrolidine-1, 2-dicarboxylic acid l-tert-butyl ester (2.2 g, 10 mmol) was dissolved in 150 mL dry diethyl ether under Ar, cooled in an ice water bath, added dry pyridine (2.8 mL, 34 mmol) followed by the dropwise addition of oxalyl chloride (1.5 mL, 17 mmol). A precipitate forms immediately. The reaction was stirred vigorously at 0°C for 1 hours, then at ambient temperature for two hours. Added 100 mL diethyl ether, filtered off solids washing with diethyl ether.
Concentrated the filtrates to an off-white oil. Redissolved oil in 100 mL dry DCM under Ar, cooled to 0°C, added 3 L pyridine followed by 2-chloro-4- bromoaniline ( 1.8 g, 8.5 mmol). The reaction was allowed to warm to ambient temperature and stirred over the weekend. Concentrated reaction, redissolved in 250 L EtOAc, washed with 10% citric acid (3x100 mL), water, (2x100 mL), brine (100 mL), dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluted with an automated system with gradient of 0-60% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound as, a yellow solid. (2.7 g, 79%) APCI (AP-): 401.0, 403.0, 405.0 (M-H)".
Step 3: 2-(3-Chloro-2'-methylsuIfanyl-biphenyl-4-ylcarbamoyl)-pyrroIidine- 1 -carboxylic acid tert-butyl ester
2-(4-Bromo-2-chloro-pheny]carbamoy])-pyrrolidine-l -carboxylic acid tert-butyl ester (1 g, 2.5 mmol), 2-(methylthio)benzene boronic acid (0.5 g, 3 mmol), and tetrabutyl ammonium bromide (40 mg, 0.12 mmol) were combined in 10 mL toluene, added 2 mL of a 2M aqueous Na2CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.14 g, 0.12 mmol). Heated reaction at reflux for 5 hours, cooled, dissolved in EtOAc (150 mL), washed with water (3x50 mL), brine (50 mL), dried with MgSO4, filtered, and concentrated. Purified on a silica gel column eluted using an automated system with gradient of 0-50% EtOAc in hexanes over 40 minutes. Combined and concentrated pure fractions to yield title compound as a white foam. (1.01 g, 91%) APCI (AP-): 445.1, 447.1
(M-H)".
Step 4: 2-(3-Chloro-2'-methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine- 1-carboxylic acid tert-butyl ester
2-(3-Chloro-2'-methylsulfanyl-biphenyl-4-ylcarbamoyl)-ρyrrolidine-l- carboxylic acid tert-butyl ester (1 g, 2 mmol) was dissolved in 20 mL EtOAc, added m-chloroperoxybenzoic acid (2.6 g, 8.9 mmol) in one portion and stirred at ambient temperature for 3 hours. A 10% aqueous solution (30 mL) of Na2S2θ3 was added to the vigorously stirring reaction in order to quench peroxide. After 20 minutes the solution was diluted with 100 L EtOAc, separated layers, washed organics with sat. NaHCO3 (3x100 mL), brine, dried with MgSO4, filtered and concentrated to yield title compound as a clear oil. (1 g, 100%) APCI (AP-): 477.1, 479.1 (M-H)-.
Step 5: PyrroIidine-2-carboxylic acid (3-chIoro-2'-methanesulfonyl-biphenyl- 4-yl)-amide
2-(3-Chloro-2'-methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester (1 g, 2 mmol) was dissolved in 20 mL DCM and 20 mL trifluoroacetic acid and stirred at ambient temperature for 2 hours. Concentrated solution, redissolved in 100 mL CHCI3, repeated CHCI3 co- concentration 4 times to yield title compound as a yellow foam, (quant, yield) APCI (AP+): 379.1, 381.1 (M+H)+.
Step 6: Pyrrolidine-1, 2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl- biphenyl-4-yl)-amide] l-[(5-chloro-pyridin-2-yl)-amide]
Pyrrolidine-2-carboxylic acid (3-chloro-2'-methanesulfonyl-biphenyl-4- y])-amide (0.1 1 g, 0.29 mmol) and (5-Chloro-pyridin-2-yl)-carbamic acid 4-nitro- phenyl ester (0.085 g, 0.29 mmol; see Example 3, step 3a) were combined in 3 mL DMF and heated at 50°C for 2 hours, dissolved in 100 mL EtOAc, washed with sat. NaHCO3 (3x50 mL), brine, dried with MgSO4, filtered and concentrated.
Purified on a silica gel column eluting using an automated system with gradient of 0-100% EtOAc in hexanes over 40 minutes. Combined and concentrated pure fractions, redissolved in acetonitrile/water and lyophilized to yield title compound as a white powder. (1 10 mg, 71 %) APCI (AP+): 533.0, 535.0 (M+H)+.
Example 15
Pyrrolidine-l,2-dicarboxylic acid 2-[(3-chloro-2'-methanesuIfonyl-biphenyl- 4-yl)-amide] l-[(4-chloro-phenyl)-amide]
Figure imgf000184_0001
Step 1: Pyrrolidine-l,2-dicarboxyIic acid l-tert-butyl ester
DL-proline (10 g, 86.9 mmol) was dissolved in 120 mL of THF: H2O
(2:1), added 87 L of a 2M NaOH solution followed by B0C2O (24.6 g, 113 mmol). Stirred at ambient temperature overnight. Removed THF in vacuo, acidified water to pH 3 with citric acid, extracted twice with EtOAc, washed organics with water, brine, dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)-.
Step 2: 2-(4-Bromo-2-chloro-phenylcarbamoyl)-pyrrolidine-l-carboxylic acid tert-butyl ester
Pyrrolidine- 1 ,2-dicarboxylic acid l-tert-butyl ester (2.2 g, 10 mmol) was dissolved in 150 mL dry diethyl ether under Ar, cooled in an ice water bath, added dry pyridine (2.8 mL, 34 mmol) followed by the dropwise addition of oxalyl chloride (1.5 mL, 17 mmol). A precipitate forms immediately. The reaction was stirred vigorously at 0°C for 1 hours, then at ambient temperature for two hours. Added 100 mL diethyl ether, filtered off solids washing with diethyl ether. Concentrated the filtrates to an off-white oil. Redissolved oil in 100 mL dry DCM under Ar, cooled to 0°C, added 3 mL pyridine followed by 2-chloro-4- bromoaniline ( 1.8 g, 8.5 mmol). The reaction was allowed to warm to ambient temperature and stirred over the weekend. Concentrated reaction, redissolved in 250 mL EtOAc, washed with 10% citric acid (3x100 mL), water, (2x100 mL), brine (100 mL), dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluted with an automated system with gradient of 0-60% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound as a yellow solid. (2.7 g, 79%) APCI (AP-): 401.0, 403.0, 405.0 (M-H)".
Step 3: 2-(3-Chloro-2'-methylsulfanyl-biphenyl-4-ylcarbamoyI)-pyrrolidine- 1 -carboxylic acid tert-butyl ester
2-(4-Bromo-2-chloro-phenylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (1 g, 2.5 mmol), 2-(methylthio)benzene boronic acid (0.5 g, 3 mmol), and tetrabutylammonium bromide (40 mg, 0.12 mmol) were combined in 10 mL toluene, added 2 mL of a 2M aqueous Na2CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.14 g, 0.12 mmol). Heated reaction at reflux for 5 hours, cooled, dissolved in EtOAc (150 mL), washed with water (3x50 mL), brine (50 mL), dried with MgSO4, filtered, and concentrated. Purified on a silica gel column eluted using an automated system with gradient of 0-50% EtOAc in hexanes over 40 minutes. Combined and concentrated pure fractions to yield title compound as a white foam. (1.01 g, 91 %) APCI (AP-): 445.1, 447.1
(M-H)".
Step 4: 2-(3-Chloro-2'-methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrroIidine- 1 -carboxylic acid tert-butyl ester 2-(3-Chloro-2'-methylsulfanyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester (1 g, 2 mmol) was dissolved in 20 mL EtOAc, added m-chloroperoxybenzoic acid (2.6 g, 8.9 mmol) in one portion and stirred at ambient temperature for 3 hours. A 10% aqueous solution (30 mL) of Na2S2θ3 was added to the vigorously stirring reaction in order to quench peroxide. After 20 minutes the solution was diluted with 100 L EtOAc, separated layers, washed organics with sat. NaHCO3 (3x100 mL), brine, dried with MgSO4, filtered and concentrated to yield title compound as a clear oil. (1 g, 100%) APCI (AP-):
477.1, 479.1 (M-H)".
Step 5: PyrroIidine-2-carboxylic acid (3-chloro-2'-methanesulfonyl-biphenyl- 4-yl)-amide 2-(3-Chloro-2'-methanesulfonyl-biphenyl-4-yIcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester (1 g, 2 mmol) was dissolved in 20 mL DCM and 20 mL trifluoroacetic acid and stirred at ambient temperature for 2 hours. Concentrated solution, redissolved in 100 mL CHCI3, repeated CHCI3 co- concentration 4 times to yield title compound as a yellow foam, (quant, yield)
APCI (AP+): 379.1 , 381.1 (M+H)+.
Step 6: Pyrrolidine-1, 2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl- biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide] Pyrrolidine-2-carboxylic acid (3-chloro-2'-methanesulfonyl-biphenyl-4- yl)-amide (0.16 g, 0.42 mmol) was dissolved in 5 mL THF, added diisopropylethylamine (0.22 mL, 1.3 mmol) followed by 4- chlorophenylisocyanate (65 mg, 0.42 mmol). Stirred at ambient temperature for 20 hours. The reaction was concentrated and purified using an automated system with gradient of 0-100% EtOAc in hexanes over 40 minutes. Combined and concentrated pure fractions, redissolved in acetonitrile/water and lyophilized to yield title compound as a white powder. (0.175 g, 78%) APCI (AP+): 532.0,
534.0(M-H)+.
Example 16
Pyrrolidine-1, 2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)-amide] 2-{[5-(2- sulfamoyl-phenyl)-pyridin-2-yl]-amide}
Figure imgf000186_0001
Step 1: Pyrrolidine-l,2-dicarboxylic acid l-tert-butyl ester DL-proIine (10 g, 86.9 mmol) was dissolved in 120 mL of THF: H2O (2: 1 ), added 87 L of a 2M NaOH solution followed by B0C2O (24.6 g, 1 13 mmol). Stirred at ambient temperature overnight. Removed THF in vacuo, acidified water to pH 3 with citric acid, extracted twice with EtOAc, washed organics with water, brine, dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)- .
Step 2: 2-(5-Bromo-pyridin-2-ylcarbamoyl)-pyrrolidine-l-carboxylic acid tert-butyl ester Pyrrolidine- 1 ,2-dicarboxylic acid l-tert-butyl ester (1.97 g, 9.2 mmol) was dissolved in 150 mL dry diethyl ether under Ar, cooled in an ice water bath, added dry pyridine (3.7 mL,' 45.8 mmol) followed by the dropwise addition of oxalyl chloride (2 L, 22.9 mmol). A precipitate forms immediately. The reaction was stirred vigorously at 0°C for 2 hours, then at ambient temperature for one hour. Added 100 L diethyl ether, filtered off solids washing with diethyl ether.
Concentrated the filtrates to an off-white oil. Redissolved oil in 100 L dry DCM under Ar, cooled to 0°C, added 3 mL pyridine followed by 2-amino-5- bromopyridine (1.32 g, 7.6 mmol). The reaction was allowed to warm to ambient temperature, stirred for 3 hours then concentrated. Redissolved in 250 mL EtOAc, washed with 10% HCl (3x 100 mL), brine ( 100 mL), dried with MgSO filtered and concentrated to yield title compound as a yellow sticky solid. (2.74 g, 97%) APCI (AP-): 368.0, 370.0 (M-H)".
Step 3: 2-[5-(2-tert-Butylsulfamoyl-phenyI)-pyridin-2-ylcarbamoyl]- pyrrolidine-1-carboxylic acid tert-butyl ester
2-(5-Bromo-pyridin-2-ylcarbamoyl)-pyrrolidine-l-carboxylic acid tertbutyl ester (0.92 g, 2.48 mmol), 2-(N-tert-butyl)phenylsulfonamide boronic acid (0.64 g, 2.48 mmol), and tetrabutylammonium bromide (40 mg, 0.12 mmol) were combined in 10 mL toluene, added 2 L of an aqueous 2M sodium carbonate solution followed by the addition of tetrakistriphenylphosphine palladium(O) (144 mg, 0.12 mmol). Refluxed solution for 4 hours, cooled to room temperature, partitioned between EtOAc (150 mL) and water (100 mL), washed organics with water (3 100 mL), brine, dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluted with 40% moving to 50% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound as a white solid. (0.92 g, 74%) APCI (AP-): 501.1 (M-H)".
Step 4: Pyrrolidine-2-carboxyIic acid [5-(2-tert-butylsulfamoyI-phenyl)- pyridin-2-yl]-amide
2-[5-(2-tert-Butylsulfamoyl-phenyl)-pyridin-2-ylcarbamoyl]-pyrrolidine- 1 -carboxylic acid tert-butyl ester (0.92 g, 1.83 mmol) was dissolved in 30 mL
DCM, added 10 mL trifluoroacetic acid and stirred at ambient temperature for one hour. Concentrated solution, redissolved in CHCI3 and reconcentrated. Repeated co-concentration twice to yield title compound as an oil. (quant, yield) APCI
(AP-): 401.1 (M-H)". Step 5: PyrroIidine-l,2-dicarboxylic acid 2-{[5-(2-tert-butylsuIfamoyl- phenyl)-pyridin-2-yl]-amide} l-[(5-chloro-pyridin-2-yl)-amide]
Pyrrolidine-2-carboxylic acid [5-(2-tert-butylsulfamoyl-phenyl)-pyridin-2- yl]-amide (0.17 g, 0.25 mmol) and (5-Chloro-pyridin-2-yl)-carbamic acid 4-nitro- phenyl ester (0.074 g, 0.25 mmol; see Example 3, step 3a) were combined in 3 mL DMF, added diisopropylethylamine (0.18 L, 1 mmol) and heated at 50°C for 2 hours. Dissolved in 100 mL EtOAc, washed with sat. NaHCO3 (3x50 mL), brine, dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluting using an automated system with gradient of 30-100% EtOAc in hexanes over 40 minutes. Combined and concentrated pure fractions to yield title compound as a white solid. (90 mg, 64%) APCI (AP-): 555.2, 557.2 (M-H)".
Example 17
(2R,4R)-4-Hydroxy-pyrrolidine-l,2 -dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-[(3-fluoro-2'-methanesulfonyI-biphenyl-4-yl)-amide]
Figure imgf000189_0001
Step 1: (2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxylic acid l-tert-butyl ester Cis-4-hydroxy-D-proline (1.1 g, 8.4 mmol) was dissolved in 18 mL of
THF/ H2O (2:1), added 2M aqueous NaOH solution (6.3 mL, 13 mmol), followed by B0C2O. Reaction was stirred at ambient temperature over the weekend.
Solution was taken up in 150 mL EtOAc, washed with 10% HCl (3x100 mL), dried organics with M SO4, filtered and concentrated to yield title compound as a white foam. (1.5 g, 77%) APCI (AP-): 230.1 (M-H)".
Step 2: (2R,4R)-4-(tert-Butyl-dimethyI-silanyIoxy)-pyrroIidine-l,2- dicarboxylic acid l-tert-butyl ester
(2R,4R)-4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid l-tert-butyl ester (1.5 g, 6.5 mmol) was dissolved in 20 mL DMF, added imidazole (1.1 g, 16 mmol), dimethylaminopyridine (80 mg, 0.65 mmol), and tert-butyldimethylsilyl chloride (1.08 g, 7.1 mmol). Stirred at ambient temperature overnight, dissolved in 150 mL EtOAc, washed with 10% citric acid (3x100 L), water (2x100 mL), brine, dried with MgSO4, filtered, and concentrated. Redissolved in 50 mL CHCI3 and reconcentrated to yield title compound as a clear oil. (1.54 g, 69%) APCI (AP-): 344.2 (M-H)".
Step 3: (2R,4R)-2-(4-Bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl- dimethyl-silanyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-pyrrolidine-l , 2-dicarboxylic acid l-tert-butyl ester (1.54 g, 4.5 mmol) was dissolved in 50 mL diethyl ether under an Ar atmosphere, cooled in an ice water bath, added dry pyridine (1.4 mL, 17.8 mmol), followed by the dropwise addition of oxalyl chloride (0.58 mL, 6.7 mmol). Reaction was stirred at 0°C for 1 hour, then at ambient temperature for 1 hour. Diluted reaction with 50 mL diethyl ether, filtered off solids and concentrated filtrates. Redissolved filtrate in 30 mL dry DCM under an Ar atmosphere, cooled in an ice water bath, added 1 mL dry pyridine followed by 4- bromo-2-fluoroaniline (0.85 g, 4.5 mmol). Stirred reaction at ambient temperature for 20 hours. Concentrated solution, redissolved in EtOAc (150 mL), washed with 10% citric acid (3x100 mL), water (2x100 mL), brine, dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluting with an automated system with gradient of 0-60% EtOAc in hexanes over 40 minutes. Combined and concentrated pure fractions to yield "title compound as a clear oil. (0.96 g, 42%) APCI (AP-): 515.1, 517.1 (M-H)".
Step 4: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methylsulfanyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l-carboxylic acid tertbutyl ester (2R,4R)-2-(4-Bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl-dimethyl- silanyloxy)-pyrrolidine-l -carboxylic acid tert-butyl ester (0.95 g, 1.84 mmol), 2- (methylthio)benzene boronic acid (0.37 g, 2.2 mmol), and tetrabutylammonium bromide (30 mg, 0.09 mmol) were combined in 15 mL toluene, added 2 mL of a 2M aqueous Na CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.11 g, 0.09 mmol). Heated reaction at reflux for 5 hours, cooled, dissolved in EtOAc (100 mL), washed with water (3x50 L), brine (50 mL), dried with MgSO4, filtered, and concentrated. Purified on a silica gel column eluted using an automated system with gradient of 0-60% EtOAc in hexanes over 40 minutes. Combined and concentrated pure fractions to yield title compound as a light yellow foam. (0.77 g, 74%) APCI (AP-): 559.3 (M-H)". Step 5: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrroIidine-l-carboxylic acid tertbutyl ester
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'-methylsulfanyl- biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (0.84 g, 1.35 mmol) was dissolved in 20 L EtOAc, added added m-chloroperoxybenzoic acid (1.6 g, 5.4 mmol) in one portion and stirred at ambient temperature for 3 hours. A 10% aqueous solution (50 mL) of Na2S2θ3 was added to the vigorously stirring reaction in order to quench peroxide. After 20 minutes the solution was diluted with 100 L EtOAc, separated layers, washed organics with sat. NaHCO3
(3x100 mL), water (2x100 mL), brine, dried with MgSO4, filtered and concentrated to yield title compound as a light brown foam. (0.8 g, 100%) APCI
(AP-): 591.3 (M-H)".
Step 6: (2R,4R)-4-Hydroxy-pyrrolidine-2-carboxyIic acid (3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (0.8 g, 1.35 mmol) was dissolved in 30 mL DCM, added 10 mL trifluoroacetic acid and stirred reaction at ambient temperature for 90 minutes. Solution was concentrated to yield title compound as an amber oil. (100% crude yield) APCI (AP-): (M-H)".
Step 7: (2R,4R)-4-Hydroxy-pyrrolidine-l,2 -dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
(2R,4R)-4-Hydroxy-pyrroIidine-2-carboxylic acid (3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide (0.51 g, 1.35 mmol) was dissolved in 20 mL THF, added diisopropylethylamine (0.94 L, 5.4 mmol) followed by 4- chlorophenylisocyanate (0.21 g, 1.35 mmol). Stirred at ambient temperature for 2 hours. The reaction was dissolved in 100 mL EtOAc, washed with 10% citric acid (3x50 mL), water (2x50 mL), brine, dried with MgSO4, filtered and concentrated. Purified using an automated system with gradient of 50-100% EtOAc in hexanes over 40 minutes. Compound was still eluting at end of run. Switched gradient to 0-15% MeOH in EtOAc over 40 minutes. Combined and concentrated pure fractions to yield title compound as a white solid. (0.54 g, 75%) APCI (AP+): 530.1, 532.1(M-H)+.
Example 18
Pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[4-(l- methyl-4,5-dihydro-lH-imidazol-2-yl)-phenyl]-amide}
Figure imgf000192_0001
Step 1: Pyrrolidine-l,2-dicarboxylic acid l-tert-butyl ester
DL-proline (10 g, 86.9 mmol) was dissolved in 120 mL of THF: H2O (2:1), added 87 mL of a 2M NaOH solution followed by B0C2O (24.6 g, 113 mmol). Stirred at ambient temperature overnight. Removed THF in vacuo, acidified water to pH 3 with citric acid, extracted twice with EtOAc, washed organics with water, brine, dried with M SO4, filtered and concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)".
Step 2: 2-(4-Cyano-phenylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester
Pyrrolidine- 1 ,2 -dicarboxylic acid l-tert-butyl ester (2.1 g, 9.8 mmol) was dissolved in 100 L dry diethyl ether under an argon atmosphere, added dry pyridine (3.3 mL, 32.5 mmol), cooled to 0°C then added oxalyl chloride (1.4 mL, 16.3 mmol) dropwise. A precipitate forms immediately upon addition of oxalyl chloride and therefore reaction requires vigorous stirring. Stirred at 0°C for one hour than at ambient temperature for 2 hours. Dry diethyl ether (100 mL) was added and the solids were filtered off, washing with more diethyl ether. The filtrates were concentrated, then redissolved in dry DCM under argon, cooled to 0°C, added 1 mL dry pyridine then added 4-amino-benzonitrile (0.96 g, 8.1 mmol) in one portion. Stirred at ambient temperature for 2 hours, concentrated, redissolved in ethyl acetate (250 L), washed with 10% citric acid (3x100 mL), water, brine, dried with MgSO4, filtered and concentrated to yield title compound as a white foam. (2.4 g, 93%) APCI (AP-): 314.1 (M-H)".
Step 3: PyrroIidine-2-carboxylic acid (4-cyano-phenyl)-amide
2-(4-Cyano-phenylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (3 g, 8 mmol) was dissolved in 90 mL of a 1 :2 mixture of trifluoroacetic acid and dichloromethane. The reaction was stirred at ambient temperature for one hour then concentrated to yield title compound as an amber oil which was carried onto next step as is. APCI (AP-): 214.1 (M-H)".
Step 4: Pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(4- cyano-phenyI)-amide] Pyrrolidine-2-carboxylic acid (4-cyano-phenyl)-amide (0.9 g, 4 mmol) was dissolved in 25 mL tetrahydrofuran, added diisopropylethylamine (3.5 mL, 20 mmol), followed by the addition of 4-chlorophenylisocyanate (0.61 g, 4 mmol). The reaction was stirred at ambient temperature for one hour then concentrated solution. Redissolved in 100 L ethyl acetate, washed with 10% citric acid (2x 100 mL), water, brine, dried with MgSO4, filtered and concentrated.
Recrystallized from ethyl acetate and hexanes to yield title compound as a white powder. (1.1 g, 75%) APCI (AP-): 367.1, 369.1 (M-H)".
Step 5: Pyrrolidine-l,2-dicarboxyIic acid l-[(4-chloro-phenyl)-amide] 2-{[4- (l-methyl-4,5-dihydro-lH-imidazol-2-yl)-phenyI]-amide} Pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(4- cyano-phenyl)-amide] (0.2 g, 0.54 mmol) was dissolved in 2 mL dry methanol under argon, cooled in an ice bath, bubbled in HCl(g) for 10 minutes, removed argon line and HCl line and sealed off flask. Stirred at 0°C for 20 minutes, then at ambient temperature for 4 hours. The solution was concentrated in vacuo to a yellow foam. The foam was redissolved in 4 L dry methanol under argon, added N-methylethylenediamine (0.048 mL, 0.54 mmol) and stirred at ambient, temperature overnight. The solution was concentrated in vacuo then purified by preparatory HPLC. Combined and lyophilized pure fractions to yield the TFA salt of the title compound as a white fluffy powder. (0.2 g, 69%) APCI (AP-): 424.1 ,
426.1 (M-H)".
Example 19
Pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesuIfonyI-biphenyl-4-yI)-amide]
Figure imgf000194_0001
Step 1: Pyrrolidine-1, 2-dicarboxylic acid l-tert-butyl ester DL-proline (10 g, 86.9 mmol) was dissolved in 120 mL of THF: H2O
(2:1), added 87 mL of a 2M NaOH solution followed by B0C2O (24.6 g, 113 mmol). Stirred at ambient temperature overnight. Removed THF in vacuo, acidified water to pH 3 with citric acid, extracted twice with EtOAc, washed organics with water, brine, dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)". Step 2: 2-(4-Bromo-phenylcarbamoyl)-pyrroIidine-I -carboxylic acid tertbutyl ester
Pyrrolidine-1 , 2-dicarboxylic acid l-tert-butyl ester (5 g, 23 mmol) was dissolved in 250 mL dry diethyl ether under Ar, cooled in an ice water bath, added dry pyridine ( 1 1.3 mL, 139 mmol) followed by the dropwise addition of oxalyl chloride (6.1 mL, 69 mmol). A precipitate forms immediately. The reaction was stirred vigorously at 0°C for one hour, then at ambient temperature for one hour. Added 100 mL diethyl ether, filtered off solids washing with diethyl ether. Concentrated the filtrates to an off white oil. Redissolved (3.66 g, 15 mmol) oil in 40 mL dry DCM under Ar, cooled to 0°C, added 4.6 mL pyridine followed by 4- bromoaniline (2.7 g, 15 mmol). The reaction was allowed to warm to ambient temperature, stirred for 3 hours then concentrated. Redissolved in 100 mL EtOAc, washed with 1 N HCl (2x100 mL), brine (100 L), dried with MgSO4, filtered and concentrated to yield title compound. (4.56 g, 80%) APCI (AP-): 369.0, 370.0 (M-H)".
Step 3: 2-(2'-Methylsulfanyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester
2-(4-Bromo-phenylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (2.57 g, 6.9 mmol), 2-(methylthio)benzene boronic acid (1.4 g, 8.3 mmol), and tetrabutylammonium bromide (110 mg, 0.33 mmol) were combined in 30 mL toluene, added 6.9 mL of a 2M aqueous Na2CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.40 g, 0.34 mmol). Heated reaction at reflux overnight, cooled, concentrated, redissolved in EtOAc (250 mL), washed with water (3x200 mL), brine (200 mL), dried with MgSO4, filtered, and concentrated. Purified on a silica gel column eluted with 20% moving to 40% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound. (1.75 g, 60%) APCI (AP-): 411.1 (M-H)-.
Step 4: 2-(2'-Methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester 2-(2'-Methylsulfanyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (1.0 g, 2.4 mmol) was dissolved in 10 mL acetonitrile, added oxone (2.98 g, 4.8 mmol) in one portion and stirred at ambient temperature for 1 week and then concentrated. Redissolved in 100 mL EtOAc and 100 L sat. NaHCO3, separated layers, washed organics with brine, dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluted with 20% moving to 40% EtOAc in hexanes. Combined and concentrated pure fractions to yield , title compound. (0.80 g, 75%) APCI (AP-): 443.1 (M-H)-.
Step 5: Pyrrolidine-2 -carboxylic acid (2'-methanesulfonyl-biphenyl-4-yl)- amide
2-(2'-Methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l-carboxylic acid tert-butyl ester (0.8 g, 1.7 mmol) was dissolved in 25 mL DCM and 5 L trifluoroacetic acid and stirred at ambient temperature for one hour and concentrated. Redissolved in 100 mL EtOAc and 100 L sat. NaHCO3, separated layers, washed organics with brine, dried with MgSO4, filtered and concentrated to yield title compound as an oil (quant, yield) APCI (AP-): 343.1 (M-H)".
Step 6: Pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-biphenyI-4-yl)-amide]
Pyrrolidine-2-carboxylic acid (2'-methanesulfonyl-biphenyl-4-yl)-amide (0.61 g, 1.8 mmol) was dissolved in 20 L THF, added diisopropylethylamine (0.92 mL, 5.3 mmol), followed by 4-chlorophenylisocyanate (270 mg, 1.7 mmol). Stirred reaction at ambient temperature for one hour then concentrated. Crystallized from EtOAc in hexanes and filtered to yield title compound as a white powder. (0.71 g, 80%) APCI (AP-): 496.1, 498.1 (M-H)". Example 20
PyrroIidine-l,2-dicarboxyIic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesuIfonyl-3-methyl-biphenyl-4-yI)-amide]
Figure imgf000197_0001
Step 1: PyrroIidine-l,2-dicarboxylic acid l-tert-butyl ester
DL-proline (10 g, 86.9 mmol) was dissolved in 120 L of THF: H2O
(2: 1), added 87 mL of a 2M NaOH solution followed by B0C2O (24.6 g, 113 mmol). Stirred at ambient temperature overnight. Removed THF in vacuo, acidified water to pH 3 with citric acid, extracted twice with EtOAc, washed organics with water, brine, dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)~.
Step 2: 2-(4-Bromo-2-methyl-phenylcarbamoyl)-pyrrolidine-l-carboxylic acid tert-butyl ester
Pyrrolidine-1, 2-dicarboxylic acid l-tert-butyl ester (2 g, 9.3 mmol) was dissolved in 100 L dry diethyl ether under Ar, cooled in an ice water bath, added dry pyridine (4.5 mL, 55 mmol) followed by the dropwise addition of oxalyl chloride (2.4 mL, 27 mmol). A precipitate forms immediately. The reaction was stirred vigorously at 0°C for one hour, then at ambient temperature for one hour. Added 100 mL diethyl ether, filtered off solids washing with diethyl ether. Concentrated the filtrates to an off white oil. Redissolved (0.95 g, 4.0 mmol) oil in 40 mL dry DCM under Ar, cooled to 0°C, added 1.3 mL pyridine followed by 4-bromo-2-methylaniline (0.75 g, 4.0 mmol). The reaction was allowed to warm to ambient temperature, stirred overnight then concentrated. Redissolved in 100 mL EtOAc, washed with 1 N HCl (3x50 mL), brine (100 mL), dried with MgSO4, filtered and concentrated to yield title compound. (1.09 g, 70%) APCI (AP-): 381.0, 383.0 (M-H)".
Step 3: 2-(3-Methyl-2'-methylsulfanyl-biphenyI-4-ylcarbamoyl)-pyrrolidine- 1-carboxylic acid tert-butyl ester
2-(4-Bromo-2-methyl-phenylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (1.07 g, 2.7 mmol), 2-(methylthio)benzene boronic acid (0.56 g„ 3.3 mmol), and tetrabutyl ammonium bromide (322 mg, 0.13 mmol) were combined in 20 L toluene, added 2.8 mL of a 2M aqueous Na2CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.161 g, 0.13 mmol).
Heated reaction at reflux 4 hours, cooled, concentrated, redissolved in EtOAc (250 mL), washed with water (3x200 mL), brine (200 mL), dried with MgSO4, filtered, and concentrated. Purified on a silica gel column eluted with 20% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound. (0.59 g, 50%) APCI (AP-): 425.1 (M-H)".
Step 4: 2-(2'-MethanesulfonyI-3-methyl-biphenyl-4-ylcarbamoyI)- pyrrolidine-1-carboxylic acid tert-butyl ester
2-(3-Methyl-2'-methylsulfanyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester (0.57 g, 1.3 mmol) was dissolved in 10 L EtOAc, added added m-chloroperoxybenzoic acid (1.76 g, 6.1 mmol) in one portion and stirred at ambient temperature for 3 hours. Reaction not complete. Concentrated and redissolved in 10 L acetonitrile and added oxone (1.5 g, 2.4 mmol) in one portion and stirred at ambient temperature overnight and then concentrated. Redissolved in 100 mL EtOAc and 100 mL sat. NaHCO3, separated layers, washed organics with brine, dried with MgSO4, filtered and concentrated.
Purified on a silica gel column eluted with 20% moving to 40% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound.
(0.44 g, 72%) APCI (AP-): 457.1 (M-H)". Step 5: Pyrrolidine-2-carboxyIic acid (2'-methanesulfonyl-3-methyl-biphenyl- 4-yl)-amide
2-(2'-Methanesulfonyl-3-methyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l- carboxylic acid tert-butyl ester (0.4 g, 0.87 mmol) was dissolved in 15 mL DCM and 5 L trifluoroacetic acid and stirred at ambient temperature for 2 hour and concentrated. Redissolved in 100 mL EtOAc and 100 mL sat. NaHCO3, separated layers, washed organics with brine, dried with MgSO4, filtered and concentrated to yield title compound as an oil (0.29 g, 93%) APCI (AP-): 357.1 (M-H)".
Step 6: Pyrrolidine-1 ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-3-methyl-biphenyl-4-yl)-amide]
Pyrrolidine-2-carboxylic acid (2'-methanesulfonyl-3-methyl-biphenyl-4- yl)-amide (0.29 g, 0.80 mmol) was dissolved in 10 mL THF, added diisopropylethylamine (0.42 mL, 2.4 mmol), followed by 4- chlorophenylisocyanate (124 mg, 0.80 mmol). Stirred reaction at ambient temperature for one hour then concentrated. Purified on a silica gel column eluted with 20% moving to 40% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound. (0.32 g, 78%) APCI (AP-): 510.1 , 512.1 (M-H)"
Example 21
(2R,4R)-4-methoxy-pyrrolidine-l, 2 -dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yI)-amide]
Figure imgf000199_0001
Step 1 : (2R,4R)-4-hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-tert-butyl ester
Cis-4-hydroxy-D-proline (1.1 g, 8.4 mmol) was dissolved in 18 mL of THF/ H2O (2:1), added 2M aqueous NaOH solution (6.3 mL, 13 mmol), followed by B0C2O. Reaction was stirred at ambient temperature over the weekend.
Solution was taken up in 150 mL EtOAc, washed with 10% HCl (3x100 mL), dried organics with MgSO4, filtered and concentrated to yield title compound as a white foam. (1.5 g, 77%) APCI (AP-): 230.1 (M-H)".
Step 2: (2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-l,2- dicarboxylic acid l-tert-butyl ester
(2R,4R)-4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid l-tert-butyl ester (1.5 g, 6.5 mmol) was dissolved in 2 mL DMF, added imidazole (1.1 g, 16 mmol), dimethylaminopyridine (80mg, 0.65 mmol), and tert-butyldimethylsilyl chloride (1.08 g, 7.1 mmol). Stirred at ambient temperature overnight, dissolved in 150 mL EtOAc, washed with 10% citric acid (3x 100 L), water (2x100 mL), brine, dried with MgSO4, filtered, and concentrated. Redissolved in 50 mL CHCI3 and reconcentrated to yield title compound as a clear oil. (1.54 g, 69%) APCI (AP-):
344.2 (M-H)".
Step 3: (2R,4R)-2-(4-bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl- dimethyl-silanyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-pyrrolidine-l, 2 -dicarboxylic acid l-tert-butyl ester (1.54 g, 4.5 mmol) was dissolved in 50 mL diethyl ether under an Ar atmosphere, cooled in an ice water bath, added dry pyridine (1.4 mL, 17.8 mmol), followed by the dropwise addition of oxalyl chloride (0.58 L, 6.7 mmol). Reaction was stirred at 0°C for 1 hour, then at ambient temperature for 1 hour. Diluted reaction with 50 mL diethyl ether, filtered off solids and concentrated filtrates. Redissolved filtrate in 30 mL dry DCM under an Ar atmosphere, cooled in an ice water bath, added 1 L dry pyridine followed by 4- bromo-2-fluoroaniline (0.85 g, 4.5 mmol). Stirred reaction at ambient temperature for 20 hours. Concentrated solution, redissolved in EtOAc (150 mL), washed with 10% citric acid (3x 100 mL), water (2x100 mL), brine, dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluting with an automated system with gradient of 0-60% EtOAc in hexanes over 40 minutes. Combined and concentrated pure fractions to yield title compound as a clear oil.
(0.96 g, 42%) APCI (AP-): 515.1, 517.1 (M-H)".
Step 4: (2R,4R)-4-(tert-Butyl-dimethyl-siIanyloxy)-2-(3-fluoro-2'- methylsulfanyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l-carboxylic acid tert- butyl ester
(2R,4R)-2-(4-Bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl-dimethyl- silanyloxy)-pyrrolidine-l -carboxylic acid tert-butyl ester (0.95 g, 1.84 mmol), 2- ( ethylthio)benzene boronic acid (0.37 g, 2.2 mmol), and tetrabutylammonium bromide (30mg, 0.09 mmol) were combined in 15 mL toluene, added 2 mL of a 2M aqueous Na CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.1 1 g, 0.09 mmol). Heated reaction at reflux for 5 hours, cooled, dissolved in EtOAc (100 mL), washed with water (3x50 mL), brine (50 mL), dried with MgSO4, filtered, and concentrated. Purified on a silica gel column eluted using an automated system with gradient of 0-60% EtOAc in hexanes over 40 minutes. Combined and concentrated pure fractions to yield title compound as a light yellow foam. (0.77 g, 74%) APCI (AP-): 559.3 (M-H)".
Step 5: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l-carboxylic acid tert- butyl ester
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'-methylsulfanyl- biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (0.84 g, 1.35 mmol) was dissolved in 20 mL EtOAc, added added m-chloroperoxybenzoic acid (1.6 g, 5.4 mmol) in one portion and stirred at ambient temperature for 3 hours. A 10% aqueous solution (50 mL) of Na2S2U3 was added to the vigorously stirring reaction in order to quench peroxide. After 20 minutes the solution was diluted with 100 mL EtOAc, separated layers, washed organics with sat. NaHCO3 (3x100 L), water (2x100 mL), brine, dried with MgSO4, filtered and concentrated to yield title compound as a light brown foam. (0.8 g, 100%) APCI (AP-): 591.3 (M-H)-.
Step 6: (2R,4R)-4-hydroxy-pyrrolidine-2-carboxyIic acid (3-fluoro-2'- methanesuIfonyl-biphenyl-4-yl)-amide
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (0.8 g, 1.35 mmol) was dissolved in 30 mL DCM, added 10 mL trifluoroacetic acid and stirred reaction at ambient temperature for 90 minutes. Solution was concentrated to yield title compound as an amber oil. (100% crude yield) APCI (AP-): 434.1 (M-H)".
Step 7: (2R,4R)-4-hydroxy -pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yI)-amide]
(2R,4R)-4-Hydroxy-pyrrolidine-2-carboxylic acid (3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide (0.51 g, 1.35 mmol) was dissolved in 20 L THF, added diisopropylethylamine (0.94 mL, 5.4 mmol) followed by 4- chlorophenylisocyanate (0.21 g, 1.35 mmol). Stirred at ambient temperature for 2 hours. The reaction was dissolved in 100 L EtOAc, washed with 10% citric acid (3x50 mL), water (2x50 mL), brine, dried with MgSO4, filtered and concentrated.
Purified using an automated system with gradient of 50-100% EtOAc in hexanes over 40 minutes. Compound was still eluting at end of run. Switched gradient to 0-15% MeOH in EtOAc over 40 minutes. Combined and concentrated pure fractions to yield title compound as a white solid. (0.54 g, 75%) APCI (AP+):
530.1, 532.1(M+H)+.
Step 8: (2R,4R)-4-methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] (2R,4R)-4-hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyI-biphenyl-4-yl)-amide] (0.070 g, 0.13 mmol) was dissolved in 1.5 mL dry acetonitrile under an Argon atmosphere. Freshly prepared A 2θ (45mg, 0.19 mmol) was added followed by methyl iodide
5 (9 L, 0.14 mmol). The reaction was stirred for 2 hours with no reaction seen by HPLC. Added 10 equivalents each of Ag2θ and methyl iodide. After 2 hours the reaction was complete by HPLC. The solids were filtered through celite, washing with ethyl acetate. The filtrates were concentrated, then purified by preparatory HPLC. Pure fractions were combined and lyophilized to yield title compound.
10 (28mg, 40%) APCI (AP-): 544.0, 546.1 (M-H)".
Example 22
(2R)-4-oxo-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyI)-amide] 2- ] 5 [(3-fluoro-2'-nιethanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000203_0001
Step 1: (2R,4R)-4-hydroxy-pyrrolidine-l,2-dicarboxyIic acid l-tert-butyl ester
Cis-4-hydroxy-D-proline (15 g, 114 mmol) was dissolved In 150 mL of 0 THF/ H2O (2: 1 ), added 2M aqueous NaOH solution (86μmL, 172 mmol), followed by B0C2O (27 g, 126 mmol). Reaction was stirred at ambient temperature overnight. The solution was acidified with 10% citric acid then extracted with EtOAc (2x250 mL), washed with water, brine, dried organics with MgSO4, filtered and concentrated to yield title compound. (16 g, 61%) APCI 5 (AP-): 230.1 (M-H)". Step 2: (2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-l,2- dicarboxylic acid l-tert-butyl ester
(2R,4R)-4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid l-tert-butyl ester (16 g, 69 mmol) was dissolved in 100 mL DMF, added imidazole (12 g, 173 mmol), dimethylaminopyridine (0.85 g, 6.9 mmol), and tert-butyldimethylsilyl chloride (12.5 g, 83 mmol). Stirred at ambient temperature overnight, dissolved in 350 L EtOAc, washed with 10% citric acid (3x200 L), water (2x200 mL), brine, dried with MgSO4, filtered, and concentrated to yield title compound. (20 g, 84%) APCI (AP-): 344.2 (M-H)".
Step 3: (2R,4R)-2-(4-bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl- dimethyl-silanyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-pyrrolidine-l, 2-dicarboxylic acid l-tert-butyl ester (4.45 g, 12.9 mmol) was dissolved in 50 mL dry CHCI3 under an Ar atmosphere, added 4-bromo-2-fluoroaniline (2.45 g, 12.9 mmol), EEDQ (3.8 g, 15 mmol), and triethylamine (2.6 mL, 19.3 mmol). Reaction was refluxed for 6 hours, cooled and concentrated. Redissolved in EtOAc (250 mL), washed with 10% HCl (2x200 mL), 0.1M NaOH (2x200 mL), water, brine, dried with MgSO4, filtered and concentrated to yield title compound. (5.5 g, 82%)
APCI (AP-): 515.1, 517.1 (M-H)".
Step 4: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methylsulfanyl-biphenyl-4-ylcarbamoyI)-pyrroIidine-l-carboxylic acid tert- butyl ester
(2R,4R)-2-(4-Bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl-dimethyl- silanyloxy)-pyrrolidine-l -carboxylic acid tert-butyl ester (5.7 g, 10 mmol), 2- (methylthio)benzene boronic acid (2.1 g, 12.6 mmol), and tetrabutylammonium bromide (0.17 g, 0.52 mmol) were combined in 50 L toluene, added 10 mL of a 2M aqueous Na2CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.61 g, 0.52 mmol). Heated reaction at reflux for 4 hours, cooled, dissolved in EtOAc (250 mL), washed with water (200 L), brine, dried with MgSO4, filtered, and concentrated in the presence of 15 g coarse silica. Slurried silica in mobile phase and loaded onto a silica gel column, eluted with 25% EtOAc in hexanes. Combined and concentrated fractions to yield title compound. (4.1 g, 70%) APCI (AP-): 559.3 (M-H)-.
Step 5: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrroIidine-l-carboxylic acid tertbutyl ester (2R,4R)-4-(tert-Butyl-dimethy]-silanyloxy)-2-(3-fluoro-2'-methy]sulfanyl- biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (4.1 g, 7.3 mmol) was dissolved in 20 mL EtOAc, added added m-chloroperoxybenzoic acid (7.2 g, 29 mmol) in one portion and stirred at ambient temperature for 3 hours. A 10% aqueous solution (50 mL) of Na2S2θ3 was added to the vigorously stirring reaction in order to quench peroxide. After 20 minutes the solution was diluted with 100 mL EtOAc, separated layers, washed organics with sat. NaHCO3 (3x100 mL), water (2x100 mL), brine, dried with MgSO4, filtered and concentrated to yield title compound. (4.3 g, 99%) APCI (AP-): 591.3 (M-H)".
Step 6: (2R,4R)-4-hydroxy-pyrrolidine-l,2-dicarboxyIic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2 - methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (3.25 g, 5.5 mmol) was dissolved in 50 mL DCM, added 25 mL trifluoroacetic acid and stirred reaction at ambient temperature for 90 minutes. Solution was concentrated. The resulting oil was dissolved in 75 L THF, added triethylamine (3.8 mL, 5.4 mmol) followed by 4-chlorophenylisocyanate (0.84 g, 5.5 mmol). Stirred at ambient temperature for 2 hours. The reaction was concentrated and purified on a silica gel column eluted with straight ethyl acetate initially moving to 5% MeOH in ethyl acetate. Combined and concentrated pure fractions to yield title compound. (2.5 g, 85%) APCI (AP-): 530.1, 532.1 (M-H)". Step 7: (2R)-4-oxo-pyrrolidine-l,2 -dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yI)-amide]
(2R,4R)-4-hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyI-4-yl)-amide] (0.78 g, 1.5 mmol) was dissolved in 10 mL dry DCM under an Argon atmosphere, added 0.5 g celite, 0.5 g of 4 angstrom crushed molecular sieves, and pyridinium chlorochromate (0.47 g, 2.2 mmol). Stirred at ambient temperature for 6 hours, reaction appears to have stalled. Added 1 g pyridinium chlorochromate and stirred at RT overnight. HPLC did not change. Added 40 mL of a 1 :1 mixture of hexanes:Et2O. Filtered through a filter funnel with silica gel. Washed with DCM. Compound did not elute. Washed with DCM:MeOH (90:10). Concentrated filtrates. Suspect pyridinium chlorochromate also eluted judged by dark color. Redissolved in DCM, washed with sat. NaHCO3, dried DCM with MgSO4, filtered and concentrated in vacuo. Purified on a silica gel column using an automated ISCO system with gradient of 50-100% EtOAc in hexanes over 30 minutes, then 100% EtOAc for 10 minutes. Combined and concentrated pure fractions, redissolved in acetonltrile and lyophilized to yield title compound. (0.12 g, 15%)
Example 23
(2R,4S)-4-FIuoro-pyrroIidine-l,2-dicarboxyIic acid l-[(4-chloro-phenyl)- amide]-2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000206_0001
Step 1: (2R,4R)-4-hydroxy-pyrrolidine-l,2-dicarboxylic acid l-tert-butyl ester
Cis-4-hydroxy-D-proline (15 g, 1 14 mmol) was dissolved In 150 L of THF/ H2O (2:1), added 2M aqueous NaOH solution (86 mL, 172 mmol), followed by B0C2O (27 g, 126 mmol). Reaction was stirred at ambient temperature overnight. The solution was acidified with 10% citric acid then extracted with EtOAc (2x250 mL), washed with water, brine, dried organics with MgSO4, filtered and concentrated to yield title compound. (16 g, 61%) APCI
(AP-): 230.1 (M-H)'.
Step 2: (2R,4R)-4-(tert-butyl-dimethyl-siIanyloxy)-pyrrolidine-l,2- dicarboxylic acid l-tert-butyl ester
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-tert-butyl ester (16 g, 69 mmol) was dissolved in 100 mL DMF, added imidazole (12 g, 173 mmol), dimethylaminopyridine (0.85 g, 6.9 mmol), and tert-butyldimethylsilyl chloride (12.5 g, 83 mmol). Stirred at ambient temperature overnight, dissolved in 350 mL EtOAc, washed with 10% citric acid (3x200 mL), water (2x200 mL), brine, dried with MgSO4, filtered, and concentrated to yield title compound. (20 g, 84%) APCI (AP-): 344.2 (M-H)".
Step 3: (2R,4R)-2-(4-bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl- dimethyl-silanyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-pyrrolidine-l, 2-dicarboxylic acid l-tert-butyl ester (4.45 g, 12.9 mmol) was dissolved in 50 mL dry CHCI3 under an Ar atmosphere, added 4-bromo-2-fluoroaniline (2.45 g, 12.9 mmol), EEDQ (3.8 g, 15 mmol), and triethylamine (2.6 mL, 19.3 mmol). Reaction was refluxed for 6 hours, cooled and concentrated. Redissolved in EtOAc (250 mL), washed with 10% HCl (2x200 L), 0.1M NaOH (2x200 mL), water, brine, dried with MgSO4, filtered and concentrated to yield title compound. (5.5 g, 82%) APCI (AP-): 515.1, 517.1 (M-H)". Step 4: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methylsulfanyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l-carboxylic acid tertbutyl ester (2R,4R)-2-(4-Bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl-dimethyl- silanyloxy)-pyrrolidine-l -carboxylic acid tert-butyl ester (5.7 g, 10 mmol), 2- (methylthio)benzene boronic acid (2.1 g, 12.6 mmol), and tetrabutylammonium bromide (0.17 g, 0.52 mmol) were combined in 50 mL toluene, added 10 mL of a 2M aqueous Na2CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.61 g, 0.52 mmol). Heated reaction at reflux for 4 hours, cooled, dissolved in EtOAc (250 L), washed with water (200 mL), brine, dried with MgSO4, filtered, and concentrated in the presence of 15 g coarse silica. Slurried silica in mobile phase and loaded onto a silica gel column, eluted with 25% EtOAc in hexanes. Combined and concentrated fractions to yield title compound. (4.1 g, 70%) APCI (AP-): 559.3 (M-H)".
Step 5: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methanesuIfonyl-biphenyl-4-ylcarbamoyI)-pyrrolidine-l-carboxyIic acid tertbutyl ester (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'-methylsulfanyl- biphenyl-4-ylcarbamoyl)-pyrrolidine-l-carboxylic acid tert-butyl ester (4.1 g, 7.3 mmol) was dissolved in 20 mL EtOAc, added added m-chloroperoxybenzoic acid (7.2 g, 29 mmol) in one portion and stirred at ambient temperature for 3 hours. A 10% aqueous solution (50 mL) of Na2S2θ3 was added to the vigorously stirring reaction in order to quench peroxide. After 20 minutes the solution was diluted with 100 L EtOAc, separated layers, washed organics with sat. NaHCO3 (3x100 L), water (2x100 mL), brine, dried with MgSO4, filtered and concentrated to yield title compound. (4.3 g, 99%) APCI (AP-): 591.3 (M-H)".
Step 6: (2R,4R)-4-hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro- phenyI)-amide] 2-[(3-fluoro-2'-methanesulfonyI-biphenyl-4-yl)-amide] (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (3.25 g, 5.5 mmol) was dissolved in 50 mL DCM, added 25 mL trifluoroacetic acid and stirred reaction at ambient temperature for 90 minutes. Solution was concentrated. The resulting oil was dissolved in 75 L THF, added triethylamine (3.8 mL, 5.4 mmol) followed by 4-chlorophenylisocyanate (0.84 g, 5.5 mmol). Stirred at ambient temperature for 2 hours. The reaction was concentrated and purified on a silica gel column eluted with straight ethyl acetate initially moving to 5% MeOH in ethyl acetate. Combined and concentrated pure fractions to yield title compound. (2.5 g, 85%) APCI (AP-): 530.1 , 532.1 (M-H)".
Step 7: (2R,4S)-4-Fluoro-pyrroIidine-l,2 -dicarboxylic acid l-[(4-chloro- phenyI)-amide]-2-[(3-fluoroι2'-methanesulfonyl-biphenyl-4-yl)-amide]
(2R,4R)-4-hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] (0.1 g, 0.19 mmol) in 3 mL dry DCM was added to a solution of [Bis(2- methoxyethyl)amino]-sulfur trifluoride (38 μl, 0.21 mmol) in 3. L dry DCM at - 78°C under Argon. Stirred at -78°C for 30 minutes then allowed to warm to room temperature. Stirred for one hour then concentrated reaction. Purified by preparatory HPLC, combined and lyophilized fractions to yield title compound.
(0.020 g, 20%) APCI (AP-): 532.1, 534.1 (M-H)".
Example 24
(2R,4R)-4-Hydroxy-pyrroIidine-l, 2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide] 1-p-tolylamide
Figure imgf000210_0001
Step 1: (2R,4R)-4-hydroxy-pyrrolidine-l, 2-dicarboxylic acid l-tert-butyl ester
Cis-4-hydroxy-D-proline (15 g, 114 mmol) was dissolved In 150 mL of THF/ H2O (2: 1 ), added 2M aqueous NaOH solution (86 mL, 172 mmol), followed by B0C2O (27 g, 126 mmol). Reaction was stirred at ambient temperature overnight. The solution was acidified with 10% citric acid then extracted with EtOAc (2x250 mL), washed with water, brine, dried organics with MgSO4, filtered and concentrated to yield title compound. (16 g, 61%) APCI (AP-): 230.1 (M-H)".
Step 2: (2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-l,2- dicarboxylic acid l-tert-butyl ester
(2R,4R)-4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid l-tert-butyl ester (16 g, 69 mmol) was dissolved in 100 mL DMF, added imidazole (12 g, 173 mmol), dimethylaminopyridine (0.85 g, 6.9 mmol), and tert-butyldimethylsilyl chloride (12.5 g, 83 mmol). Stirred at ambient temperature overnight, dissolved in 350 L EtOAc, washed with 10% citric acid (3x200 mL), water (2x200 mL), brine, dried with MgSO4, filtered, and concentrated to yield title compound. (20 g, 84%) APCI (AP-): 344.2 (M-H)-.
Step 3: (2R,4R)-2-(4-bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl- dimethyl-silanyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-pyrrolidine-l,2-dicarboxyIic acid l-tert-butyl ester (4.45 g, 12.9 mmol) was dissolved in 50 mL dry CHCI3 under an Ar atmosphere, added 4-bromo-2-fluoroaniline (2.45 g, 12.9 mmol), EEDQ (3.8 g, 15 mmol), and triethylamine (2.6 L, 19.3 mmol). Reaction was refluxed for 6 hours, cooled and concentrated. Redissolved in EtOAc (250 mL), washed with 10% HCl (2x200 mL), 0.1 M NaOH (2x200 mL), water, brine, dried with MgSO4, filtered and concentrated to yield title compound. (5.5 g, 82%)
APCI (AP-): 515.1, 517.1 (M-H)".
Step 4: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methylsuIfanyl-biphenyl-4-yIcarbamoyl)-pyrrolidine-l-carboxylic acid tert- butyl ester
(2R,4R)-2-(4-Bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl-dimethyl- silanyloxy)-pyrrolidine-l -carboxylic acid tert-butyl ester (5.7 g, 10 mmol), 2- (methylthio)benzene boronic acid (2.1 g, 12.6 mmol), and tetrabutylammonium bromide (0.17 g, 0.52 mmol) were combined in 50 mL toluene, added 10 mL of a 2M aqueous Na2CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.61 g, 0.52 mmol). Heated reaction at reflux for 4 hours, cooled, dissolved in EtOAc (250 mL), washed with water (200 mL), brine, dried with MgSO4, filtered, and concentrated in the presence of 15 g coarse silica. Slurried silica in mobile phase and loaded onto a silica gel column, eluted with 25% EtOAc in hexanes. Combined and concentrated fractions to yield title compound.
(4.1 g, 70%) APCI (AP-): 559.3 (M-H)".
Step 5: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l-carboxyIic acid tert- butyl ester
(2R,4R)-4-(tert-Buty]-dimethyl-silanyloxy)-2-(3-fluoro-2'-methylsulfanyl- biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (4.1 g, 7.3 mmol) was dissolved in 20 mL EtOAc, added added m-chloroperoxybenzoic acid (7.2 g, 29 mmol) in one portion and stirred at ambient temperature for 3 hours. A 10% aqueous solution (50 mL) of Na2S2θ3 was added to the vigorously stirring reaction in order to quench peroxide. After 20 minutes the solution was diluted with 100 mL EtOAc, separated layers, washed organics with sat. NaHCO3 (3x100 mL), water (2x 100 mL), brine, dried with MgSO4, filtered and concentrated to yield title compound. (4.3 g, 99%) APCI (AP-): 591.3 (M-H)".
Step 6: (2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxylic acid 2-[(3-fluoro-2*- methanesulfonyl-biphenyl-4-yl)-amide] 1-p-tolylamide
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (0.35 g, 0.59 mmol) was dissolved in 10 mL DCM, added 5 mL trifluoroacetic acid and stirred reaction at ambient temperature for 2 hours.
Solution was concentrated. The resulting oil was dissolved in 20 mL THF, added triethylamine (0.41 mL, 3 mmol) followed by p-tolylisocyanate (0.079 g, 0.59 mmol). Stirred at ambient temperature for 2 hours. The reaction was concentrated and purified on a silica gel column eluted using an automated ISCO system with gradient of 0-10% MeOH in ethyl acetate over 40 minutes.
Concentrated fractions then redissolved in acetonitrile/water and lyophilized to yield title compound. (0.17 g, 56%) APCI (AP-): 510.1 (M-H)-.
Example 25 (2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide] l-[(4-fluoro-phenyl)-amide]
Figure imgf000212_0001
Step 1: (2R,4R)-4-hydroxy-pyrrolidine-l,2-dicarboxylic acid l-tert-butyl ester Cis-4-hydroxy-D-proline (15 g, 1 14 mmol) was dissolved In 150 mL of
THF/ H2O (2:1), added 2M aqueous NaOH solution (86 mL, 172 mmol), followed by B0C2O (27 g, 126 mmol). Reaction was stirred at ambient temperature overnight. The solution was acidified with 10% citric acid then extracted with EtOAc (2x250 mL), washed with water, brine, dried organics with MgSO4, filtered and concentrated to yield title compound. (16 g, 61 %) APCI (AP-): 230.1 (M-H)".
Step 2: (2R,4R)-4-(tert-butyI-dimethyl-silanyloxy)-pyrroIidine-l,2- dicarboxylic acid l-tert-butyl ester
(2R,4R)-4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid l-tert-butyl ester (16 g, 69 mmol) was dissolved in 100 mL DMF, added imidazole (12 g, 173 mmol), dimethylaminopyridine (0.85 g, 6.9 mmol), and tert-butyldimethylsilyl chloride (12.5 g, 83 mmol). Stirred at ambient temperature overnight, dissolved in 350 mL EtOAc, washed with 10% citric acid (3x200 mL), water (2x200 mL), brine, dried with MgSO4, filtered, and concentrated to yield title compound. (20 g, 84%) APCI (AP-): 344.2 (M-H)".
Step 3: (2R,4R)-2-(4-bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl- dimethyl-silanyloxy)-pyrrolidine-l-carboxylic acid tert-butyl ester
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-pyrrolidine-l, 2-dicarboxylic acid 1 -tert-butyl ester (4.45 g, 12.9 mmol) was dissolved in 50 L dry CHCI3 under an Ar atmosphere, added 4-bromo-2-fluoroaniline (2.45 g, 12.9 mmol), EEDQ (3.8 g, 15 mmol), and triethylamine (2.6 mL, 19.3 mmol). Reaction was refluxed for 6 hours, cooled and concentrated. Redissolved in EtOAc (250 mL), washed with 10% HCl (2x200 mL), 0.1M NaOH (2x200 mL), water, brine, dried with MgSO4, filtered and concentrated to yield title compound. (5.5 g, 82%)
APCI (AP-): 515.1 , 517.1 (M-H)-.
Step 4: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methylsulfanyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l-carboxylic acid tert- butyl ester (2R,4R)-2-(4-Bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl-dimethyl- silanyloxy)-pyrrolidine-l -carboxylic acid tert-butyl ester (5.7 g, 10 mmol), 2- (methylthio)benzene boronic acid (2.1 g, 12.6 mmol), and tetrabutylammonium bromide (0.17 g, 0.52 mmol) were combined in 50 mL toluene, added 10 mL of a 2M aqueous Na CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.61 g, 0.52 mmol). Heated reaction at reflux for 4 hours, cooled, dissolved in EtOAc (250 mL), washed with water (200 mL), brine, dried with MgSO4, filtered, and concentrated in the presence of 15 g coarse silica. Slurried silica in mobile phase and loaded onto a silica gel column, eluted with 25% • EtOAc in hexanes. Combined and concentrated fractions to yield title compound.
(4.1 g, 70%) APCI (AP-): 559.3 (M-H)".
Step 5: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l-carboxylic acid tert- butyl ester
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'-methylsulfanyl- biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (4.1 g, 7.3 mmol) was dissolved in 20 L EtOAc, added added m-chloroperoxybenzoic acid (7.2 g, 29 mmol) in one portion and stirred at ambient temperature for 3 hours. A 10% aqueous solution (50 mL) of Na2S2©3 was added to the vigorously stirring reaction in order to quench peroxide. After 20 minutes the solution was diluted with 100 mL EtOAc, separated layers, washed organics with sat. NaHCO3 (3x100 L), water (2x100 mL), brine, dried with MgSO4, filtered and concentrated to yield title compound. (4.3 g, 99%) APCI (AP-): 591.3 (M-H)".
Step 6: (2R,4R)-4-Hydroxy-pyrroIidine-l, 2-dicarboxylic acid 2-[(3-fluoro-2'- methanesuIfonyl-biphenyl-4-yl)-amide] l-[(4-fluoro-phenyI)-amide]
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (0.35 g, 0.59 mmol) was dissolved in 10 mL DCM, added 5 mL trifluoroacetic acid and stirred reaction at ambient temperature for 2 hours. Solution was concentrated. The resulting oil was dissolved in 20 mL THF, added triethylamine (0.41 mL, 3 mmol) followed by 4-fluorophenylisocyanate (0.081 g, 0.59 mmol). Stirred at ambient temperature for 2 hours. The reaction was concentrated and purified on a silica gel column eluted using an automated ISCO system with gradient of 80-100% ethyl acetate in hexanes for 20 minutes then straight ethyl acetate for 20 minutes. Concentrated fractions then redissolved in acetonitrile/water and lyophilized to yield title compound. (0.175 g, 57%) APCI
(AP-): 514.1(M-H)-.
Example 26
(2R,4R)-4-Hydroxy-pyrrolidine-l,2 -dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000215_0001
Step 1: (2R,4R)-4-hydroxy-pyrrolidine-l,2 -dicarboxylic acid l-tert-butyl ester
Cis-4-hydroxy-D-proline (15 g, 1 14 mmol) was dissolved In 150 mL of THF/ H2O (2:1), added 2M aqueous NaOH solution (86 mL, 172 mmol), followed by B0C2O (27 g, 126 mmol). Reaction was stirred at ambient temperature overnight. The solution was acidified with 10% citric acid then extracted with EtOAc (2x250 mL), washed with water, brine, dried organics with MgSO4, filtered and concentrated to yield title compound. (16 g, 61%) APCI
(AP-): 230.1 (M-H)".
Step 2: (2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-l,2- dicarboxylic acid l-tert-butyl ester (2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid l -tert-butyl ester (16 g, 69 mmol) was dissolved in 100 mL DMF, added imidazole (12 g, 173 mmol), dimethylaminopyridine (0.85 g, 6.9 mmol), and tert-butyldimethylsilyl chloride (12.5 g, 83 mmol). Stirred at ambient temperature overnight, dissolved in 350 mL EtOAc, washed with 10% citric acid (3x200 mL), water (2x200 mL), brine, dried with MgSO4, filtered, and concentrated to yield title compound. (20 g, 84%) APCI (AP-): 344.2 (M-H)".
Step 3: (2R,4R)-2-(4-bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyI- dimethyl-silanyloxy)-pyrroIidine-l-carboxyIic acid tert-butyl ester
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-pyrrolidine-l , 2-dicarboxylic acid l-tert-butyl ester (4.45 g, 12.9 mmol) was dissolved in 50 mL dry CHCI3 under an Ar atmosphere, added 4-bromo-2-fluoroaniline (2.45 g, 12.9 mmol), EEDQ (3.8 g, 15 mmol), and triethylamine (2.6 mL, 19.3 mmol). Reaction was refluxed for 6 hours, cooled and concentrated. Redissolved in EtOAc (250 mL), washed with 10% HCl (2x200 mL), 0.1M NaOH (2x200 mL), water, brine, dried with MgSO4, filtered and concentrated to yield title compound. (5.5 g, 82%)
APCI (AP-): 515.1, 517.1 (M-H)".
Step 4: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methylsulfanyl-biphenyl-4-ylcarbamoyI)-pyrrolidine-l-carboxylic acid tertbutyl ester
(2R,4R)-2-(4-Bromo-2-fluoro-phenylcarbamoyl)-4-(tert-butyl-dimethyl- silanyloxy)-pyrrolidine-l -carboxylic acid tert-butyl ester (5.7 g, 10 mmol), 2- (methylthio)benzene boronic acid (2.1 g, 12.6 mmol), and tetrabutylammonium bromide (0.17 g, 0.52 mmol) were combined in 50 mL toluene, added 10 mL of a 2M aqueous Na2CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.61 g, 0.52 mmol). Heated reaction at reflux for 4 hours, cooled, dissolved in EtOAc (250 mL), washed with water (200 mL), brine, dried with MgSO4, filtered, and concentrated in the presence of 15 g coarse silica. Slurried silica in mobile phase and loaded onto a silica gel column, eluted with 25% EtOAc in hexanes. Combined and concentrated fractions to yield title compound. (4.1 g, 70%) APCI (AP-): 559.3 (M-H)".
Step 5: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-nuoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrroIidine-l-carboxylic acid tertbutyl ester
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'-methylsulfanyl- biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (4.1 g, 7.3 mmol) was dissolved in 20 mL EtOAc, added added m-chloroperoxybenzoic acid (7.2 g, 29 mmol) in one portion and stirred at ambient temperature for 3 hours. A 10% aqueous solution (50 mL) of Na2S2U3 was added to the vigorously stirring reaction in order to quench peroxide. After 20 minutes the solution was diluted with 100 mL EtOAc, separated layers, washed organics with sat. NaHCO3 (3x100 mL), water (2x 100 mL), brine, dried with MgSO4, filtered and concentrated to yield title compound. (4.3 g, 99%) APCI (AP-): 591.3 (M-H)".
Step 6: (2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyI-4-yI)-amide]
(2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (0.35 g, 0.59 mmol) was dissolved in 10 mL DCM, added 5 mL trifluoroacetic acid and stirred reaction at ambient temperature for 2 hours. Solution was concentrated. The resulting oil was dissolved in 15 mL DMF, added triethylamine (0.41 mL, 3 mmol) followed by (5-Chloro-pyridin-2-yl)-carbamic acid 4-nitro-phenyl ester (0.17 g, 0.0.59 mmol; see Example 3, step 3a). Stirred at 50°C for 2 hours. The reaction was cooled, dissolved in 100 mL ethyl acetate, washed with sat. NaHCO3 (3x50 mL), 10% citric acid (2x50 mL), brine, dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluted using an automated ISCO system with gradient of 0-10% MeOH in ethyl acetate over 40 minutes. Concentrated fractions then redissolved in acetonitrile/water and lyophilized to yield title compound. (0.20 g, 64%?) APCI (AP-): 531.1, 533.0(M- H)-.
Example 27
Pyrrolidine-1, 2 -dicarboxylic acid I-[(4-chloro-phenyl)-amide] 2-[(2'- methanesuIfonyl-3-trifluoromethyl-biphenyl-4-yI)-amide]
Figure imgf000218_0001
Step 1: Pyrrolidine-1, 2 -dicarboxylic acid l-tert-butyl ester
DL-proline (10 g, 86.9 mmol) was dissolved in 120 mL of THF: H2O
(2: 1), added 87 L of a 2M NaOH solution followed by B0C2O (24.6 g, 113 mmol). Stirred at ambient temperature overnight. Removed THF in vacuo, acidified water to pH 3 with citric acid, extracted twice with EtOAc, washed organics with water, brine, dried with MgSO4, filtered and concentrated to yield title compound as a white solid. (18.7 g, quant.) APCI (AP-): 214.1 (M-H)".
Step 2: 2-(4-Bromo-2-trifluoromethyl-phenylcarbamoyI)-pyrrolidine-l- carboxylic acid tert-butyl ester Pyrrolidine-1 , 2-dicarboxylic acid l-tert-butyl ester (4 g, 18.6 mmol) was dissolved in 200 mL dry diethyl ether under Ar, cooled in an ice water bath, added dry pyridine (9 mL, 111 mmol) followed by the dropwise addition of oxalyl chloride (4.8 mL, 54 mmol). A precipitate forms immediately. The reaction was stirred vigorously at 0°C for one hour, then at ambient temperature for one hour. Added 100 mL diethyl ether, filtered off solids washing with diethyl ether. Concentrated the filtrates to an off white oil. Redissolved (2 g, 8.5 mmol) oil in 40 mL dry DCM under Ar, cooled to 0°C, added 2.8 mL pyridine followed by 4- bromo-2-trifluoromethylaniline (2.05 g, 8.6 mmol). The reaction was allowed to warm to ambient temperature, stirred overnight then concentrated. Redissolved in 100 mL EtOAc, washed with 1 N HCl (3x50 L), brine ( 100 mL), dried with MgSO4, filtered and concentrated to yield title compound. (1.98 g, 53%) APCI
(AP-): 435.0, 437.0 (M-H)".
Step 3: 2-(2'-Methylsulfanyl-3-trifluoromethyl-biphenyl-4-ylcarbamoyl)- pyrrolidine-1-carboxylic acid tert-butyl ester
2-(4-Bromo-2-trifluoromethyl-phenylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (1.92 g, 4.4 mmol), 2-(methylthio)benzene boronic acid (0.88 g, 5.2 mmol), and tetrabutylammonium bromide (70 mg, 0.22 mmol) were combined in 40 mL toluene, added 4.4 mL of a 2M aqueous Na2CO3 solution followed by tetrakistriphenylphosphine palladium(O) (0.253 g, 0.22 mmol).
Heated reaction at reflux 4 hours, cooled, concentrated, redissolved in EtOAc (250 mL), washed with water (3x200 mL), brine (200 L), dried with MgSO4, filtered, and concentrated. Purified on a silica gel column eluted with 20% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound. (1.8 g, 85%) APCI (AP-): 479.1 (M-H)".
Step 4: 2-(2'-Methanesulfonyl-3-trifluoromethyl-biphenyl-4-ylcarbamoyl)- pyrrolidine-1-carboxylic acid tert-butyl ester
2-(2'-Methylsulfanyl-3-trifluoromethyl-biphenyl-4-ylcarbamoyl)- pyrrolidine-1 -carboxylic acid tert-butyl ester (1.8 g, 3.7 mmol) was dissolved in 20 L acetonitrile, and added oxone (4.6 g, 6.8 mmol) in one portion and stirred at ambient temperature 4 days and then concentrated. Redissolved in 100 mL EtOAc and 100 mL sat. NaHCO3, separated layers, washed organics with brine, dried with MgSO4, filtered and concentrated. Purified on a silica gel column eluted with 20% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound. (1.05 g, 55%) APCI (AP-): 511.1 (M-H)". Step 5: Pyrrolidine-2-carboxylic acid (2'-methanesulfonyI-3-trifluoromethyl- biphenyl-4-yl)-amide
2-(2'-Methanesulfonyl-3-trifluoromethyl-biphenyl-4-ylcarbamoyl)- pyrrolidine-1 -carboxylic acid tert-butyl ester (0.97 g, 1.9 mmol) was dissolved in 10 L DCM and 5 mL trifluoroacetic acid and stirred at ambient temperature overnight and concentrated. Redissolved in 100 L EtOAc and 100 mL sat. NaHCO3, separated layers, washed organics with brine, dried with MgSO4, filtered and concentrated to yield title compound as an oil (0.78 g, 100%) APCI (AP-): 41 1.0 (M-H)-.
Step 6: Pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyI)-amide] 2-[(2'- methanesuIfonyl-3-trifluoromethyl-biphenyl-4-yl)-amide]
Pyrrolidine-2-carboxylic acid (2'-methanesulfonyl-3-trifluoromethyl- biphenyl-4-yl)-amide (0.4 g, 0.97 mmol) was dissolved in 10 mL THF, added diisopropylethylamine (0.5 mL, 2.9 mmol), followed by 4-chlorophenylisocyanate (148 mg, 0.96 mmol). Stirred reaction at ambient temperature for one hour then concentrated. Purified on a silica gel column eluted with 20% moving to 50% EtOAc in hexanes. Combined and concentrated pure fractions to yield title compound. (0.48 g, 88%) APCI (AP-): 564.0, 566.0 (M-H)".
General Procedure for Preparation of Examples 28 et. seq.i
Step l
Route 1
B, Base
Y-A-Z Y-A-B
K3PO4, dioxane Cul, 110°C
1
Figure imgf000221_0001
Route 2
B, Base
Y-A-Z Y-A-B
Cul, K2C03, DMSO 130°C
Figure imgf000221_0002
Z= Br, I, OTf
Step 2
Figure imgf000221_0003
Y= NH2
A= substituted aryl, or substituted heteroaryl
Synthesis of 2 (Step 1): As provided in Route 1 , a mixture of 1 (where the structure of YAZ is as provided in the Scheme), B (where B is a nitrogen in a heteroaryl or heterocyloalkly ring, an acyclic alkyl primary or secondary amine, or an acyclic primary or secondary amide), K3PO4, Cul, and trans- diaminocyclohexane is heated in dioxane at reflux to obtain compound 2, wherein the point of attachment of YA to B is the nitrogen of the heteroaryl or heterocyloalkly ring, or the nitrogen of the acyclic primary or secondary alkyl amine, or the nitrogen of the acyclic primary or secondary amide. In the case where Y is a nitro group, the moiety is reduced to the amino group with RaNi and EtOH under a hydrogen atmosphere. Alternatively, as provided in Route 2, Cul, K2CO3, and 8- hydroxyquinoline in DMSO can be used to carry out the coupling reaction.
Synthesis of 4 (Step 2): The appropriate aniline (2= YAB), N-ethoxycarbonyl-2- ethoxy-1 ,2-dihydroquinoline (EEDQ), triethylamine and carboxylic acid (3) are heated at reflux in chloroform to produce 4.
Synthesis of 5: A solution of compound 4, TFA and DCM is stirred at room temperature for 1 h and then concentrated under reduced pressure. The resulting oil is dissolved in THF and cooled to 0 °C followed by the addition of triethylamine and the appropriate isocyanate to produce compound 5.
Example 28
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}
Figure imgf000222_0001
Step 1: (2R,4R)-4-Hydroxy-pyrrolidine-2-carboxylic acid methyl ester.
G'.y-4-Hydroxy-D-proline (15g, 1 15mmol) was suspended in 150mL anhydrous methanol under an argon atmosphere, then cooled to 0°C before bubbling in HCl gas for 15 minutes. The solution gradually became homogenous. The argon and HCl gas lines were removed and the solution was refluxed for 4h. The solution was cooled and then concentrated under reduced pressure. The crude material was redissolved in lOOmL methanol and diethyl ether was added until a precipitate formed. The precipitate was filtered off, washed with diethyl ether, and dried in vacuo overnight to reveal 1 (20 g, 95%) as a white solid. MS: APCI (AP+): 146 (M)+.
Step 2: (2R,4R)-4-Hydroxy-l-trityl-pyrroIidine-2-carboxyIic acid methyl ester (2).
Into a solution of 1 (lOg, 55mmol) in anhydrous CHC1 (lOOmL) was added triethylamine (19mL, 138mmol) and triphenylmethyl chloride (14.5g, 52mmol). The mixture was stirred at RT for 3d before concentrating and redissolving in EtOAc. The solution was washed sequentially with 10% aq. citric acid, water, and brine before drying over MgSO4 and concentrating under reduced pressure to reveal 2 (20g, 100%) as a yellow solid.
Step 3: (2R,4R)-4-Methoxy-l-trityl-pyrrolidine-2-carboxylic acid methyl ester (3).
Into a solution of 2 (5.7 l g, 14.7mmol) in anhydrous DMF (20mL) and anhydrous THF (20mL) was added Mel (3.67mL, 58.9mmol). The solution was cooled to 0°C in an ice bath and NaH (0.766g, 19.2mmol) was added in one portion. The mixture was stirred at RT for 26h before adding EtOAc and washing sequentially with water and brine. The organic layer was dried over MgSO4 and concentrated under reduced pressure. Purification of the crude material by flash chromatography revealed 3 (4.67g, 79%) as a white solid.
Step 4: (2R,4R)-4-Methoxy-pyrrolidine-2-carboxylic acid methyl ester (4). To a flask containing 3 (4.67g, 1 1.6mmol) was added a solution of CH2C12
(27mL), water (0.3mL), and TFA (3.0mL, 38.9mmol). The solution was stirred at RT for 3h before concentrating under reduced pressure to reveal impure 4. MS: APCKAP+): 160.1 (M)+.
Step 5: (2R,4R)- 4-Methoxy-pyrroIidine-l,2-dicarboxylic acid l-tert-butyl ester 2-methyl ester (5). Into a solution of 4 (1.85g, 1 1.6mmol) in CH2C12 (20mL) was added triethylamine (6.49mL, 46.5mmol), di-tert-buty] dicarbonate (5.08g, 23.3mmol), and dimethylaminopyridine (0.142g, l .l όmmol). The mixture was stirred at RT for 22h before concentrating under reduced pressure and redissolving in EtOAc. The solution was washed sequentially with 10% aq. citric acid and brine before drying over MgSO4 and concentrating under reduced pressure. The crude material was purified by flash chromatography to reveal 5 (2.54g, 84% over two steps) as a yellow solid. MS: APCI (AP+): 260.1 (M)+.
Step 6: (2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-tert-butyl ester (6).
Into a solution of 5 (2.54g, 9.80mmol) in acetonitrile (20mL) was added water (20mL) and LiOHH2O (1.64g, 39.2mmol). The mixture was stirred at RT for 28h before removing the acetonitrile under reduced pressure. EtOAc was added to the residue that was then washed with IN HCl. The aqueous layer was extracted with additional EtOAc and the combined organic layers were washed with brine and dried over MgSO4. The solution was concentrated under reduced pressure to reveal 6 (2.16g, 90%) as a white solid. MS: APCI (AP-): 244.1 (M)-.
Step 7: l-(4-Amino-3-fluoro-phenyl)-piperidin-2-one (7).
2-Fluoro-4-iodoaniline (lO.Og, 42.2mmol) was combined with δ- valerolactam (6.27g, 63.3mmol), Cul (0.804g, 4.22mmol), and K3PO4 (22.4g, 105mmol). 1 ,4-Dioxane (60mL) was added followed by trans- 1,2- diaminocyclohexane (l.OlmL, 8.44mmol). The mixture was heated to reflux for 22h before cooling and diluting with EtOAc. The mixture was filtered through a plug of silica, eluting with EtOAc, and the filtrate concentrated under reduced pressure. Purification of the crude product by flash chromatography revealed 7 (3.40g, 39%) as a brown solid. MS: APCI (AP+): 209.1 (M)+.
Step 8: (2R,4R)-2-[2-Fluoro-4-(2-oxo-piperidin-l-yl)-phenylcarbamoyl]-4- methoxy-pyrrolidine-1 -carboxylic acid tert-butyl ester (8). Into a solution of 6 (0.250g, 1.02mmol) in CHC13 (lOmL) was added 7 (0.212g, 1.02mmol), EEDQ (0.302g, 1.22mmol), and triethylamine (0.213mL, 1.53mmol). The solution was stirred at reflux for 19h before cooling to RT and adding EtOAc. The solution was washed sequentially with 10% aq. citric acid, IN NaOH, water, and brine, before drying over MgSO4 and concentrating under reduced pressure. The crude material was purified by flash chromatography to reveal 8 (0.329g, 74%) as a tan foam. MS: APCI (AP+): 436.1 (M)+, (AP-): 434.1 (M)-.
Step 9: (2R, 4R)-4-Methoxy-pyrrolidine-2-carboxylic acid [2-fluoro-4-(2-oxo- piperidin-l-yl)-phenyl]-amide (9).
Into a solution of 8 (0.329g, 0.761 mmol) in anhydrous CH2C12 (5mL) was added TFA (5mL). The solution was stirred at RT for 0.5h before concentrating under reduced pressure to reveal 9 (0.255g, 100%) as a tan oil.
Step 10: (2R,4R)- 4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro- pheny -a ide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}(10).
Into a solution of 9 (0.128g, 0.380mmol) in anhydrous THF (5mL) at 0°C was added triethylamine (0.265mL, 1.90mmol) and 4-chlorophenyl isocyanate (0.058g, 0.380mmol). The solution was stirred at RT for 3.5h before concentrating under reduced pressure. The crude material was purified by flash chromatography, followed by filtration through a fritted funnel and concentration under reduced pressure. Remaining EtOAc was azeotroped off with CHC13. The resulting solid was lyophilized from acetonitrile / water to reveal 10 (0.186g, 100%) as a white solid. MS: APCI (AP+): 489.1 (M)+, (AP-): 487.1 (M)-; CHN calc'd for C24H26ClιF,N4O4: %C 50.75; %H 4.58; %N 9.07. Found: %C 50.62; %H 4.19; %N 9.02. Example 29
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxyIic acid l-[(4-chloro-phenyl)- amide] 2-{[4-(2-oxo-piperidin-l-yl)-phenyI]-amide}
Figure imgf000226_0001
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 457.1 (M)+.
Example 30
(2R,4R)-4-Hydroxy -pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}
Figure imgf000226_0002
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 475.1 (M)+. Example 31
(2R,4R)-4-Hydroxy-pyrrolidine-l,2 -dicarboxylic acid l-[(5-chloroφ\τidin-2- yl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}
Figure imgf000227_0001
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 476.1 (M)+.
Example 32
(2R,4R)-4-Methoxy -pyrrolidine-1, 2-dicarboxylic acid l-[(5-chloroφyridin-2- yl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyI]-amide}
F
H
Figure imgf000227_0002
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 490.1 (M)+. Example 33
(2R,4R)-4-Ethoxy -pyrrolidine-1, 2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyI]-amide}
Figure imgf000228_0001
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 504.1 (M)+.
Example 34
(2R,4R)-4-Ethoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yI)-phenyl]-amide}
Figure imgf000228_0002
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 503.1 (M)+. Example 35
(2R,4R)-4-Propoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}
Figure imgf000229_0001
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 517.2 (M)+.
Example 36
(2R,4R)-4-Propoxy-pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}
Figure imgf000229_0002
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 518.2 (M)+. Example 37
(2R,4R)-4-Cyano-pyrroIidine-l,2 -dicarboxylic acid l-[(4-chloroφhenyl)- amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]- amide}
Figure imgf000230_0001
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 484.2 (M)+.
Example 38
(2R,4R)-4-Fluoro-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yI)-phenyl]-amide)
Figure imgf000230_0002
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 477.1 (M)+. Example 39
(2R,4R)-4-Methoxy-pyrrolidine-l, 2 -dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-{[2-fluoro-4-(2-oxo-azetidin-l-yl)-phenyl]-amide}
Figure imgf000231_0001
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 461.1 (M)+.
Example 40
(2R,4R)-4-Methoxy-pyrroIidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yI)-amide] 2-{[2-fluoro-4-(2-oxo-azetidin-l-yl)-phenyl]-amide}
Figure imgf000231_0002
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 462.1 (M)+. Example 41
(2R,4R)-4-Methoxy-pyrroIidine-l,2-dicarboxyIic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-pyrroIidin-l-yl)-phenyl]-amide}
Figure imgf000232_0001
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 475.2 (M)+.
Example 42
(2R,4R)-4-Methoxy-pyrroIidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[2-fluoro-4-(2-oxo-pyrrolidin-l-yl)-phenyl]-amide}
Figure imgf000232_0002
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 476.2 (M)+. Example 43
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxyIic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-azepan-l-yl)-phenyl]-amide}
Figure imgf000233_0001
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 503.2 (M)+.
Example 44
(2R,4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[2-fluoro-4-(2-oxo-azepan-l-yl)-phenyl]-amide}
Figure imgf000233_0002
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 504.2 (M)+. Example 45
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000234_0001
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 468.2 (M)+.
Example 46
(2R,4R)-4-Methoxy -pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000234_0002
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 467.2 (M)+. Example 47
(2R,4R)-4-Ethoxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyI]-amide}
Figure imgf000235_0001
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 499.2 (M)+.
Example 48
(2R,4R)-4-Ethoxy-pyrroIidine-l,2-dicarboxyIic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000235_0002
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 500.2 (M)+. Example 49
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-{[2-fluoro-4-(2-hydroxymethyl-5-oxo-pyrrolidin-l-yl)-phenyl]- amide}
Figure imgf000236_0001
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 505.2 (M)+.
Example 50
(2R,4R)-4-Hydroxy -pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-{[4-(2,3-dimethyl-5-oxo-2,5-dihydro-pyrazol-l-yl)-phenyl]-amide}
Figure imgf000236_0002
The compound was prepared as generally provided in Example 28. MS: APCI (AP+): 470.2 (M)+. Example 51
4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- {[4-(2-hydroxymethyl-pyrrolidin-l-yl)-phenyl]-amide}
Figure imgf000237_0001
The compound was prepared as generally provided in Example 28. APCI (AP+): 459.2 (M+H)+.
Example 52
(2R,4R)-4-Hydroxy -pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-[(4-pyrroIidin-l-yl-phenyl)-amide]
Figure imgf000237_0002
The compound was prepared as generally provided in Example 28. APCI (AP+): 429.1 (M)+. Example 53
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(4-pyrazol-l-yl-phenyl)-amide]
Figure imgf000238_0001
The compound was prepared as generally provided in Example 28. APCI (AP+): 426.1 (M)+.
Example 54
(2R,4R)-4-Hydroxy-pyrrolidine-l,2 -dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-[(2-fluoro-4-pyrazol-l-yl-phenyl)-amide]
Figure imgf000238_0002
The compound was prepared as generally provided in Example 28. APCI (AP+): 444.1 (M)+.
Example 55 (2R,4R)-4-Hydroxy-pyrroIidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(4-[l,2,4]triazol-l-yI-phenl)-amide]
Figure imgf000239_0001
The compound was prepared as generally provided in Example 28. APCI (AP+): 427.1 (M)+.
Example 56
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxyIic acid l-[(4-chloro-phenyl)- amide] 2-[(4-[l ,2,3]triazol-2-yl-phenyl)-amide]
Figure imgf000239_0002
The compound was prepared as generally provided in Example 28. APCI (AP+): 427.1 (M)+.
Example 57
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(4-[l,2,3]triazol-l-yl-phenyl)-amide]
Figure imgf000240_0001
The compound was prepared as generally provided in Example 28. APCI (AP+): 427.1 (M)+.
Example 58
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid 2-[(4-acetylamino- phenyl)-amide] l-[(4-chloro-phenyl)-amide]
Figure imgf000240_0002
The compound was prepared as generally provided in Example 28. APCI (AP+): 417.1 (M)+.
Example 59
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-{[4-(cycIopentanecarbonyl-amino)-phenyI]-amide}
Figure imgf000241_0001
The compound was prepared as generally provided in Example 28. APCI (AP+): 471.2 (M)+.
Example 60
4-Hydroxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-
[(4-pyrimidin-5-yl-phenyI)-amide]
Figure imgf000241_0002
The compound was prepared as generally provided in Example 28. APCI (AP+): 484.2 (M)+.
Example 61
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(4-pyrazol-l-yl-phenyl)-amide]
Figure imgf000242_0001
The compound was prepared as generally provided in Example 28. APCI (AP+): 440.2 (M)+.
Example 62
(2R,4R)-4-Methoxy-pyrroIidine-l,2 -dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-[(2-fluoro-4-pyrazol-l -yl-phenyl)-amide]
Figure imgf000242_0002
The compound was prepared as generally provided in Example 28. APCI (AP+): 458.1 (M)+.
Example 63
(2R,4R)-4-Ethoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2-fluoro-4-pyrazol-l-yl-phenyl-amide]
Figure imgf000243_0001
The compound was prepared as generally provided in Example 28. APCI (AP+): 472.1 (M)+.
Example 64
(2R,4R)-4-Ethoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-[(4-pyrazol-l-yl-phenyl)-amide]
Figure imgf000243_0002
The compound was prepared as generally provided in Example 28. APCI (AP+): 454.2 (M)+.
Example 65
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(3-methyl-pyrazoI-l-yl)-phenyl]-amide}
Figure imgf000244_0001
Step 1: 2-Fluro-4-(3-methyl-pyrazol-l-yl)phenylamine (1)
2-Fluoro-4-iodoaniline (3. 0 g, 12.6 mmol), 3-methylpyrazole (1.22 mL, 15.18 mmol), Cs2CO3 (8.66 g, 26.58 mmol) and Cul (0.072 g, 0.379 mmol) were placed in a flask under nitrogen. The flask was evacuated under vacuum and refilled with nitrogen (5 times). 1 ,4-Dioxane (15 mL) was added followed by trans- 1,2-diaminocyclohexane (152 μL, 1.266 mmol). The reaction mixture was heated under reflux for 36 h. Mixture cooled and filtered. Solvents removed. Residue purified by silica gel flash chromatography eluting with a gradient of EtOAc in hexanes (0 to 30%). This purification afforded 1 as a pale brown solid (0.917 g, 38%). MS: APCI (AP+): 192.0 (M)+.
From the same purification, 2-Fluro-4-(5-methyl-pyrazoI-l- yl)phenylamine (2) was obtained as pale brown solid (0.265 g, 11%). MS: APCI (AP+): 192.0 (M)+.
Step 2: (2R,4R)-2-[2-Fluoro-4-(3-methyl-pyrazol-l-yl)-phenylcarbamoyl]-4- methoxy-pyrrolidine-1-carboxylic acid tert-butyl ester (3).
(2R,4R)-4-methoxy-pyrrolidine-l , 2-dicarboxylic acid l-tert-butyl ester (0.350 g, 1.427 mmol), aniline 1 (0.273 g, 1.427 mmol) and EEDQ (0.529 g,
2.140 mmol) were dissolved in CHC13 (30 L). Et3N (0.6 mL, 4.281 mmol) was added and the reaction mixture was heated at reflux for 18 h. The mixture was allowed to cool and diluted with CHC13 (100 mL) and washed with 5% HCl, 0.5 N NaOH, water and brine (40 mL each), the organic extract was dried over MgSO , filtered and the solvent removed to give a pale tan foam. The crude product was used for the next step without purification. MS: APCI (AP+): 419.2 (M)+, (AP-): 417.2 (M)-.
Step 3: (2R, 4R)-4-Methoxy-pyrrolidine-2-carboxyIic acid [2-fluoro-4-(3- methyl-pyrazol-l-yl)-phenyl]-amide (4)
Boc-amine 3 (-0.6 g, 1.427 mmol) was dissolved in 25% TFA in dichloromethane. The mixture was stirred at ambient temperature for 2 h. The solvents were removed and the residue dried under vacuum to give 4 as a tan oil (-0.450 g).
Step 4: (2R,4R)-4-Methoxy-pyrroIidine-l,2 -dicarboxylic acid l-[(4-ch!oro- phenyl)-amide] 2-{[2-fluoro-4-(3-methyl-pyrazol-l-yl)-phenyl]-amide} (5)
A solution of amine 4 (-0.450 g, 1.427 mmol) in dichloromethane (35 mL) was cooled at 0°C. Triethylamine (1.5 mL, 10.7 mmol) was added and the mixture stirred for 15 min. Then, 4-chlorophenyl isocyanate (0.24 g, 1.569 mmol) was incoφorated. The solution was stirred at ambient temperature for 18 h. The mixture was diluted with CHC13 (100 mL) and washed with 5% HCl, water, brine (40 mL each). The organic extracts were dried over MgSO4, filtered and the solvent removed. The residue was purified by flash chromatography on silica gel eluting with a gradient of EtOAc in hexanes (0 to 65%) to provide 5 as white solid (0.56 g, 83% in 3 steps). MS: APCI (AP+): 472.2 (M)+, (AP-): 470.2 (M)-. Anal, calcd for C23H23ClFN5O3: C, 58.54; H, 4.91 ; N, 14.84. Found: C, 58.35; H, 4.59; N, 14.49.
Example 66
(2R,4R)-4-Hydroxy-pyrroIidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-{[2-fluoro-4-(5-methyl-pyrazol-l-yl)-phenyI]-amide}
Figure imgf000246_0001
The compound was prepared as generally provided for Example 65. APCI (AP+): 458.2 (M)+.
Example 67
(2R,4R)-4-Methoxy-pyrroIidine-l,2-dicarboxyIic acid l-[(4-chloro-phenyl)- a ide] 2-{[2-fluoro-4-(5-methyl-pyrazol-l-yl)-phenyI]-amide}
Figure imgf000246_0002
The compound was prepared as generally provided for Example 65. APCI (AP+): 472.2 (M)+.
Example 68
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[4-(5-methyl-pyrazol-l-yl)-phenyl]-amide}
Figure imgf000247_0001
The compound was prepared as generally provided for Example 65. APCI (AP+): 454.3 (M)+.
Example 69
(2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-{[4-(3,5-dimethyl-pyrazol-l-yl)-phenyl]-amide}
Figure imgf000247_0002
The compound was prepared as generally provided for Example 65. APCI (AP+): 454.2 (M)+.
Example 70
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[4-(3,5-dimethyl-pyrazoI-l-yl)-phenyI]-amide}
Figure imgf000248_0001
The compound was prepared as generally provided for Example 65. APCI (AP+): 468.2 (M)+.
Example 71
(2R,4R)-4-Methoxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-{[4-(3,5-dimethyl-pyrazol-l-yl)-2-fluoro-phenyI]-aιnide}
Figure imgf000248_0002
The compound was prepared as generally provided for Example 65. APCI (AP+): 486.2 (M)+.
Example 72 l-(4-Amino-3-fluoro-phenyl)-lH-pyridin-2-one
Figure imgf000248_0003
According to Route 2 for the preparation of YAB as provided in the General Procedure for the Preparation of Examples 28-60, 2-Fluoro-4-iodoaniline (lO.Og, 42.2mmol) was combined with ]H-pyridin-2-one (l .Og, 4.22mmol), Cul (0.120g, 0.633mmol), K2CO3 (0.64 lg, 4.64mmol), and 8-hydroxyquinoline (0.092g, O.633mmol) in DMSO (3mL). The mixture was degassed with a stream of argon and then heated at reflux for 20h before cooling to ambient temperature. 10% aq. NΗ4OΗ and EtOAc were added, and the mixture was filtered through a plug of layered celite and decolorizing charcoal, eluting with EtOAc. The filtrate was concentrated under reduced pressure. Purification of the crude product by mplc revealed the title compound (0.53g, 62%) as a yellow solid. MS: APCI (AP+): 205.1 (M)+.
Example 73 4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid 2-[(4-tert-butyl-phenyl)- amide] l-[(4-chloro-phenyI)-amide]
Figure imgf000249_0001
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 414.2 (M)+.
Example 74 (2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2[(3,5'dinuoro-2l-sulfamoyl-biphenyl-4-yI)-amide]
Figure imgf000250_0001
Step 1: N-tert-Butyl-4-fluoro-benzenesulfonamide
Into a DCM solution (50 L) of tert-butylamine (5.9 mL, 56.5 mmol) and triethylamine (7.16 mL, 51.3 mmol) at 0°C was slowly added a DCM solution (20 L) of 4-fluoro-benzenesulfonyl chloride (10 g, 51.3 mmol), and the reaction stirred at RT for 19h. The reaction was concentrated and the resulting solid recrystalized from ether/hexanes to get the product (9.5 g, 80%)as white crystals. MS: APCI (AP+): 230.1 (M)+.
Step 2: N-tert-Butyl-4-fluoro-benzenesuIfonamide-3-boronic acid
Butyllithium (2.2 M, 4.3 L, 9.51 mmol) was added drop-wise to a 0°C solution of N-terr-butyl-4-fluoro-benzenesulfonamide (1.0 g, 4.32 mmol), and the solution stirred for 15 min. at 0°C and then RT for 1.5 h. Triisopropyl borate (1.19 L, 5.18 mmol) was added, and the solution stirred at RT of 2.5 h. The mixture was cooled to 0°C, 10% aq. HCl was added slowly, and the reaction was stirred for 1.5h. The reaction was then extracted with EtOAc three times and the organics combined and concentrated. The resulting oil was dissolved in ether and extracted with IN ΝaOH three times, and the extracts combined and acidified at 0°C with 6Ν HCl. The solution was extracted with ether three times and the organics were combined and dried over MgSO4. Filtration and concentration of the organics revealed the product as an oil which formed a solid upon addition of hexanes and concentration under reduced pressure. (0.641 g, 54%) APCI (AP-): 274.1 (M)-. Step 3: (2R, 4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(2-fluoro-4-iodo- phenylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester.
4-(tert-Butyl-dimethyl-silanyloxy)-pyrrolidine-l ,2-dicarboxylic acid 1- tert-butyl ester (0.673 g, 1.94 mmol), 2-fluoro-4-iodoaniline (0.46 g, 1.94 mmol), EEDQ (0.575 g, 2.32 mmol) and triethylamine (0.408 mL, 2.91 mmol) were heated at reflux in CHC13 (10 mL) for 22 h. The solution was concentrated and resulting oil partitioned between EtOAc and water. The organic layer was washed with brine and dried over MgSO4. The product was purified by mplc to produce the product as a clear oil (1 ,0g, 90%). MS: APCI (AP-): 563.2 (M)-.
Step 4: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(2*-tert-butylsulfamoyl- 3,5'-difluoro-biphenyl-4-ylcarbamoyl)-pyrrolidine-l-carboxylic acid tertbutyl ester
A mixture of 4-(tert-butyl-dimethyl-silanyloxy)-2-(2-fluoro-4-iodo- phenylcarbamoyl)-pyrrolidine-l -carboxylic acid tert-butyl ester (0.56g, 0.99 mol), Pd(PPh3)4 (0.11 g, 0.1 mmol), N-tert-buty]-4-fluoro-benzenesulfonamide-3- boronic acid (0.33 g, 1.19 mmol), tetrabutylammonium bromide (0.016 g, 0.05 mmol), sodium carbonate (0.210 g, 1.98 mmol), water (2.0 mL) and toluene (10 mL) was degassed with a stream of argon gas and then heated at reflux 21.5 h. The mixture was then allowed to cool to RT, concentrated and partitioned between water and EtOAc. The organic layer was washed with brine, dried over MgSO4 and concentrated. The resulting oil was purified by mplc to reveal the product as an oil (0.119g, 18%). MS: APCI (AP-): 666.4 (M)-.
Step 5: (2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid 2-[(2'-tert- butylsulfamoyI-3,5'-difluoro-biphenyl-4-yl)-amideJ l-[(4-chloro-phenyl)- amide]
A solution of 4-(tert-butyl-dimethyl-silanyloxy)-2-(2'-tert-butylsulfamoyl- 3,5'-difluoro-biphenyl-4-ylcarbamoyl)-pyrrolidine- 1 -carboxylic acid tert-butyl ester (0.228g, 0.342 mmol) and trifluoroacetic acid (1.5 mL) in CHC13 (1.5 mL) was stirred at ambient temperature for 1 h. The solution was concentrated, hexanes added and then the solution concentrated again. The resulting oil was dissolved in THF and cooled 0°C. Triethylamine (0.190 mL, 1.36 mmol) was added followed by 4-chlorophenyl isocyanate (0.052 g, 0.342 mmol) and the solution stirred at RT for 5.5 h. The solution was concentrated and the oil purified by mplc to reveal the product as a solid (0.078g, 38%). MS: APCI (AP-): 605.2 (M>.
Step 6: (2R,4R)-4-Hydroxy-pyrrolidine-l, 2 -dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2[(3,5'difluoro-2'-sulfamoyI-biphenyl-4-yl)-amide]
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(2'-tert-butylsulfamoyl- 3,5'-difluoro-biphenyl-4-yl)-amide] 1 -[(4-chloro-phenyl)-amide] (0.078g, 0.128 mmol) was dissolved in TFA (3 mL) and stirred at RT for 1 h. The reaction was concentrated and dissolved in MeCN and water and purified by reverse phase HPLC to reveal the product as a white solid (0.05g, 77%) after lyophilization. MS: APCI (AP+): 551.1 (M)+.
Example 75
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-5'-yl)-amide]
Me
H
Figure imgf000252_0001
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 472.2 (M)+. Example 75a. Alternative Procedure.
Y-A-NH2 = B
Figure imgf000253_0001
Λ 2. KOffiu. THF 2 3
Figure imgf000253_0002
Synthesis of 2: A solution of 1 where Y is a nitro group is treated with a halo- alkoylchloride in the presence of base and refluxing toluene to produce an intermediate halo-amide that is then cyclized in the presence of potassium tert- butoxide in THF to produce a cyclic lactam B.
Synthesis of 3:
A solution of 2 where Y is a nitro group is reduced under RaNi mediated hydrogenation to produce 3 where Y is an amino group.
Synthesis of 5 and 6: Intermediates 5 and 6 were prepared as provided in Example 28.
Example 76
(2R,4R)-4-Methox -pyrrolidine-1, 2 -dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide]
Figure imgf000254_0001
Step 1: 5'-Nitro-3,4,5,6-tetrahydro-[l,2']bipyridinyl-2-one.
See Example 75a. 2-Amino-5-nitro-pyridine (2.0 g, 14.3 mmol), 5-bromo- pentanoyl chloride (2.86 g, 14.3 mmol), triethylamine (2.39 g, 17.2 mmol), catalytic DMAP were heated at reflux in toluene (70 mL) 22 h. The reaction was allowed to cool to RT, concentrated and the resulting oil portioned between EtOAc and water. The organic layer was separated, washed with brine, dried over MgSO4 and filtered. Concentration of the filtrate produced an oil which was dissolved in THF (140 mL). Potassium tert-Butoxide (1.68g, 15.0 mmol) was added portion-wise and the reaction stirred at RT for 2h. Water was then added, and the reaction extracted with EtOAc. The organics were then washed with brine and dried over MgSO4. Purification of the crude material by mplc revealed the product as an orange solid. MS: APCI (AP+): 222.1 (M)+.
Step 2: 5'-Amino-3,4,5,6-tetrahydro-[l,2']bipyridinyl-2-one.
5'-Nitro-3,4,5,6-tetrahydro-[l ,2']bipyridinyl-2-one (0.66 g, 2.98 mmol) was dissolved in 1 :1 MeOH/THF (50 mL) and hydrogenated over RaNi (lg) at 4285 psi/mole for 0.8 h. The catalyst was filtered, and the filtrate concentrated. The crude solid was purified by recrystalization from THF and hexanes to give the product as a yellow solid (0.275g, 48%). MS: APCI (AP+): 192.1 (M)+.
Step 3: (2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)- amide]. The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 472.2 (M)+.
Example 77
(2R,4R)-4-Methoxy-pyrroIidine-l, 2-dicarboxylic acid l-[(5-chloro-pyridin-2- yI)-amide] 2-{[4-(2,3-dimethyI-5-oxo-2,5-dihydro-pyrazol-l-yI)-phenyI]- amide}
M
H
Figure imgf000255_0001
The compound was prepared as generally provided for Example 28. Formation of the 5-chloro-pyridin-2-yl moiety can be found in Example 26. MS: APCI (AP+): 485.3 (M)+.
Example 78
(2R,4R)-4-Methoxy -pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[4-(2,3-dimethyl-5-oxo-2,5-dihydro-pyrazol-l-yl)-phenyl]-amide}
M
H
Figure imgf000255_0002
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 484.3 (M)+.
Example 79
(2R,4R)-4-Methoxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2-oxo-2H-[l,3,]bipyridinyl-6'-yl)-amide]
Figure imgf000256_0001
Step 1. 6'-Amino-[l,3']bipyridinyI-2-one.
2-Amino-5-iodopyridine (5.0g, 22.7mmol) was combined with 1H- pyridin-2-one (2.59g, 27.27 mmol), Cul (0.65g, 3.41 mmol), K2CO3 (3.45 g, 24.9mmol), and 8-hydroxyquinoline (0.49 g, 3.40 mmol) in DMSO (20 mL). The mixture was degassed with a stream of argon and then heated at reflux for 18h before cooling to RT. 10% aq. NΗ OΗ and EtOAc were added, and the mixture was filtered through a plug of layered celite and decolorizing charcoal, eluting with EtOAc. The filtrate was concentrated under reduced pressure. Purification of the crude product by mplc revealed A (0.40g, 10%) as a yellow solid. MS: APCI (AP+): 188.1 (M)+.
Step 2: (2R,4R)-4-Methoxy-pyrroIidine-l, 2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2-oxo-2H-[l,3']bipyridinyl-6'-yl)-amide].
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 468.3 (M)+. Example 80
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[1 ']bipyridinyl-6'-yl)-amide]- TFA Salt
Figure imgf000257_0001
The compound was prepared as generally provided for in Examples 28 and 75a. Formation of the 5-chloro-pyridin-2-yl moiety can be found in Example 26. Purification was accomplished via reverse phase HPLC. MS: APCI (AP+): 473.2 (M)+.
Example 81
4-Ethoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyI)-amide] 2-[(2- oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide]
Figure imgf000257_0002
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 486.3 (M)+. Example 82
(2R,4R)-Ethoxy -pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2-oxo-2H-[l,3,]bipyridinyl-6'-yI)-amide]
Figure imgf000258_0001
The compound was prepared as generally provided for Examples 28 and 79. MS: APCI (AP+): 482.3 (M)+.
Example 83
(2R,4R)-4-Methoxy-pyrrolidine-l,2 -dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(6-oxo-6H-pyridazin-l-yl)-phenyl]-amide}
Figure imgf000258_0002
Step 1: 2-(4-Amino-3-fluoro-phenyl)-2H-pyridazin-3-one.
2-Fluoro-4-iodoaniline (0.5 g, 2.10 mmol) was combined with 2H- Pyridazin-3-one (0.243 g, 2.53 mmol), Cul (0.06 g, 0.315 mmol), K2CO3 (0.32 g, 2.31 mmol), and 8-hydroxyquinoline (0.046 g, 0.315 mmol) in DMSO (3mL). The mixture was degassed with a stream of argon and then heated at reflux for 23 h before cooling to RT. 10% aq. NH4OH and EtOAc were added, and the mixture was filtered through a plug of layered celite and decolorizing charcoal, eluting with EtOAc. The filtrate was concentrated under reduced pressure. Purification of the crude product by mplc revealed A (0.16 g, 37%) as a yellow solid. MS: APCI (AP+): 206.1 (M)+.
Step 2: (2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(6-oxo-6H-pyridazin-l-yI)-phenyl]-amide}. The compound was prepared as generally provided for Example 28. MS:
APCI (AP+): 486.1 (M)+.
Example 84
(2R,4S)-4-Amino-pyrrolidine-l,2 -dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yI)-amide]
Figure imgf000259_0001
Step 1: (2R,4R)-toluene-4-sulfonic acid l-(4-chloro-phenylcarbamoyI)-5-(3- fluoro-2'-methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidin-3-yl ester.
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] (see example 17, 0.41 g, 0.77 mmol) was dissolved in 5ml dry DCM, added Et3N (0.21 mL, 1.54 mmol), DMAP (10 mg, 0.8 mmol), and TsCl (0.16 g, 0.85 mmol). Stirred at ambient temperature overnight. The solution was dissolved in 100ml EtOAc, washed with 10% citric acid (3x50ml), sat NaHCO3 (3x50ml), brine (100ml), dried with MgSO4, filtered and concentrated to yield title compound. (0.54 g, 97%) MS: APCI (AP-): 684.1 (M)-.
Step 2: (2R,4S)-4-Azido-pyrroIidine-l, 2 -dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyI-biphenyl-4-yl)-amide].
(2R,4R)-toluene-4-sulfonic acid 1 -(4-chloro-phenylcarbamoyl)-5-(3- fluoro-2'-methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidin-3-yl ester (0.2 g, 0.29 mmol) was dissolved in 4ml dry DMF under Ar, added sodium azide (0.38 mg, 0.58 mmol) and stirred at 60°C for 6 hours. The reaction was cooled, taken up in 100ml EtOAc, washed with water, sat. NaHCO3, brine, dried with MgSO4, filtered and concentrated to yield title compound. (0.155 g, 95%) MS: APCI (AP+): 557.0 (M)+.
Step 3: (2R,4S)-4-Amino-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide].
(2R,4S)-4-Azido-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] (0.145 g, 0.26 mmol) was shaken with Raney Nickel (300mg) in 16 L tetrahydrofuran in a hydrogen atmosphere under pressure for 3 days. Reaction was filtered and concentrated. Purified by HPLC and lyophilized pure fractions to yield title compound. (105 mg, 76%) MS: APCI (AP-): 529.1 (M)-.
Example 85
(2R,4R)-4-Amino-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000261_0001
The compound was prepared as generally provided for Example 85 substituting (2R,4S)-toluene-4-sulfonic acid l-(4-chloro-phenylcarbamoyl)-5-(3- fluoro-2'-methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidin-3-yl ester for (2R,4R)-toluene-4-sulfonic acid 1 -(4-chloro-phenylcarbamoyl)-5-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-pyrrolidin-3-yl ester. MS: APCI (AP+): 531.1 (M)+.
Example 86
(2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
Figure imgf000261_0002
The compound was prepared as generally provided for Example 17, substituting 2-(N-tert-butyl)phenylsuIfonamide boronic acid for 2- ( ethylthio)benzene boronic acid. MS: APCI (AP- ): 533.0 (M)+. Example 87
(2R)-4-Hydroxyimino-pyrrolidine-l, 2 -dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000262_0001
The compound was prepared as generally provided for Example 22. MS: APCI (AP-f-): 545.0 (M)+.
Example 88
(2R,4R)-4-Hydroxy -pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methylsulfamoyl-biphenyl-4-yl)-amide]
Figure imgf000262_0002
The compound was prepared as generally provided for Example 86. MS: APCKAP+): 547.2 (M)+. Example 89
(2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxyJic acid l-[(4-chloro-phenyl)- amide] 2-[(2'-dimethylsulfamoyl-3-fluoro-biphenyl-4-yl)-amide]
Figure imgf000263_0001
The compound was prepared as generally provided for Example 86. MS: APCI (AP+): 561.2 (M)+.
Example 90
(2R,4R)-4-Methoxy-pyrrolidine-l,2 -dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000263_0002
The compound was prepared as generally provided for Example 28, substituting 3-fluoro-2'-methanesulfonyl-biphenyl-4-ylamine for l-(4-amino-3- fluoro-phenyl)-piperidin-2-one. MS: APCI (AP+): 547.1 (M)+. Example 91
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
Figure imgf000264_0001
The compound was prepared as generally provided for Example 28, substituting 4'-amino-3'-fluoro-biphenyl-2-sulfonic acid tert-butylamide for l-(4- amino-3-fluoro-phenyl)-piperidin-2-one . MS: APCI (AP+): 549.0 (M)+.
Example 92
(2R,4R)-4-Ethoxy-pyrrolidine-l,2 -dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000264_0002
The compound was prepared as generally provided for Example 90, substituting (2R,4R)-4-ethoxy-pyrrolidine- 1 ,2-dicarboxylic acid l-tert-butyl ester for (2R,4R)-4-methoxy-pyrrolidine- 1,2-dicarboxylic acid l-tert-butyl ester. MS: APCI (AP+): 561.1 (M)+. Example 93
(2R,4R)-4-Ethoxy-pyrroIidine-l, 2 -dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000265_0001
The compound was prepared as generally provided for Example 28, substituting (2R,4R)-4-ethoxy-pyrrolidine-l , 2-dicarboxylic acid l-tert-butyl ester for (2R,4R)-4-methoxy-pyrrolidine-l , 2-dicarboxylic acid 1 -tert-butyl ester. MS: APCI (AP+): 560.2 (M)+.
Example 94
(2R,4R)-4-Ethoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-pheπyl)- a ide] 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
Figure imgf000265_0002
The compound was prepared as generally provided for Example 91, substituting (2R,4R)-4-ethoxy-pyrrolidine-l ,2-dicarboxylic acid l-tert-butyl ester for (2R,4R)-4-methoxy-pyrrolidine-l ,2-dicarboxylic acid 1-terr-butyl ester. MS: APCKAP+): 561.1 (M)+.
Example 95
(2R,4S)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000266_0001
The compound was prepared as generally provided for Example 28, substituting (2R,4S)-4-methoxy-pyrrolidine- 1,2-dicarboxylic acid l-tert-butyl ester for (2R,4R)-4-methoxy-pyrrolidine- 1 ,2-dicarboxylic acid l-tert-butyl ester. MS: APCI (AP+): 546.0 (M)+.
Example 96
(2R,4R)-4-Fluoro-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesuIfonyl-biphenyl-4-yI)-amide]
Figure imgf000266_0002
The compound was prepared as generally provided for Example 28, substituting (2R,4R)-4-ethoxy-pyrrolidine-l , 2-dicarboxylic acid l-tert-butyl ester for (2R,4R)-4-methoxy-pyrrolidine- 1 ,2-dicarboxylic acid l-tert-butyl ester MS: APCI (AP+): 534.0 (M)+.
Example 97
(2R)-4,4-Difluoro-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-[(3-fluoro-2'-methanesulfonyI-biphenyl-4-yl)-amide]
Figure imgf000267_0001
The compound was prepared as generally provided for Example 28, substituting (2R)-4-difluoro-pyrrolidine-l , 2-dicarboxylic acid l-tert-butyl ester for (2R,4R)-4-methoxy-pyrrolidine-l ,2-dicarboxyIic acid l-tert-butyl ester. MS: APCI (AP+): 552.0 (M)+.
Example 98
(2R,4R)-4-Methoxy -pyrrolidine-1, 2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide] l-[(4-fluoro-phenyl)-amide]
Figure imgf000268_0001
The compound was prepared as generally provided for Example 28, substituting 4-fluorophenyl isocyanate for 4-chlorophenyl isocyanate. MS: APCI (AP+): 530.2 (M)+.
Example 99
(2R,4R)-4-Acetylamino-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000268_0002
The compound was prepared as generally provided for Example 84. MS: APCKAP+): 573.2 (M)+. Example 100
(2R,4R)-4-Methanesulfonylamino-pyrrolidine-l,2-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yI)-amide]
Figure imgf000269_0001
The compound was prepared as generally provided for Example 84. MS: APCKAP+): 609.2 (M)+.
Example 101
(2R,4S)-4-(lH-Tetrazol-5-yl)-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}
Figure imgf000269_0002
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 527.2 (M)+. Exa ple 102
(2R,4S)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-ch!oro-phenyl)- a ide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}
Figure imgf000270_0001
The compound was prepared as generally provided for Example 28, substituting (2R,4S)-4-methoxy-pyrrolidine- 1 ,2-dicarboxylic acid l-tert-butyl ester for (2R,4R)-4-methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -tert-butyl ester. MS: APCI (AP+): 489.2 (M)+.
Example 103
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-methyI-imidazol-l-yl)-phenyI]-amide}
Figure imgf000270_0002
The compound was prepared as generally provided for Example 28, substituting 2-Fluoro-4-(2-methyl-imidazol-l-yl)-phenylamine for l-(4-amino-3- fluoro-phenyl)-piperidin-2-one. MS: APCI (AP+): 472.2 (M)+. Example 104
(2R,4R)-4-Cyano-pyrrolidine-l, 2 -dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}
Figure imgf000271_0001
The compound was prepared as generally provided for Example 28 substituting substituting (2R,4R)-4-cyano-pyrrolidine- 1 ,2-dicarboxylic acid l-tert- butyl ester for (2R,4R)-4-methoxy-pyrrolidine-l , 2-dicarboxylic acid l-tert-butyl ester. MS: APCKAP+): 484.2 (M)+.
Example 105
(2R,4R)-4-(lH-Tetrazol-5-yl)-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}
Figure imgf000271_0002
The compound was prepared as generally provided for Example 104. MS: APCI (AP-): 525.3 (M)-. Example 106
(2R,4R)-4-Trifluoromethyl-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yI)-phenyI]-amide}
Figure imgf000272_0001
The compound was prepared as generally provided for Example 28, (2R,4R)-4-trifluoromethyl-pyrrolidine-l, 2-dicarboxylic acid l-tert-butyl ester for (2R,4R)-4-methoxy-pyrrolidine-l, 2-dicarboxylic acid l-tert-butyl ester.. MS: APCI (AP+): 527.2 (M)+.
Example 107
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloroφhenyl)- amide] 2-[(2'-cyano-3-fluoro-biphenyl-4-yl)-amide]
Figure imgf000272_0002
The compound was prepared as generally provided for Example 1, substituting 2-cyanobenzene boronic acid for 2-(methylthio)benzene boronic acid. MS: APCI (AP+): 493.3 (M)+. Example 108
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxyIic acid 2-[(2'-aminomethyl-3- fluoro-biphenyI-4-yl)-amide] l-[(4-chloro-phenyI)-amide]
Figure imgf000273_0001
The compound was prepared as generally provided for Example 107. MS: APCI (AP+): 497.3 (M)+.
Example 109
(2R,4R)-4'-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyI]-amino}-3'-fluoro-biphenyl-2-carboxylic acid methyl ester
Figure imgf000273_0002
The compound was prepared as generally provided for Example 107. MS: APCI (AP+): 526.2 (M)+.
General Procedure for Example 110
Figure imgf000274_0001
(CH3)3Si0K THF
Figure imgf000274_0002
Synthesis of 3: The carboxylic acid (1), aniline or amine (2), EEDQ, and triethylamine are heated at reflux in chloroform to produce 3.
Synthesis of 4: A solution of compound 3, TFA, and DCM is stirred at room temperature for 1 h and then concentrated under reduced pressure. The resulting oil is dissolved in THF and cooled to 0 °C followed by the addition of triethylamine orNN-diisopropylethylamine (DIEA) and the appropriate isocyanate to produce compound 4.
Synthesis of 5: To solution of compound 4 in THF is added potassium trimethylsilanolate and is stirred at room temperature overnight to produce 5.
Synthesis of 7: To solution of compound 5 in DMF is added N,N- diisopropylethylamine, PyBOP, and ΝHG]G2 and is stirred at room temperature overnight to produce 7.
Example 110 (2R,4R)-4-Methoxy -pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2- {[4-(2,5-dihydro-pyrrole-l-carbonyl)-phenyl]-amide}
Figure imgf000275_0001
Step 1: (2R,4R)-4-Hydroxy-pyrroIidine-2-carboxylic acid methyl ester (1).
Cϊs-4-Hydroxy-D-proline (15 g, 1 15 mmol) was suspended in 150 mL anhydrous methanol under an argon atmosphere, then cooled to 0°C before bubbling in HCl gas for 15 minutes. The solution gradually became homogenous.
The argon and HCl gas lines were removed and the solution was refluxed for 4h. The solution was cooled and then concentrated under reduced pressure. The crude material was redissolved in 100 mL methanol and diethyl ether was added until a precipitate formed. The precipitate was filtered off, washed with diethyl ether, and dried in vacuo overnight to give 1 (20 g, 95%) as a white solid. MS: APCI
(AP+): 146 (M)+.
Step 2: (2R,4R)-4-Hydroxy-l-trityl-pyrrolidine-2-carboxylic acid methyl ester (2).
Into a solution of 1 (10 g, 55 mmol) in anhydrous CHC13 (100 mL) was added triethylamine (19 mL, 138 mmol) and triphenylmethyl chloride (14.5 g, 52 mmol). The mixture was stirred at RT for 3d before concentrating and redissolving in EtOAc. The solution was washed sequentially with 10% aq. citric acid, water, and brine before drying over MgSO4 and concentrating under reduced pressure to give 2 (20 g, 100%) as a yellow solid.
Step 3: (2R,4R)-4-Methoxy-l-trityl-pyrroIidine-2-carboxylic acid methyl ester (3). Into a solution of 2 (5.71 g, 14.7 mmol) in anhydrous DMF (20 mL) and anhydrous THF (20 mL) was added Mel (3.67 mL, 58.9 mmol). The solution was cooled to 0°C in an ice bath and NaH (0.766 g, 19.2 mmol) was added in one portion. The mixture was stirred at RT for 26h before adding EtOAc and washing sequentially with water and brine. The organic layer was dried over MgSO4 and concentrated under reduced pressure. Purification of the crude material by flash chromatography revealed 3 (4.67 g, 79%) as a white solid.
Step 4: (2R,4R)-4-Methoxy-pyrroIidine-2-carboxyIic acid methyl ester (4). To a flask containing 3 (4.67 g, 11.6 mmol) was added a solution of
CH2C12 (27 mL), water (0.3 mL), and TFA (3.0 mL, 38.9 mmol). The solution was stirred at RT for 3h before concentrating under reduced pressure to reveal impure 4. MS: APCKAP+): 160.1 (M)+.
Step 5: (2R,4R)- 4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-tert-butyl ester 2-methyI ester (5).
Into a solution of 4 (1.85 g, 11.6 mmol) in CH2C12 (20 mL) was added triethylamine (6.49 mL, 46.5 mmol), di-tert-butyl dicarbonate (5.08 g, 23.3 mmol), and dimethylaminopyridine (0.142 g, 1.16 mmol). The mixture was stirred at RT for 22h before concentrating under reduced pressure and redissolving in EtOAc. The solution was washed sequentially with 10% aq. citric acid and brine before drying over MgSO4 and concentrating under reduced pressure. The crude material was purified by flash chromatography to reveal 5 (2.54 g, 84% over two steps) as a yellow solid. MS: APCI (AP+): 260.1 (M)+.
Step 6: (2R,4R)-4-Methoxy-pyrroIidine-l,2-dicarboxylic acid l-tert-butyl ester (6).
Into a solution of 5 (2.54 g, 9.80 mmol) in acetonitrile (20 mL) was added water (20 mL) and LiOH H2O (1.64 g, 39.2 mmol). The mixture was stirred at RT for 28h before removing the acetonitrile under reduced pressure. EtOAc was added to the residue that was then washed with IN HCl. The aqueous layer was extracted with additional EtOAc and the combined organic layers were washed with brine and dried over MgSO4. The solution was concentrated under reduced pressure to reveal 6 (2.16 g, 90%) as a white solid. MS: APCI (AP-): 244.1 (M)-.
Step 7: (2R,4R)-4-Methoxy-2-(4-methoxycarbonyl-phenylcarbamoyl)- pyrrolidine-1 -carboxylic acid tert-butyl ester (7).
Into a solution of 6 (8.1 1 g, 33.0 mmol) in CHC13 (200 mL) was added 4- amino-benzoic acid methyl ester (5.00 g, 33.0 mmol), EEDQ (9.81 g, 39.6 mmol), and triethylamine (6.9 mL, 49.6 mmol). The solution was stirred at reflux for 19h before cooling to RT and adding EtOAc. The solution was washed sequentially with IN HCl, 0.1N NaOH, water, and brine, before drying over MgSO and concentrating under reduced pressure to give 7 (12.50 g, 100%). MS: APCI (AP+): 379.3 (M)+, (AP-): 377.3 (M)-.
Step 8: (2R,4R)-4-[(4-Methoxy-pyrrolidine-2-carbonyl)-amino]-benzoic acid methyl ester (8).
Into a solution of 7 (12.5 g, 33.0 mmol) in anhydrous CH2C12 (70 mL) was added TFA (20 L). The solution was stirred at RT overnight before concentrating under reduced pressure to give 8 (9.19 g, 100%).
Step 9: (2R,4R)-4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyI]-amino}-benzoic acid methyl ester (9).
Into a solution of 8 (9.19 g, 33.0 mmol) in anhydrous THF (200 mL) at 0°C was added N,N-diisopropylethylamine (DIEA) (28.7 mL, 165 mmol) and 4- chlorophenyl isocyanate (5.07 g, 33.0 mmol). The solution was stirred at RT overnight before concentrating under reduced pressure. The crude material was purified on a silica gel column eluted with 10% moving to 50% EtOAc in hexanes. Combined and concentrated pure fractions. Remaining EtOAc was azeotroped off with acetonitrile and was lyophilized from acetonitrile / water to give 9 (13.37 g, 94%) as a solid. MS: APCI (AP+): 432.1 (M)+, (AP-): 430.1 (M)-. Step 10: (2R,4R)-4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine- 2-carbonyl]-amino}-benzoic acid (10).
Into a solution of 9 (3.0 g, 6.94 mmol) in THF (50 mL) was added potassium trimethylsilanolate (3.85 g, 27.3 mmol). The solution was stirred at RT for48h before concentrating under reduced pressure and adding EtOAc. The solution was washed sequentially with IN HCl, and brine, before drying over MgSO and concentrating under reduced pressure to give 10 (2.9 g, 100%). MS: APCI (AP- ): 418.1 (M)+, (AP-): 416.1 (M)-.
Step 11: (2R,4R)-4-Methoxy -pyrrolidine-1, 2 -dicarboxylic acid l-[(4-ch!oro- phenyl)-amide] 2-{[4-(2,5-dihydro-pyrrole-l-carbonyI)-phenyl]-amide} (11).
Into a solution of 10 (0.25 g, 0.589 mmol) in DMF (3 mL) was added N,N- diisopropylethylamine (DIEA) (0.4 mL, 2.32 mmol), PyBOP (0.34 g, 0.653 mmol), and 3-pyrroline (0.09 L, 1.19 mmol). The solution was stirred at RT for 19h and EtOAc added. The solution was washed sequentially with IN HCl, saturated ΝaHCO3, water, and brine, before drying over MgSO4 and concentrating under reduced pressure. The crude material was purified on a silica gel column eluted with 20% EtOAc in hexanes moving to 1 % MeOH in EtOAc. Combined and concentrated pure fractions. Remaining EtOAc was azeotroped off with acetonitrile and was lyophilized from acetonitrile / water to give 11 (0.1 16 g, 41 %) as a solid. MS: APCI (AP+): 469.2 (M)+, (AP-): 468.1 (M)-.
General Procedure for Example 111
Figure imgf000279_0001
2) H2, RaNi.THF
Figure imgf000279_0002
Synthesis of 2: The carboxylic acid (1) is converted to the acid chloride (2) upon treatment with oxalyl chloride and DMF (catalytic) in dichloromethane.
Synthesis of 3: To the acid chloride (2) in dichloromethane is then added NHG]G2 and triethylamine in dichloromethane. Alternatively NHG)G2 can be coupled directly to the carboxylic acid with addition of PyBOP and N,N- diisopropylethylamine in DMF. Reduction of the nitro group to the corresponding aniline is readily achieved with a transition metal such as palladium on carbon or Raney nickel and hydrogen to give 3.
Synthesis of 5: The carboxylic acid (4), aniline (3), EEDQ, and triethylamine are heated at reflux in chloroform to produce 5.
Synthesis of 6: A solution of compound 5, TFA, and DCM is stirred at room temperature for 1 h and then concentrated under reduced pressure. The resulting oil is dissolved in THF and cooled to 0 °C followed by the addition of triethylamine or N,N-diisopropylethylamine (DIEA) and the appropriate isocyanate to produce compound 6.
Example 111
(2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-[(4-dimethylcarbamoyl-2-fluoro-phenyl)-amide]
Figure imgf000280_0001
Step 1: (2R,4R)-4-hydroxy-pyrrolidine-l,2-dicarboxylic acid l-tert-butyl ester
(1).
Cis-4-hydroxy-D-proline (15 g, 1 14 mmol) was dissolved In 150 mL of THF/ H2O (2:1 ), added 2M aqueous ΝaOH solution (86 mL, 172 mmol), followed by B0C2O (27 g, 126 mmol). Reaction was stirred at ambient temperature overnight. The solution was acidified with 10% citric acid then extracted with EtOAc (2x250 mL), washed with water, brine, dried organics with MgSO filtered and concentrated to give 1 (16 g, 61 %) APCI (AP-): 230.1 (M-
H)-.
Step 2: (2R,4R)-4-(tert-butyl-dimethyl-silanyloxy)-pyrrolidine-l,2- dicarboxylic acid l-tert-butyl ester (2).
(2R,4R)-4-Hydroxy-pyrrolidine-l , 2-dicarboxylic acid l-tert-butyl ester (16 g, 69 mmol) was dissolved in 100 L DMF, added imidazole (12 g, 173 mmol), dimethylaminopyridine (0.85 g, 6.9 mmol), and tert-butyldimethylsilyl chloride (12.5 g, 83 mmol). Stirred at ambient temperature overnight, dissolved in 350 L EtOAc, washed with 10% citric acid (3x200 mL), water (2x200 mL), brine, dried with MgSO filtered, and concentrated to give 2 (20 g, 84%) APCI
(AP-): 344.2 (M-H)'.
Step 3: 3-Fluoro-4-nitro-benzoyl chloride (3).
Into a solution of 3-fluoro-4-nitro-benzoic acid (4.0 g, 21.6 mmol) in anhydrous CH2C12 (200 mL) at 0°C was slowly added oxalyl chloride (2.45 mL, 28.0 mmol) and a drop of DMF. The solution was stirred and allowed to warm to RT overnight before concentrating under reduced pressure to give 3 (4.39 g, 300%).
Step 4: 3-Fluoro-N,N-dimethyI-4-nitro-benzamide (4).
Into a solution of 3 (1.50 g, 7.36 mmol) in CH2C12 (30 mL) at 0°C was added triethylamine (1.5 mL, 10.9 mmol) and dimethylamine 40% in water (0.83 mL, 7.36 mmol) dropwise. The solution was stirred and allowed to warm to RT overnight before concentrating under reduced pressure and adding EtOAc. The solution was washed sequentially with saturated NaHCO3, water, and brine, before drying over MgSO4 and concentrating under reduced pressure to give impure 4 (0.78 g, 50%). MS: APCI (AP+): 213.1 (M)+, (AP-): 212.1 (M)-.
Step 5: 4-Amino-3-fluoro-N,N-dimethyl-benzamide (5).
To a Parr apparatus was added 4 (0.78 g, 3.67 mmol), Raney nickel (1.2 g), and THF (50 mL). The vessel was sealed under a hydrogen atmosphere and shaken under pressure at room temperature for 15h. The vessel was then depressurized and the solids filtered off, washing with THF. The filtrate was concentrated under reduced pressure to give impure 5 (0.66 g, 100%). MS: APCI (AP+): 183.1 (M)+, (AP-): 181.0 (M)-.
Step 6: (2R,4R)-4-(tert-Butyl-dimethyl-silanyloxy)-2-(4-dimethylcarbamoyl- 2-fluoro-phenylcarbamoyl)-pyrrolidine-l-carboxylic acid tert-butyl ester (6). Into a solution of 2 (1.25 g, 3.61 mmol) in CHC13 (25 mL) was added 5 (0.66 g, 3.61 mmol), EEDQ (1.07 g, 4.32 mmol), and triethylamine (0.74 mL, 5.33 mmol). The solution was stirred at reflux for 19h before cooling to RT and adding EtOAc. The solution was washed sequentially with IN HCl, 0.1N NaOH, water, and brine, before drying over MgSO and concentrating under reduced pressure. The crude material was purified on a silica gel column eluted with 20% moving to 50% EtOAc in hexanes. Combined and concentrated pure fractions, to give 6 (0.33 g, 18%). MS: APCI (AP+): 510.3 (M)+, (AP-): 508.4 (M)-.
Step 7: (2R,4R)-4-Hydroxy-pyrrolidine-2-carboxylic acid (4- dimethylcarbamoyl-2-fluoro-phenyl)-amide (7). Into a solution of 6 (0.33 g, 0.647 mmol) in anhydrous CH2C12 (10 mL) was added TFA (2 mL). The solution was stirred at RT for 4h before concentrating under reduced pressure to give 7 (0.19 g, 100%).
Step 8: (2R,4R)-4-Hydroxy-pyrrolidine-l, 2 -dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-dimethy arbamoyl-2-fluoro-phenyl)-amide] (8).
Into a solution of 7 (0.19 g, 0.643 mmol) in anhydrous THF (10 L) at 0°C was added N,N-diisopropylethylamine (DIEA) (0.56 mL, 3.21 mmol) and 4- chlorophenyl isocyanate (0.099 g, 0.643 mmol). The solution was stirred at RT overnight before concentrating under reduced pressure. Crystallized from EtOAc in hexanes and filtered to give 8 (0.12 g, 43%) as a solid. MS: APCI (AP+): 449.2 (M)+, (AP-): 447.1 (M)-.
Example 112
(2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[4-(pyrroIidine-l-carbonyl)-phenyl]-amide} )
Figure imgf000283_0001
The compound was prepared as generally provided for Example 11 1. MS: APCI (AP+): 457.1 (M)+, (AP-): 455.1 (M)-.
Example 113
Pyrrolidine-1, 2 -dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[4- (pyrrolidine-l-carbonyl)-phenyl]-amide}
Figure imgf000283_0002
The compound was prepared as generally provided for Example 111. MS: APCI (AP+): 441.1 (M)+, (AP-): 439.1 (M)-.
Example 114
(2R,4R)-4-Hydrox -pyrrolidine-1, 2 -dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[4-(2-methyI-pyrrolidine-l-carbonyl)-phenyl]-amide}
Figure imgf000284_0001
The compound was prepared as generally provided for Example 111. MS: APCI (AP+): 471.2 (M)+, (AP-): 469.2 (M)-.
Example 115
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[4-(ethyl-methyl-carbamoyI)-phenyl]-amide}
Figure imgf000284_0002
The compound was prepared as generally provided for Example 111. MS: APCI (AP+): 445.2 (M)+, (AP-): 443.1 (M)-.
Example 116
(2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(4-dimethylcarbamoyl-phenyl)-amide]
Figure imgf000285_0001
The compound was prepared as generally provided for Example 111. MS: APCI (AP+): 431.1 (M)+, (AP-): 429.1 (M)-.
Example 117
(2R,4R)-4-Hydroxy-pyrrolidine-l,2 -dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-{[4-(2R-methyl-pyrrolidine-l-carbonyI)-phenyl]-amide}
Figure imgf000285_0002
The compound was prepared as generally provided for Example 111. MS: APCI (AP+): 471.2 (M)+, (AP-): 469.2 (M)-.
Example 118
(2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[4-(2S-methyl-pyrroIidine-l-carbonyl)-phenyI]-amide}
Figure imgf000286_0001
The compound was prepared as generally provided for Example 111. MS: APCI (AP+): 471.2 (M)+, (AP-): 469.2 (M)-.
Example 119
(2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(pyrroIidine-l-carbonyI)-phenyl]-amide}
Figure imgf000286_0002
The compound was prepared as generally provided for Example 111. MS: APCI (AP+): 475.2 (M)+, (AP-): 473.1 (M)-.
Example 120
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-{[4-(pyrrolidine-l-carbonyl)-2-pyrroIidin-l-yl-phenyl]-amide}
Figure imgf000287_0001
The compound was prepared as generally provided for Example 111. MS: APCI (AP+): 526.2 (M)+, (AP-): 524.3 (M)-.
Example 121
(2R,4R)-4-{[l-(4-ChIoro-phenylcarbamoyl)-4-hydroxy-pyrrolidine-2- carbonyl]-amino}-3-pyrroIidin-l-yl-benzoic acid methyl ester
Figure imgf000287_0002
The compound was prepared as generally provided for Example 111. MS: APCI (AP+): 487.2 (M)+, (AP-): 485.2 (M)-.
Example 122
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxyIic acid 2-{[4-(azetidine-l- carbonyl)-phenyl]-amide} l-[(4-ch!oro-phenyl)-amide]
Figure imgf000288_0001
The compound was prepared as generally provided for Example 1 1 lo. MS: APCI (AP+): 443.2 (M)+, (AP-): 441.1 (M .
Example 123
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[2-fluoro-4-(pyrrolidine-l-carbonyl)-phenyl]-amide}
Figure imgf000288_0002
The compound was prepared as generally provided for Example 111. Formation of the 5-chloro-pyridin-2-yl moiety can be found in Example 26. MS: APCI (AP+): 476.2 (M)+, (AP-): 474.2 (M)-.
Example 124
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[4-(pyrroIidine-l-carbonyl)-phenyl]-amide}
Figure imgf000289_0001
The compound was prepared as generally provided for Example 11 1. Formation of the 5-chloro-pyridin-2-yl moiety can be found in Example 26. MS: APCI (AP+): 458.2 (M)+, (AP-): 456.2 (M>.
Example 125
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-[(4-dimethylcarbamoyl-phenyl)-amide]
Figure imgf000289_0002
The compound was prepared as generally provided for Example 111. Formation of the 5-chloro-pyridin-2-yl moiety can be found in Example 26. MS: APCI (AP+): 432.1 (M)+, (AP-): 430.1 (M)-.
Example 126
(2R,4R)-4-{[l-(4-Chloro-phenylcarbamoyl)-4-hydroxy-pyrrolidine-2- carbonyI]-amino}-3-dimethylamino-benzoic acid methyl ester
Figure imgf000290_0001
The compound was prepared as generally provided for Example 111. MS: APCI (AP+): 461.2 (M)+, (AP-): 459.1 (M)-.
Example 127
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-ch!oro-phenyI)- amide] 2-{[4-(pyrrolidine-l-carbonyl)-phenyl]-amide}
Figure imgf000290_0002
The compound was prepared as generally provided for Example 110 and/or DD-2. MS: APCI (AP+): 471.2 (M)+, (AP-): 469.2 (M)-.
Example 128
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxyIic acid l-[(4-chloro-phenyl)- amide] 2-[(4-dimethylcarbamoyl-phenyl)-amide]
Figure imgf000291_0001
The compound was prepared as generally provided for Example 1 10 and/or 1 11. MS: APCI (AP+): 445.2 (M)+, (AP-): 443.2 (M)-.
Example 129
(2R,4R)-4-Ethoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-{[4-(pyrrolidine-l-carbonyI)-phenyl]-amide}
Figure imgf000291_0002
The compound was prepared as generally provided for Example 1 11. MS: APCI (AP+): 485.3 (M)+, (AP-): 483.3 (M)-.
Example 130
(2R,4R)-4-Ethoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-[(4-dimethylcarbamoyl-phenyl)-amide]
Figure imgf000292_0001
The compound was prepared as generally provided for Example 1 1 1. MS: APCI (AP+): 459.2 (M)+, (AP-): 457.2 (M)-.
Example 131
(2R,4R)-4-Methoxy-pyrroIidine-l,2-dicarboxyIic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(pyrrolidine-l-carbonyl)-phenyl]-amide}
Figure imgf000292_0002
The compound was prepared as generally provided for Example 1 10 and/or 111. MS: APCI (AP+): 489.3 (M)+, (AP-): 487.2 (M)-.
Example 132
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(4-dimethylcarbamoyl-2-fluoro-phenyl)-amide]
Figure imgf000293_0001
The compound was prepared as generally provided for Example 110 and/or 1 1 1. MS: APCI (AP+): 463.2 (M)+, (AP-): 461.2 (M)-.
Example 133
(2R,4R)-4-Ethoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(pyrrolidine-l-carbonyl)-phenyl]-amide}
Figure imgf000293_0002
The compound was prepared as generally provided for Example 111. MS: APCI (AP+): 503.3 (M)+, (AP-): 501.3 (M)-.
Example 134
(2R,4R)-4-Ethoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(4-dimethylcarbamoyI-2-fluoro-phenyl)-amide]
Figure imgf000294_0001
The compound was prepared as generally provided for Example 111. MS: APCI (AP+): 477.3 (M)+, (AP-): 475.2 (M)-.
Example 135
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxyIic acid l-[(4-chloro-phenyl)- amide] 2-{[2-methyl-4-(2-oxo-piperidin-l-yI)-phenyI]-amide}
Figure imgf000294_0002
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 485.3 (M)+, (AP-): 483.3 (M)-.
Example 136
(2R,4R)-4-Ethoxy-pyrrolidine-l,2 -dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-methyl-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}
Figure imgf000295_0001
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 499.2 (M)+, (AP-): 497.2 (M)-.
Example 137
Pyrrolidine-l,2-dicarboxyIic acid l-[(4-chloro-phenyl)-amide] 2-[(2-fluoro-4- quinolin-S-yl-phenyl)-amide]
Figure imgf000295_0002
The compound was prepared as generally provided for Example 19. MS: APCI (AP+): 489.1 (M)+, (AP-): 488.1 (M>.
Example 138
Pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3,5- difIuoro-2'-methanesulfonyl-biphenyl-4-yI)-amide]
Figure imgf000296_0001
The compound was prepared as generally provided for Example 19. MS: APCI (AP+): 534.1 (M)+, (AP-): 532.0 (M)-.
Example 139
Pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-2-methyI-biphenyl-4-yl)-amide]
Figure imgf000296_0002
The compound was prepared as generally provided for Example 19. MS: APCI (AP+): 512.1 (M)+, (AP-): 510.1 (M)-.
Example 140
(2R,4R)-4-Hydroxy-pyrrolidine-l,2 -dicarboxylic acid l-[(4-chloro-pheny!)- amide] 2-[(2'-methanesulfonyl-biphenyI-4-yI)-amide]
Figure imgf000297_0001
The compound was prepared as generally provided for Example 17. MS: APCI (AP+): 514.0 (M)+, (AP-): 512.0 (M .
Example 141
(2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2'-methanesuIfinyl-biphenyl-4-yl)-amide]
Figure imgf000297_0002
The compound was prepared as generally provided for Example 17. MS: APCI (AP+): 498.2 (M)+, (AP-): 496.2 (M)-.
Example 142
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-[(3-methyl-2'-methyIsulfanyl-biphenyl-4-yI)-amide]
Figure imgf000298_0001
The compound was prepared as generally provided for Example 17. MS: APCI (AP+): 496.1 (M)+, (AP-): 494.1 (M)-.
Example 143
(2R,4R)-4-Hydroxy-pyrrolidine-l,2 -dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000298_0002
The compound was prepared as generally provided for Example 17. MS: APCI (AP+): 532.0 (M)+, (AP-): 530.0 (M)-.
Example 144
(2R,4R)-4-Hydroxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-[(2'-methanesulfonyI-3-methyl-biphenyl-4-yl)-amide] -298-
Figure imgf000299_0001
The compound was prepared as generally provided for Example 17. MS: APCI (AP+): 528.1 (M)+, (AP-): 526.1 (M)-.
Example 145
(2R,4R)-4-Hydroxy -pyrrolidine-1, 2-dicarboxylic acid l-[(4-chIoro-phenyl)- amide] 2-[(2'-methanesulfonyl-3-trifluoromethyl-biphenyl-4-yI)-amide]
Figure imgf000299_0002
The compound was prepared as generally provided for Example 17. MS: APCI (AP+): 582.1 (M)+, (AP-): 580.1 (M)-.
Example 146
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2'-methoxy-biphenyl-4-yI)-amide]
Figure imgf000300_0001
Step 1: 2-Methoxy-4'-nitro-biphenyI (146a).
1 -Bromo-4-nitrobenzene (l .OOg, 4.95mmol), 2-methoxyphenylboronic acid (1.13g, 7.43mmol), K3PO4 (1.58g, 7.43mmol), and anhydrous DMF (5mL) were combined in a flask and degassed with argon. Tetrakistriphenylphosphine palladium(O) (0.858g, 0.743mmol) was added to the mixture which was again degassed with argon. The mixture was heated at 1 10°C for 3h before cooling, diluting with EtOAc, and filtering through a plug of silica gel. The solution was washed sequentially with water and brine before drying over MgSO . The solution was concentrated under reduced pressure and purified by flash chromatography to provide 146-a (1.05g, 93%) as a yellow solid. MS: APCI (AP+): 230.1 (M)+.
Step 2: 2'-Methoxy-biphenyl-4-ylamine (146-b).
To a Parr apparatus was added 146-a (1.05g, 4.58mmol), Raney nickel (0.66g), and a 4:1 mixture of THF:MeOH (50mL). The vessel was sealed under a hydrogen atmosphere and shaken under pressure at RT for 18h. The vessel was then depressurized and the solids filtered off, washing with THF. The filtrate was concentrated under reduced pressure to reveal an unknown amount of 146-b as a tan oil that was carried on without further purification. MS: APCI (AP+): 200,0 (M)+.
The title compound (146) was prepared from 146b as generally provided for in Examples 26 28. MS: APCI (AP+): 466.1 (M)+. Example 147
(2R,4R)-4-Hydroxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2'-hydroxy-biphenyl-4-yI)-amide]
Figure imgf000301_0001
In a flask was dissolved 146a (O.lOOg, 0.215mmol) in anhydrous DCM (5mL). At 0°C, boron tribromide (0.203mL, 2.15mmol) was added dropwise. The solution was stirred at RT for 25min before concentrating under reduced pressure. The crude material was purified by silica gel flash chromatography followed by lyophilization from acetonitrile / water to provide the title compound (0.039g, 40%) as a white solid. MS: APCI (AP+): 452.1 (M)+.
Example 148
(2R,4R)-4-Methoxy -pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2-fluoro-4-iodo-phenyl)-amide]
Figure imgf000301_0002
The compound was prepared as generally provided for Example 28. MS:
APCI (AP+): 518.0 (M)+. Example 149
(2R,4R)-4-Methoxy-pyrroIidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000302_0001
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 485.2 (M)+.
Example 150
(2R, 4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000302_0002
The compound was prepared as generally provided for Example 28 and Example 3, step 3a. MS: APCI (AP+): 486.2 (M)+.
Example 151 (2R, 4R)-4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-ch!oro-phenyl)- amide] 2-{[2-fluoro-4-(3-hydroxy-2-oxo-piperidin-l-yI)-phenyl]-amide}]
Figure imgf000303_0001
The compound was prepared as generally provided for Example 28. MS:
APCI (AP+): 505.3 (M)+.
Example 152
(2R, 4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-tetrahydro-pyrimidin-l-yl)-phenyl]-amide}
Figure imgf000303_0002
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 490.3 (M)+.
Example 153
(2R, 4R)-4-Methoxy-pyrroIidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-imidazoIidin-l-yI)-phenyl]-amide}
Figure imgf000304_0001
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 476.2 (M)+.
Example 154
(2R, 4R)-4-Methoxy-pyrroIidine-l,2 -dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-{[2-fluoro-4-(2-oxo-oxazolidin-3-yI)-phenyI]-amide}
Figure imgf000304_0002
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 477.2 (M)+.
Example 155
(2R, 4R)-l-(4-{[l-(4-ChIoro-phenylcarbamoyI)-4-methoxy-pyrrolidine-2- carbonyI]-amino}-3-fluoroφhenyl)-2-oxo-piperidine-3-carboxylic acid ethyl ester
Figure imgf000305_0001
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 561.3 (M)+.
Example 156
(2R, 4R)-4-Methox -pyrrolidine-1, 2 -dicarboxylic acid l-[(4-chloro-phenyϊ)- amide] 2-{[2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin-l-yl)-phenyI]-amide}
Figure imgf000305_0002
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 515.2 (M)+.
Example 157
(2R, 4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000306_0001
The compound was prepared as generally provided for Example 28 and Example 23, step 3a. MS: APCI (AP+): 516.2 (M)+.
Example 158
(2R, 4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-{[4-(3-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000306_0002
Step 1: 3-Methyl-l-(4-nitro-phenyl)-lH-pyridin-2-one (158-a). l-Iodo-4-nitrobenzene (1.61g, 6.45mmol) was combined with 3-methyl-2- pyridone (0.845g, 7.74mmol), Cul (0.246g, 1.29mmol), and K3PO4 (2.74g, 12.9mmol). 1,4-Dioxane (6mL) was added followed by trans-1,2- diaminocyclohexane (0.194mL, 1.61 mmol). The mixture was heated to reflux for 19h before cooling and diluting with EtOAc. The mixture was filtered through a plug of silica, eluting with EtOAc, and the filtrate concentrated under reduced pressure. Purification of the crude product by flash chromatography provided 158-a (0.528g, 36%) as a brown solid. MS: APCI (AP+): 231.1 (M)+. Step 2: l-(4-Amino-phenyI)-3-methyl-lH-pyridin-2-one (158-b).
To a flask was added 158a (0.523g, 2.27mmol), glacial acetic acid (7.6mL), cone. HCl (3.8mL, 45.4mmol), and mossy tin (0.539g, 4.54mmol). The mixture was heated to reflux for 90min before cooling and concentrating under reduced pressure. The residue was dissolved in EtOAc and washed with aq. IN NaOH until shown basic with pH paper. The aqueous layer was extracted twice with EtOAc and the combined organics washed with brine and dried over MgSO4. After placing under vacuum, 158-b (0.407g, 89%) was revealed as a tan solid that was carried on without further purification. MS: APCI (AP+): 201.1 (M)+.
The title compound (158) was prepared from 158-b as generally provided for Example 28. MS: APCI (AP+): 481.3 (M)+.
Example 159
(2R, 4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[4-(3-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000307_0001
The compound was prepared as generally provided for Example 158 and
Example 3, step 3a. MS: APCI (AP+): 482.3 (M)+. r
Example 160
(2R, 4R)-4-Methoxy-pyrrolidine-l,2-dicarboxyIic acid l-[(4-chIoro-phenyI)- amide] 2-[(4-morpholin-4-yl-phenyl)-amide]
Figure imgf000308_0001
Step 1: 4-(4-Nitro-phenyl)-morpholine (160-a).
1 -Fluoro-4-nitrobenzene (3.00mL, 28.3mmol) was combined in a flask with anhydrous 2-propanol (28mL), triethylamine (4.34mL, 31.1 mmol), and moφholine (2.47mL, 28.3mmol). The mixture was refluxed for 3.5h before adding additional moφholine (2.47mL, 28.3mmol) and refluxing for 20h. The mixture was then cooled and concentrated under reduced pressure. Purification by silica gel flash chromatography provided 160-a (6.09g, 98%) as a 95% pure solid. MS: APCI (AP-): 207.1 (M)-.
The title compound (160) was prepared from 160-a as generally provided for 146 and Example 28. MS: APCI (AP+): 459.3 (M)+.
Example 161
(2R, 4R)-4-Methoxy-pyrrolidine-l,2 -dicarboxylic acid l-[(4-chloro-phenyI)- amide] 2-{[4-(2-methyl-5-oxo-pyrrolidin-l-yl)-phenyl]-amide}
H
Figure imgf000308_0002
The compound was prepared as generally provided for in Example 28 and 146. MS: APCI (AP+): 471.3 (M)+. Example 162
(2R, 4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[4-(2-methyl-5-oxo-pyrrolidin-l-yl)-phenyl]-amide}
Figure imgf000309_0001
The compound was prepared as generally provided for in Example 3, step 3a, and Example 161. MS: APCI (AP+): 472.2 (M)+.
Example 163
(2R, 4R)-4-Methoxy-pyrroIidine-l, 2 -dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000309_0002
The compound was prepared as generally provided for Example 28. MS: APCI (AP+): 499.2 (M)+.
Example 164 (2R, 4R)-4-Methoxy -pyrrolidine-1, 2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-l-yI)-phenyl]-amide}]
Figure imgf000310_0001
The compound was prepared as generally provided for Example 28 and Example 3, step 3a. MS: APCI (AP+): 500.2 (M)+.
General Procedure for Examples 165-173:
Figure imgf000310_0002
r do *. HgN-A'B - X H 1-TWDCM « Λ « X γ E CEHDCQI3.^ v 6 'V O s B m. NC° c-Y O iV O
Et3N/THF
Synthesis of 2: A mixture of 1 (where Z is a halide), B (where B is a nitrogen in a ring), K2CO3, Cul, and 8-hydroxyquinoline is heated in DMSO at 130°C to obtain compound 2.
Synthesis of 4: The appropriate aniline (2), EEDQ, triethylamine and carboxylic acid (3) are heated at reflux in chloroform to produce 4. Synthesis of 5: A solution of compound 4, TFA and DCM is stirred at room temperature for I h and then concentrated under reduced pressure. The resulting oil is dissolved in THF and cooled to 0 °C followed by the addition of triethylamine and the appropriate isocyanate to produce compound 5.
Example 166
(2R, 4R)-4-Methoxy-pyrroIidine-l, 2 -dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(5-methyI-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000311_0001
Step 1: l-(4-Amino-3-fluoro-phenyI)-5-methyl-lH-pyridin-2-one (167-a).
2-Fluoro-4-iodoaniline (0.905g, 42.2mmol) was combined with 5-methyl- lH-pyridin-2-one (0.500g, 4.58mmol), 8-hydroxyquinoline (0.083g, 0.573mmol), Cul (0.109g, 0.0.573mmol), and K2CO3 (0.580g, 4.20mmol), in DMSO (3mL). The mixture was degassed with a stream of argon and then heated at reflux for 16h before cooling to RT. 10% aq. NΗ4OΗ and EtOAc were added, and the mixture was filtered through a plug of layered celite and decolorizing charcoal, eluting with EtOAc. The filtrate was concentrated under reduced pressure. Purification of the crude product by silica gel flash chromatography revealed 167- a (0.673g, 81%) as a white solid. MS: APCI (AP+): 219.1 (M)+.
The title compound (166) was prepared from 166-a as generally provided for in Example 28. MS: APCI (AP+): 499.2 (M)+.
Example 167 (2R, 4R)-4-Methoxy -pyrrolidine-1 ,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[2-fluoro-4-(5-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000312_0001
The compound was prepared as generally provided for in Example 166 and Example 3, step 3a. MS: APCI (AP+): 500.2 (M)+.
Example 168
(2R, 4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- a ide] 2-{[2-fluoro-4-(4-methoxy-2-oxo-2H-pyridin-l-yI)-phenyl]-amide}
Figure imgf000312_0002
The compound was prepared as generally provided for in Example 166.
MS: APCI (AP+): 515.2 (M)+.
Example 169
(2R, 4R)-4-Methoxy-pyrroIidine-l,2-dicarboxylic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[2-fluoro-4-(4-methoxy-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000313_0001
The compound was prepared as generally provided for in Example 167. S: APCI (AP+): 516.2 (M)+.
Example 170
(2R, 4R)-4-Methoxy-pyrrolidine-l,2 -dicarboxylic acid l-[(4-ch!oro-phenyl)- amide] 2-{[2-fluoro-4-(3-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000313_0002
The compound was prepared as generally provided for in Example 166. S: APCI (AP+): 499.2 (M)+.
Example 171
(2R, 4R)-4-Methoxy-pyrrolidine-l,2-dicarboxyIic acid l-[(5-chloro-pyridin-2- yl)-amide] 2-{[2-fIuoro-4-(3-methyl-2-oxo-2H-pyridin-l-yI)-phenyl]-amide}
Figure imgf000314_0001
The compound was prepared as generally provided for in Example 166. S: APCI (AP+): 500.2 (M)+.
Example 172
(2R, 4R)-4-Methoxy -pyrrolidine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(6-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}
Figure imgf000314_0002
The compound was prepared as generally provided for in Example 166. S: APCI (AP+): 499.2 (M)+.
Example 173
(2R,4R)-4-Methoxy-pyrrolidine-l,2-dicarboxylic acid 2-{[4-(5-chloro-2-oxo- 2H-pyridin-l-yI)-2-fluoro-phenyI]-amide} l-[(4-chloro-phenyl)-amide]
Figure imgf000315_0001
The compound was prepared as generally provided for in Example 166. MS: APCI (AP+): 519.1 (M)+.
General Procedure for the Preparation of Examples 174-180 Route 1
Figure imgf000315_0002
R1 = H or alkyl
A= aryl or heteroaryl reaction with isocyanate
Figure imgf000315_0003
Synthesis of 2:
Aniline 1 is converted to an acrylamide 2 by the addition of acryoyl chloride and a base, such as saturated sodium bicarbonate, in a solvent such as ethyl acetate at room temperature. Alternatively, the aniline may be converted to 2 by the addition of an acrylic acid and adding a coupling reagent such as dicyclohexylcarbodi-imide (DCC), O-(7-Azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (HATU), or EEDQ. 12
-315-
Synthesis of 3 and 4:
To the acrylamide 2 is added an excess of trimethylsilyl diazomethane in a solvent such as ethyl acetate or dichloromethane. The resulting dihydropyrazole 3 may then be treated with an isocyanate, in the presence of base such as pyridine or triethylamine, in a solvent such as dichloromethane, to afford compound 4.
Route 2 formation of conversion to
Figure imgf000316_0001
coupling with compound B
Figure imgf000316_0002
Figure imgf000316_0003
Synthesis of 5-8:
The chemistry for the preparation of compounds 5-8 is similar to that described in Route 1.
Synthesis of 9:
Compound 8 may be converted to 9 by a Suzuki coupling with a boronic acid, although other coupling conditions commonly known to the skilled practitioner may also be used. This route is particularly useful for compounds containing a biaryl A-B group. In situations where a tert-butylsulphonamide is present in B, which occurs in some of the particularly preferred compouinds, the sulphonamide may be formed by stirring with trifluoroacetic acid for 16 h. Route 3 formation of . conversion to H N-
Figure imgf000317_0001
R1 = H or alkyl reaction with isocyanate
Figure imgf000317_0002
Synthesis of 10:
The synthetic routes commences with formation of acrylamide 10 as described for Route 1.
Synthesis of 11: Ethyl diazoacetate is mixed with acrylamide 10 to afford the appropriately substituted dihydropyrazole 11.
Synthesis of 12 and 13:
Similar chemistry to that described in Route 1 allows conversion of 11 to 12. Reduction of the ester moietry in 12 is then achieved using a reducing agent such as super-hydride to afford the alcohol 13.
Route 4
Alternatively compounds may be prepared according to scheme 2d. Here the acrylic ester (14) is reacted with a diazo compound to form the dihydropyrazole (15). Addition of a chloroformate affords compounds of formula (16). Deprotection of the ester is achieved by acid, such as TFA or hydrogen chloride to afford compounds of formula (17). Addition of an aniline with a coupling reagent such as EEDQ and base affords compounds of formula (18). Deprotection of the carbamate with Pd/C and hydrogen affords compounds of formula (19) which may then be reacted with isocyanates to afford compounds of formula (20)
R
Figure imgf000318_0001
Selective deprotection of ester
Figure imgf000318_0002
Example 174
5-MethyI-4,5-dihydro-pyrazole-l,5-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
Figure imgf000318_0003
Step 1 : N-(2'-tert-Butylsulfamoyl-3-fluoro-biphenyl-4-yI)-2-methyl- acrylamide
To 4'-Amino-3'-fluoro-biphenyl-2-sulfonic acid tert-butylamide (5.000 g, 15.51 mmoles) at room temperature in ethyl acetate (50 ml) was added saturated sodium bicarbonate, aqueous, 50 ml and then 2-methyl-acryloyl chloride (1.25 equiv.). Stirred for 2 hours then added a further 1 ml of the acid chloride. After 2 hours an aliquot showed product by NMR. Product seems to co-run with starting material. Extracted into ethyl acetate, washed with brine, dried MgSO , and then concentrated in vacuo. Collected some crystalline product from ethyl acetate hexane, 0.48 g. Columned mother liquor to afford product. Combined with previously crystallized fraction to afford N-(2'-tert-Butylsulfamoyl-3-fluoro- biphenyl-4-yl)-2-methyl-acrylamide (4.520 g). APCI (AP+): 391 (M+H)+.
Step 2: 3-Methyl-3,4-dihydro-2H-pyrazole-3-carboxyIic acid (2'-tert- butylsulf amoyl-3-fluoro-biphenyl-4-yI)-amide
To N-(2'-tert-Butylsulfamoyl-3-fIuoro-biphenyl-4-yl)-2-methyl-acrylamide (0.525g) in ethyl acetate (3.5ml) was added 2M trimethylsilyl diazomethane (3.5ml) and the mixture stirred at room temperature overnight. NMR indicated complete reaction. Evaporated and then dissolved in acetonitrile (20ml) and treated with aq. HF (1 ml). Stirred for lh. Added sat. NaHCO3 (5ml), extracted into EtOAc (25ml). Washed with brine, dried MgSO4, evaporated in vacuo from methylene chloride to afford a white foam of the product: 3-Methyl-3,4-dihydro- 2H-pyrazole-3-carboxylic acid (2'-tert-butylsulfamoyl-3-fluoro-biphenyl-4-yl)- amide (0.592g).APCI (AP+): 433 (M+H)+.
Step 3: 5-Methyl-4,5-dihydro-pyrazole-l,5-dicarboxyIic acid 5-[(2'-tert- butylsulfamoyl-3-fluoro-biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide]
To a solution of 3-methyl-3,4-dihydro-2H-pyrazole-3-carboxylic acid (2'- tert-butylsulfamoyl-3-fluoro-biphenyl-4-yI)-amide (0.416g) in methylene chloride (4ml) was added pyridine (1ml) and 4-chlorophenyl isocyanate (3.25g). Stirred at room temperature for 16 hours. A further amount of 4-chlorophenyl isocyanate (0.200g) and pyridine (0.2ml) was added. Stirred for 48 hours. Columned, silica gel - eluant 10-100 EtOAc in hexane over 25mins. Affords: 5-methyl-4,5- dihydro-pyrazole-1 ,5-dicarboxylic acid 5-[(2'-tert-butylsulfamoyl-3-fluoro- biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide]; 0.365g
Step 4: 5-MethyI-4,5-dihydro-pyrazole-l,5-dicarboxyIic acid l-[(4-chloro- phenyl)-amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
To 5-methyl-4,5-dihydro-pyrazole-l, 5-dicarboxylic acid 5-[(2'-tert- butylsulfamoyl-3-fluoro-biphenyl-4-yl)-amide] 1 -[(4-chloro-phenyl)-amide] (0.300g) was added trifluoroacetic acid (lO.Og). Stirred at room temperature overnight and then evaporated the TFA. Redissolved in hot methanol and added water until cloudy white. Lyophilized to afford 5-methyl-4,5-dihydro-pyrazole- 1, 5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5-[(3-fluoro-2'-sulfamoyl- biphenyl-4-yl)-amide] 0.256 g. APCI (AP+): 530 (M+H)+
Example 175
3-Hydroxymethyl-4,5-dihydro-pyrazole-l,5-dicarboxylic acid l-[(4-ch!oro- phenyl)-amide] 5-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]
Figure imgf000320_0001
Step 1: N-(3-Fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acrylamide
To 3-Fluoro-2'-methanesulfonyl-biphenyl-4-ylamine (8.510 g) in ethyl acetate (400 ml) was added sat. NaHCO3 (100 ml) and then acryolyl chloride (1.3 equiv.). Stirred at room temperature for 3 hours. Washed EtOAc extract with brine, dried over MgSO and evaporated in vacuo. Triturated with ether and then filtered to afford N-(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acrylamide (9.670 g, 94%).
Step 2: 5-(3-Fluoro-2'-methanesulfonyl-biphenyl-4-ylcarbamoyl)-4,5- dihydro-lH-pyrazole-3-carboxyϋc acid ethyl ester
To N-(3-Fluoro-2'-methanesulfonyl-biphenyl-4-yl)-acrylamide (4.47g) in ethyl acetate (150ml) was added ethyl diazoacetate (1.5 equiv.) and the mixture heated at 60 °C for 24 hours. Evaporated and then columned: eluant 10-100 EtOAc in hexane. Collected 5-(3-fluoro-2'-methanesulfonyl-biphenyl-4- ylcarbamoyl)-4,5-dihydro-lH-pyrazole-3-carboxylic acid ethyl ester (1.67g)
Step 3: l-(4-Chloro-phenylcarbamoyI)-5-(3-fluoro-2'-methanesulfonyl- biphenyl-4-ylcarbamoyl)-4,5-dihydro-lH-pyrazole-3-carboxylic acid ethyl ester To a solution of 5-(3-Fluoro-2'-methanesulfonyl-biphenyl-4-ylcarbamoyl)-
4,5-dihydro-lH-pyrazole-3-carboxylic acid ethyl ester (1.520g) in methylene chloride (12ml) was added pyridine (4 equiv.) and 4-chlorophenyl isocyanate (1.25 equiv.). Stirred at room temperature for 16 hours. Evaporated and recorded crude IH: 80156xl34RMl - revealed expected product and relatively clean. Purified by silica gel chromatography, eluant 10-100% EtOAc in hexane over 25 mins. Collected 1 -(4-chloro-phenylcarbamoyl)-5-(3-fluoro-2'-methanesulfonyl- biphenyl-4-ylcarbamoyl)-4,5-dihydro-lH-pyrazole-3-carboxylic acid ethyl ester (1.480g).
Step 4: 3-Hydroxymethyl-4,5-dihydro-pyrazole-l,5-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 5-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yI)-amide]
To a solution of l-(4-Chloro-phenylcarbamoyl)-5-(3-fluoro-2'- methanesulfonyl-biphenyl-4-ylcarbamoyl)-4,5-dihydro-lH-pyrazole-3-carboxylic acid ethyl ester (0.228g) in THF (3ml) at O °C was added a 1M solution of super- hydride in THF (1.17ml). Stirred for 30 mins and then quenched with sat. NftjCl. Extracted into EtOAc and washed with brine. Evaporated in vacuo. Crude IH indicated clean reaction to product. Column - eluant 0-5% methanol in ethyl acetate. Affords 3-Hydroxymethyl-4,5-dihydro-pyrazole-l, 5-dicarboxylic acid 1- [(4-chloro-phenyl)-amide] 5-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)- amide]after lyophilization from MeCN/H2O: 0.230 g; MS (APCI) +ve: 545
Example 176
4,5-Dihydro-pyrazole-l,5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yI)-amide]
Figure imgf000322_0001
This compound was prepared using the same procedures as found for Example 175 with acryloyl chloride substituted for 2-Methyl-acryloyl chloride in step 1. APCI (AP-): 514 (M-H)".
Example 177
(5R) 4,5-Dihydro-pyrazole-l,5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]
Figure imgf000322_0002
This compound was prepared using the same procedures as found for Example 176 and the enantiomers separated by chiral HPLC Column: Chrial Pak AD 250x4.6 mm; 254 nm, mobile phase: Hexane (20); Ethanol (20); Methanol (60) Affords: (R) enantiomer @ 1 1.038 mins APCI (AP-): 514 (M-H)" and (S) enantiomer @ 36.084 mins APCI (AP-): 514 (M-H)"-
Example 178
4,5-Dihydro-pyrazole-l ,5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5- {[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}
Figure imgf000323_0001
This compound was prepared using the same procedures as found for Example 175 with acryloyl chloride substituted for 2-Methyl-acryloyl chloride in step 1 and l -(4-Amino-3-fluoro-phenyl)-piperidin-2-one subsubstituted for 4'- Amino-3'-fluoro-bipheny]-2-sulfonic acid tert-butylamide. APCI (AP-): 456 (M-
H)-.
Example 179
4,5-Dihydro-pyrazole-l,5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5-[(3- fluoro-2'-methanesulfonyI-biphenyl-4-yl)-amide]
Figure imgf000323_0002
This compound was prepared using the same procedures as found for Example 176 with acryloyl chloride substituted for 2-Methyl-acryloyl chloride in step 1 and 3-Fluoro-2'-methanesulfonyl-biphenyl-4-ylamine substituted for 4'- Amino-3'-fluoro-biphenyl-2-sulfonic acid tert-butylamide. APCI (AP-): 513 (M- ID-
Example 180 l-(4-ChIoro-phenyIcarbamoyl)-5-(3-fluoro-2'-methanesulfonyl-biphenyI-4- ylcarbamoyI)-4,5-dihydro-lH-pyrazole-3-carboxyIic acid ethyl ester
Figure imgf000324_0001
This compound was prepared using the same procedures as found for
Example 175 wherein step 4 was omitted. APCI (AP-): 585 (M-H)".
Example 181 FORMULATIONS
The compounds of the present invention can be administered alone or in combination with one or more therapeutic agents. These include, for example, other anticoagulant, antiplatelet, or platelet inhibitory agents which include nonsteroidal anti-inflammatory agents such as aspirin, ibuprofen, naproxen sodium, indomethacin, piroxica, and ticlopidine; thrombin inhibitors such as argatroban, efegatran, inogatran, factor Vila inhibitors, thrombolytic or fibrinolytic agents such as tissue plasminogen activator, urokinase or streptokinase; GP Ilb-HIa antagonists, and P2Y12 antagonists. The compounds are thus well suited to formulation for convenient administration to mammals for the prevention and treatment of such disorders.
The following examples further illustrate typical formulations provided by the invention.
Formulation 1
Figure imgf000325_0001
The above ingredients are mixed and dissolved in the saline for IN administration to a human suffering from, for example, arterial thrombosis.
Formulation 2
Figure imgf000325_0002
The ingredients are blended to uniformity and pressed into a tablet that is well suited for oral administration to a human for preventing, for example, cerebral infarction. Formulation 3
Figure imgf000326_0001
The ingredients are combined and milled to afford material suitable for , filling hard gelatin capsules administered to humans suffering from, for example, venous thrombosis.
Formulation 4
Figure imgf000326_0002
The ingredients are combined via melting and then poured into molds containing 2.5 g total weight.
While embodiments of the invention have been illustrated and described, it is not intended that these embodiments illustrate and describe all possible forms of the invention. Rather, the words used in the specification are words of description rather than limitation, and it is understood that various changes may be made without departing from the spirit and scope of the invention.

Claims

What is claimed is:
1. A compound of Formula I:
Figure imgf000327_0001
or a pharmaceutically acceptable salt thereof wherein: A is aryl or substituted aryl or monocyclic heteroaryl or substituted monocyclic heteroaryl;
O O
II II
B is -NH— C— (C C6)alkyl, -NH — C— (C3-C7)cycloalkyl, -
NH
Figure imgf000327_0002
, (C3-C7)cycloalkyl, (C3- C7)heterocyclo, (C -C7)cycloalkenyl, unsaturated (C4-C7)heterocyclo, aryl, or heteroaryl, any of which may be optionally substituted by halo, (C1-C6)alkyl, or halo(Ci-C6)alkyl,
Figure imgf000327_0003
-CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido;
C is phenyl or heteroaryl, wherein phenyl or heteroaryl is optionally substituted with one or more substituents selected from aryl, heteroaryl, halogen, hydroxy, -CO2 2, -COR2, -CONR2R2', alkoxy, alkyl, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido;
G is H, halo, (d-C6)alkyl, halo -Q alkyl, hydroxy(C!-C6)alkyl, -CH2O-(C1-C6)alkyl, -CH2-CO2(C1-C6)alkyl, -CH2-NR2R2', or -CH2-
CONH(C1-C6)alkyl;
W1 is a saturated or unsaturated, substituted or unsubstituted hydrocarbon chain or hydrocarbon-heteroatom chain having from 2 to 6 atoms, wherein W^ connects the nitrogen atom at position 1 to the carbon atom at position 2 to form a four to eight membered ring;
R1 is (C C6)alkoxy, (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, (C4- C7)cycloalkenyl, (C4-C7)heterocycloalkenyl, aryl, monocyclic heteroaryl, or -
NR R4;
R2 and R2' are each independently H or (C1-C6)alkyl; and
R3 and R4 are each independently H, (CrC6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring.
A compound of formula IV:
IV
or a pharmaceutically acceptable salt thereof wherein " - - - " is a bond or is absent; Z is C-H, C-halo, C-( -C6)alkyl, C-halo(C C6)alkyl, C-(CrC6)alkoxy, or
N;
Xπis CH2, CH, NH or N; io , ,
R and R are each independently H, -OH, halo, alkyl, haloalkyl, -
NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4, aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4 or are taken together to form
Figure imgf000329_0001
or =CR2H, with the proviso that when " — - " is a bond, R1 ' is absent, and Xπ is CH or N, and R10 is H, -OH, halo, alkyl, haloalkyl, -NR8R9, -OR2, -CN, -CH2OH, -CH2-NR3R4 aryl, monocyclic heteroaryl, alkylaryl, -CH=O, -CH2OR2, -COR2, -CO2R2, or -CONR3R4;
O O
B is -NH— C— (C C6)alkyl, -NH — C— (C3-C7)cycloalkyl -NH(C
C6)alkanoyl, R1 , (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, (C - C7)cycloalkenyl, (C -C )heterocycloalkenyl, aryl, or heteroaryl, any of which may be optionally substituted, wherein Rl is (C1-C6)alkoxy, (C3-C7)cycloalkyl, (C3- C )heterocycloalkyl, (C4-C7)cycloalkenyl, (C4-C7)heterocycloalkenyl, aryl, monocyclic heteroaryl, or -NR3R4;
G is H, halo, ( -C6)alkyl, halo(Cι-C6)alkyl, hydroxy(C1-C6)alkyl, -CH2O-(CrC6)alkyl, -CH2-CO2(C1-C6)alkyl, -CH2-CONH2, or -CH2-CONH(d- C6)alkyl; R2 and R2' are each independently H or (C1-C6)alkyl; and
R3 and R4 are independently H, (Cι-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2al yl, or joined together to form a saturated or unsaturated 5 to 7 membered ring;
12 ]3
R and R are each independently H, halo, (Q-C^alkyl, or halo(d- C6)alkyl, or (C C6)alkoxy;
R and R15 are each independently H, halo, alkyl, or haloalkyl, or NR R wherein R8 and R9 are as defined for R3 and R4;
X and Y are each C, or one of X and Y is C and the other is N, provided that when one of X or Y is N, Rl40r R 5 is absent at that position.
3. The compound of claim 2, wherein B is
Figure imgf000330_0001
, wherein " ™- " indicates the point of attachment,
Q is NH or is absent; and wherein R1' is OH, — O-(C C6), or NR3'R4', wherein R3' and R4' are independently H, (C]-C6)alkyl, or are joined together to form a optionally substituted saturated or unsaturated 5 to 7 membered ring;
Figure imgf000330_0002
, wherein " ™ " indicates the point of attachment, or B is optionally substituted phenyl or pyridyl with formyl, H2NSO2, MeSO2, MeSO, MeS, (Cl-C6)alkoxycarbonyl, cyano, aminomethyl, methoxy, or hydroxy;
Figure imgf000330_0003
" indicates the point of attachment and which is an optionally substituted 4, 5, 6 or 7-membered ring; wherein R and Ry are H, halo, (d-C6)alkyl, (d-C6)alkoxy, or (d-C6)carboxyalkyl, or taken together are O=; Xm is CH2, CH-OH, CH-CO2(d-C6)alkyl, O, S, NH, or N(C C6)alkyl, provided that when Rx and Ry taken together are O=, Xm is CH2. provided that when Rx and Ry taken together are O=, Xm is CH2;
Figure imgf000330_0004
or a tautomer thereof, wherein Yπ is CH2, CH(d-C6)alkyl, or N and R18 is H, (d-C6)alkyl, hydroxymethyl, CH2O-(d-C6)alkyl, CONR2R2', or
CH2NR2R2'. a 5-membered heteroaryl ring which contains at least one nitrogen atom, which is selected from imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxadiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, thiazolyl, or isothiazolyl, any of which may be optionally substituted with halo, (d-C6)alkyl, hydroxy(d-C6)alkyl, CH2O-(C1-
C6)alkyl, or halo(d-C6)alkyl, or is
Figure imgf000331_0001
, wherein " ™* " indicates the point of attachment; Xa, Ya, and Za are each independently CRC or N, wherein Rc is H or (C C6)alkyl; and R18 is H, (d-C6)alkyl, hydroxymethyl, CH2O-(C1-
C6)alkyl, or NR3R4;
Figure imgf000331_0002
, wherein " ™ " indicates the point of attachment;
Ji, J2, J3, and J4 are each C, or any of J1; J2, J3, or J4 is N; and R19, R20, R21, and R22 are each independently H, halo, hydroxy, NH2, NR23R24, NO2, SH, (d-C6)alkyl, halo(C1-C6)alkyl, (C1-C6)alkanoyl, (d-C6)alkoxycarbonyl, or (d-C6)alkoxy, wherein R23 and R24 are each independently H, (Cj-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2 alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring, or R19 and R20, R20 and R21, or R21 and R22, together with the carbons to which they are attached, form a 5, 6, or seven membered saturated or unsaturated cycloalkyl or heterocycloalkyl ring, or an aryl or heteroaryl ring; provided that when any of Ji, J2, J3, or J4 is N, R19, R20, R21 or R22, respectively, is absent at that position.
4. A compound which is:
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; Pyrrolidine- 1,2-dicarboxylic acid l-[(2,4-difluoro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] 1-p-tolylamide;
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] l-[(4-methoxy-phenyl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-bromo-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] 1 -[(4-isopropyl-phenyl)-amide] ; Pyrrolidine- 1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] 1-phenylamide;
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] l-[(4-trifluoromethyl-phenyl)-amide];
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] l-[(3-methoxy-phenyl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)-amide] 2-[(3- fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; Pyrrolidine- 1,2-dicarboxylic acid l-[(4-ethyl-phenyl)-amide] 2-[(3-fluoro-
2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(3,4-difluoro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(3-fluoro-4-methyl-phenyl)-amide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ;
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[5-(2- sulfamoyl-phenyl)-pyridin-2-yl] -amide } ; Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl- biphenyl-4-yl)-amide] 1 - [(5-chloro-pyridin-2-yl)-amide] ;
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2 -sulfamoyl-biphenyl-4-yl)-amide] ; Pyrrolidine- 1,2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl- biphenyl-4-yl)-amide] 1 -[(4-chloro-phenyl)-amide] ;
Pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)-amide] 2-{ [5- (2-sulf amoyl-phenyl)-pyridin-2-yl] -amide } ;
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [4-(lH- tetrazol-5-yl)-phenyl]-amide};
4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; 4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro-phenyl)-amide]
2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Oxo-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Methylene-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Methyl-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4,4-Difluoro-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ; 4-Amino-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-
[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ;
4-Hydroxymethyl-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ; l-(4-Chloro-phenylcarbamoyl)-5-(3-fluoro-2'-methanesulfonyl-biphenyl- 4-ylcarbamoyl)-pyrrolidine-3-carboxylic acid; l-(4-Chloro-phenylcarbamoyl)-5-(3-fluoro-2'-methanesulfonyl-biphenyl- 4-ylcarbamoyl)-pyrrolidine-3-carboxylic acid methyl ester; Pyrrolidine-1, 2,4-tricarboxylic acid 4-amide l-[(4-chloro-phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Aminomethyl-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ; 4-Methoxymethyl-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ;
4-Ethoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Methylamino-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Acetylamino-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ;
4-Methanesulfonylamino-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; 5-Oxo-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-
[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
Piperidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3-fluoro- 2'-methanesulfonyl-biphenyl-4-yl)-amide];
Morpholine-3,4-dicarboxylic acid 4-[(4-chloro-phenyl)-amide] 3-[(3- fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ;
Piperazine-1, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3-fluoro- 2'-methanesulfonyl-biphenyl-4-yl)-amide];
2,5-Dihydro-pyrrole- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-3-methyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'-methanesulfonyl-3-methyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-biphenyl-4-yl)-amide] ;
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'-methanesulfonyl-biphenyl-4-yl)-amide]; Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[5-(2- methanesulfonyl-phenyl)-pyrimidin-2-yl]-amide } ;
4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2- { [5-(2-methanesulfonyl-phenyl)-pyrimidin-2-yl]-amide] ; Pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2- { [5-(2- methanesulfonyl-phenyl)-3-methyl-pyridin-2-yl]-amide } ;
4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro-phenyl)-amide] 2-{ [5-(2-methanesulfonyl-phenyl)-3-methyl-pyridin-2-yl]-amide};
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-3-trifluoromethyl-biphenyl-4-yl)-amide] ;
4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(2'-methanesulfonyl-3-trifluoromethyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[5-(2- methanesulfonyl-phenyl)-6-methyl-pyridin-2-yl]-amide } ; 4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2- { [5-(2-methanesulfonyl-phenyl)-6-methyl-pyridin-2-yl]-amide } ;
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3-ethyl- 2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(3-ethyl-2'-methanesulfonyl-biphenyl-4-yl)-amide] ;
4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3,5-difluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3,5- dichloro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; 4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-[(3,5-dichloro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-3 ,5-dimethyl-biphenyl-4-yl)-amide] ;
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'-methanesulfonyl-3,5-dimethyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-chloro-2'-methanesulfonyl-5- methyl-biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide]; 4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid 2-[(3-chloro-2'- methanesulfonyl-5-methyl-biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide];
Pyrrolidine- 1 ,2-dicarboxylic acid 2-[(2-chloro-2'-methanesulfonyl- biphenyl-4-yl)-amide] 1 -[(4-chloro-phenyl)-amide] ; 4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid 2-[(2-chloro-2'- methanesulfonyl-biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-2-methyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'-methanesulfonyl-2-methyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2- fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; 4- { [ 1 -(4-Chloro-phenylcarbamoyl)-pyrrolidine-2-carbonyl] -amino } -2'- methanesulfonyl-biphenyl-3-carboxylic acid methyl ester;
4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-hydroxy-pyrrolidine-2-carbonyl]- amino}-2'-methanesulfonyl-biphenyl-3-carboxylic acid methyl ester;
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] l-[(4-trifluoromethyl-phenyl)-amide];
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] 1-m-tolylamide;
Pyrrolidine- 1,2-dicarboxylic acid l-[(3-acetyl-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; Pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro-2-methyl-phenyl)-amide] 2-
[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(2-fluoro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(3-chloro-4-fluoro-phenyl)-amide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ;
Pyrrolidine- 1,2-dicarboxylic acid l-[(3-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; Pyrrolidine- 1,2-dicarboxylic acid l-[(4-cyano-phenyl)-amide] 2-[(3- fluoro-2'-sulf amoyl-biphenyl-4-yl)-amide] ;
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-2-methyl-phenyl)-amide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; Pyrrolidine- 1,2-dicarboxylic acid l-[(3,4-dichloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine-1 ,2-dicarboxylic acid 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4- yl)-amide] 1 -[(3-trifluoromethyl-phenyl)-amide] ;
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-dimethylamino-phenyl)-amide] 2- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ;
(2S)-Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(4- cyano-phenyl)-amide] ; 4-Methoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide] 1 -[(4-fluoro-phenyl)-amide] ;
4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro-pyridin-2-yl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide] 1 -p-tolylamide;
4-Oxo-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(3-fluoro-2'-methanesulf onyl-biphenyl-4-yl)-amide] ; and 4-Fluoro-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-
[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ; or a pharmaceutically acceptable salt thereof.
5. A compound which is: (R)-Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide]; (S)-Pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3- fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; (2R,4S)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide] 1 -[(4-fluoro-phenyl)-amide] ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(5-chloro- pyridin-2-yl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulfonyl-biphenyl-4-yl)-amide] 1 -p-tolylamide; (2R)-4-Oxo-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ; and
(2R,4S)-4-Fluoro-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ;or a pharmaceutically acceptable salt thereof.
6. A compound which is:
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide);
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide } ; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ; (2R,4R)-4-Ethoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro-pyridin- 2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Ethoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl] -amide}; (2R,4R)-4-Propoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Propoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin- 2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Fluoro-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-azetidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-azetidin-l-yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-pyrrolidin-l-yl)-phenyl] -amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-pyrrolidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-azepan-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-azepan-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(2-oxo-2H-pyridin- l-yl)-phenyl] -amide } ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [4-(2-oxo-2H-pyridin- 1 -yl)-phenyl] -amide } ;
(2R,4R)-4-Ethoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro-pyridin- 2-yl)-amide] 2- { [2-fluoro-4-(2-oxo-2H-pyridin- 1 -yl)-phenyl] -amide } ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-hydroxymethyl-5-oxo-pyrrolidin-l-yl)-phenyl]- amide}; (2R,4R)-4-Hydroxy-pyrroli dine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(2,3-dimethyl-5-oxo-2,5-dihydro-pyrazol-l-yl)-phenyl]- amide};
4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [4-(2-hydroxymethyl-pyrrolidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-pyrrolidin-l-yl-phenyl)-amide] ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(4-pyrazol-l -yl-phenyl)-amide] ; (2R,4R)-4-Hydroxy-pyrroli dine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- [(2-fluoro-4-pyrazol- 1 -yl-phenyl)-amide] ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-[l ,2,4]triazol- 1 -yl-phenyl)-amide] ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-[l,2,3]triazol-2-yl-phenyl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(4-[l,2,3]triazol-l-yl-phenyl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 2-[(4-acetylamino- phenyl)-amide] 1 -[(4-chloro-phenyl)-amide] ; (2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-{[4-(cyclopentanecarbonyl-amino)-phenyl]-amide}; and
4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(4-pyrimidin-5-yl-phenyl)-amide] ; or a pharmaceutically acceptable salt thereof.
7. A compound which is: l-(4-Chloro-phenylcarbamoyl)-5-[2-fluoro-4-(2-oxo-piperidin-l-yl)- phenylcarbamoyl]-pyrrolidine-3-carboxylic acid; l-(4-Chloro-phenylcarbamoyl)-5-[2-fluoro-4-(2-oxo-piperidin-l-yl)- phenylcarbamoyl]-pyrrolidine-3-carboxylic acid methyl ester; l-(4-Chloro-phenylcarbamoyl)-5-[2-fluoro-4-(2-oxo-piperidin-l-yl)- phenylcarbamoyl]-pyrrolidine-3-carboxylic acid ethyl ester; Pyrrolidine-1, 2,4-tricarboxylic acid 4-amide l-[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
4-Cyano-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ; 4-(lH-Tetrazol-5-yl)-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
4-Aminomethyl-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
4-Methylaminomethyl-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
4-Dimethylaminomethyl -pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
4- Acetyl-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ; Pyrrolidine- 1 ,2,4-tricarboxylic acid 1 - [(4-chloro-phenyl)-amide] 2- { [2- fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} 4-methylamide;
Pyrrolidine-1, 2,4-tricarboxylic acid l-[(4-chloro-phenyl)-amide] 4- dimethylamide 2-{ [2-fluoro-4-(2-oxo-piperidin- l-yl)-phenyl] -amide } ;
4-Trifluoromethyl-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
4-Methyl -pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
4-Isopropoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ; 4-Fluoro-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-
{ [2-fluoro-4-(2-oxo-piperidin- l-yl)-phenyl] -amide } ;
4,4-Difluoro-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ; l-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino }-phenyl)-pyrrolidine-2-carboxylic acid; l-(4-{ [l-(4-Chloro-phenylcarbamoyl)-4-hydroxy-pyrrolidine-2-carbonyl]- amino } -phenyl)-pyrrolidine-2-carboxylic acid; 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-5'-yl)-amide]; 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 2-{ [5-(2-oxo-piperidin-l-yl)-pyrimidin-2-yl]-amide};
4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro-pyridin-2-yl)- amide] 2-{ [2-(2-oxo-piperidin-l-yl)-pyrimidin-5-yl] -amide};
4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro-phenyl)-amide] 2-{ [5-(2-oxo-piperidin-l-yl)-pyrimidin-2-yl]-amide} ;
4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro-phenyl)-amide] 2-{ [2-(2-oxo-piperidin-l-yl)-pyrimidin-5-yl]-amide} ;
4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [2-fluoro-4-(2-oxo- piperidin- 1 -yl)-phenyl]-amide } 1 - [(5-fluoro-pyridin-2-yl)-amide] ; 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-fluoro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-fluoro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-5'-yl)-amide];
4-Fluoro-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide];
4-Fluoro-pyrrolidine-l, 2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide];
4-Fluoro-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-fluoro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide]; 4-Fluoro-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-
[(2-oxo-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-5'-yl)-amide];
4-Fluoro-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(5-chloro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-5'-yl)-amide];
4-Fluoro-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-fluoro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-5'-yl)-amide];
4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-hydroxymethyl-5-oxo-pyrrolidin-l-yl)-phenyl]-amide}; l-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino } -3-fluoro-phenyl)-5-oxo-pyrrolidine-2-carboxylic acid;
1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl] - amino } -3-fluoro-phenyl)-5-oxo-pyrrolidine-2-carboxylic acid; 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{[4-(4,4-dimethyl-2,5-dioxo-imidazolidin-l-yl)-2-fluoro-phenyl]-amide};
[ 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-2,5-dioxo-imidazolidin-4-yl]-acetic acid;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [4-(5,5-dimethyl-2,4-dioxo-oxazolidin-3-yl)-2-fluoro-phenyl]-amide} ;
4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [4-(2,5-dioxo-pyrrolidin-l-yl)-2-fluoro-phenyl]-amide} ;
4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-oxazolidin-3-yl)-phenyl]-amide} ; 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{ [4-(2,5-dioxo-oxazolidin-3-yl)-2-fluoro-phenyl] -amide} ;
4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-imidazolidin-l-yl)-phenyl]-amide} ;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [4-(2,5-dioxo-imidazolidin-l-yl)-2-fluoro-phenyl]-amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{[2-fluoro-4-(3-methyl-2,5-dioxo-imidazolidin-l-yl)-phenyl]-amide};
3-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino } -3-fluoro-phenyl)-2-oxo-imidazolidine-4-carboxylic acid; 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{ [2-fluoro-4-(2,4,5-trioxo-imidazolidin- l-yl)-phenyl] -amide } ;
4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro-phenyl)-amide] 2-{[4-(2,5-dioxo-2,5-dihydro-pyrrol-l-yl)-2-fluoro-phenyl]-amide};
4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2- { [4-(2-aminomethyl-5- oxo-pyrrolidin-1 -yl)-2-fluoro-phenyl]-amide} 1 -[(4-chloro-phenyl)-amide] ;
4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(2-aminomethyl-5- oxo-pyrrolidin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide]; 4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(2-carbamoyl-5-oxo- pyrrolidin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(2-carbamoyl-5-oxo- pyrrolidin-1 -yl)-2-fluoro-phenyl]-amide } 1 -[(4-chloro-phenyl)-amide] ; 4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2- { [4-(2,2-bis- hydroxymethyl-5-oxo-pyrrolidin- 1 -yl)-2-fluoro-phenyl] -amide } 1 -[(4-chloro- phenyl)-amide];
3-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl] - amino } -3-fluoro-phenyl)-2-oxo-imidazolidine-4-carboxylic acid; 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{[4-(3,3-dimethyl-2,5-dioxo-pyrrolidin-l-yl)-2-fluoro-phenyl]-amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[2-fluoro-4-(3,3,4-trimethyl-2,5-dioxo-pyrrolidin-l-yl)-phenyl]-amide}; l-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino } -3-fluoro-phenyl)-5-oxo-pyrrolidine-2,2-dicarboxylic acid;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [2-fluόro-4-(2-methyl-5-oxo-pyrrolidin-l-yl)-phenyl]-amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-methyl-6-oxo-piperidin-l-yl)-phenyl]-amide} ; 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2- { [2-fluoro-4-(3-hydroxy-2-oxo-piperidin- 1 -yl)-phenyl]-amide } ;
4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [2-fluoro-4-(5-methyl-2,6-dioxo-tetrahydro-pyrimidin-l-yl)-phenyl]-amide};
4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro-phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-tetrahydro-pyrimidin- 1 -yl)-phenyl] -amide } ;
4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[2-fluoro-4-(3-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{ [4-(2,5-dioxo-piperazin-l-yl)-2-fluoro-phenyl]-amide} ; 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{ [2-fluoro-4-(3-hydroxy-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}; 4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2- { [2-fluoro-4-(3 -methoxy-2-oxo-2H-pyridin- 1 -yl)-phenyl] -amide } ;
4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{[2-fluoro-4-(6-methyl-2-oxo-4-trifluoromethyl-2H-pyridin-l-yl)-phenyl]- amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{ [4-(2,6-dioxo-piperidin-l-yl)-2-fluoro-pheinyl]-amide} ;
1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino } -3-fluoro-phenyl)-2-oxo-piperidine-3-carboxylic acid; 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{[4-(5,5-dihydroxy-2,4,6-trioxo-tetrahydro-pyrimidin-l-yl)-2-fluoro-phenyl]- amide};
4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-{[2-fluoro-4-(2,4,6-trioxo-tetrahydro-pyrimidin-l-yl)-phenyl]-amide}; 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{[4-(4,4-dimethyl-2,6-dioxo-piperidin-l-yl)-2-fluoro-phenyl]-amide};
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- { [2-fluoro-4-(2-hydroxy-4-oxo-azetidin- 1 -yl)-phenyl]-amide } ;
4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(acetyl-methyl-amino)- 2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
4-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino}-3-fluoro-phenyl)-lH-pyrrole-3-carboxylic acid;
2-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino } -3-fluoro-phenyl)-2H-pyrazole-3-carboxylic acid; 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino}-3-fluoro-phenyl)-lH-imidazole-2-carboxylic acid; l-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino } -3-fluoro-phenyl)-lH-pyrrole-2-carboxylic acid;
3-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino }-3-fluoro-phenyl)-lH-pyrrole-2-carboxylic acid;
3-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino } -3-fluoro-phenyl)-furan-2-carboxylic acid; 3-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino } -3-fluoro-phenyl)-thiophene-2-carboxylic acid;
4-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino } -3-fluoro-phenyl)-furan-3-carboxylic acid; 4-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2-carbonyl]- amino } -3-fluoro-phenyl)-thiophene-3-carboxylic acid;
4,5-Dihydro-pyrazole- 1 ,5-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 5-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
3-Oxo-pyrazolidine-l, 5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5- [(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ;
3-Oxo-pyrazolidine-l, 5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5- { [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
4,5-Dihydro-pyrazole- 1 ,5-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 5-{ [4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ; 4,5-Dihydro-pyrazole-l, 5-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 5- { [2-fluoro-4-(2-oxo-piperidin- 1 -yl)-phenyl] -amide } ;
4,5-Dihydro-pyrazole- 1 ,5-dicarboxylic acid 1 -[(5-chloro-pyridin-2-yl)- amide] 5- { [4-(2-oxo-piperidin- 1 -yl)-phenyl]-amide } ;
4,5-Dihydro-pyrazole-l, 5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide];
4,5-Dihydro-pyrazole-l ,5-dicarboxylic acid 1 -[(5-chloro-pyridin-2-yl)- amide] 5-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 2-[(3,5'-difluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ; 4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide]
2-[(5'-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 2-[(3,5'-difluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3,5'-difluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ;
4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(5'-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; 4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2- [(3 ,5 '-difluoro-2 '-methanesulf onyl-biphenyl-4-yl)-amide] ;
4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 2-[(3,5'-difluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(3,5'-difluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(3 ,5 '-difluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] , or a pharmaceutically acceptable salt thereof.
8. A compound which is:
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(4-pyrazol-l-yl-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(2-fluoro-4-pyrazol-l-yl-phenyl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2-fluoro-4-pyrazol- 1 -yl-phenyl)-amide] ;
(2R,4R)-4-Ethoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(4-pyrazol-l-yl-phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methyl-pyrazol-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-methyl-pyrazol-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(5-methyl-pyrazol- l-yl)-phenyl] -amide } ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3,5-dimethyl-pyrazol-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3,5-dimethyl-pyrazol-l-yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3,5-dimethyl-ρyrazol-l-yl)-2-fluoro-phenyl]-amide} ; (2R,4S)-4-Amino-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ;
(2R,4R)-4-Amino-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ; (2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ;
(2R)-4-Hydroxyimino-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methylsulfamoyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-[(2'-dimethylsulfamoyl-3-fluoro-biphenyl-4-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ;
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin- 2-yl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
(2R,4S)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; (2R,4R)-4-Fluoro-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2- [(3-fluoro-2'-methanesulf onyl-biphenyl-4-yl)-amide] ;
(2R)-4,4-Difluoro-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2- [(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(3-fluoro-2'- methanesulf onyl-biphenyl-4-yl)-amide] 1 -[(4-fluoro-phenyl)-amide] ;
(2R,4R)-4-Acetylamino-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- [(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ; (2R,4R)-4-Methanesulfonylamino-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4- chloro-phenyl)-amide] 2- [(3-fluoro-2'-methanesulf onyl-biphenyl-4-yl)-amide] ;
(2R,4S)-4-(lH-Tetrazol-5-yl)-pyrrolidine- 1,2-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-piperidin- 1 -yl)-phenyl] -amide } ; (2R,4S)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Cyano-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-(lH-Tetrazol-5-yl)-ρyrrolidine- 1,2-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Trifluoromethyl-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2'-cyano-3-fluoro-biphenyl-4-yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-[(2'-aminomethyl-
3-fluoro-biphenyl-4-yl)-amide] l-[(4-chloro-phenyl)-amide];
(2R,4R)-4'- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3'-fluoro-biphenyl-2-carboxylic acid methyl ester;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(2,5-dihydro-pyrrole-l-carbonyl)-phenyl]-amide};
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-dimethylcarbamoyl-2-fluoro-phenyl)-amide] ;
(2R,4R)-4-Hydroxy-pyrroli dine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(pyrrolidine-l-carbonyl)-phenyl]-amide} ; Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-{[4-
(pyrrolidine-l-carbonyl)-phenyl]-amide};
(2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(2-methyl-pyrrolidine-l-carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(ethyl-methyl-carbamoyl)-phenyl]-amide} ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-dimethylcarbamoyl-phenyl)-amide] ; (2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2R-methyl-pyrrolidine-l-carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2S-methyl-pyrrolidine-l-carbonyl)-phenyl]-amide} ; (2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(pyrrolidine-l-carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [4-(pyrrolidine- 1 -carbonyl)-2-pyrrolidin- 1 -yl-phenyl] -amide } ;
(2R,4R)-4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-hydroxy-pyrrolidine-2- carbonyl]-amino}-3-pyrrolidin-l-yl-benzoic acid methyl ester;
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(azetidine-l- carbonyl)-phenyl]-amide} l-[(4-chloro-phenyl)-amide] ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(pyrrolidine-l-carbonyl)-phenyl]-amide} ; (2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(pyrrolidine-l-carbonyl)-phenyl]-amide};
(2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-[(4-dimethylcarbamoyl-phenyl)-amide] ;
(2R,4R)-4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-hydroxy-pyrrolidine-2- carbonyl] -amino } -3 -dimethylamino-benzoic acid methyl ester;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(pyrrolidine-l-carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-dimethylcarbamoyl-phenyl)-amide] ; (2R,4R)-4-Ethoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2- { [4-(pyrrolidine- 1 -carbonyl)-phenyl] -amide } ;
(2R,4R)-4-Ethoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(4-dimethylcarbamoyl-phenyl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- ρhenyl)-amide] 2-{ [2-fluoro-4-(pyrrolidine-l-carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Ethoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(pyrrolidine-l-carbonyl)-phenyl]-amide} ; (2R,4R)-4-Ethoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)- amide] 2-[(4-dimethylcarbamoyl-2-fluoro-phenyl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-methyl-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ; (2R,4R)-4-Ethoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{ [2-methyl-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2- fluoro-4-quinolin-8-yl-phenyl)-amide];
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(3,5- difluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ;
Pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2'- methanesulfonyl-2-methyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2'-methanesulfonyl-biphenyl-4-yl)-amide]; (2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2- [(2'-methanesulfιnyl-biphenyl-4-yl)-amide] ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3-methyl-2'-methylsulfanyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide] ;
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2'-methanesulfonyl-3-methyl-biphenyl-4-yl)-amide];
(2R,4R)-4-Hydroxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-[(2'-methanesulfonyl-3-trifluoromethyl-biphenyl-4-yl)-amide]; 5-Methyl-4,5-dihydro-pyrazole-l,5-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ;
3-Hydroxymethyl-4,5-dihydro-pyrazole- 1 ,5-dicarboxylic acid 1 -[(4- chloro-phenyl)-amide] 5-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide];
4,5-Dihydro-pyrazole-l,5-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ;
(R) 4,5-Dihydro-pyrazole-l, 5-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ; 4,5-Dihydro-pyrazole- 1 ,5-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 5-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
4,5-Dihydro-pyrazole- 1 ,5-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 5-[(3-fluoro-2'-methanesulfonyl-biphenyl-4-yl)-amide]; l-(4-Chloro-phenylcarbamoyl)-5-(3-fluoro-2'-methanesulfonyl-biphenyl-
4-ylcarbamoyl)-4,5-dihydro-lH-pyrazole-3-carboxylic acid ethyl ester;
(2R,4R)-4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2'-methoxy-biphenyl-4-yl)-amide] ;
(2R,4R)-4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2'-hydroxy-biphenyl-4-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-[(2-fluoro-4-iodo-phenyl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-hydroxy-2-oxo-piperidin-l-yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-tetrahydro-pyrimidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-imidazolidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-oxazolidin-3-yl)-phenyl]-amide} ;
(2R,4R)-l-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl] -amino } -3-fluoro-phenyl)-2-oxo-piperidine-3-carboxylic acid ethyl ester;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin-l -yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(3-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-morpholin-4-yl-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [4-(2-methyl-5-oxo-pyrrolidin- 1 -yl)-phenyl] -amide } ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [4-(2-methyl-5-oxo-pyrrolidin- 1 -yl)-phenyl]-amide } ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(4-methoxy-2-oxo-2H-pyridin- 1 -yl)-phenyl] - amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(4-methoxy-2-oxo-2H-pyridin- 1 -yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-chloro-2- oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl]-amide } l-[(4-chloro-phenyl)-amide] ; 4-Hydroxy-pyrrolidine- 1,2-dicarboxylic acid 2-[(4-tert-butyl-phenyl)- amide] 1 -[(4-chloro-phenyl)-amide] ;
4-Hydroxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2[(3 ,5'difluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ;
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,2']bipyridinyl-5'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro-pyridin-2-yl)- amide] 2-{[4-(2,3-dimethyl-5-oxo-2,5-dihydro-pyrazol-l-yl)-phenyl]-amide}; 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
2-{ [4-(2,3-dimethyl-5-oxo-2,5-dihydro-pyrazol-l-yl)-phenyl]-amide};
4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2-[(2-oxo-2H-[l,3']biρyridinyl-6'-yl)-amide];
4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro-pyridin-2-yl)- amide] 2-[(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']bipyridinyl-6'-yl)-amide]-TFA Salt;
4-Ethoxy-pyrrolidine-l, 2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(2-oxo-3,4,5,6-tetrahydro-2H-[l,3']biρyridinyl-6,-yl)-amide]; 4-Ethoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)-amide] 2- [(2-oxo-2H-[l ,3']bipyridinyl-6'-yl)-amide]; or
4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 2- { [2-fluoro-4-(6-oxo-6H-pyridazin- 1 -yl)-phenyl] -amide } ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(6-methyl-5-oxo-5H-[l ,2,4]triazin-4-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3-chloro-5- methyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3-methyl-5-oxo-4,5-dihydro-pyrazol-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(5-chloro-3- methyl-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl] -amide } 1 - [(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [4-(3,5-dimethoxy-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(5-methoxy-2-oxo-2H-pyridin- 1 -yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4~(2-oxo-3-pyrrol-l-yl-2H-pyridin-l-yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-3-phenyl-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(3-methyl-2-oxo-pyrrolidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methyl-2-oxo-imidazolidin-l-yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(3,5-dimethyl-2-oxo-imidazolidin-l-yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3,5,5-trimethyl-2-oxo-imidazolidin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(3-isopropyl-5,5-dimethyl-2-oxo-imidazolidin-l- yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(5-methyl-2-oxo-imidazolidin- 1 -yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [4-(5,5-dimethyl-2-oxo-imidazolidin- 1 -yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(3,4-dimethyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(4-chloro-2- oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl]-amide } 1 - [(4-chloro-phenyl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(3-methyl-2-oxo-pyrrolidin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-methyl-2-oxo-imidazolidin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(3,5-dimethyl-2-oxo-imidazolidin-l-yl)-2-fluoro- phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(3,5,5-trimethyl-2-oxo-imidazolidin-l-yl)- phenyl] -amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(3-isopropyl-5,5-dimethyl-2-oxo- imidazolidin- 1 -yl)-phenyl]-amide } ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(5-methyl-2-oxo-imidazolidin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [4-(5,5-dimethyl-2-oxo-imidazolidin- 1 -yl)-2-fluoro- phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(3,4-dimethyl-2-oxo-2H-pyridin-l-yl)-2-fluoro- phenyl] -amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(4-chloro-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2-yl)-amide]; or a pharmaceutically acceptable salt thereof.
9. A compound which is:
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-2H-quinolin- 1 -yl)-phenyl]-amide } ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-oxo-3H-isoquinolin-2-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(l-oxo-lH-isoquinolin-2-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-oxo-5H-[l ,2,4]triazin-4-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(6-oxo-6H-pyrimidin-l-yl)-phenyl]-amide} ;
2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyrazin-l-yl)-phenyl]-amide} ; (2R,4R)- 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-2H-pyrimidin-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-2H-[l,3,5]triazin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(6-methyl-2-oxo-2H-[l,3']bipyridinyl-6'-yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(l-methyl-lH-imidazol-2-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(l-methyl-lH-pyrrol-2-yl)-phenyl]-amide} ;
(2R,4R)-5-Aza-spiro[2.4]heptane-5,6-dicarboxylic acid 5-[(4-chloro- phenyl)-amide] 6-{[2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridine-l-carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methyl-3H-imidazol-4-yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-methyl-2H-pyrazol-3-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [5-(2,5-dihydro-pyrrole-l-carbonyl)-pyridin-2-yl]-amide} ;
(2R,4R)- 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-methyl-5-oxo-2,5-dihydro-pyrazol-l-yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(5-methoxymethyl-3-methyl-pyrazol-l-yl)- phenyl] -amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(3-methoxymethyl-5-methyl-pyrazol-l-yl)- phenyl] -amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-ethyl-3-methyl-pyrazol-l-yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(5-isobutyl-3-methyl-pyrazol-l-yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-isopropyl-pyrazol-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-ethyl-pyrazol-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(5-isobutyl-pyrazol- 1 -yl)-phenyl]-amide } ;
(2R,4R)-2-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolodine-2- carbonyl]-amino}-3-fluoro-phenyl)-2H-pyrazole-3-carboxylic acid methyl ester;
(2R,4R)-2-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolodine-2- carbonyl]-amino}-3-fluoro-phenyl)-2H-pyrazole-3-carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(5-methoxymethyl-pyrazol- 1 -yl)-phenyl] -amide } ;
(2R,4R)-5-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-oxazole-4-carboxylic acid ethyl ester; (2R,4R)-5-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-hydroxy-pyrrolidine-2- carbonyl] -amino }-3-fluoro-phenyl)-oxazole-4-carboxylic acid ethyl ester;
(2R,4R)-5-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino }-3-fluoro-phenyl)-oxazole-4-carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(4-methoxymethyl-oxazol-5-yl)-phenyl]-amide } ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(4-ethyl-oxazol-5-yl)-2-fluoro-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-isopropyl-oxazol-5-yl)-phenyl]-amide} ; (2R,4R)-5-(6-{ [l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-pyridin-3-yl)-oxazole-4-carboxylic acid ethyl ester;
(2R,4R)-5-(6- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl] -amino }-pyridin-3-yl)-oxazole-4-carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-{ [5-(4-methoxymethyl-oxazol-5-yl)-pyridin-2-yl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [5-(4-ethyl-oxazol-5-yl)-pyridin-2-yl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-{ [5-(4-vinyl-oxazol-5-yl)-pyridin-2-yl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [5-(4-isobutyl-oxazol-5-yl)-pyridin-2-yl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-methyl-isoxazol-3-yl)-phenyl] -amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(4-methyl-isoxazol-3-yl)-phenyl]-amide};
(2R,4R)-3-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-isoxazole-4-carboxylic acid methyl ester;
(2R,4R)-3-(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino } -3-fluoro-phenyl)-isoxazole-4-carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(4-methoxymethyl-isoxazol-3-yl)-phenyl] -amide } ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-isopropyl-isoxazol-3-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-cyclopropyl-isoxazol-3-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(4-cyclopropyl-isoxazol-3-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-methyl-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2- { [2-methyl-4-(2-oxo-2H-pyridin- 1 -yl)-phenyl] -amide } ; (2R,4R)-4-Ethoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro-pyridin-
2-yl)-amide] 2-{ [2-methyl-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-[(4-chloro- phenyl)-amide] l-{ [2,6-difluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(5-chloro- pyridin-2-yl)-amide] 1 - { [2,6-difluoro-4-(2-oxo-2H-pyridin- 1 -yl)-phenyl]-amide } ;
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(4-chloro-phenyl)- amide] l-{[2,6-difluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide}; (2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid 2-[(5-chloro-pyridin- 2-yl)-amide] l-{ [2,6-difluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(5'-methyl-2-oxo-2H-[l,3']bipyridinyl-6'-yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-[(5'-methyl-2-oxo-2H-[l,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(5'-methyl-2-oxo-2H-[l,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro-pyridin- 2-yl)-amide] 2-[(5'-methyl-2-oxo-2H-[l ,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(2'-methyl-2-oxo-2H-[l ,3']bipyridinyl-6'-yl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-[(2'-methyl-2-oxo-2H-[l,3']bipyridinyl-6'-yl)-amide]; (2R,4R)-4-Ethoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-[(2'-methyl-2-oxo-2H-[l ,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro-pyridin- 2-yl)-amide] 2-[(2'-methyl-2-oxo-2H-[l,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(ethyl-isopropyl-carbamoyl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(ethyl-isopropyl-carbamoyl)-2-fluoro-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3-ethyl-pyrrolidine-l-carbonyl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(3-ethyl-pyrrolidine-l-carbonyl)-2-fluoro-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3R-amino- pyrrolidine- 1 -carbonyl)-phenyl] -amide } 1 -[(4-chloro-phenyl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3R-amino- pyrrolidine-l-carbonyl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3S-amino- pyrrolidine- 1 -carbonyl)-phenyl]-amide } 1 -[(4-chloro-phenyl)-amide] ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3S-amino- pyrrolidine-l-carbonyl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-{[4-(3R-methylamino-pyrrolidine-l-carbonyl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(3R-methylamino-pyrrolidine-l-carbonyl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3S-methylamino-pyrrolidine-l-carbonyl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(3S-methylamino-pyrrolidine-l-carbonyl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[4-(3R-ethylamino-pyrrolidine-l-carbonyl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrroli dine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(3R-ethylamino-pyrrolidine- 1 -carbonyl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2- { [4-(3S-ethylamino-pyrrolidine- 1 -carbonyl)-phenyl]-amide } ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(3S-ethylamino-pyrrolidine- 1 -carbonyl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(2,5-dihydro-pyrrole-l-carbonyl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2,5-dihydro-pyrrole-l -carbonyl)-2-fluoro-phenyl] -amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(2,5-dihydro-pyrrole-l-carbonyl)-2-fluoro-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(pyrrole-l-carbonyl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(pyrrole-l-carbonyl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(pyrrole-l-carbonyl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(pyrrole-l-carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrroli dine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-fluoro-2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R,4R)- 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l ,6-dihydro-pyridine-3-carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(6-hydroxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)- 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbon yl]-amino } -3-fluoro-phenyl)-2-oxo- 1 ,2-dihydro-pyridine-3-carboxylic acid;
(2R,4R)- 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l,6-dihydro-pyridine-2-carboxylic acid methyl ester;
(2R,4R)- [ 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-phenyl)-2,5-dioxo-imidazolidin-4-yl]-acetic acid;
(2R,4R)-l-(4-{[l-(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl] -amino } -3-fluoro-phenyl)-2-oxo- 1 ,2-dihydro-pyridine-3-carboxylic acid methyl ester;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-3-trifluoromethyl-2H-pyridin-l-yl)- phenyl] -amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-hydroxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide}; (2R,4R)- 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l,6-dihydro-pyridine-2-carboxylic acid; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-5-trifluoromethyl-2H-pyridin- 1 -yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [4-(6-cyclopropyl-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl] - amide};
(2R,4R)- 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbonyl]-amino } -3-fluoro-phenyl)-6-oxo- 1 ,6-dihydro-pyridine-3-carboxylic acid ethyl ester; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3,3-dimethyl-2-oxo-azetidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(7-oxo-7H-thieno[2,3-c]pyridin-6-yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-l-aza-spiro[4.5]dec-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3-benzoyl-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{[4-(3- acetylsulfamoyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro- phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-thiazolidin-3-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3 -methyl-2-oxo-piperidin-l-yl)-phenyl] -amide } ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-3-sulfamoyl-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2,5-dioxo-2,5-dihydro-pyrrol-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3-amino-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-3-phenoxy-2H-pyridin- 1 -yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2,2-dimethyl-5-oxo-pyrrolidin-l-yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-nitro-2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)- 1 -(4- { [ 1 -(4-Chloro-phenylcarbamoyl)-4-methoxy-pyrrolidine-2- carbon yl] -amino }-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3-carboxylic acid tert-butyl ester;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2,5-dioxo-pyrrolidin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{[4-(3- benzothiazol-2-yl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro- phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3-amino-4,6- dimethyl-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl]-amide } 1 - [(4-chloro-phenyl)- amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [4-(3-diethylaminomethyl-2-oxo-2H-pyridin- 1 -yl)-2-fluoro- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{[4-(3- aminomethyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro- phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(3-methyl-5-nitro-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)- Acetic acid l-(4-{ [l-(4-chloro-phenylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridin-3-yl ester; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-({4-[3-(cyclopentanecarbonyl-amino)-2-oxo-2H-pyridin-l-yl]- 2-fluoro-phenyl } -amide) ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(5-amino-3- methyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-({2-fluoro-4-[2-oxo-3-(pyridin-4-ylcarbamoyl)-2H-pyridin-l- yl]-phenyl } -amide); (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(3,5-dichloro-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3-amino-5- bromo-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3-cyano-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3-cyano-2-oxo-5-phenyl-2H-pyridin-l-yl)-2-fluoro- phenyl] -amide } ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(3-ethyl-6-methyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [4-(3-cyano-4-dimethylamino-2-oxo-2H-pyridin-l-yl)-2- fluoro-phenyl] -amide } ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-methyl-3-nitro-2-oxo-2H-pyridin-l -yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(5-nitro-2-oxo-3-trifluoromethyl-2H-pyridin-l-yl)- phenyl] -amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-amino-6- oxo-6H-[3,4']bipyridinyl-l -yl)-2-fluoro-phenyl]-amide} 1 -[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-chloro-3- nitro-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3-carbamoyl- 2-oxo-5-trifluoromethyl-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro- phenyl)-amide]; (2R,4R)-5-Bromo-l-(4-{ [l-(4-chloro-phenylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3- carboxylic acid isobutyl ester;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3-chloro-2- oxo-5-trifluoromethyl-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro- phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-bromo-5- chloro-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl] -amide } 1 -[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-bromo-3- nitro-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(3-nitro-2-oxo-5-trifluoromethyl-2H-pyridin- 1 -yl)- phenyl] -amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(5-methyl-3-nitro-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-5-Chloro- 1 -(4- { [ 1 -(4-chloro-phenylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3- carboxylic acid methyl ester; (2R,4R)-5-Chloro-l-(4-{ [l-(4-chloro-phenylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3- carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(4-benzyloxy- 2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl] -amide } 1 -[(4-chloro-phenyl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(4-amino-5- fluoro-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(6-methyl-3-oxo-3H-isoquinolin-2-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(4-methyl-5-nitro-2-oxo-2H-pyridin-l -yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2- { [4-(5- acetylamino-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl]-amide } 1 -[(4-chloro- phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(4-amino-2- oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl]-amide} 1 -[(4-chloro-phenyl)-amide] ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(6-oxo-6H-[3,4']bipyridinyl-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(4-bromo-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-oxo-4H-furo[3,2-c]pyridin-5-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(l-oxo-lH-[2,6]naphthyridin-2-yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2- { [4-(5-bromo-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(4-chloro-phenyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(4-oxo-4H-thieno[3,2-c]pyridin-5-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-oxo-l ,4-dihydro-imidazo[4,5-c]pyridin-5-yl)- phenyl] -amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(5-chloro-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(5-fluoro-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-l-(4-{[l-(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l,6-dihydro-pyridine-3- carboxylic acid; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(6-hydroxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-1 -(4- { [ 1 -(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3- carboxylic acid;
(2R,4R)- 1 -(4- { [ 1 -(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l,6-dihydro-pyridine-2- carboxylic acid methyl ester;
(2R,4R)-[ 1 -(4- { [ 1 -(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-phenyl)-2,5-dioxo-imidazolidin-4-yl]-acetic acid;
(2R,4R)- 1 -(4- { [ 1 -(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3- carboxylic acid methyl ester;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(2-oxo-3-trifluoromethyl-2H-pyridin- 1 -yl)- phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(4-hydroxy-2-oxo-2H-pyridin- 1 -yl)-phenyl]- amide};
(2R,4R)- 1 -(4- { [ 1 -(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l,6-dihydro-pyridine-2- carboxylic acid;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(2-oxo-5-trifluoromethyl-2H-pyridin- 1 -yl)- phenyl] -amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [4-(6-cyclopropyl-2-oxo-2H-pyridin- 1 -yl)-2-fluoro- phenyl] -amide};
(2R,4R)- 1 -(4- { [ 1 -(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-6-oxo-l,6-dihydro-pyridine-3- carboxylic acid ethyl ester;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(3-hydroxy-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(3,3-dimethyl-2-oxo-azetidin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(7-oxo-7H-thieno[2,3-c]pyridin-6-yl)- phenyl] -amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-l-aza-spiro[4.5]dec-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3-benzoyl-2- oxo-2H-pyridin- l-yl)-2-fluoro-phenyl] -amide } 1 -[(5-chloro-pyridin-2-yl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-methyl-5-oxo-pyrrolidin-l-yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(2-methyl-6-oxo-piperidin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{[4-(3- acetylsulfamoyl-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl]-amide } 1 -[(5-chloro- pyridin-2-yl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-thiazolidin-3-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-methyl-2-oxo-piperidin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(2-oxo-3-sulfamoyl-2H-pyridin- 1 -yl)- phenyl] -amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(2,5-dioxo-2,5-dihydro-pyrrol-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3-amino-2- oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]-amide } 1 -[(5-chloro-pyridin-2-yl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-3-phenoxy-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(2,2-dimethyl-5-oxo-pyrrolidin-l-yl)-2-fluoro-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(3-nitro-2-oxo-2H-pyridin- 1 -yl)-phenyl]- amide};
(2R,4R)- 1 -(4- { [ 1 -(5-Chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino } -3-fluoro-phenyl)-2-oxo- 1 ,2-dihydro-pyridine-3- carboxylic acid tert-butyl ester;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(2,5-dioxo-pyrrolidin-l-yl)-phenyl] -amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3- benzothiazol-2-yl-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl]-amide } 1 -[(5-chloro- pyridin-2-yl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3-amino-4,6- dimethyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2- yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(3-diethylaminomethyl-2-oxo-2H-pyridin-l-yl)-2- fluoro-phenyl] -amide } ; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2- { [4-(3- aminomethyl-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl] -amide } 1 -[(5-chloro- pyridin-2-yl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(3-methyl-5-nitro-2-oxo-2H-pyridin- 1 -yl)- phenyl]-amide};
(2R,4R)- Acetic acid l-(4-{ [l-(5-chloro-pyridin-2-ylcarbamoyl)-4- methoxy-pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro- pyridin-3-yl ester;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-( { 4- [3-(cyclopentanecarbonyl-amino)-2-oxo-2H-pyridin- 1 - yl]-2-fluoro-phenyl } -amide);
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(5-amino-3- methyl-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl] -amide } 1 -[(5-chloro-pyridin-2- yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-({2-fluoro-4-[2-oxo-3-(pyridin-4-ylcarbamoyl)-2H- pyri din- 1 -yl] -phenyl } -amide) ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[4-(3,5-dichloro-2-oxo-2H-pyridin-l-yl)-2-fluoro- phenyl] -amide}; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-amino-5- bromo-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2- yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [4-(3-cyano-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl] - amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [4-(3-cyano-2-oxo-5-phenyl-2H-pyridin- 1 -yl)-2-fluoro- phenyl] -amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [4-(3-ethyl-6-methyl-2-oxo-2H-pyridin- 1 -yl)-2-fluoro- phenyl] -amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [4-(3-cyano-4-dimethylamino-2-oxo-2H-pyridin- 1 -yl)-2- fluoro-phenyl]-amide } ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(4-methyl-3-nitro-2-oxo-2H-pyridin- 1 -yl)- phenyl] -amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(5-nitro-2-oxo-3-trifluoromethyl-2H-pyridin- l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2- { [4-(5-amino-6- 0X0-6H- [3 ,4']bipyridinyl- 1 -yl)-2-fluoro-phenyl]-amide } 1 - [(5-chloro-pyridin-2- yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2- { [4-(5-chloro-3- nitro-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl] -amide} l-[(5-chloro-pyridin-2-yl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-carbamoyl- 2-oxo-5-trifluoromethyl-2H-pyridin-l -yl)-2-fluoro-phenyl]-amide} 1 -[(5-chloro- pyridin-2-yl)-amide]; (2R,4R)-5-Bromo-l-(4-{ [l-(5-chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3- carboxylic acid isobutyl ester;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3-chloro-2- oxo-5-trifluoromethyl-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro- pyridin-2-yl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(3-bromo-5- chloro-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl] -amide } 1 - [(5-chloro-pyridin-2- yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2- { [4-(5-bromo-3- nitro-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2-yl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(3-nitro-2-oxo-5-trifluoromethyl-2H-pyridin- l-yl)-phenyl] -amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(5-methyl-3-nitro-2-oxo-2H-pyridin-l-yl)- phenyl] -amide};
(2R,4R)-5-Chloro- 1 -(4- { [ 1 -(5-chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino } -3-fluoro-phenyl)-2-oxo- 1 ,2-dihydro-pyridine-3- carboxylic acid methyl ester;
(2R,4R)-5-Chloro-l-(4-{ [l-(5-chloro-pyridin-2-ylcarbamoyl)-4-methoxy- pyrrolidine-2-carbonyl]-amino}-3-fluoro-phenyl)-2-oxo-l,2-dihydro-pyridine-3- carboxylic acid; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2- { [4-(4-benzyloxy-
2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl]-amide } 1 -[(5-chloro-pyridin-2-yl)- amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [4-(4-amino-5- fluoro-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl] -amide} l-[(5-chloro-pyridin-2- yl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(5-nitro-2-oxo-2H-pyridin- 1 -yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(6-methyl-3-oxo-3H-isoquinolin-2-yl)- phenyl]-amide};
(2R,4R)-4-Methoxy-pyrroli dine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(4-methyl-5-nitro-2-oxo-2H-pyridin- 1 -yl)- phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2- { [4-(5- acetylamino-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro- pyridin-2-yl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-( 1 -oxo- 1 H-isoquinolin-2-yl)-phenyl] -amide } ; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2- { [4-(4-amino-2- oxo-2H-pyridin-l -yl)-2-fluoro-phenyl]-amide } 1 -[(5-chloro-pyridin-2-yl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(6-oxo-6H-[3,4']bipyridinyl-l-yl)-phenyl]- amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-oxo-3H-isoquinolin-2-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(4-bromo-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(4-oxo-4H-furo[3,2-c]pyridin-5-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-( 1 -oxo-lH-[2,6] naphthyridin-2-yl)-phenyl] - amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 2- { [4-(5-bromo-2- oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl] -amide } 1 -[(5-chloro-pyridin-2-yl)-amide] ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(4-oxo-4H-thieno[3 ,2-c]pyridin-5-yl)- phenyl] -amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyri'din-2-yl)-amide] 2-{ [2-fluoro-4-(4-oxo-l,4-dihydro-imidazo[4,5-c]pyridin-5- yl)-phenyl] -amide } ;
4,5-Dihydro-pyrazole- 1 ,5-dicarboxylic acid 1 -[(4-chloro-phenyl)-amide] 5-{ [2-fluoro-4-(2-oxo-2H-pyridin- l-yl)-phenyl] -amide } ;
3-Hydroxymethyl-4,5-dihydro-pyrazole-l, 5-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 5-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
5-Methyl-4,5-dihydro-pyrazole-l ,5-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 5- { [2-fluoro-4-(2-oxo-2H-pyridin- 1 -yl)-phenyl] -amide } ;
3-Methoxymethyl-4,5-dihydro-pyrazole- 1 ,5-dicarboxylic acid 1 -[(4- chloro-phenyl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide}; 4,5-Dihydro-pyrazole-l,5-dicarboxylic acid l-[(5-chloro-pyridin-2-yl)- amide] 5-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
3-Hydroxymethyl-4,5-dihydro-pyrazole- 1 ,5-dicarboxylic acid 1 -[(5- chloro-pyridin-2-yl)-amide] 5- { [2-fluoro-4-(2-oxo-2H-pyridin- 1 -yl)-phenyl]- amide}; 5-Methyl-4,5-dihydro-pyrazole-l, 5-dicarboxylic acid l-[(5~chloro-pyridin-
2-yl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
3-Methoxymethyl-4,5-dihydro-pyrazole-l, 5-dicarboxylic acid l-[(5- chloro-pyridin-2-yl)-amide] 5-{[2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]- amide}; 4,5-Dihydro-pyrazole-l, 5-dicarboxylic acid l-[(4-chloro-phenyl)-amide]
5-{ [4-(2-methyl-thiazol-4-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-2-methyl -pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4- chloro-phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-piperidin- 1 -yl)-phenyl]-amide } ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(3,4,5,6-tetrahydro-2H-[l,4']bipyridinyl-4-ylmethyl)-amide]; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(2-dimethylaminomethyl-imidazol-l-yl)-2-fluoro-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [2-chloro-4-(2- oxo-2H-pyridin- 1 -yl)-phenyl] -amide } 1 -[(4-chloro-phenyl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [2-chloro-4-(2- oxo-2H-pyridin- 1 -yl)-phenyl] -amide } 1 -[(5-chloro-pyridin-2-yl)-amide] ;
(2R,4R)-4-Methyl -pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide}; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-methylamino-imidazol-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-isopropyl-imidazol-l-yl)-phenyl] -amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [4-(2-ethyl-imidazol- 1 -yl)-2-fluoro-phenyl]-amide } ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(2-ethyl-imidazol-l-yl)-2-fluoro-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-isopropyl-imidazol- l-yl)-phenyl] -amide } ; (2R,4R)-2-Ethyl-4-methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ;
4-Methoxy-2-methoxymethyl -pyrrolidine- 1,2-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
2-Hydroxymethyl-4-methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4- chloro-phenyl)-amide] 2-{[2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide};
{ l-(4-Chloro-phenylcarbamoyl)-2-[2-fluoro-4-(2-oxo-piperidin-l-yl)- phenylcarbamoyl]-4-methoxy-pyrrolidin-2-yl} -acetic acid methyl ester;
{ l-(4-Chloro-phenylcarbamoyl)-2-[2-fluoro-4-(2-oxo-piperidin-l-yl)- phenylcarbamoyl]-4-methoxy-pyrrolidin-2-yl } -acetic acid; 4-Hydroxymethyl-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide}; { 1 -(4-Chloro-phenylcarbamoyl)-5-[2-fluoro-4-(2-oxo-piperidin- 1 -yl)- phenylcarbamoyl]-pyrrolidin-3-yl } -acetic acid;
{ l-(4-Chloro-phenylcarbamoyl)-5-[2-fluoro-4-(2-oxo-piperidin-l-yl)- phenylcarbamoyl]-pyrrolidin-3-yl} -acetic acid methyl ester; (2R,4R)-4-Ethyl -pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Isopropyl-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-2H-pyridin- 1 -yl)-phenyl] -amide } ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(3-fluoro-2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(3-fluoro-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2- { [4-(3-chloro-2- oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl] -amide } 1 -[(5-chloro-pyridin-2-yl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-chloro-2- oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl] -amide } 1 - [(4-chloro-phenyl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-bromo-2- oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl]-amide } 1 - [(4-chloro-phenyl)-amide] ; (2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 2-{ [4-(3-bromo-2- oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]-amide} l-[(5-chloro-pyridin-2-yl)-amide];
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(3-iodo-2-oxo-2H-pyridin- 1 -yl)-phenyl]-amide } ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(3-iodo-2-oxo-2H-pyridin- 1 -yl)-phenyl] - amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [4-(3-ethyl-2-oxo-2H-pyridin-l-yl)-2-fluoro-phenyl]- amide}; and (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [4-(3-ethyl-2-oxo-2H-pyridin- 1 -yl)-2-fluoro-phenyl]-amide; a pharmaceutically acceptable salt thereof.
10. A compound which is:
(2R,4R) 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ; (2R,4R) 4-Ethoxy-pyrrolidine-l,2-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 2- { [2-fluoro-4-(2-oxo-2H-pyridin- 1 -yl)-phenyl] -amide } ;
(2R,4R) 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(2-oxo-2H-pyridin- 1 -yl)-phenyl] -amide } ;
(2R,4R) 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R,4R) 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2-oxo-2H-[l,3,]bipyridinyl-6'-yl)-amide];
(2R,4R) 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(3-methoxy-2-oxo-2H-pyridin- 1 -yl)-phenyl]- amide};
(2R,4R) 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(3-methyl-2-oxo-2H-pyridin-l-yl)-phenyl] -amide} ;
(2R,4R) 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(2-methyl-imidazol- 1 -yl)-phenyl]-amide } ; (2R,4R) 4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro- phenyl)-amide] 2-[(4-dimethylcarbamoyl-2-fluoro-phenyl)-amide];
(2R,4R) 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-fluoro-4-(5-methyl-pyrazol-l-yl)-phenyl]-amide};
(2R,4R) 4,5-Dihydro-pyrazole- 1,5-dicarboxylic acid l-[(4-chloro-phenyl)- amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide];
(2R,4R) 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(2-fluoro-4-pyrazol- 1 -yl-phenyl)-amide] ;
(2R,4R) 4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl) -amide] 2-{ [2-fluoro-4-(pyrrolidine-l -carbonyl)-phenyl] -amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-piperidin-l-yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl] -amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(5-chloro- pyridin-2-yl)-amide] 2- { [2-fluoro-4-(2-oxo-2H-pyridin- 1 -yl)-phenyl]-amide } ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [4-(3-methyl-2-oxo-2H-pyridin- 1 -yl)-phenyl]-amide } ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(2-methyl-imidazol-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-[(2-oxo-2H-[l,3']bipyridinyl-6'-yl)-amide];
(2R,4R)-4-Ethoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 - [(4-chloro-phenyl)- amide] 2-{ [2-fluoro-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-[(4-dimethylcarbamoyl-2-fluoro-phenyl)-amide] ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-methyl-pyrazol-l-yl)-phenyl]-amide} ;
5-Methyl-4,5-dihydro-pyrazole- 1,5-dicarboxylic acid l-[(4-chloro- ρhenyl)-amide] 5-[(3-fluoro-2'-sulfamoyl-biphenyl-4-yl)-amide] ;
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [2-fluoro-4-(3-methyl-2-oxo-2H-pyridin- 1 -yl)-phenyl]-amide } ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid 2-{ [2-chloro-4-(2- oxo-2H-pyridin- 1 -yl)-phenyl] -amide } 1 -[(4-chloro-phenyl)-amide] ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[2-methyl-4-(2-oxo-2H-pyridin-l-yl)-phenyl]-amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(6-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{ [2-fluoro-4-(3-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(5-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]- amide};
(2R,4R)-4-Methoxy-pyrrolidine-l ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(5-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(5-chloro- pyridin-2-yl)-amide] 2-{[2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]- amide;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [4-(2,5-dihydrom-pyyrole- 1 -carbonyl)-2-fluoro-phenyl- amide};
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{[4-(2,5-dihydrom-pyyrole-l-carbonyl)-phenyl-amide}
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2- { [4-(2-methyl-5-oxo-pyrrolidin- 1 -yl)-phenyl] -amide } ; (2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{ [4-(2,5-dihydro-pyrrole-l-carbonyl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1 ,2-dicarboxylic acid 1 -[(4-chloro- phenyl)-amide] 2-{ [2-fluoro-4-(4-methyl-2-oxo-2H-pyridin-l-yl)-phenyl]-amide} ;
(2R,4R)-4-Methoxy-pyrrolidine- 1,2-dicarboxylic acid l-[(4-chloro- phenyl)-amide] 2-{[4-(2,5-dihydro-pyrrole-l-carbonyl)-2-fluoro-phenyl]-amide}; or a pharmaceutically acceptable salt thereof.
11. A pharmaceutical composition comprising a compound of formula I
or a pharmaceutically acceptable salt thereof wherein: A is aryl or substituted aryl or monocyclic heteroaryl or substituted monocyclic heteroaryl;
O O
B is -NH— C— (d-C6)alkyl, -NH — C— (C3-C7)cycloalkyl -NH(d-
C6)alkanoyl, R1 , (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, (C4- C7)cycloalkenyl, (C4-C7)heterocycloalkenyl, aryl, or heteroaryl, any of which may be optionally substituted;
C is phenyl or heteroaryl, wherein phenyl or heteroaryl is optionally substituted with one or more substituents selected from halogen, hydroxy, -
CO2R2, -COR2, -CONR2R2', alkoxy, alkyl, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido;
G is H, halo, (d-C6)alkyl, halo(C C6)alkyl, hydroxy(d-C6)alkyl, -CH2O-(d-C6)alkyl, -CH2-CO2(d-C6)alkyl, -CH2-CONH2, or -CH2-CONH(d- C6)alkyl;
W is a saturated or unsaturated, substituted or unsubstituted hydrocarbon chain or hydrocarbon-heteroatom chain having from 2 to 6 atoms, wherein W1- ' connects the nitrogen atom at position 1 to the carbon atom at position 2 to form a four to eight membered ring;
R1 is (CrC6)alkoxy, (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, (C4- C )cycloalkenyl, (C4-C7)heterocycloalkenyl, aryl, monocyclic heteroaryl, or - NR3R4;
R2 and R2' are each independently H or (d-C6)alkyl; and
R3 and R4 are each independently H, (C1-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring; admixed with a carrier, diluent, or excipient.
12. A method for preventing or treating acute, subacute, and chronic thrombotic disorder in a mammal comprising administering to a mammal in need thereof a therapeutically effective amount of a compound of claim 1.
13. The method of claim 10, wherein the acute, subacute, and chromic thrombotic disorder is venous thrombosis, arterial thrombosis, pulmonary embolism, myocardial infarction, cerebral infarction, restenosis, cancer, angina, diabetes, atrial fibrillation, or heart failure.
14. A method for inhibiting Factor Xa in a mammal, comprising administering to a mammal in need of Factor Xa inhibition a Factor Xa inhibition amount of a compound of claim 1.
15. A process for preparing a compound of Formula I:
Figure imgf000382_0001
or a pharmaceutically acceptable salt thereof wherein: A is aryl or substituted aryl or monocyclic heteroaryl or substituted monocyclic heteroaryl;
O O
B is -NH— C— (d-C6)alkyl, -NH — C— (C3-C7)cycloalkyl, -NH(d-
C6)alkanoyl,
Figure imgf000382_0002
, (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, (C4- C7)cycloalkenyl, (C4-C )heterocycloalkenyl, aryl, or heteroaryl, any of which may be optionally substituted by halo, (C1-C6)alkyl, or halo(C1-C6)alkyl, (C C6)alkoxy, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido;
C is phenyl or heteroaryl, wherein phenyl or heteroaryl is optionally substituted with one or more substituents selected from halogen, hydroxy, -
CO2R2, -COR2, -CONR2R2', alkoxy, alkyl, -CN, haloalkyl, amino, alkylamino, amidino, amido, or sulfonamido;
G is H, halo, (d-C6)alkyl, halo(d-C6)alkyl, hydroxy(d-C6)alkyl, -CH2O-(d-C6)alkyl, -CH2-CO2(C1-C6)alkyl, -CH2-NR2R2\ or -CH2- CONH(C C6)alkyl;
W1 is a saturated or unsaturated, substituted or unsubstituted hydrocarbon chain or hydrocarbon-heteroatom chain having from 2 to 6 atoms, wherein W connects the nitrogen atom at position 1 to the carbon atom at position 2 to form a four to eight membered ring;
R1 is (d-C6)alkoxy, (C3-C7)cycloalkyl, (C3-C7)heterocycloalkyl, (C4- C7)cycloalkenyl, (C4-C7)heterocycloalkenyl, aryl, monocyclic heteroaryl, or - NR3R4;
R2 and R2' are each independently H or (d-C6)alkyl; and
R3 and R4 are each independently H, (Cι-C6)alkyl, aralkyl, aryl, monocyclic heteroaryl, alkoxycarbonyl, aralkoxycarbonyl, -SO2alkyl, or joined together to form a saturated or unsaturated 3 to 7 membered ring; comprising:
(a) reacting an amino acid of formula IA
Figure imgf000383_0001
IA
with a reagent capable of placing a protecting group P1 on the amino group of an amino acid to form a protected amino acid given by formula IB:
Figure imgf000384_0001
ΓB
wherein P1 is a protecting group and W^ is the same as defined above;
(b) converting the acid moiety in the compound of formula IB to a acid halide;
(c) reacting the acid halide with a haloaniline or a haloamino- heterocycle to form a compound having formula IC:
Figure imgf000384_0002
wherein Zi is a halogen and A is as defined above;
(d) coupling the compound of formula IC with a compound H-B to give a compound having formula ID:
Figure imgf000385_0001
ΓD
(e) removing the protecting group from Compound ID and reacting the resulting acid moiety with a C-isocyanate to form a compound of the invention.
PCT/IB2002/004757 2001-11-29 2002-11-14 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade WO2003045912A1 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
IL16182602A IL161826A0 (en) 2001-11-29 2002-11-14 Inhibitors of factor xa and other serine proteasesinvolved in the coagulation cascade
HU0402529A HUP0402529A3 (en) 2001-11-29 2002-11-14 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade, process for producing them and pharmaceutical compositions containing them
DK06110738T DK1671949T3 (en) 2001-11-29 2002-11-14 Substituted pyridinylamines
MXPA04003606A MXPA04003606A (en) 2001-11-29 2002-11-14 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade.
JP2003547364A JP4238135B2 (en) 2001-11-29 2002-11-14 Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
SI200230316T SI1465864T1 (en) 2001-11-29 2002-11-14 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
YUP-436/04A RS51087B (en) 2001-11-29 2002-11-14 INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE
EA200400606A EA007579B1 (en) 2001-11-29 2002-11-14 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
CN028238370A CN1582274B (en) 2001-11-29 2002-11-14 Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
KR1020047008251A KR100688814B1 (en) 2001-11-29 2002-11-14 INHIBITORS OF FACTOR Xa AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE
UA20040504094A UA77456C2 (en) 2001-11-29 2002-11-14 Inhibitors of factor xa and other serineproteases involved to the coagulation cascade
EP02803885A EP1465864B1 (en) 2001-11-29 2002-11-14 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
NZ532384A NZ532384A (en) 2001-11-29 2002-11-14 Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
BR0214519-7A BR0214519A (en) 2001-11-29 2002-11-14 Factor xa and other serine protease inhibitors involved in the coagulation cascade
DE60209944T DE60209944T2 (en) 2001-11-29 2002-11-14 INHIBITORS OF FACTOR XA AND OTHER SERIN PROTEINASES INVOLVED IN THE COAGULATION CASCADE
CA2468715A CA2468715C (en) 2001-11-29 2002-11-14 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
AU2002365313A AU2002365313B2 (en) 2001-11-29 2002-11-14 Inhibitors of factor XA and other serine proteases involved in the coagulation cascade
APAP/P/2004/003035A AP1744A (en) 2001-11-29 2002-11-14 Inhibitors of factor XA and other serine proteases involved in the coagulation cascade
IS7220A IS2552B (en) 2001-11-29 2004-04-15 Inhibits Factor Xa and other serine proteases associated with clotting chain activity
HR20040470A HRP20040470A2 (en) 2001-11-29 2004-05-27 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
TNP2004000098A TNSN04098A1 (en) 2001-11-29 2004-05-28 INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE CASCADE OF COAGULATION
CY20061100448T CY1105374T1 (en) 2001-11-29 2006-03-30 INHIBITORS OF FACTOR HA AND OTHER SEPIN PROTEANS INVOLVED IN THE COAGULATION CASCADE

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33416801P 2001-11-29 2001-11-29
US60/334,168 2001-11-29
US38489502P 2002-05-31 2002-05-31
US60/384,895 2002-05-31

Publications (2)

Publication Number Publication Date
WO2003045912A1 true WO2003045912A1 (en) 2003-06-05
WO2003045912A8 WO2003045912A8 (en) 2003-10-02

Family

ID=26989068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2002/004757 WO2003045912A1 (en) 2001-11-29 2002-11-14 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade

Country Status (42)

Country Link
US (6) US7030141B2 (en)
EP (3) EP2085391A3 (en)
JP (1) JP4238135B2 (en)
KR (2) KR100712782B1 (en)
CN (1) CN1582274B (en)
AP (1) AP1744A (en)
AR (1) AR037676A1 (en)
AT (2) ATE320414T1 (en)
AU (1) AU2002365313B2 (en)
BR (1) BR0214519A (en)
CA (1) CA2468715C (en)
CR (2) CR7332A (en)
CY (2) CY1105374T1 (en)
DE (2) DE60209944T2 (en)
DK (2) DK1671949T3 (en)
DO (1) DOP2002000525A (en)
EA (1) EA007579B1 (en)
EC (1) ECSP045126A (en)
ES (2) ES2308653T3 (en)
GE (1) GEP20063871B (en)
GT (2) GT200200248AA (en)
HR (1) HRP20040470A2 (en)
HU (1) HUP0402529A3 (en)
IL (1) IL161826A0 (en)
IS (1) IS2552B (en)
MA (1) MA27146A1 (en)
MX (1) MXPA04003606A (en)
MY (1) MY132419A (en)
NO (1) NO327006B1 (en)
NZ (1) NZ532384A (en)
OA (1) OA13064A (en)
PA (1) PA8559101A1 (en)
PE (1) PE20030662A1 (en)
PL (1) PL370134A1 (en)
PT (2) PT1671949E (en)
RS (1) RS51087B (en)
SI (2) SI1671949T1 (en)
SV (1) SV2004001414A (en)
TN (1) TNSN04098A1 (en)
TW (1) TWI324515B (en)
UY (1) UY27558A1 (en)
WO (1) WO2003045912A1 (en)

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087646A2 (en) * 2003-04-03 2004-10-14 Merck Patent Gmbh Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases
WO2004110433A1 (en) * 2003-06-18 2004-12-23 Merck Patent Gmbh Pyrrolidin-1, 2- dicarboxylic acid- 1- [(4- ethinyl- phenyl) - amid]- 2- [(phenyl)- amid] derivative as inhibitors of coagulation factor xa and viia for the treatment of thrombosis
WO2005058817A1 (en) * 2003-12-16 2005-06-30 Merck Patent Gmbh Prolinylarylacetamides
WO2005085200A1 (en) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. Pyridone derivative
WO2005092881A1 (en) * 2004-03-26 2005-10-06 F. Hoffmann-La Roche Ag Novel pyrrolidine-3,4-dicarboxamide derivatives
WO2005092849A1 (en) * 2004-03-26 2005-10-06 Merck Patent Gmbh Prolinyl derivatives for treating thrombosis
WO2005097783A1 (en) * 2004-04-03 2005-10-20 Merck Patent Gmbh Thiocarbamoylprolines
WO2006032342A2 (en) * 2004-09-22 2006-03-30 Merck Patent Gmbh Carbonyl compound-containing drug and the use thereof
WO2006034769A1 (en) * 2004-09-29 2006-04-06 Merck Patent Gmbh Carbonyl compounds usable as coagulation factor xa inhibitors
WO2006034789A1 (en) * 2004-09-29 2006-04-06 Merck Patent Gmbh Proline derivatives
WO2006048152A3 (en) * 2004-11-03 2006-09-21 Hoffmann La Roche Dicarboxamide derivatives and their use as factor xa inhibitors
US7115646B2 (en) 2003-10-08 2006-10-03 Bristol Myers Squibb, Co. Cyclic diamines and derivatives as factor Xa inhibitors
JP2006265254A (en) * 2005-03-24 2006-10-05 Warner-Lambert Co Llc CRYSTAL FORM OF FACTOR Xa INHIBITOR
DE102005017116A1 (en) * 2005-04-13 2006-10-26 Novartis Ag Inhibitors of Inhibitors of Apoptosis Proteins (IAP)
US7192968B2 (en) 2000-04-05 2007-03-20 Daiichi Pharmaceutical Co., Ltd. Ethylenediamine derivatives
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
EP1847537A1 (en) 2006-04-21 2007-10-24 F. Hoffmann-La Roche Ag Dicarboxamide derivatives
US7342014B2 (en) 2001-06-20 2008-03-11 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
WO2008064218A2 (en) * 2006-11-21 2008-05-29 Smithkline Beecham Corporation Amido anti-viral compounds
WO2008065503A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. (r) -5-methyl-4, 5-dihydro- pyrazole-1, 5-dicarboxylic acid 1- [ ( 4 -chlorophenyl) amide 5-{ [2-fluoro-4- (2-oxo-2h-pyridin-1-yl) -phenyl]amide) as a factor xa inhibitor
US7417144B2 (en) 2005-07-15 2008-08-26 Hoffman-La Roche Inc. Factor Xa inhibitors
US7601752B2 (en) 2005-11-16 2009-10-13 Hoffmann-La Roche Inc. Pyrrolidine derivatives
US7629340B2 (en) * 2005-12-12 2009-12-08 Smithkline Beecham Corporation N-(6-membered aromatic ring)-amido anti-viral compounds
US7678917B2 (en) 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
US7687665B2 (en) 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
US7776874B2 (en) 2004-05-07 2010-08-17 Incyte Corporation Amido compounds and their use as pharmaceuticals
US7807693B2 (en) 2006-05-16 2010-10-05 Boehringer Ingelheim International Gmbh Substituted prolinamides, manufacturing, and the use thereof as medicaments
US7902373B2 (en) 2006-12-19 2011-03-08 Pfizer Inc Nicotinamide derivatives
WO2011042797A1 (en) * 2009-10-08 2011-04-14 Icozen Therapeutics Pvt. Ltd. Pyrazole derivatives as modulators of calcium release -activated calcium channel
US8455440B2 (en) 2007-04-13 2013-06-04 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
WO2013102242A1 (en) * 2012-01-06 2013-07-11 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
US8779157B2 (en) 2009-09-04 2014-07-15 Vanderbilt University MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US9085555B2 (en) 2011-01-04 2015-07-21 Novartis Ag Complement pathway modulators and uses thereof
EP2875001A4 (en) * 2012-07-18 2016-06-01 Sunshine Lake Pharma Co Ltd Nitrogenous heterocyclic derivatives and their application in drugs
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9464081B2 (en) 2012-06-28 2016-10-11 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9468661B2 (en) 2012-06-28 2016-10-18 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9487483B2 (en) 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
US9550755B2 (en) 2012-07-12 2017-01-24 Novartis Ag Complement pathway modulators and uses thereof
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
EP3113772A4 (en) * 2014-03-07 2017-08-30 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
US10010536B2 (en) 2005-05-10 2018-07-03 Intermune, Inc. Method of modulating stress-activated protein kinase system
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
WO2019113236A1 (en) * 2017-12-06 2019-06-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
US20210017131A1 (en) * 2018-03-29 2021-01-21 Centre National De La Recherche Scientifique P2rx7 modulators in therapy
US11066360B2 (en) 2015-10-01 2021-07-20 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US11186554B2 (en) 2017-05-03 2021-11-30 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
US11192865B2 (en) 2017-08-21 2021-12-07 Vivace Therapeutics, Inc. Benzosulfonyl compounds
US11661403B2 (en) 2018-05-16 2023-05-30 Vivace Therapeutics, Inc. Oxadiazole compounds

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10113379B4 (en) * 2001-03-20 2006-08-24 Karl Eugen Fischer Gmbh Maschinenfabrik Feed device, in particular for cord bands
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
KR20030080810A (en) * 2002-04-11 2003-10-17 주식회사 엘지생명과학 Selective thrombin inhibitors with an aminopyridoaryl group
US20040138269A1 (en) * 2002-10-11 2004-07-15 Sugen, Inc. Substituted pyrroles as kinase inhibitors
DE10329457A1 (en) * 2003-04-03 2005-01-20 Merck Patent Gmbh New 1,2-bis-phenylaminocarbonyl-pyrrolidine derivatives, useful for treating or preventing e.g. thrombosis, myocardial infarct and arteriosclerosis, are inhibitors of coagulation factor Xa
WO2006038119A1 (en) * 2004-10-08 2006-04-13 Warner-Lambert Company Llc Stereoselective synthesis of n-protected alkoxy prolines
CN104803916B (en) * 2004-11-16 2017-08-11 詹森药业有限公司 Hete rocyclic derivatives as SARM (SARMS)
WO2007053610A2 (en) * 2005-11-01 2007-05-10 The Regents Of The University Of California Methods of treating atrial fibrillation wtih pirfenidone
US20110039893A1 (en) * 2006-10-11 2011-02-17 Takeda Pharmaceutical Company Limited Gsk-3beta inhibitor
TW200911787A (en) * 2007-07-03 2009-03-16 Astrazeneca Ab New aza-bicyclohexane compounds useful as inhibitors of thrombin
CN101932577B (en) * 2007-11-30 2013-07-17 拜耳知识产权有限责任公司 Heteroaryl-substituted piperidines
CA2731097A1 (en) * 2008-07-15 2010-01-21 Novartis Ag Organic compounds
EP2802608A4 (en) * 2012-01-12 2015-08-05 Univ Yale Compounds&methods for the enhanced degradation of targeted proteins&other polypeptides by an e3 ubiquitin ligase
EA201300843A1 (en) * 2013-08-01 2015-04-30 Арсений Валерьевич Айбушев CARBAMOILPHENYL DERIVATIVES FOR STOPPING, PREVENTION AND PREVENTION OF BLEEDING OR STRENGTHENING OF THE HEMOSTASIS SYSTEM
CN103570699A (en) * 2013-09-29 2014-02-12 北京万全德众医药生物技术有限公司 Method for preparing prucalopride
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
EP3270917A4 (en) 2015-03-18 2018-08-08 Arvinas, Inc. Compounds and methods for the enhanced degradation of targeted proteins
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
EP3512842B1 (en) 2016-09-15 2024-01-17 Arvinas, Inc. Indole derivatives as estrogen receptor degraders
CA3038979A1 (en) 2016-10-11 2018-04-19 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US11458123B2 (en) 2016-11-01 2022-10-04 Arvinas Operations, Inc. Tau-protein targeting PROTACs and associated methods of use
RU2750484C2 (en) 2016-12-01 2021-06-28 Эрвинэс Оперейшнс, Инк. Derivatives of tetrahydronaphtalene and tetrahydroisoquinoline as deconstructors of estrogen receptor
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
JP2020504741A (en) 2016-12-23 2020-02-13 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Compounds and methods for targeted degradation of RAF (rapidly aggressive fibrosarcoma) polypeptides
CA3047586A1 (en) 2016-12-23 2018-06-28 Arvinas Operations, Inc. Egfr proteolysis targeting chimeric molecules and associated methods of use
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
IL300417A (en) 2017-01-26 2023-04-01 Arvinas Operations Inc Bifunctional benzthiophene compounds, compositions comprisng them and their use in treatment
WO2019099926A1 (en) 2017-11-17 2019-05-23 Arvinas, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
CN110240591A (en) * 2018-03-08 2019-09-17 天津药物研究院有限公司 Proline derivative and its preparation method and application
KR20230130752A (en) 2018-04-04 2023-09-12 아비나스 오퍼레이션스, 인코포레이티드 Modulators of proteolysis and associated methods of use
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
BR112022012110A2 (en) 2019-12-19 2022-12-13 Arvinas Operations Inc COMPOUNDS AND METHODS FOR TARGETED ANDROGEN RECEPTOR DEGRADATION
KR20230015933A (en) 2020-05-09 2023-01-31 아비나스 오퍼레이션스, 인코포레이티드 Methods for preparing bifunctional compounds, ultrapure forms of bifunctional compounds, and dosage forms comprising the same
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028420A1 (en) * 1994-04-18 1995-10-26 Corvas International, Inc. Methionine sulfone and s-substituted cysteine sulfone derivatives as enzyme inhibitors
WO1997005161A1 (en) * 1995-07-28 1997-02-13 Novartis Ag Boronic acid derivatives
WO1997046576A1 (en) * 1996-06-05 1997-12-11 Gyógyszerkutató Intézet Kft. Anticoagulant peptidyl-arginine aldehyde derivatives
WO2001064642A2 (en) * 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US91116A (en) * 1869-06-08 Improvement in guard for door-knobs
US2947755A (en) * 1959-02-05 1960-08-02 Wallace & Tiernan Inc Substituted 1-m-aminophenyl-2-pyridones
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (en) 1983-08-30 1985-04-24 Oreal COSMETIC OR PHARMACEUTICAL COMPOSITION IN AQUEOUS OR ANHYDROUS FORM WHOSE FATTY PHASE CONTAINS OLIGOMER POLYETHER AND NEW OLIGOMER POLYETHERS
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5118691A (en) * 1990-09-20 1992-06-02 Warner-Lambert Co. Substituted tetrahydropyridines as central nervous system agents
DE4326465A1 (en) 1993-01-20 1995-02-09 Thomae Gmbh Dr K Amino acid derivatives, pharmaceutical compositions containing these compounds and process for their preparation
DE19544687A1 (en) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Amino acid derivatives, medicaments containing these compounds and processes for their preparation
ATE546139T1 (en) 1997-05-07 2012-03-15 Univ Pittsburgh ISOPRENT TRANSFERASE PROTEINS INHIBITORS
CA2290520C (en) * 1997-05-23 2009-01-27 Bayer Corporation Inhibition of p38 kinase activity by aryl ureas
ZA985247B (en) * 1997-06-19 1999-12-17 Du Pont Merck Pharma Guanidine mimics as factor Xa inhibitors.
JP2001521934A (en) * 1997-11-03 2001-11-13 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Aromatic heterocyclic compounds as anti-inflammatory drugs
US6632815B2 (en) 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
ES2316383T3 (en) 1999-09-17 2009-04-16 Millennium Pharmaceuticals, Inc. RELATED BENZAMIDS AND INHIBITORS OF FACTOR XA.
CZ2002959A3 (en) 1999-09-17 2002-07-17 Millennium Pharmaceuticals, Inc. Inhibitors of Xa factor
DE10008329A1 (en) 2000-02-23 2001-08-30 Merck Patent Gmbh New aminosulfonyl-biphenyl derivatives are Factor Xa and Factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, arteriosclerosis, inflammation or angina pectoris
US7211601B2 (en) * 2000-03-27 2007-05-01 Applied Research Systems Ars Holding N.V. Pharmaceutically active pyrrolidine derivatives
EP1268418B1 (en) * 2000-03-27 2006-06-14 Applied Research Systems ARS Holding N.V. Pharmaceutically active pyrrolidine derivatives as bax inhibitors
GB0030303D0 (en) 2000-12-13 2001-01-24 Lilly Co Eli Compounds
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
DE10036121A1 (en) 2000-07-25 2002-02-07 Merck Patent Gmbh N-Substituted-1-amino-1,1-dialkyl-carboxylic acid derivatives
DE10046272A1 (en) 2000-09-19 2002-03-28 Merck Patent Gmbh New biphenyl-substituted amino-(iso)quinoline derivatives, are factor Xa and factor VIIa inhibitors useful e.g. for treating thrombosis, myocardial infarction, inflammation, angina pectoris or restenosis
DE10050723A1 (en) 2000-10-13 2002-04-25 Merck Patent Gmbh New N-substituted amino acid derivatives for treating thromboembolic diseases e.g. thrombosis, myocardial infarct, arteriosclerosis, inflammation, stroke, angina, restenosis are factor Xa inhibitors
DE10063008A1 (en) 2000-12-16 2002-06-20 Merck Patent Gmbh carboxamide
DE10102322A1 (en) 2001-01-19 2002-07-25 Merck Patent Gmbh New disubstituted and trisubstituted benzene derivatives useful as coagulation inhibitors for the treatment of thromboembolic diseases
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
JP2007510647A (en) * 2003-10-30 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド Aralkylamines as cannabinoid receptor modulators
FR2864958B1 (en) * 2004-01-12 2006-02-24 Sanofi Synthelabo N - [(1,5-DIPHENYL-1H-PYRAZOL-3-YL) METHYL] SULFONAMIDE DERIVATIVE, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
DE102005038537A1 (en) * 2005-08-16 2007-02-22 Merck Patent Gmbh 1-Acyldihydropyrazolderivate
WO2008062739A1 (en) * 2006-11-20 2008-05-29 Japan Tobacco Inc. Pyrazoles and use thereof as drugs
DE102007037017A1 (en) * 2007-08-06 2009-02-19 Clariant International Ltd. 1-Alkyl-5-oxo-pyrrolidine-3-carboxylic acid ester with improved biodegradability

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995028420A1 (en) * 1994-04-18 1995-10-26 Corvas International, Inc. Methionine sulfone and s-substituted cysteine sulfone derivatives as enzyme inhibitors
WO1997005161A1 (en) * 1995-07-28 1997-02-13 Novartis Ag Boronic acid derivatives
WO1997046576A1 (en) * 1996-06-05 1997-12-11 Gyógyszerkutató Intézet Kft. Anticoagulant peptidyl-arginine aldehyde derivatives
WO2001064642A2 (en) * 2000-02-29 2001-09-07 Cor Therapeutics, Inc. Benzamides and related inhibitors of factor xa

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ERIK VERNER ET AL.: "Development of Serine Protease Inhibitors Displaying a Multicenter Short Hydrogen Bond Binding Mode: Inhibitors of Urokinase-Type Plasminogen Activator and Factor Xa", JOURNAL OF MEDICINAL CHEMISTRY., vol. 44, no. 17, 2001, AMERICAN CHEMICAL SOCIETY., US, pages 2753 - 2771, XP002216503, ISSN: 0022-2623 *
F AL-OBEIDI & JAOSTREM: "Factor Xa Inhibitors", EXPERT OPINION ON THERAPEUTIC PATENTS., vol. 9, no. 7, 1999, ASHLEY PUBLICATIONS., GB, pages 931 - 953, XP001000512, ISSN: 1354-3776 *
MICHAEL R. WILEY ET AL.: "Structure-Based Design of Potent, Amidine-Derived Inhibitors of Factor Xa: Evaluation of Selectivity, Anticoagulant Activity, and Antithrombotic Activity", JOURNAL OF MEDICINAL CHEMISTRY., vol. 43, no. 5, 2000, AMERICAN CHEMICAL SOCIETY., US, pages 883 - 899, XP002186966, ISSN: 0022-2623 *
YING K.YEE ET AL.: "N-Aroylanthranilamide Inhibitors of Human Factor Xa", JOURNAL OF MEDICINAL CHEMISTRY., vol. 43, no. 5, 2000, AMERICAN CHEMICAL SOCIETY., US, pages 873 - 882, XP002186965, ISSN: 0022-2623 *

Cited By (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192968B2 (en) 2000-04-05 2007-03-20 Daiichi Pharmaceutical Co., Ltd. Ethylenediamine derivatives
US7935824B2 (en) 2000-04-05 2011-05-03 Daiichi Pharmaceutical Co., Ltd. Ethylenediamine derivatives
US7342014B2 (en) 2001-06-20 2008-03-11 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US7365205B2 (en) 2001-06-20 2008-04-29 Daiichi Sankyo Company, Limited Diamine derivatives
US7205318B2 (en) 2003-03-18 2007-04-17 Bristol-Myers Squibb Company Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors
US7906516B2 (en) 2003-04-03 2011-03-15 Merck Patent Gmbh Carbonyl compounds
WO2004087646A3 (en) * 2003-04-03 2005-01-06 Merck Patent Gmbh Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases
AU2004226278B2 (en) * 2003-04-03 2010-07-29 Merck Patent Gmbh Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor Xa in the treatment of thrombo-embolic diseases
US8129373B2 (en) 2003-04-03 2012-03-06 Merck Patent Gmbh Carbonyl compounds
WO2004087646A2 (en) * 2003-04-03 2004-10-14 Merck Patent Gmbh Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases
JP2006527708A (en) * 2003-06-18 2006-12-07 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 1-[(4-Ethynylphenyl)]-2-[(phenyl)]-pyrrolidine-1,2-dicarboxamide derivatives as inhibitors of coagulation factors Xa and VIIa for the treatment of thrombosis
US7557222B2 (en) 2003-06-18 2009-07-07 Merck Patent Gmbh 1-[(4-Ethynylphenyl)]-2-[(phenyl)]-pyrrolidine-1,2-dicarboxamide derivatives as inhibitors of coagulation factors Xa and VIIa for the treatment of thrombosis
AU2004246766B2 (en) * 2003-06-18 2009-09-17 Merck Patent Gmbh Pyrrolidin-1, 2- dicarboxylic acid- 1- [(4- ethinyl- phenyl) - amid]- 2- [(phenyl)- amid] derivative as inhibitors of coagulation factor Xa and VIIa for the treatment of thrombosis
WO2004110433A1 (en) * 2003-06-18 2004-12-23 Merck Patent Gmbh Pyrrolidin-1, 2- dicarboxylic acid- 1- [(4- ethinyl- phenyl) - amid]- 2- [(phenyl)- amid] derivative as inhibitors of coagulation factor xa and viia for the treatment of thrombosis
US7115646B2 (en) 2003-10-08 2006-10-03 Bristol Myers Squibb, Co. Cyclic diamines and derivatives as factor Xa inhibitors
US7732481B2 (en) 2003-12-16 2010-06-08 Merck Patent Gesellschaft Mit Beschrankter Haftung Prolinylarylacetamides
AU2004299197B2 (en) * 2003-12-16 2010-08-05 Merck Patent Gmbh Prolinylarylacetamides
JP4800969B2 (en) * 2003-12-16 2011-10-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Prolinyl arylacetamide
JP2007513988A (en) * 2003-12-16 2007-05-31 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Prolinyl arylacetamide
WO2005058817A1 (en) * 2003-12-16 2005-06-30 Merck Patent Gmbh Prolinylarylacetamides
US7732456B2 (en) 2004-03-05 2010-06-08 Banyu Pharmaceutical Co., Ltd. Pyridone derivative
WO2005085200A1 (en) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd. Pyridone derivative
KR100847191B1 (en) * 2004-03-26 2008-07-17 에프. 호프만-라 로슈 아게 Novel pyrrolidine-3,4-dicarboxamide derivatives
JP2007530469A (en) * 2004-03-26 2007-11-01 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Prolinyl derivatives for the treatment of thrombosis
JP2007530479A (en) * 2004-03-26 2007-11-01 エフ．ホフマン−ラ　ロシュ　アーゲー Novel pyrrolidine-3,4-dicarboxamide derivatives
CN1938294B (en) * 2004-03-26 2012-09-26 弗·哈夫曼-拉罗切有限公司 Novel pyrrolidine-3,4-dicarboxamide derivatives
WO2005092881A1 (en) * 2004-03-26 2005-10-06 F. Hoffmann-La Roche Ag Novel pyrrolidine-3,4-dicarboxamide derivatives
WO2005092849A1 (en) * 2004-03-26 2005-10-06 Merck Patent Gmbh Prolinyl derivatives for treating thrombosis
US7550487B2 (en) 2004-03-26 2009-06-23 Hoffmann-La Roche Inc. Pyrrolidine-3,4-dicarboxamide derivatives
AU2005225489B2 (en) * 2004-03-26 2011-02-10 Merck Patent Gmbh Prolinyl derivatives for treating thrombosis
NO338531B1 (en) * 2004-03-26 2016-08-29 Hoffmann La Roche Pyrrolidine-3,4-dicarboxamide derivatives, pharmaceutical compositions comprising such compounds, such compounds for use as therapeutic substances, and the use of such compounds for the treatment and or prevention of diseases
AU2005225523B2 (en) * 2004-03-26 2011-10-13 F. Hoffmann-La Roche Ag Novel pyrrolidine-3,4-dicarboxamide derivatives
WO2005097783A1 (en) * 2004-04-03 2005-10-20 Merck Patent Gmbh Thiocarbamoylprolines
US9670154B2 (en) 2004-05-07 2017-06-06 Incyte Holdings Corporation Amido compounds and their use as pharmaceuticals
US9957229B2 (en) 2004-05-07 2018-05-01 Incyte Holdings Corporation Amido compounds and their use as pharmaceuticals
US7776874B2 (en) 2004-05-07 2010-08-17 Incyte Corporation Amido compounds and their use as pharmaceuticals
US9126927B2 (en) 2004-05-07 2015-09-08 Incyte Holdings Corporation Amido compounds and their use as pharmaceuticals
US8058288B2 (en) 2004-05-07 2011-11-15 Incyte Corporation Amido compounds and their use as pharmaceuticals
US7687665B2 (en) 2004-06-24 2010-03-30 Incyte Corporation 2-methylprop anamides and their use as pharmaceuticals
WO2006032342A3 (en) * 2004-09-22 2007-01-11 Merck Patent Gmbh Carbonyl compound-containing drug and the use thereof
WO2006032342A2 (en) * 2004-09-22 2006-03-30 Merck Patent Gmbh Carbonyl compound-containing drug and the use thereof
JP2008513387A (en) * 2004-09-22 2008-05-01 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Medicaments containing carbonyl compounds and uses thereof
WO2006034789A1 (en) * 2004-09-29 2006-04-06 Merck Patent Gmbh Proline derivatives
JP2008514655A (en) * 2004-09-29 2008-05-08 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Carbonyl compounds used as inhibitors of coagulation factor Xa
WO2006034769A1 (en) * 2004-09-29 2006-04-06 Merck Patent Gmbh Carbonyl compounds usable as coagulation factor xa inhibitors
JP2008518985A (en) * 2004-11-03 2008-06-05 エフ．ホフマン−ラ ロシュ アーゲー New dicarboxamide derivatives
US7501413B2 (en) 2004-11-03 2009-03-10 Hoffmann-La Roche Inc. Dicarboxamide derivatives
JP4943340B2 (en) * 2004-11-03 2012-05-30 エフ．ホフマン−ラ ロシュ アーゲー New dicarboxamide derivatives
KR100884146B1 (en) 2004-11-03 2009-02-17 에프. 호프만-라 로슈 아게 Dicarboxamide derivatives and their use as factor xa inhibitors
WO2006048152A3 (en) * 2004-11-03 2006-09-21 Hoffmann La Roche Dicarboxamide derivatives and their use as factor xa inhibitors
JP2006265254A (en) * 2005-03-24 2006-10-05 Warner-Lambert Co Llc CRYSTAL FORM OF FACTOR Xa INHIBITOR
DE102005017116A1 (en) * 2005-04-13 2006-10-26 Novartis Ag Inhibitors of Inhibitors of Apoptosis Proteins (IAP)
US10010536B2 (en) 2005-05-10 2018-07-03 Intermune, Inc. Method of modulating stress-activated protein kinase system
US7417144B2 (en) 2005-07-15 2008-08-26 Hoffman-La Roche Inc. Factor Xa inhibitors
US7678917B2 (en) 2005-09-01 2010-03-16 Hoffman-La Roche Inc. Factor Xa inhibitors
US7601752B2 (en) 2005-11-16 2009-10-13 Hoffmann-La Roche Inc. Pyrrolidine derivatives
US7629340B2 (en) * 2005-12-12 2009-12-08 Smithkline Beecham Corporation N-(6-membered aromatic ring)-amido anti-viral compounds
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
US7998959B2 (en) 2006-01-12 2011-08-16 Incyte Corporation Modulators of 11-β hydroxyl steroid dehydrogenase type 1, pharmaceutical compositions thereof, and methods of using the same
WO2007084314A3 (en) * 2006-01-12 2008-03-27 Incyte Corp MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2007122104A1 (en) * 2006-04-21 2007-11-01 F. Hoffmann - La Roche Ag Dicarboxamide derivatives
EP1847537A1 (en) 2006-04-21 2007-10-24 F. Hoffmann-La Roche Ag Dicarboxamide derivatives
US7807693B2 (en) 2006-05-16 2010-10-05 Boehringer Ingelheim International Gmbh Substituted prolinamides, manufacturing, and the use thereof as medicaments
WO2008064218A2 (en) * 2006-11-21 2008-05-29 Smithkline Beecham Corporation Amido anti-viral compounds
WO2008064218A3 (en) * 2006-11-21 2008-10-23 Genelabs Tech Inc Amido anti-viral compounds
WO2008065503A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. (r) -5-methyl-4, 5-dihydro- pyrazole-1, 5-dicarboxylic acid 1- [ ( 4 -chlorophenyl) amide 5-{ [2-fluoro-4- (2-oxo-2h-pyridin-1-yl) -phenyl]amide) as a factor xa inhibitor
US7902373B2 (en) 2006-12-19 2011-03-08 Pfizer Inc Nicotinamide derivatives
US8455440B2 (en) 2007-04-13 2013-06-04 Millennium Pharmaceuticals, Inc. Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor
USRE47142E1 (en) 2008-06-03 2018-11-27 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
US8779157B2 (en) 2009-09-04 2014-07-15 Vanderbilt University MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US10246450B2 (en) 2009-10-08 2019-04-02 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US10174034B2 (en) 2009-10-08 2019-01-08 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
CN102834382B (en) * 2009-10-08 2016-08-03 理森制药股份公司 The pyrazole derivatives of calcium channel modulators is activated as calcium release
US8921364B2 (en) 2009-10-08 2014-12-30 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US10668051B2 (en) 2009-10-08 2020-06-02 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
CN102834382A (en) * 2009-10-08 2012-12-19 理森制药股份公司 Pyrazole derivatives as modulators of calcium release-activated calcium channel
EA024630B1 (en) * 2009-10-08 2016-10-31 Ризен Фармасьютикалз С.А. Pyrazole derivatives as calcium release-activated calcium (crac) channel inhibitors
US9944631B2 (en) 2009-10-08 2018-04-17 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US9758514B2 (en) 2009-10-08 2017-09-12 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
WO2011042797A1 (en) * 2009-10-08 2011-04-14 Icozen Therapeutics Pvt. Ltd. Pyrazole derivatives as modulators of calcium release -activated calcium channel
US9085555B2 (en) 2011-01-04 2015-07-21 Novartis Ag Complement pathway modulators and uses thereof
US9624243B2 (en) 2012-01-06 2017-04-18 Novartis Ag Heterocyclic compounds and methods of their use
US10370388B2 (en) 2012-01-06 2019-08-06 Novartis Ag Heterocyclic compounds and methods of their use
AU2013202982B2 (en) * 2012-01-06 2016-05-12 Novartis Ag Heterocyclic compounds and methods for their use
WO2013102242A1 (en) * 2012-01-06 2013-07-11 Spinifex Pharmaceuticals Pty Ltd Heterocyclic compounds and methods for their use
AU2013202982C1 (en) * 2012-01-06 2017-01-05 Novartis Ag Heterocyclic compounds and methods for their use
US9468661B2 (en) 2012-06-28 2016-10-18 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9487483B2 (en) 2012-06-28 2016-11-08 Novartis Ag Complement pathway modulators and uses thereof
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
US9464081B2 (en) 2012-06-28 2016-10-11 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9388199B2 (en) 2012-06-28 2016-07-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9550755B2 (en) 2012-07-12 2017-01-24 Novartis Ag Complement pathway modulators and uses thereof
EP2875001A4 (en) * 2012-07-18 2016-06-01 Sunshine Lake Pharma Co Ltd Nitrogenous heterocyclic derivatives and their application in drugs
US10898474B2 (en) 2012-10-02 2021-01-26 Intermune, Inc. Anti-fibrotic pyridinones
US9675593B2 (en) 2012-10-02 2017-06-13 Intermune, Inc. Anti-fibrotic pyridinones
US10376497B2 (en) 2012-10-02 2019-08-13 Intermune, Inc. Anti-fibrotic pyridinones
US10633345B2 (en) 2014-03-07 2020-04-28 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US11203574B2 (en) 2014-03-07 2021-12-21 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US11708333B2 (en) 2014-03-07 2023-07-25 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US11230530B2 (en) 2014-03-07 2022-01-25 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US11685721B2 (en) 2014-03-07 2023-06-27 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US10125102B2 (en) 2014-03-07 2018-11-13 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US10689346B2 (en) 2014-03-07 2020-06-23 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US11708332B2 (en) 2014-03-07 2023-07-25 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
EP3113772A4 (en) * 2014-03-07 2017-08-30 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US11192861B2 (en) 2014-03-07 2021-12-07 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US10329260B2 (en) 2014-03-07 2019-06-25 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
US10544161B2 (en) 2014-04-02 2020-01-28 Intermune, Inc. Anti-fibrotic pyridinones
US11066360B2 (en) 2015-10-01 2021-07-20 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
CN114591212A (en) * 2015-10-01 2022-06-07 拜奥克里斯特制药公司 Human plasma kallikrein inhibitors
US11807605B2 (en) 2015-10-01 2023-11-07 Biocryst Pharmaceuticals, Inc. Human plasma kallikrein inhibitors
US11186554B2 (en) 2017-05-03 2021-11-30 Vivace Therapeutics, Inc. Non-fused tricyclic compounds
US11192865B2 (en) 2017-08-21 2021-12-07 Vivace Therapeutics, Inc. Benzosulfonyl compounds
US11524943B1 (en) 2017-12-06 2022-12-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
WO2019113236A1 (en) * 2017-12-06 2019-06-13 Vivace Therapeutics, Inc. Benzocarbonyl compounds
US20210017131A1 (en) * 2018-03-29 2021-01-21 Centre National De La Recherche Scientifique P2rx7 modulators in therapy
US11919854B2 (en) 2018-03-29 2024-03-05 Centre National De La Recherche Scientifique P2RX7 modulators in therapy
US11661403B2 (en) 2018-05-16 2023-05-30 Vivace Therapeutics, Inc. Oxadiazole compounds

Also Published As

Publication number Publication date
US20080287674A1 (en) 2008-11-20
UY27558A1 (en) 2003-06-30
CN1582274B (en) 2011-03-09
IS2552B (en) 2009-10-15
NZ532384A (en) 2006-10-27
IS7220A (en) 2004-04-15
PT1465864E (en) 2006-06-30
MXPA04003606A (en) 2004-07-27
DE60227853D1 (en) 2008-09-04
WO2003045912A8 (en) 2003-10-02
EP1671949A3 (en) 2006-07-19
TW200300675A (en) 2003-06-16
TWI324515B (en) 2010-05-11
GT200200248A (en) 2003-06-27
CR7332A (en) 2006-08-09
BR0214519A (en) 2004-10-13
RS43604A (en) 2006-12-15
ATE320414T1 (en) 2006-04-15
US20050267118A1 (en) 2005-12-01
JP2005515985A (en) 2005-06-02
KR100712782B1 (en) 2007-05-02
EP2085391A2 (en) 2009-08-05
KR20060100481A (en) 2006-09-20
HRP20040470A2 (en) 2004-10-31
GT200200248AA (en) 2007-07-06
CA2468715A1 (en) 2003-06-05
ES2259113T3 (en) 2006-09-16
SI1465864T1 (en) 2006-08-31
DE60209944T2 (en) 2006-11-23
KR20040066851A (en) 2004-07-27
MA27146A1 (en) 2005-01-03
AU2002365313B2 (en) 2008-03-06
EP1465864B1 (en) 2006-03-15
GEP20063871B (en) 2006-07-10
CY1109068T1 (en) 2014-07-02
ES2308653T3 (en) 2008-12-01
AU2002365313A1 (en) 2003-06-10
CR10190A (en) 2008-09-10
EA200400606A1 (en) 2004-10-28
AR037676A1 (en) 2004-12-01
RS51087B (en) 2010-10-31
US7407974B2 (en) 2008-08-05
ATE402148T1 (en) 2008-08-15
US20030162787A1 (en) 2003-08-28
SV2004001414A (en) 2004-05-07
US20090221546A1 (en) 2009-09-03
PE20030662A1 (en) 2003-08-11
PT1671949E (en) 2008-09-17
NO20042270L (en) 2004-06-01
HUP0402529A3 (en) 2011-05-30
MY132419A (en) 2007-10-31
AP2004003035A0 (en) 2004-06-30
SI1671949T1 (en) 2008-10-31
EP1671949B1 (en) 2008-07-23
DE60209944D1 (en) 2006-05-11
ECSP045126A (en) 2004-07-23
TNSN04098A1 (en) 2006-06-01
PA8559101A1 (en) 2003-11-12
AP1744A (en) 2007-05-29
CA2468715C (en) 2011-03-29
US20050250815A1 (en) 2005-11-10
US7407972B2 (en) 2008-08-05
DOP2002000525A (en) 2003-05-31
EP1671949A2 (en) 2006-06-21
JP4238135B2 (en) 2009-03-11
OA13064A (en) 2006-11-10
CY1105374T1 (en) 2010-04-28
DK1671949T3 (en) 2008-11-03
IL161826A0 (en) 2005-11-20
PL370134A1 (en) 2005-05-16
US20060264626A1 (en) 2006-11-23
DK1465864T3 (en) 2006-07-10
EA007579B1 (en) 2006-12-29
EP2085391A3 (en) 2010-08-18
US7030141B2 (en) 2006-04-18
NO327006B1 (en) 2009-04-06
CN1582274A (en) 2005-02-16
KR100688814B1 (en) 2007-03-02
EP1465864A1 (en) 2004-10-13
HUP0402529A2 (en) 2005-03-29

Similar Documents

Publication Publication Date Title
US7407974B2 (en) Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
AU2021200140B2 (en) Pyrazole derivatives as plasma kallikrein inhibitors
US5998424A (en) Inhibitors of factor Xa with a neutral P1 specificity group
EP0991625B1 (en) Inhibitors of factor xa with a neutral p1 specificity group
JP2001526268A (en) Nitrogen-containing heterocyclic aromatic compounds having ortho-substituted P1 as factor Xa inhibitors
MXPA05002703A (en) Inhibitors of factor xa and other serine proteases involved in the coagulation cascade.
UA77456C2 (en) Inhibitors of factor xa and other serineproteases involved to the coagulation cascade
CZ444399A3 (en) Xa factor inhibitors with neutral P1 group specificity
KR20070000487A (en) Pyrrole-derivatives as factor xa inhibitors
LT4673B (en) Nitrogen containing heteroaromatics as factor xa inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 1200400457

Country of ref document: VN

Ref document number: P-436/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/003606

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 532384

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1062/DELNP/2004

Country of ref document: IN

Ref document number: 2002365313

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 161826

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: AP/P/2004/003035

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: 2002803885

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500729

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 2004/04085

Country of ref document: ZA

Ref document number: 200404085

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: P20040470A

Country of ref document: HR

WWE Wipo information: entry into national phase

Ref document number: 5587

Country of ref document: GE

Ref document number: 2468715

Country of ref document: CA

Ref document number: 2003547364

Country of ref document: JP

Ref document number: 20028238370

Country of ref document: CN

Ref document number: 1020047008251

Country of ref document: KR

Ref document number: 200400606

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2002803885

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 2002803885

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020067017890

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: CR2008-010190

Country of ref document: CR